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THESIS ABSTRACT 
 
Making Research Translatable:  
Articulating and Shaping Synthetic Biology in the UK 
 
 
 
Synthetic biology, an engineering approach to genetic modification, has emerged at a time 
when academics are increasingly expected to translate research to other domains of society. 
Proponents of synthetic biology often deploy promissory rhetoric to create expectations of 
major improvements in medicine, energy and food production. How else are actors in the 
field of synthetic biology addressing these translational expectations? This thesis takes 
synthetic biology in the UK as an empirical site to explore the various ways in which 
research translation involves multiple rhetorical, organisational and material transformations.   
 
In this project I developed a conceptual framework using post-Actor Network Theory, post-
social theory and other STS concepts. I generated data by employing qualitative research 
methods including observations, interviews and by collecting documentation from various 
institutions. I visited field sites such as academic science laboratories, academic events and 
administrative offices. Participants included scientific researchers, research administrators, 
industry representatives and policymakers. I transcribed the interview data, typed up field 
notes and iteratively coded the texts and documents to generate themes.  
 
From my analysis I identified a variety of strategies and practices that appear to make 
synthetic biology translatable. These included: articulating synthetic biology research with 
absences in other areas of society (e.g. state economic and industrial deficits, problems with 
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private-public collaborations) and imagining a future industry; demarcating synthetic biology 
research from other programmes such as genetically modified organisms; realising rhetorical 
promises in the everyday organisation, research training and material work of synthetic 
biology practices.  
 
My research indicates that translation in synthetic biology involves multiple groups 
orientating research facilities and researcher training, particularly towards industrial 
manufacturing. I go on to theorise synthetic biology as an unfolding multiple. Actors expand 
synthetic biology and in the process they entangle the state, institutions, laboratories, cells 
and molecules. To achieve this, actors mobilise vulnerabilities that others have identified in 
science, state and society to create a central heroic object of synthetic biology. These 
conclusions offer a conceptual framework to further investigate and interpret contemporary 
technoscience and its connections in society.  
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Chapter One  
 
Introductions 
 
 
 
Matters grow from the middle, and from many places. But one also has to start 
somewhere.  
(Law 2002, p.1) 
 
 
Research and innovation policymakers have identified a number of challenges facing 
contemporary society. The European Commission, for example, discerns problem areas in 
the health and wellbeing of changing populations; food security and sustainable agriculture; 
secure energy; integrated transport; climate change and resource usage; inclusive societies; 
and liberty (European Commission 2014, pp.11–15). In the UK, policymakers include the 
digital economy, energy, global food security, security for all in a changing world, 
environmental change and lifelong health and wellbeing as research foci (Research Councils 
UK 2015a). These are not clearly defined technical goals, like putting a man on the moon or 
mapping a human genome, but open-ended social projects that “pertain to heterogeneous 
elements and forces, which have to be mobilised, guided and integrated” (Kuhlmann & Rip 
2014, p.1). A challenge facing allocators and recipients of public funds for research is to 
demonstrate how knowledge production contributes to these complex projects.  
 
This thesis is concerned with how scientists, engineers, administrators and policymakers 
shape a field of scientific research to be relevant to society in the UK. Broadly, the thesis is 
connected to perspectives associated with the Social Shaping of Technology (SST) that 
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reject technological determinism and linear models of innovation (Bijker & Law 1992; 
MacKenzie & Wajcman 1999; Sorensen & Williams 2002; Williams & Edge 1996). Instead, I 
emphasise multiplicity and contingency. To do so, I use a variety of conceptual tools to a) 
describe the different activities in which actors engage b) to understand the ways that actors 
make and unmake connections between a field of science and other domains in society and 
c) to explore how their activities and connections shape a field of research.  
 
First, in this introductory chapter, I suggest a number of different places to begin this thesis 
in order to highlight some of the intersecting issues I address in later chapters. I then 
introduce the context for this study – an emerging field of research called ‘synthetic biology’ 
which involves researchers collaborating to ‘make biology easier to engineer’ (Endy 2008; 
Lentzos et al. 2008; Silver 2009; Jefferson et al. 2014a). In the final section I explain the 
structure of the thesis, outline how each chapter contributes to the development of the 
overall arguments and propose the ways in which the thesis builds on knowledge about the 
organisation of science, innovation practices and social theory. 
 
 
1.1 Origins   
 
A central concern of this thesis is how things are connected to one another. This thesis is 
itself connected to many things, academically, empirically, materially and philosophically. So, 
following John Law’s (2002) strategy in his introduction to Aircraft Stories: Decentering the 
Object in Technoscience, I offer four places to start other than with the societal challenges in 
the opening paragraph. This thesis is connected to the idea of translating academic research 
and innovation; to changes in academic biosciences; to social research about translating 
knowledge in biomedicine; and to my own biography.  
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One place to begin is with the meanings of translation and the use of translation as a 
metaphor in research and innovation. The term translation has different dictionary meanings:  
 
• The process of rendering of a text or word in another language 
• The conversion of something from one form to another 
o In biology, the reading of RNA to produce an amino acid sequence 
• The formal process of moving something from one place to another, such as 
relocating a religious relic from one site to another  
o In maths, the movement of a body, without deformation, in a given 
direction 
(Google 2015) 
 
Translation therefore implies both movement from one place or text to another and a change 
in meaning, a betrayal (Law 2006).  
 
In contemporary biomedicine, “translational research” refers to transferring laboratory 
research to clinical practice, sometimes called ‘bench to bedside’ research (Woolf 2008). 
Translational research can be seen as a new “agenda for public health policy, commercial 
pharmaceutical innovation and academic science” (Mittra & Milne 2013, p.xiii). Since the turn 
of the millennium researchers have increasingly included “translational research” in 
abstracts and titles of published biomedical research (Kraft 2013). A translational research 
“imperative” (Harrington & Hauskeller 2014) can be understood partly as a response to the 
perceived slowness of innovation, which is conceived as a ‘gap’ between laboratory and 
clinic (van der Laan & Boenink 2012). The emphasis on translation can also be understood 
as a result of the global investment in the Human Genome Project (HGP) and the lack of 
expected clinical benefits (Kraft 2013; Rajan & Leonelli 2013). 
 
Translation is not a new metaphor for transferring research. For instance, it appeared in 
medical literature, in France, in the 1970s (Greenhalgh & Wieringa 2011). Furthermore, 
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translation is not confined to the domain of academic biomedicine. The metaphor crops up in 
various policies referring to academic funding and knowledge transfer in other biosciences 
and beyond (Cooksey 2006; House of Commons Science and Technology Committee 2013; 
House of Commons Science and Technology Committee 2010; Technology Strategy Board 
2012b). Science and Technology Studies (STS) commentators have used the metaphor in a 
broad sense to refer to sociotechnical systems that may need to be “reconfigured, 
‘translated’ and redesigned to meet the new requirements” (Williams & Edge 1996, p.874). 
David Edge (1995) used the metaphor reflexively:  
 
Perhaps the next phase in the development of STS must be a more urgent concern for 
communication and translation: for “making real” its true potential. 
(Edge 1995, p.4) 
 
Researchers note that academic knowledge needs to undergo some kind of process to be of 
use beyond the bench, desk or laboratory. Thus, the metaphor of translation seems to 
capture the imaginations of academics, clinicians and policymakers. This thesis contributes 
to the ways practitioners and scholars understand the metaphor of translation by describing 
how translation is enacted in a contemporary field of biotechnology.  
 
A second place to begin this thesis is with changes in bioscience at large. When the media 
reported a draft of the human genome in 2000, they announced scientists had produced a 
“map”; a “blueprint”; a “manual”; a “book of life” (Nerlich et al. 2002). Researchers in the 
HGP had “cracked the code” and could now “read, write and spell” with genetic information 
(Nerlich et al. 2002, p.456). The metaphors implied a new ability to understand life. But there 
was a surprise. The whole genome, which had been estimated to contain up to 100 000 
genes, turned out to be made up of 20 000-25 000 genes (Stein 2000). In a response that 
had implications for how genomic knowledge might be utilised in healthcare, scientists had 
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to rethink their understanding, from deterministic genes to genomes as a more holistic entity 
that interacted with cells’ environments (Fox Keller 2014).  
 
Raising expectations for applications of research, such as with the HGP, are an important 
part of securing funding for projects (Brown & Michael 2003; Brown 2003; van Lente 1993):  
 
A key factor is the need for innovators and their sponsors to create high expectations to 
get access to the very considerable resources (money, people, and intellectual property) 
required to develop new medical technologies. No one is going to invest in a start-up 
company, or a large-scale scientific endeavour, such as the Human Genome Project, 
unless they genuinely believe it has the potential to yield significant returns in a defined 
timescale. The emergence of the biotechnology industry has rested heavily on the 
creation of these high hopes and many people in the sector have been active in 
promoting the idea of a biotech revolution. 
(Nightingale & Martin 2004, pp.566–567) 
 
But, despite the promises of genomics and biotechnology more broadly, there does not 
appear to have been a ‘biotech revolution’ in healthcare and instead innovation progresses 
incrementally, slowly and nonlinearly (Hopkins et al. 2007; Nightingale & Martin 2004). 
Furthermore, following the HGP, other biosciences including “epigenetics, immunology, 
physiology, cell biology and ecology” have enjoyed renewed interest and status (Rajan & 
Leonelli 2013, p.11). The heyday of genomics funding appears to have passed and given 
way to other biosciences such as the focus of this study: synthetic biology.  
 
An exemplar of this shift beyond genomics can be found in the biography of American 
geneticist Craig Venter. He left the HGP to set up a private company, Celera Genomics, 
which then competed with the publicly funded HGP to be the first to sequence the whole 
genome (Shreeve 2004). Venter was first author on an important paper published in 
Science, jointly written by Celera staff and HGP scientists (Venter et al. 2001). After he was 
Making Research Translatable: Connections 
	 22 
fired from Celera in 2005 Venter set up a new company, Synthetic Genomics, which 
received $600m investment from Exxon Mobil to develop engineered algal strains that could 
manufacture biofuels (Howell 2009). Synthetic Genomics later announced that it was the first 
to create “a synthetic life-form” (Sample 2010; Gibson et al. 2010). Furthermore, Venter is 
well known for his attempts to patent genes (Pottage 2006; Calvert 2008). His story 
highlights some of the contemporary issues in biotechnology including how life is valued in 
processes of commercialisation, ownership and the potential for future applications.  
 
At the same time as a shift from genomics, the working practices and the expectations of 
academic knowledge production are changing. There is already an on-going debate that the 
relationships between society, industries, governments and university-based research are in 
flux. This includes the ideas that research and development is non-linear, multidisciplinary 
and produced by heterogeneous groups (Gibbons et al. 1994; Nowotny et al. 2001) and that 
university, government and industry are intertwined in a relational triple helix (Leydesdorff 
2000; Leydesdorff & Etzkowitz 1996; Etzkowitz & Leydesdorff 2000; Etzkowitz 2011). There 
are increasing audit systems, imported from the finance sector, aimed at ensuring 
accountability and promoting responsibility in academia (Shore & Wright 2004). One 
example, the Research Assessment Framework (REF) is a “new system for assessing the 
quality of UK research” and “provides accountability for public investment” (Research 
Excellence Framework 2014, p.3). Another example, the Responsible Research and 
Innovation (RRI) agenda, particularly in European and US academia, emphasises the 
production of knowledge “for society, with society” and the inclusion of stakeholders in the 
production of knowledge (Owen et al. 2012). Thus, claims that “translational research” in 
biomedicine can be understood within a framework of, on the one hand, changes 
emphasising accountability of academic bioscience and, on the other hand, changes in 
bioscience resulting from globalisation and capitalisation of life sciences (Rajan & Leonelli 
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2013) also apply to the biosciences more broadly. This thesis addresses ways in which, 
along with these shifts, the field of synthetic biology is emerging.  
 
Third, there are small bodies of academic literature in STS that report and theorise 
translational research in the UK. One of these literatures examines translation in stem cell 
research (SCR) (Cribb et al. 2008; Wainwright et al. 2006b; Wainwright et al. 2006a; 
Wainwright et al. 2009; Williams et al. 2008). Here, the research mostly focuses on the 
cultural and ethical differences between laboratory researchers and clinical researchers. A 
second set of publications examines the translation of genomic research in Genetics 
Knowledge Parks (Swan et al. 2007; McGivern & Dopson 2010; Robertson 2007; Swan et 
al. 2010). These papers examine different logics of academic knowledge production and the 
‘lives of objects’ (Engestrom & Blackler 2005) as groups of researchers, clinicians and health 
administrators develop knowledge and medical technologies. Related scholarship explores 
the roles of “knowledge brokers” (Meyer 2010; Meyer & Kearnes 2013) that include research 
translators and clinician-scientists (Vignola-Gagne 2013; Wilson-Kovacs & Hauskeller 2012; 
Morgan et al. 2011). These literatures address translation particularly between biomedical 
science and medical practice. They focus, for the most part, on genomics and stem cells. 
However, as I have mentioned, translation does not only take place between laboratory and 
clinical practice. There is currently little ethnographic sociology on the relations between 
academia and industry and this thesis develops some of the approaches in the above 
literature to inquire into how academics prepare for research translation and the problems 
that may or may not transpire.  
 
A fourth place to start is with a flashback to a biomedical laboratory in Sheffield circa 2002. A 
recent graduate (me) is watching two PhD students, in white coats no less, talking by the 
computers on one side of the lab. One is explaining to the other their theory. Holding their 
hands apart like a raconteur fisherman boasting about a catch, they say schizophrenia is 
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better understood as a spectrum of symptoms rather than as a single disease. For instance, 
delusions over here (waving one hand) and diminished affect here (waving the other hand). 
They say the drug companies are instrumental in maintaining schizophrenia as a single 
thing, because producing a single drug to combat a single disease would yield greater 
profits, because of economies of scale.  
 
The student’s disillusionment reflected my own. I had originally enrolled at university to study 
biology and philosophy. However, after some brief discussions, I decided to focus on biology 
and deferred my interest in social and philosophical questions. I graduated with a degree in 
Biomedical Science and continued working in the laboratory in which I had written my final 
year dissertation. The work was on the side effects of atypical antipsychotics in rat models. 
Specifically, many patients experience weight gain when medicated with atypical 
antipsychotics (Allison et al. 1999) and the project was aimed at understanding a possible 
mechanism of action. Did the drug Ziprasidone, which appeared to cause less weight gain 
(Allison et al. 1999), affect the population density of 5-HT1A receptors in rat brains? A little bit 
(Meckin et al. 2003).  
 
Yes, the laboratory was partly funded by a drug company, despite being a university facility. 
Yes, we reported to the drug company. But it was the distance between our work and patient 
experiences that I found hard to reconcile, rather than the academic-industry relationship. 
We worked in rat models. I once received fifty frozen rat brains in the post. I used various 
apparatus to create purees of rat brains to which I added radioactive ligands that could bind 
to the target receptors. Using more equipment I transformed tiny amounts of radioactive 
compounds to numbers that represented luminosity. From this it was possible to estimate 
population density of those particular receptors in each brain. But how would this work ever 
end up being relevant to patients to whom it was meant to benefit? In fact, who was it for? 
This links to a variant of the first problem I introduced – how does research in the laboratory 
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relate to patients and clinic? Biography and history are intertwined, and one cannot 
understand either without taking account of the other (Wright Mills 2000). So, a decade later, 
I came to study translation in bioscience. In this way, my own story of moving into socially 
investigating life sciences exemplifies broader concerns that research should be delivering 
on its promise to address problems.  
 
By acknowledging several origins of the thesis I aim to perform a central point of my 
argument – objects of knowledge are composites. I turn now to give an introduction to my 
research site, synthetic biology.  
 
 
1.2 Synthetic Biology in the UK 
 
Synthetic biology is an emerging field of science that involves collaborations of engineers, 
biologists, chemists, computer scientists, mathematicians, among others (Vogel 2014; 
Kearnes 2013; Royal Society of Chemistry 2008; Frow 2013; TNS-BMRB 2010). The official 
definition in the UK, the one that most actors acknowledged in documents and during 
interviews, is the Royal Academy of Engineering definition:  
 
Synthetic biology aims to design and engineer biologically based parts, novel devices and 
systems as well as redesigning existing, natural biological systems. Synthetic biology 
strives to make the engineering of biology easier and more predictable.  
(Royal Academy of Engineering 2009, p.6) 
 
The logic of synthetic biology is connected to “maker’s knowledge” – the “doctrine that 
building-brings-understanding” (Radick 2013, p.790). Proponents of synthetic biology 
repeatedly mention the design and engineering principles they are attempting to apply to 
biology (Calvert 2013). These include:  
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• Abstraction (or abstraction hierarchy): a system for managing biological 
complexity by eliminating unnecessary details; abstraction allows researchers at 
various levels (and in various fields) to work with and share details about 
biological data without specialized knowledge  
• Modularization: developing interconnecting parts that can be combined in various 
ways 
• Standardization: devising a broad consensus on the composition of parts, devices, 
and systems so that they may be used reliably in any setting. The biological parts 
should be discrete, fit together in standard ways, and be well characterised 
(Kitney & Freemont 2012, p.2035).  
• Decoupling: de-linking the requirements for design from requirements for 
manufacture to allow non-biologists to use biological components in various 
applications  
• Modelling: testing the projected design and its function  
(Joyce et al. 2013, p.12) 
 
The overall approach is then, at least rhetorically, a systematic approach to creating 
knowledge and technologies with life. However, there are many different forms of interest in 
synthetic biology.  
 
One typology of synthetic biology is composed of six domains, each interested in 
manipulating life for different purposes (see Figure 1 on the next page). At the molecular 
level, synthetic biology can involve researchers reengineering existing DNA and making new 
forms of ‘unnatural’ genetic molecules. At the cellular level researchers may engineer 
protocells that could help understand evolution or act as ‘chasses’ to carry other DNA. At the 
community level, researchers manipulate microbial DNA to make different populations of 
organisms interact with one another in specific ways.  
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Figure 1. Six domains of synthetic biology (Martins dos Santos et al. 2009, p.26) 
 
Some of the different domains have different underpinning epistemic commitments (see 
Figure 2 below). 
 
 
Figure 2. Epistemic commitments in synthetic biology (O’Malley et al. 2008, p.60) 
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Researchers interested in DNA parts, for example, are not specifically interested in how 
complex interactions produce emergent properties. Meanwhile, they do concern themselves 
with the wider cellular milieu (O’Malley et al. 2008). On the other hand, those interested in 
protocells are less wedded to the idea of genetic determinism than those engineering the 
whole genome (O’Malley et al. 2008). Thus, synthetic biology is composed of various 
projects with different epistemic concerns and foci.  
 
A notable feature of synthetic biology is the international genetically engineered machine 
(iGEM) competition. The iGEM competition involves multidisciplinary teams of students 
conducting a summer project that uses and develops standardised biological parts known as 
BioBricks. Typically, the projects involve ‘wet lab’ (e.g. microbiology), ‘dry lab’ (e.g. computer 
modelling) and ‘social’ (e.g. outreach to schools) components. A guiding principle is that 
projects should “strive to create a positive contribution to their communities and the world” 
(iGEM 2015b). Winning undergraduate projects include Heidelberg’s heat-stable proteins 
that can function at high temperatures to speed up reactions (iGEM team Heidelberg 2014) 
and their gold recycling strain of E. coli (iGEM team Heidelberg 2013). Other winners have 
been a modified strain of B. subtilis that could potentially detect meat spoilage (iGEM team 
Groningen 2012) and a project that demonstrated it was possible to reengineer bacteria to 
produce components of diesel fuel and, separately, break down gluten (iGEM team 
Washington 2011). The iGEM competition promotes and encourages high ambitions for 
synthetic biology.  
 
The competition began in 2003 when Tom Knight, Randy Rettburg and Drew Endy, all 
members of Massachusetts Institute of Technology (MIT), started a competition to inspire 
undergraduates (Cockerton 2011, p.27). The following year they widened the competition 
and five US universities competed. The competition increased rapidly in size. By 2014, the 
year I acted as advisor to a team, 245 institutions entered the various sub-competitions and 
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over 2300 participants attended the final “Giant Jamboree” event held in Boston, MA (iGEM 
2015c). The attendance was large because, to celebrate the tenth anniversary, there were 
no regional heats and all the competing teams were invited to the finale.  
 
The foundation that runs the iGEM competition, currently directed by Randy Rettburg, casts 
itself as:  
 
An independent, non-profit organization dedicated to education and competition, the 
advancement of synthetic biology, and the development of an open community and 
collaboration. 
(iGEM 2015a) 
 
However, taking part in iGEM had an almost hypnotic effect on me: sitting in the enormous 
auditorium; watching the stage relayed live on large projector screens; clapping for iGEM 
Alumni; watching teams glorified for their hard work. The event felt consuming, proselytising. 
In the conclusion of her PhD thesis, an ethnographic study of two iGEM teams, Caitlin 
Cockerton wrote:  
 
[The iGEM competition] has turned into a competition that educates, inspires and 
indoctrinates hundreds of students so that they help build, and take forward, synthetic 
biology’s technical and socio-cultural foundations. It is a kind of evangelism that converts 
students to the cause. 
(Cockerton 2011, p.302) 
 
The competition is aimed at educating and promoting one particular strand of synthetic 
biology – the standardised, BioBrickTM approach – and some teams of students conduct 
outreach at community ‘do-it-yourself’ biology clubs (Radick 2013). Though I did not 
concentrate on this global competition in my research, many participants cited it in various 
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arguments regarding synthetic biology: it appears to play an important role in the formation 
of the field (Frow & Calvert 2013a; Molyneux-Hodgson & Meyer 2009). 
 
Aside from its disciplinary organisation, synthetic biology has proven a site amenable to 
study the emergence of research communities (Molyneux-Hodgson & Meyer 2009; 
Kastenhofer 2013); the promises and realisations of biotechnology (Frow & Calvert 2013a; 
Mackenzie 2010; Mackenzie 2013b); the application of standards to life (Steedman 2013; 
Mackenzie et al. 2013; Calvert 2013); the relationship between epistemic expectations and 
support for certain kinds of institutions (Schyfter & Calvert 2015); the difficulties in promoting 
innovation in a conservative industry (Molyneux-Hodgson & Balmer 2014); the practices of 
teams in iGEM (Balmer & Bulpin 2013; Cockerton 2011). This is partly because social 
research is often an integral component of funded projects, though this is not always a 
straightforward collaboration (Calvert & Martin 2009).  
 
I focused on synthetic biology in the UK because of the changing emphases in funding 
between 2007 and 2014. The first main tranche of synthetic biology funding was aimed at 
forming a UK synthetic biology community (Molyneux-Hodgson & Meyer 2009). This was a 
total of approximately £800 000 (Biotechnology and Biological Sciences Research Council 
2007). As I was designing my research, the government identified synthetic biology as one 
the UK’s eight great technologies (Willetts 2013a). Total funding in the UK has exceeded 
£180m, with a proportion of investment specifically for commercialisation and innovation 
(Willetts 2013b). In UK synthetic biology a key aim is to accelerate commercialisation and 
make synthetic biology into a profitable industry (SynbiCITE 2015a). Indeed, 
“industrialisation is an important end point of synthetic biology” (Kitney & Freemont 2012, 
p.2035). The global synthetic biology industry is anticipated to be worth US$13.4 billion by 
2019 (Transparency Market Research 2015) and the overarching aim of this thesis is to 
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investigate how, in the absence of an established industry to which knowledge might be 
translated, actors render UK synthetic biology translatable.  
 
The administration of public funds for research is also relevant to this research project. The 
majority of UK research funding is administered by a set of quangos through two systems. In 
UK, the Higher Education Funding Council for England (HEFCE) and its devolved 
counterparts administer and allocate funds directly to universities. These can be spent as 
institutions see fit. Research is also funded directly via seven research councils, whose 
cooperation is facilitated by Research Councils UK (RCUK). Each council has a remit for a 
different area of research. The research councils are:  
 
• Arts and Humanities Research Council (AHRC) 
• Biotechnology and Biological Sciences Research Council (BBSRC)  
• Engineering and Physical Science Research Council (EPSRC) 
• Economic and Social Research Council (ESRC) 
• Medical Research Council (MRC)  
• Natural Environment Research Council (NERC) 
• Science and Technology Facilities Council (STFC)  
 
Councils can agree to co-fund projects. For synthetic biology, the main funders to date have 
been BBSRC and EPSRC.  
 
The two funding routes, one through HEFCE via universities and the other through RCUK, 
constitute the ‘dual support system’. In addition to this system there is another quango called 
Innovate UK. This is the UK’s innovation agency and is located at the same site as RCUK in 
Swindon, but in a different building. Innovate UK funds businesses and companies to 
develop products and services and, in partnership with RCUK, have co-funded synthetic 
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biology among other biotechnology projects (Technology Strategy Board 2012b). Innovate 
UK was previously known as the Technology Strategy Board (TSB). The name change 
happened towards the end of my data generation period.  
 
The thesis research incorporated various participants including researchers in synthetic 
biology and administrators and policymakers from universities, RCUK and Innovate UK. This 
research project is especially timely given the rise in synthetic biology funded by public 
monies, the emphases on academic accountability and actors’ own commitments to 
‘industrial translation’.  
 
 
1.3 Outline of the thesis   
 
The thesis is presented in seven chapters and below I describe the contents of the 
remaining six chapters and their contributions to the overall argument. Part I contains two 
further chapters. In Chapter Two I review the main literature that is pertinent to the thesis 
arguments. I conceptualise translation as an entity for social investigation by introducing 
some of the analytical tools that researchers have employed to study translation in 
innovation. I review the relevant STS research on biotechnology and synthetic biology. I then 
move on to discuss methodological principles and ‘rules’ in STS. I describe how certain 
theorists expanded the idea of symmetry to include both humans and nonhumans in 
analyses of technoscience. This leads onto a theoretical discussion of objects with the idea 
that it is important to conceptualise synthetic biology in order to understand how it is, or 
could be, translated to something else. Overall in this chapter, I argue that a) ethnographic 
research can enrich understanding of academia-industrial translation in biotechnology and b) 
it may be possible to develop theories by bringing synthetic biology into dialogue with 
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specific STS conceptual frameworks. From these points I define the principal research 
questions.  
 
In Chapter Three I discuss the way I conducted the research and justify the choices I made. 
I use a narrative approach to detail the project and attempt to highlight the complexities and 
problems I encountered. In order to attend to the heterogeneity and potential multiplicity of 
synthetic biology, the project took the form of a “multi-sited ethnography” that involved 
elements of “virtual ethnography” that took place in various locations, both on- and off-line 
(Marcus 1995; Hine 2007). I detail the various data-generation methods including interviews, 
observations and document analyses and how they contributed to the ‘extension’ of the 
project (Knorr-Cetina 2005a). I explain how I analysed the data and how the writing up of the 
thesis played an important role in shaping what it was possible to say. In closing, I 
summarise the positions I took regarding ontology, epistemology and methodology.  
 
Part II details my analysis and contributions. It is structured using an adapted version of 
Fujimura’s “three levels of work organisation” (Fujimura 1987, p.258).  
 
These levels include the experiment as a set of tasks; the laboratory as a bundle of 
experiments and other tasks; and the social world as the work of laboratories, colleagues, 
sponsors and other players, all focused on the same family of problems. 
(Fujimura 1987, p.258) 
 
My ‘levels’ are alignment practices in the ‘wider world’ of state and science; institutional 
practices of universities and businesses; and laboratory experiments. Chapter Four 
concerns the level of the wider worlds of the UK state and academic biology. I describe how 
actors make synthetic biology into an object that can meet the state’s desire to be a global 
leader of bioscience. I then show how actors rhetorically demarcate synthetic biology from 
controversial bioscience, such as genetically modified (GM) organisms, and claim that 
Making Research Translatable: Connections 
	 34 
synthetic biology can create wealth for the UK state by being a more controlled and powerful 
science. I argue that actors make their field of research relevant to state and society by 
imagining a future industry that involves using engineered microbes to produce chemicals 
and materials, but that does not involve releasing any modified organisms. It is a future 
industry of contained bio-manufacturing. This future makes synthetic biology translatable to 
the state in two ways – it maps out a plausible route for synthetic biology to realise the 
state’s desire for international research status and, by addressing issues with GM 
technology, a plausible route to national economic recovery.  
 
Chapter Five concerns the level of the institutions of universities and industry. First of all, I 
detail how collaborations are framed as an important part of translation, not only to ensure 
alignment of partners’ expectations, but also as leverage to secure further resources. I argue 
that universities and sponsors attempt to initiate collaborations via events and funding 
mechanisms and that retelling ‘success stories’ about collaborations and successful 
innovation further perform the importance of collaboration. Section 5.2 consists of my 
analysis of observations and interviews in which participants enacted various problems with 
collaborations between academia and commercial enterprise. These include the timings and 
deadlines of project work, the different goals of each institution, the way knowledge is 
protected in the different domains and the skill sets or competencies of different workers. In 
the final section I argue that the new institutions of synthetic biology that have been funded 
in the UK, such as research centres and innovation centres, ‘embed’ commercialisation in 
the naming of biological parts, facilities and the training of newer scientists. Translating 
synthetic biology appears to involve (re)labelling objects and disciplining researchers to 
consider the applications and the impacts of their projects.  
 
In Chapter Six, I move to the level of laboratory and tell a story of an academic collaboration 
which was aimed at engineering microbes to produce materials that could be used in 
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medical surgery. A group of academic tissue engineers had identified a clinical problem: 
when burns and ulcer patients need cell or skin grafts, the grafts may not ‘take’ and the cells 
can die. They reasoned this was because wounds are deficient in many important 
macromolecules. To remedy this, synthetic biologists wanted to redesign microbes so that 
they could produce biomaterials that could help skin grafts adhere to wound sites. In the 
chapter, I explore the material and rhetorical work that collaborators employed to maintain 
the project’s alignment with both industrial hopes of producing a platform for manufacturing 
biomaterials and the medical hopes of a potential therapy. I show how making synthetic 
biology translatable partly involves inscribing values into the technological products of 
scientific research in order to maintain alignment with different futures. The project ends ‘on 
the cusp’ and I suggest that it is a realisation of a contained bio-manufacturing imaginary I 
developed in Chapter 4. Furthermore, there are enactments of problems in timings and skills 
that I discussed in Chapter 5.  
 
In Chapter 7 I summarise the answers to my research questions and synthesise some of the 
earlier points into two generalizable concepts. This chapter stands as my empirical and 
theoretical contributions. Having answered the research questions, I conceptualise synthetic 
biology as an unfolding multiple that is expanding in different directions and incorporating 
practices as it spreads. I suggest that a mechanism driving this expansion is that actors 
identify different ‘lacks’ in synthetic biology and seek to extend knowledge in different ways. 
Thus, translation is a multitude of deficits that different groups of actors can address. The 
unfolding multiple is a reflexive theory in that I identified a ‘lack’ in the understanding of 
translation and extended synthetic biology in particular ways. Specifically, in making new 
links between actors and positing social theory. Secondly, many proponents of synthetic 
biology mobilise vulnerabilities to argue that their field of research can solve problems in skin 
graft surgery, in university-industry collaborations and ameliorate the poor state of the 
national economy. But they also mobilise synthetic biology’s vulnerabilities. Actors point to a 
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hostile public, sensationalist media and to other issues that threaten their emerging 
‘immature’ science. Actors, then, mobilise vulnerabilities in multiple ways to obtain and 
maintain support and resources for their research. In closing, this raises a question of 
accountability: I suggest that reframing ‘compelling start out stories’ (Deuten & Rip 2000) in 
this way may impact the way proposals are assessed and grants awarded.  
 
This thesis makes several contributions to knowledge. First, my thesis adds to collective 
understanding of bioscience by empirically examining translation in the emerging field of 
synthetic biology. By contributing detailed descriptions and analyses of the different 
practices that make science relevant to society other researchers may be able to identify 
elements of this research that apply to their own situations.  
 
Second, in Section 5.2, I present an analysis of the enactment of ‘gaps’ between universities 
and industry in synthetic biology. These are consistent with some literature, but also offer 
new points that demarcate science, particularly between academic and commercial 
knowledge production. This work may be of use to actors in both academic research and 
partnership administration who are considering commercialisation or instigating 
collaborations with industry. Although this project is focused on translation in synthetic 
biology in the UK, I suggest some of the theoretical findings are generalisable to other 
situations. 
 
Third, I offer a synthesis of STS theory to conceptualise synthetic biology. I argue that 
elements of post-ANT and post-social theory are needed to theorise the emerging field of 
research. This framework may provide a novel and possibly more satisfying way to 
understand how complex and abstract objects can be an important aspect of contemporary 
sociality.  
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Fourth, I present a reframing of expectations and innovation narratives. Engineers and 
scientists identify (and create) problems and tell stories to convince sponsors to invest in 
their projects (Deuten & Rip 2000). These start out stories change over time – the promises 
of innovations can change (Deuten & Rip 2000; Marris 2013). I argue that rather than think 
about ‘getting resources to solve problems’ it may be profitable, in a climate of increasing 
accountability and responsibility in research, to consider how actors identify weaknesses 
and deficits as a way to acquire support and assets. I suggest that thinking about 
‘vulnerabilities’ may increase awareness of how researchers claim to tackle issues and the 
relationship between those claims and the resources they obtain. This could impact the 
assessment of proposals in both public and private funding regimes.  
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Chapter Two  
 
Difference and Do-ability in Scientific Work   
 
 
 
This chapter reviews the bodies of literature and concepts that are important to this study. 
Section 2.1 frames science as a topic that can be studied sociologically and details some of 
the findings from this approach with respect to translational research in biomedicine. I focus 
on translational research as there is a body of STS literature that is focused on the life 
sciences and these works include examples of applications of STS theory. The concepts in 
this section also provide an important starting place, particularly for the argument in Chapter 
5. Section 2.2 covers theories and concepts that have emerged in the social studies of 
biotechnology and relates some of the contributions to understanding synthetic biology. In 
particular, I focus on the roles and realisations of hype and technological promises, and the 
way that biotechnology changes how actors understand life, which are particularly relevant 
throughout Chapters 4, 5 and 6.  
 
In Section 2.3 I turn to reviewing methodological principles in STS including the development 
of symmetrical analyses. Furthermore, “translation” is itself a term of art in STS and I explore 
various meanings associated with the term. This leads me to a discussion of co-production, 
the idea that knowledge and social order are made at the same time (Jasanoff 2004). This is 
particularly relevant to this study because actors involved in synthetic biology promote their 
epistemic commitments and organise institutions, such as iGEM, to deliver on the promises 
of synthetic biology. Then, in Section 2.4, I concentrate on STS perspectives on ontologies 
because, if translation is partly about movement and change, then what is moving and 
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changing? This forms an important underlying concern throughout Part II of this thesis and 
to which I return in earnest in Chapter 7.  
 
 
2.1 Science as Culture   
 
One way to understand science is that it consists of a community of actors behaving in 
accordance with specific norms (Merton 1942). Merton argued that science has four main 
tenets:  
 
Communalism meaning the way researchers make findings available through publishing 
to allow others to build on earlier work.  
 
Disinterestedness where scientists do not allow personal concerns to affect scientific 
investigation, which should rule out fraud because that reflects personal goals. 
 
Universalism, which means research is subjected to common, external evaluation which 
does not depend on the identity of individuals.  
 
Organised scepticism where critique is encouraged and where new findings are treated 
with caution.  
(Merton 1942) 
 
As a structural-functionalist theory, if science is working properly by actors adhering to these 
norms, then science will be able to fulfil its role in society – to extended certified knowledge 
(Sismondo 2010, p.23). Mertonian norms imply that science can be understood as a single 
culture with a unified ethic and that scientists who follow this ethic are rewarded. While this 
can be regarded as a “pure, untainted sociology of science”, the emergence of studies of 
scientific practices, coupled with sociological reflexivity, led to new ways of understanding 
science (Knorr Cetina 1991, p.526).  
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Merton’s sociology did not focus on the technical content of science. A social critique of the 
production of knowledge came later. The Structure of Scientific Revolutions (Kuhn 2012), 
first published in 1962, used a historical approach to challenge some assumptions about the 
progressive accumulation of knowledge. Kuhn argued that normal science happens when 
experimental and theoretical developments are articulated with one another within a larger 
conceptual framework. Kuhn called this overall conceptual consensus a paradigm. During a 
period of normal science, scientists engage in puzzle-solving. An example of puzzle-solving 
is when scientists, after Mendeleev proposed the overall theoretical system of the periodic 
table once, engaged in identifying specific elements to ‘fill in the blanks’. Sometimes, Kuhn 
argued, there are problems that cannot be solved. These anomalies are ‘parked’ but, over 
time, they accumulate. Eventually, they become so numerous or problematic that a new 
overall theory is proposed and a new paradigm emerges in a process Kuhn calls a 
revolution.  
 
One of the book’s pivotal examples of a revolution compares Newtonian and Einsteinian 
physics. The meaning of “mass” as an absolute attribute in Newton’s terms is 
incommensurable with the relative Einsteinian version. Therefore, for Kuhn, the new 
paradigm does not include all the knowledge and developments of the previous system. The 
upshot is that science, according to Kuhn, is not a continuous process of accumulating 
knowledge but involves jumps and disjunctures. Kuhn’s main target was the idea of scientific 
progress as incremental accumulation of knowledge. It is also evident that at least two 
communities adhering to different scientific paradigms can co-exist and that science, 
therefore, is not necessarily unified or universal. Both Kuhn’s and Merton’s works form 
important starting places for this thesis, not least because they paved the way for STS more 
broadly.  
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During the 1980s, several studies were published where sociologists and anthropologists 
had entered scientific laboratory sites and closely observed the practices of scientists (Knorr 
Cetina 1983). Later laboratory ethnographies further elucidated the cultural disunity of 
science. For example, molecular biology is organised into smaller laboratories. Individual 
researchers engage in work at their bench, and their dexterity and physical skills are 
important as they conduct experiments and produce knowledge (Knorr-Cetina 1999; Myers 
2008). On the other hand, the field of high energy physics involves large research groups, 
working in concert with large detectors and computers, organised around identifying very 
small and very fast particles (Knorr-Cetina 1999). 
 
Traweek’s (1992) ethnography contrasted high energy physics laboratories in the USA and 
Japan and found that – among other things – male dominated cultures excluded women by 
different means. In the USA laboratory, there was much phallic imagery and women tended 
to work in clerical roles. In Japan, it was not possible for women to become experimentalists 
because experimental work was often scheduled overnight, and until 1986 it was illegal for 
women to work at night in Japan. Thus, there are differences within disciplines.  
 
While these examples have quite different emphases, they highlight the notion that science 
is internally differentiated along various epistemic, material and social axes. These further 
imply that science systematically violates the tenets of communalism, disinterestedness, 
organised scepticism and universalism. So, if not by following Mertonian norms, how does a 
culture of science value and reward researchers?  
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Scientific credibility and relevance   
 
In different cultures people can gain forms of cultural, economic, social and symbolic capital 
in different ways (Bourdieu 1977). Scientists need to be funded to pay for equipment, staff, 
travel, consumables for experiments and administrative work and other things necessary to 
conduct their practices. In the ethnography Laboratory Life (Latour & Woolgar 1986) 
scientists gain access to funding by raising their status and respect in the credibility cycle. 
Researchers publish articles, get recognition, apply and win grants, buy resources, conduct 
experiments, produce data (Latour & Woolgar 1986, p.201). Then they publish their findings 
and begin the cycle again.  
 
 
Figure 3. A credibility cycle (Hessels et al. 2009, p.396) 
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Further elaborations have emphasised the idea that contemporary science also derives 
credibility from demonstrating its relevance (Hessels & van Lente 2008; Hessels et al. 2009; 
Rip 1994). Thus various specific funding and intra- and extra- institutional forms of auditing 
affect the credibility of researchers (Hessels et al. 2009, p.396). Figure 3 on the previous 
page attempts to capture multiple influences on credibility.  
 
This model acknowledges various ways in which scientists can get more resources to 
publish more, including how science is assessed and funded. Furthermore, as some 
scientists are increasingly expected to patent their findings as a way to attain status, 
‘patenting culture’ means that researchers must attend to different modes of credibility in 
academia and industry (Packer & Webster 1996). Rip’s (1994) model of various ‘struggles’ 
for status embeds the credibility cycle in a wider social milieu. This shows the interrelations 
of scientific credibility (facticity), funding, relevance to state and stakeholders, and legitimacy 
to research practices. See Figure 4 on the following page.  
 
Following Rip (1994), it is possible to see the current emphasis on research translation as 
elevating the import of achieving relevance to sponsors’ goals and legitimacy from expert 
and non-expert groups. In bioscience, for instance, recently neglected disciplines such as 
epigenetics and immunology are receiving greater interest since they better attend to 
biological complexity than the genetic determinism of the Human Genome Project (HGP) 
which, in a climate of an increasing audit culture in academia, has not produced the 
anticipated medical benefits (Rajan & Leonelli 2013; Kraft 2013). 
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Figure 4. Struggles for funding and relevance (Rip 1994, p.10) 
 
Furthermore, bioscience is shaped by other processes including capitalism and globalisation 
(Rajan & Leonelli 2013). So, the ways bioscientists achieve and maintain status is constantly 
shifting. Translation draws attention to some of these alterations, including which kinds of 
sciences successfully demonstrate their relevance. 
 
Rajan and Leonelli’s (2013) framework of epistemic and structural changes partly overlaps 
with STS discourse regarding the relationship of the shape of the knowledge economy. 
Thus, turning research into marketable products and services has emerged at a time when 
science is subject to other concerns:  
 
Interest in the commercialization of science has increased exponentially with the 
dissolution of the Cold War, the decline in military funding, hostility toward government 
interference, public skepticism about the telos of science, questions about the 
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accountability of scientists, and the push to develop connections between business and 
science. 
(Mirowski & Sent 2008, p.673) 
 
In the 1990s, two models of the changing relationships between academia and other 
institutions were proposed. The first suggested a shift from Mode 1 knowledge production to 
Mode 2 (Gibbons et al. 1994). Mode 1 research is what might be considered ‘traditional’ 
science. There are clear-cut disciplines with established hierarchies. Science is apparently 
autonomous. Mode 2 knowledge production, however, is marked by greater interdisciplinary 
working arrangements, distributed accountability and a greater emphasis on applied 
knowledge (Nowotny et al. 2001; Gibbons et al. 1994). Alternatively, these changes were 
expressed with the notion of a new triple-helix of industry, academia and government which 
was replacing the previous arrangement of industrial society which only involved 
government and industry (Etzkowitz & Leydesdorff 1997; Etzkowitz & Leydesdorff 2000; 
Leydesdorff & Etzkowitz 1996). The spreading agenda of translation, with its emphasis on 
multi-partnered knowledge making and the production of research relevant to industry and 
government, appears to be a manifestation of this more socially embedded science.  
 
Shinn (2002) contrasted these two approaches siding with the triple helix on the grounds it 
was empirically grounded, global in scope, acknowledged differences in institutions while not 
advocating a wholesale shift from one to two and, finally, that it was clear where the authors 
derived their theoretical ideas. Following up on this, Mirowski and Sent (2008) argue that 
both mode 2 and triple helix theories are too attached to a before-after notion of novelty and 
that both were guilty of overgeneralising the current structures, rather than emphasising 
plurality. Despite its limitations, mode 2 is a framework of particular interest in science policy 
because it ‘labels’ an increasing concern, facilitates policymaking and “feeds the need for 
mimesis in science policy making” (Rip 2000, p.29). Though these theories have their 
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limitations they do appear to capture trends in the way that relationships are changing and 
the desire for coordinated action between different groups.  
 
Thus, any study of translation needs to find a way to be aware of the broader academic and 
social changes. At the level of abstraction of modes and helices, the above concepts have 
left behind the idea of studying local scientific practices as pioneered by Kuhn and later 
ethnographic work. Translational research, though, has been analysed with an ethnographic 
approach, which attends to the need for specificity and plurality mentioned above.  
 
 
Cultural differences between researchers  
 
In biomedicine, translational research can be understood partly as a response to perceived 
differences between laboratory and clinical science practices and values (Kraft 2013). Stem 
Cell Research (SCR) has been a particular site in which to explore the differences of 
biological science and medical science. Medical culture, in SCR, prioritises finding the best 
outcome for patients and, as such, ‘black-boxes’ mechanisms of action or the ‘way 
treatments work’. Meanwhile, scientific culture is marked by meticulous experimentation 
where understanding the underlying processes is a priority (Wainwright et al. 2006b). Thus, 
epistemic commitments can be problematic as researchers can disagree about what would 
be the best course of action for a particular project with finite resources – more fundamental 
knowledge versus patient trials.  
 
Furthermore, SCR is often aimed at producing clinical benefit by eventually being used in 
transplantation procedures (Wainwright et al. 2008), such as tissue repair procedures I 
explore in Chapter 6. Instead, some researchers propose an alternative SCR where stem 
cells can be used to create an experimental model of a ‘disease-in-a-dish’ in order to test 
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potential therapies. This different future can be seen as a ‘more realistic’ goal for the use of 
stem cells partly because large drug companies appear reluctant to support the 
transplantation programme. Scientists can get more credibility, or expectational capital, by 
proposing a more plausible, or at least a less grand, future (Wainwright et al. 2008). Thus, 
the pursuit of credibility can affect how researchers try to make their science relevant to 
different audiences. 
 
The emphasis on translation in SCR has affected the credibility and standing of other 
communities of researchers, too. Clinician-scientists, who play a pivotal role in conducting 
phase I and II clinical trials, have found a renewed status and professional identity as 
leaders of translational research (Wilson-Kovacs & Hauskeller 2012; Vignola-Gagne 2013). 
This appears to be a shift from what was once regarded as an unsure role in biomedical 
innovation to a more secure position. Their new hierarchical standing is partly due to their 
control and administration of randomised controlled trials (RCTs). Clinician-scientists’ value 
relies on their breadth rather than their depth of knowledge and their ability to move 
between, and interact with, both laboratory or clinical professionals (Lander & Atkinson-
Grosjean 2011). This is an example of how the translational agenda is reshaping 
professional identities and roles.  
 
Furthermore, in recent years there have been increases in the number of actors engaged 
mediating knowledge between research cultures and other domains (Meyer 2010). In 2008 
the MRC trialled a ‘research translator’ as a knowledge broker between scientists and 
clinician-scientists (Morgan et al. 2011). Part of their role was to encourage a ‘translational 
ethos’. It appeared that the field of clinical science and the aims of the research translator 
were closely matched in the way that capitals might be accrued. The basic scientists, 
however, had a different cultural value system that perceived the research translator’s 
strategies as risky to their own modes of accruing capital. These studies further 
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conceptualise the ‘problem of translation’ as differences between cultural reward and value 
systems. They also rely on the production and perpetuation of a boundary between different 
research cultures.  
 
 
Maintaining boundaries  
 
So far, I have focused mainly on the internal differentiation of research. But science is a part 
of society. How, if at all, is science separated from society? Since actors must interpret 
norms (e.g. Merton’s) this makes it possible to study them as cultural resources (Sismondo 
2008, pp.29–32). One research tactic is to chart how actors deploy norms in order to 
determine what counts as science to what shall be excluded, termed boundary-work (Gieryn 
1983). This happens at specific instances in which science can be characterised in different, 
sometimes conflicting ways, depending on the argument being advanced. It also entails the 
characterisation, or differentiation, of science and pseudoscience, and is therefore aimed at 
maintaining authority, credibility and access to resources (Gieryn 1999; Gieryn 1983). This 
division is blurred and contingent. It means that science is actively defended and 
demarcated at specific points. There are at least three forms of boundary-work:  
 
Expulsion is an intra-scientific contest in which authorities battle for what counts as 
science and what does not and is often a new and radical proposition up against a 
traditional dominant paradigm.  
  
Expansion involves spokespersons for science versus those for non-science, such as 
religion, politics or folk knowledge, attempting to extend their claims to authority over a 
particular domain.  
 
Protection of autonomy is the third form of boundary-work where actors outside of 
science seek to maintain scientific credibility, but exploit research findings for market or 
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political purposes. This form also extends to when scientists claim they are not 
responsible for ‘downstream’ consequences of research.   
(Gieryn 1999, pp.15–18) 
 
 
Boundary-work can occur from inside and outside science. Boundary-work is pertinent to 
this research because of the increasing cultures of accountability in academia I have already 
mentioned. This means scientific autonomy is at stake as research scientists are 
encouraged to involve other stakeholders, such as industry, in the production of knowledge. 
The concept of boundary-work can also help analyse the formation of new disciplines 
(Lamont & Molnar 2002), such as synthetic biology.  
 
A somewhat contested boundary in science is between notions of ‘basic’ and ‘applied’ 
science. Researchers deploy the term “basic research” in various ways to mean different 
things (Calvert 2006), which can change how science is made relevant. Thus, in SCR, 
boundary-work partly consists of framing research so it advances both ‘basic’ and 
‘translational’ aspects of science by being both scientifically credible and because it begins 
the journey to the clinic, respectively (Wainwright et al. 2007). But, SCR scientists are wary 
of attempting experiments in humans, while doctors are keen to do their best for patients 
and yet are aware of the complexity and uncertainty in new, radical treatments (Cribb et al. 
2008). These two institutional ethical positions are also reflected in the conflict between 
‘regimes of hope’ and ‘regimes of truth’ in potential Parkinson’s Disease treatments (Moreira 
& Palladino 2005). A ‘regime of hope’ focuses on future promises of medical intervention 
whereas a ‘regime of truth’ focuses on the production of knowledge. So, SCR researchers 
do ‘ethical boundary work’ (Wainwright et al. 2006a). Ethical boundary-work involves: 
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both owning the ethical issues as a sign of responsible and thoughtful engagement in a 
highly contested domain, whilst concurrently devolving ethics to authorities outside 
science, especially those charged with regulation.  
(Wainwright et al. 2009).  
 
This form of boundary-work involves researchers demonstrating that they do consider ethical 
issues and, at the same time, referring ethical decisions to other groups. Maintaining ethics 
then, just like maintaining authority, takes labour. In this case, ethical boundary-work can 
increase the status of non-scientific actors, such as regulators. 
 
Translation draws attention to boundaries between different cultures. The studies show that 
researchers attempt to demarcate their own practices from other practices. However, 
boundary-work is material as well as rhetorical (Meyer 2006). In Section 4.2, I follow up the 
idea that synthetic biology is demarcated from GM science (Calvert 2013) and situate this in 
the context of gaining resources. In Section 5.2 I describe how an academic-industry divide 
is enacted at different points in time and space, which suggests translation is partly 
dependent on establishing difference.  
 
 
Crossing boundaries  
 
There is a large STS literature concerning ways that different groups communicate with one 
another. One concept, ‘trading zones’ (Galison 1987; Collins et al. 2007), suggests that 
different epistemic communities may develop pidgins and creoles in order to communicate. 
Others explore ‘tacit knowledge’ (Collins 1985; Howells 1996; Polanyi 2005; Collins 2010), 
which emphasises aspects of knowledge that cannot be articulated and need to be 
transferred in practice. Some of these concepts have been hypothetically applied to 
translating knowledge to build nuclear weapons (MacKenzie 1999) and so could be 
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profitably applied in empirical STS approaches to translation. However, I have selected to 
focus on a specific framework because it has been applied to studies of translation – 
boundary objects (Star & Griesemer 1989).  
 
These authors were investigating how professional and amateur scientists worked together 
to make knowledge at Berkeley’s Museum of Vertebrate Zoology from 1907 to 1939. 
Scientific work, such as collecting specimens, turns out to be ‘heterogeneous’ and requires 
the cooperation of different groups without, so Star and Griesemer claim, a clear consensus. 
The authors focus on the pragmatics of how “n-way translations” (ibid. p.412) between 
groups are coordinated. By comparing the ‘visions’ of scientists, collectors, trappers and 
administrators they argue that cooperation is achieved in part through the creation of 
boundary objects. They describe four types of boundary object.   
 
Repositories are collections of categorised objects like libraries and databases. These 
collections are modular and groups can access them without needing to address any 
differences of purpose.  
 
Ideal types, for example, diagrams of species. These facilitate collaboration by those 
allowing people with experience of many individual cases of a species to communicate.  
 
Coincident boundaries, which might be various maps of the state of California. These 
“have the same boundaries but different internal contents” and contain different 
information depending on whether they are used by scientists, collectors or government 
officials.  
 
Standardised forms. Amateur collectors were given standardised forms to document the 
specimens they gathered. The forms were unchanging and structured and formalised the 
way information was recorded and categorised.  
(Star & Griesemer 1989, pp.410–411) 
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This is not a complete list, but an initial taxonomy of boundary objects (Star 2010). The 
‘interpretive flexibility’ (Pinch & Bijker 1984) of these boundary objects, the different ways of 
valuing and using them, facilitates the cooperation of different social groups.  
 
Boundary objects has proved such a popular concept that there are more recent 
elaborations on what counts as a boundary object. They are objects of organisational scale 
and scope that exist between groups of people in specified contexts (Star 2010). While the 
initial formulation of boundary objects focused on the practical aspects organising different 
groups’, later work, particularly studying the biosciences, examined the symbolic meanings 
of these objects (Fox 2011; McGivern & Dopson 2010; Swan et al. 2007). Many types of 
object can exhibit interpretive flexibility but many do not facilitate collaboration in the way the 
concept initially sought to capture. However, boundary objects and other related concepts 
may exaggerate the difficulties of communication between groups (Sismondo 2010, p.21).  
 
With respect to translational research, human embryos can act as boundary objects that 
facilitate collaboration between SCR scientists and pre-implantation genetic diagnosis (PGD) 
laboratories (Williams et al. 2008). The interconnection was created by a difference: to PGD 
laboratories embryos are unwanted rubbish, but for SCR laboratories they are a valuable 
source of stem cells. The embryos became an object facilitating translation as the two 
different groups worked together to create human stem cell lines (Wainwright et al. 2009).  
 
Translation has emerged as an explicit agenda in biomedical science, though, there was 
surprisingly little sociology investigating laboratory-clinic relations (Wainwright et al. 2006b). 
Furthermore, what there is tends to have been in situations of newer and potentially 
controversial science.  Sociological research on translation in bioscience has, to date, 
focused mostly on stem cell science. However, it has demonstrated the successful 
deployment of analytical concepts including cultures, credibility and boundaries. These 
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studies have used a variety of methods, including historical analyses and ethnographic work 
predominantly based on observations and interviews. I have sought to outline how 
translation can be treated with STS approaches and now move on to literature on 
biotechnology and, more specifically, synthetic biology.  
 
 
2.2 Promises and Products of Biotechnologies  
 
Hype and expectations  
 
An idea I mentioned in Chapter 1, and return to throughout the thesis, is that synthetic 
biology is a field of research that claims to be of great potential. This is despite a more 
critical position that there is a “myth of a biotechnological revolution” (Nightingale & Martin 
2004; Hopkins et al. 2007). Even though there has been a large increase in possible drugs, 
there has been no sudden shift in the procedures and structures of industrial production and 
clinical practice, even perhaps a chance that “biotechnology has exacerbated the problems 
associated with drug development” (Hopkins et al. 2007, p.583). One of the authors’ 
conclusions is that, if biotechnology has only had a limited impact on the sector so far, the 
hopes that biotechnology can bring about an increase in health and wealth is misplaced. 
Ultimately, the hype surrounding biotechnology exists precisely because it is having a limited 
effect, is not revolutionary, and instead “shared expectations are needed to co-ordinate the 
long-term, incremental process of technological accumulation” (Hopkins et al. 2007, p.586).  
 
One of the key insights into the expectations and promises of technologies are their 
‘performative’ effects (Michael 2000). Expectations about the future are active in the present: 
they can be used to mobilise resources and materials and shape the world to different 
extents (MacKenzie 2006; Pollock & Williams 2010). Expectations can have two 
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components. The way the future is constructed in the present and the way that past futures 
are remembered in the present (Brown & Michael 2003). But, predictions such as these 
place scientists’ reputations at stake and therefore have implications for credibility (Brown 
2003). So, the future of research is an important component in the organisation of 
biotechnology.  
 
Returning to SCR innovations, the history of the translation of haematopoietic stem cell to 
therapy can be told, not as a recent “bench to bedside” initiative, but as beginning shortly 
after World War II and with many promises remaining unrealised (Martin et al. 2008). In this 
way scientists and entrepreneurs have long formed ‘communities of promise’ aimed at what 
is now being called translational research. In synthetic biology, this orientation to the future 
has been called a community of vision (Kastenhofer 2013).  
 
The promises of synthetic biology are not static, either. The most visible ‘success story’ has 
been the production of semi-synthetic artemisinin, a potent antimalarial drug, using synthetic 
biology techniques to replace the extraction of the drug precursor from cultivated plants 
(Hale et al. 2007; Martin et al. 2003; Paddon et al. 2013; Ro et al. 2006). The Artemisinin 
Project was proposed as a solution to a crisis of malaria treatment. Over time, funding 
changed. The WHO changed their regulations and the price of artemisinin began to 
fluctuate. The promise of synthetic biology as producing a dependable, controlled amount of 
chemical turned to ‘market stabilisation’ (Marris 2013). It is therefore important to track who 
makes promises and how they are or are not realised.  
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Fulfilling promises  
 
The proponents of synthetic biology are attempting to create an engineering discipline that 
“promises products rather than experiments” (Mackenzie 2010, p.194). The emphasis on 
innovation raises questions of how life can be researched and how those findings are 
applied to commercialisation and ownership practices such as patenting. Synthetic biology’s 
reductive, Biobrick-type approach makes it particularly amenable to current ownership 
regimes because the novel discrete elements can be recognised by the patent system 
(Calvert 2008). There is a good deal of  “bio-prospecting” – finding organisms which may 
have useful genes – in order to own tracts of ‘genetic land’ in the hope of future profit 
(Pottage 2006). Interestingly, the discourse of openness and sharing in synthetic biology 
appears to contradict the discourse of property ownership meaning it is an open question as 
to whether synthetic biology realises an idealised version of shared knowledge, or follows 
previous biotechnologies down a patenting route (Calvert 2012).  
 
Perhaps, the main promise of synthetic biology is that “biology is technology” (Carlson 
2010). However, the symbols of this promise such as biological oscillators, known as 
repressilators (Elowitz & Leibler 2000), can become integrated into networks of engineering 
developments.  
 
They signify iconically – through devices such as clocks and oscillators – that synthetic 
biology is a rate-controlled way of accomplishing change. Yet iconic forms become more 
infrastructural as they develop: they become more linked to other systems, and to 
complicated configurations of technical elements. At the same time, infrastructures are 
vital to realisation of the promise of synthetic biology. 
(Mackenzie 2013b, p.10) 
  
This means objects can ‘slip’ between being symbols of the promise of synthetic biology and 
being the infrastructure on which synthetic biology is built. Thus, the specific realisations of 
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synthetic biology are partly dependent on which symbols of control and engineering move 
into infrastructural roles.  
 
The emergence of synthetic biology depends on other factors as well as technical 
realisations. As the communities of synthetic biologists form they employ a range of ‘devices’ 
– journals, meetings, conferences, the international iGEM competition – to facilitate 
identification of, and identification with, the field (Molyneux-Hodgson & Meyer 2009). In the 
UK and US, the promises of applications and economic benefit have resulted in funding for 
specific research and institutional organisations (Schyfter & Calvert 2015). However, the 
funders have been more interested in the economic benefit and this has led to specific 
institutional developments which may have overlooked some key infrastructures required to 
realise synthetic biology, and may therefore forfeit subsequent profit (Schyfter & Calvert 
2015). And, while it may be tempting to imagine that synthetic biologists adhere to a 
common future, they often have different versions of how synthetic biology might be 
organised and what it might contribute (Frow & Calvert 2013b). The creation of the Biobrick, 
for example, requires alignment of different values – academic, ethical, economic – in order 
to partially stabilise the concept (Frow 2013). The dynamics of expectations and realisations 
are complex and the interplay of different actors produces contingent instantiations of 
synthetic biology.  
 
Furthermore, there may be ‘barriers’ to realising synthetic biology’s potential. One study, 
concerning the collaboration of academic and industrial scientists in the water industry, 
argued that the water industry imagined a price sensitive and unaware consumer for whom 
access to water was a right (Molyneux-Hodgson & Balmer 2014). The upshot of this was 
that innovations suggested by the academics were not developed because the conservative 
water industry felt that consumers would be unhappy to pay for new technology. Another 
reflection on how the public was constructed in the discourse surrounding synthetic biology 
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argued that UK actors routinely imagine a public fearful through lack of education (Marris 
2014). The public participation in synthetic biology operates in two modalities – validation 
and participation (Mackenzie 2013a). However, according to Mackenzie, most of the existing 
engagement either focuses on validation or assumes validation within the mode of 
participation. This relates to the earlier point that synthetic biology is actively ‘struggling for 
legitimacy’ (Rip 1994) by conducting public engagement aimed at ratification. This is despite 
a well-established line of publications in STS that there are still “misunderstood 
misunderstandings” (Wynne 1992) about why a part of society may question or reject 
scientific agendas and research.  
 
There are more general theories for how biotechnology creates value rather than the 
realisation of promises. From her analysis of observations of ‘the Visible Human Project’ that 
created ‘atlases’ of internal images of people, Waldby suggests that,  
 
…biotechnology is a means of gearing the material order of living matter, and 
biomedicine in particular seeks to produce what I term ‘biovalue’, a surplus value of 
vitality and instrumental knowledge which can be placed at the disposal of the human 
subject.  
(Waldby 2000, p.19)  
 
This imperial medical logic appropriates and alters things that are not, or not entirely, human 
(e.g. foetal matter, extracted cells, plants), for that which is deemed human in an attempt to 
increase longevity and health. This suggests that, at its heart, biotechnology is aimed at 
producing some form of surplus value. Synthetic biology fits this framework by combining 
knowledge to reconfigure biology for human ends.  
 
Furthermore, Biocapital: the constitution of postgenomic life (Rajan 2006) explored the 
landscape of drug development and biotechnology companies in the US and India arguing 
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that biotechnology can be understood only in relation to the economic system in place. 
Neoliberalism and biotechnology are completely intertwined and developments include the 
outsourcing of drug trials to ‘cheaper’ places such as India (Cooper 2008).  
 
These notions of increasing value may overgeneralise and oversimplify matters. The 
‘bioeconomic’ notions of biovalue, biocapital and life as surplus were criticised for fetishizing 
the ‘bio’ and for not recognising the main change was from a commodity to a rentier 
economy (Birch & Tyfield 2012).  
 
This section has covered some of the ways that synthetic biology is realised. The 
actualisation of synthetic biology takes many forms. It can be turned into patents to 
demonstrate value to potential investors. Synthetic biology can be turned into material forms, 
which can begin as symbolic advances, and its promises are turned into organisational and 
institutional developments.  
 
 
Design changes life  
 
Biotechnology does not only exploit that which is not classed as human for that which is, but 
it can also alter what “life” itself means. Starting a history of biotechnology, not in the 1970s 
but in the 1890s, Landecker argues that the emergence of various cloning techniques 
including freezing, amplification and synchronisation make ‘life’ a different entity:  
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As a subset of this longer twentieth-century course biotechnology, the cloning story 
makes it matter differently to be composed of cells and cell cycles. Being a cellular entity 
after cryobiology and cell synchrony means being freezable and open to artificial 
synchronisation; any living thing made of cells, after these interventions, becomes an 
object that can be stopped and started, suspended and accelerated. 
(Landecker 2007, p.232) 
 
Biology changes our concept of life. The interventions actors use to study an object changes 
the knowledge we have about that entity. In other words, the intervention in and 
manipulation of cells alters what we know of the ‘bio-’ in specific ways – life becomes 
something that seemingly can be increasingly controlled.  
 
The main thrust of synthetic biology is to apply design principles to biology to make 
engineering life easier. Claims to biological design rhetorically function to separate synthetic 
biology from other trends in biotechnology (Calvert 2013). Design also does more. The 
computer software developments flatten the space and work of synthetic biology. This is 
accomplished by exhibiting a DNA design as a line of simple icons and eliding the various 
complex operations and techniques needed to assemble them (Mackenzie 2010). The 
agenda of standardisation is also altering biology. Planning the creation of Biobricks 
changes the way scientists engage with life by removing the ‘artisanal’ nature of molecular 
and micro-biology and encouraging knowledge exchange in a market-like environment 
(Mackenzie et al. 2013). As this work continues, what is ‘synthetic’ and ‘natural’ become 
defined at specific points, such as establishing novelty in a patent application (Calvert 2010). 
Synthetic biology, as it develops, changes the meanings of biology and biological work. As 
well as causing changes in the meaning of life in local practices, synthetic biology is also 
part of a wider discourse regarding the implications of science, to which I now turn.  
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Ethical and social implications  
 
The first few years of synthetic biology saw the publication of many reports concerning the 
ethical and moral implications of the overall project (Nest High-level Expert Group 2005; 
Partliamentary Office of Science and Technology 2008; Balmer & Martin 2008; Royal 
Academy of Engineering 2009). The table on the next page summarises some main themes.  
 
These concerns have given way to different interests. An new line of argument is that the 
worries about biosecurity are misplaced because they rely on the idea that the path from 
knowledge to material instantiation of weapons is linear, and simple (Marris et al. 2014; 
Jefferson et al. 2014b). The other is that, as synthetic biology emerges, how will it be 
governed? Earlier conversations were about the community’s attempts to establish a self-
governance structure based on the Asilomar conference in 1978 (Lentzos et al. 2008). The 
Journal of Responsible Innovation published a special issue following a workshop in 2015 to 
map out various lines of social enquiry in synthetic biology. One of these was that 
“translational governance research” was needed in order to make decisions regarding the 
global regulatory structures (Kuzma 2015). But, as with any science, synthetic biology 
knowledge will always be incomplete making risks unknowable and, at the same time, its 
multidisciplinary, multinational status meant that responsibility and authority will be divided 
and clear lines of governance may be impossible (Zhang et al. 2011). This means that self-
governance, or external accountability, will be difficult to establish. In other words, the 
international multiplicity of synthetic biology makes management and regulation problematic.  
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Figure 5. Table of ethical and legal implications of synthetic biology 
Theme Commonly cited concerns 
Biosafety Accidental or intentional release of microorganisms into the 
environment could have unexpected consequences as 
synthetic organisms interact with surroundings and possibly 
evolve unpredictably  
Biosecurity / 
Bioterrorism  
The ability to construct new, modified or already existing 
microorganisms to use for malicious purposes is a threat. The 
increasing capacity to design and order DNA online from 
synthesis companies, in combination with a growing 
community of ‘do-it-yourself biologists’ practicing ‘garage 
biotechnology’ are a significant worry and difficult to regulate. 
A biosecurity threat is conceivable at both state- and 
individual- levels  
Patenting:  
Commercial vs Public 
Good 
The commercial potential of synthetic biology applications has 
led to concern that patents and monopolies could inhibit basic 
research and progress in the field. An ‘open source’ 
movement has responded to worries over burdensome patent 
thickets; for instance, the BioBricks Foundation (BBF) is a 
significant initiative working to facilitate an open research 
commons. Experts suggest both patent and open source 
frameworks are needed, but no uniform resolution yet exists  
Trade and Global 
Justice 
With the development of synthetic chemicals to replace 
cumbersome isolation and manufacture of naturally existing 
compounds (e.g. from plants), critics argue that synthetic 
biology could destroy local production in developing countries, 
thus maintaining the gap of health and wealth between rich 
and poor countries  
Playing God  The promise that synthetic biology might create ‘artificial life’ 
or is about the ‘design and construction of synthetic life forms’ 
has evoked fears that practitioners of synthetic biology might 
be ‘playing God’  
 
(adapted from Cockerton 2011, p.24) 
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An interim conclusion to this chapter: synthetic biology and an emphasis on academic 
translation have emerged at approximately the same time. Social studies of translation have 
focused on new biotechnology, but they have tended to focus on the laboratory and clinic. 
Meanwhile, studies on synthetic biology have contributed much to understanding how a 
discipline can begin to form and how promises and value can be realised. The intersection of 
the drive for academic resources in synthetic biology, and the translation agenda for 
contextualised, realisable science that delivers societal and economic returns, make this 
project relevant to contemporary bioscience, academia and policy circles. I now move on 
from the conceptual apparatus relevant to translation and synthetic biology to the 
epistemological and methodological traditions within STS.  
 
 
2.3 Producing Knowledge and Society    
 
So far I have focused on understanding translation and synthetic biology as cultural 
phenomena. STS also has a rich history of methodological philosophy. In this section I 
review a selection of approaches to tell a particular narrative of conceptual developments. I 
begin by outlining approaches to researching the production of scientific knowledge and 
move on to discuss an attempt to combine different strands of STS research. This section is 
especially relevant to the principles I used to underpin the methodology of this project, 
covered in Sections 3.1, 3.2 and 3.4.  
 
 
Symmetries and translations 
 
Methodologically, Kuhn’s The Structure of Scientific Revolutions focused on an historical 
analysis of the practices and meanings within science and related knowledge and social 
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order. This opened the door to examining science, not as a community of ideals, but as 
different communities specific to points in space and time. This approach to the sociology of 
knowledge production was extended in the 1970s by a group of scholars, based mostly at 
the University of Edinburgh, who developed an approach known as ‘the strong programme’. 
Proponents advocated that sociology, rather than being focused on the context of 
knowledge, could raise its ambitions and “explain the very content and nature of scientific 
knowledge” (Bloor 1996, p.1). This programme was to have its own four principles:  
 
It would be causal, that is, concerned with the conditions which bring about belief or 
states of knowledge. Naturally there will be other types of causes apart from social ones 
which will cooperate in bringing about belief.  
 
It would be impartial with respect to truth and falsity, rationality or irrationality, success or 
failure. Both sides of these dichotomies will require explanation.  
 
It would be symmetrical in its style of explanation. The same types of cause would 
explain, say, true or false beliefs. 
 
It would be reflexive. In principle its patterns of explanation would have to be applicable to 
sociology itself. Like the requirement of symmetry this is a response to the need to seek 
for general explanations. It is an obvious requirement of principle because otherwise 
sociology would be a standing refutation of its own theories.  
(Bloor 1991, p.5) 
 
The strong program explicitly emphasised the social factors that determine scientific 
knowledge. The explanations for ‘truth’ and ‘belief’, they argued, needed to be symmetrical 
in the sense that they should both be explained socially. Schaffer put the problem of 
asymmetry, by explaining ‘truth’ with reference to nature and ‘falsity’ with reference to the 
social, in an especially dry way in an interview for a Canadian radio series:  
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It didn’t look remotely plausible to say that Isaac Newton thought that there was an 
inverse square law of gravity acting instantly at a distance through empty space between 
the centres of distant bodies because there is an inverse square law acting instantly from 
the centre of one body to another. And Leibniz disagreed because he was German. 
(Schaffer 2009) 
 
In other words, it was inconsistent to apply one set of explanations for one outcome and 
another set for a different outcome.  
 
Scholars associated with the strong programme were able to describe the social processes 
of creating ‘the scientific method’ (Shapin & Schaffer 1985). They also described the 
processes in resolving the problem of regress, or how do you decide an experiment is right 
without doing another experiment, by showing how scientists invoke social arguments about 
competency and nationality rather than nature (Collins 1985). A related approach, the social 
construction of technology (SCOT), sought to apply similar principles in explaining how 
various technologies became stabilised (Bijker 1995; Pinch & Bijker 1984). However, the 
strong programme’s acknowledgement that ‘there will be other types of causes apart from 
social ones’ created a blind spot that could be critiqued by other groups of scholars.  
 
The strong programme was based on an identification and analysis of social groups’ 
interests. Some scholars were unhappy with what they saw as the static sociological notion 
of ‘interests’ as used by ‘The Edinburgh School’ (Yearley 2005). Instead of competing 
interests they suggested that people tried to actively engage and enrol one another.  
 
[People] try to persuade by telling one another that ‘it is in your interests to…’ . They seek 
to define their own position in relation to others by noting that ‘it is in our interests to…’. 
What are they doing when they so attempt to map and transform interests? Our view is 
that they are trying to impose order on a part of the social world.  
(Callon & Law 1982)  
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Social actors, in this line of argument, attempt to gather allies to their causes. However, a 
more radical proposition was to follow.  
 
The authors continued to develop the idea of enrolment and proposed A Sociology of 
Translation (Callon 1986). The idea of translation as a way to unify or merge different 
meanings was borrowed from philosopher Michel Serres (Brown 2002) but also drew on 
earlier ethnographic studies of science, such as Laboratory Life (Latour & Woolgar 1986). A 
Sociology of Translation was an account of a group of marine biologists attempting to study 
scallops in St. Brieuc Bay and described the process of the biologists trying to build a 
network of relations between themselves, the scallops, the local fishermen and the scientific 
community. In his analysis, Callon described four stages of translation:  
 
Problematisation involved the actors (biologists) defining a problem, their own interests 
and the way their project might benefit other actors. The study, they say, may help the 
scallops to breed more successfully and will also support the fishermen, who want a 
bigger catch and sustainable income. The scientists position their work as the obligatory 
passage point (OPP) for the other actors to realise their goals.  
 
Interessement was when the primary actors tried to persuade others to join the project (or 
network) and interrupt the associations between other actors. 
 
Enrolment was when the other actors ‘agreed’ to participate.  
 
Mobilisation is the configuration of agreements that allow the project to move forwards. If 
any of the translations fail the whole network dissolves. Networks are tentative and 
ephemeral (Law 2009).  
(Callon 1986) 
 
Translations are never perfect as translations also betray an original meaning or intention 
(Law 2009). However, translations are the way that a network can be established – by 
making one’s own project a route through which people and things can achieve their own 
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goals. In this study the project was short lived. The scallops ‘refused’ to be anchored to the 
biologists’ net and the fishermen went to sea on Christmas Eve to profit from a local Yuletide 
tradition. This paper was an early articulation of ‘super’ or generalised symmetry. This 
extended the strong programme’s symmetry of using social explanations to explain 
knowledge and scientific belief to an analytical framework that claims, as a starting point, to 
treat all entities symmetrically. Rather than think of humans and scallops as essentially 
different, Callon used the same language to describe both human and nonhuman action.  
 
The Sociology of Translation focused on the attempts at forming a largely stable network. 
Materially, scientists were using a net to fix scallops to the ocean floor to help them breed 
more effectively. And, metaphorically, scientific actors were attempting to position the actors, 
fishermen, scallops and wider scientific community in such a way that they were able to 
conduct their research. The sociology of translation became Actor-Network Theory (ANT) 
and was used in diverse ways by Callon, Law and their colleague, Latour.  
 
Indeed, the primary methodological strategy of ANT was to follow scientists and engineers 
and to “make the list, no matter how long and heterogeneous, of those who do the work” 
(Latour 1987, p.258). ANT is therefore both a material and a relational theory.  
 
As a materialist theory it [ANT] explains intuitively the successes and failures of facts and 
artifacts: they are the effects of the successful translation of actions, forces, and interests. 
As a relationalist theory it suggests novel results and promotes ecological analyses: 
humans and non-humans are bound up with each other, and features on neither side of 
that apparent divide can be understood without reference to features on the other…  it 
stands as the best known of STS’s theoretical achievements so far. 
(Sismondo 2010, p.92) 
 
However, ANT’s status as a theory is complicated. Despite being a well-known theoretical 
contribution, and one that inspired much debate, one of ANT’s most vocal proponents called 
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it a method not a theory (Latour 1999). Latour attempted to ‘recall’ his own conceptual 
technology the way one might attempt to call back a faulty product. However, he later 
reverted to his original position (Latour 2005). ANT seems to occupy a dual position as both 
method and theory.  
 
 
Inscriptions and delegations  
 
ANT scholars broadened the scope of STS to include physical matter in the analysis and 
explanation. This had its history in earlier work. Arguably, as important as Kuhn’s work 
pioneered a mode of questioning, Laboratory Life: the construction of a scientific fact (Latour 
& Woolgar 1986) laid the groundwork for empirical observation of scientific practice. Latour 
entered the Salk Institute and “followed” (see Chapter 3) the scientists as they did their work 
of producing a particular fact, that a tri-peptide Thyrotropin Releasing Factor (TRF) is Pyro-
Glu-His-Pro_NH2. Latour, as the anthropologist, treated the scientists as a ‘tribe’ and asked 
‘naïve’ questions about the practices he observed. From this perspective, the work of 
science seemed to be predominantly about writing. Scientists wrote on blackboards, 
prepared presentation slides, drew graphs and sketched diagrams. Furthermore, the 
machines that the scientists used turned materials into writing. The scientific apparatuses, 
composed of machines and techniques, were understood as inscription devices which work 
to “transform matter into written documents” (Latour & Woolgar 1986, p.51).  
 
Later work in the ANT vein took the notion of inscription further. Whereas scientists 
assembled machines and techniques to produce writing, technologies had ‘scripts’ written 
into them to say how actors will use them (Akrich 1992). It was the analysts’ job to “de-
scribe” and explain the innovators’ scenarios embedded in technological innovations.  
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Translation has also been deployed as the act of turning a large effort into a smaller one, 
such as using the technology of a hinged door instead of knocking down and re-bricking a 
wall (Johnson 1988). Translating and inscribing can be “delegating” actions and morals to 
technologies, like the Berliner Key, whose design guides a user to lock a door behind them 
(Latour 1992). It is the combination of these translations that produce “the durable and 
irreversible accomplishment” of a nature and a society (Latour 1993b, p.140). For Latour and 
ANT, translation has many meanings regarding the production of texts and technologies, 
and they are all intimately connected to the formation of networks.  
 
 
Critiquing ANT  
 
Since ANT has had an important impact on the way research is discussed in STS, I turn to 
some critiques. As a research method or methodology ANT has been debated and criticised 
for a number of reasons. Early studies tended to focus on a single actor or group (Restivo 
2011). ANT accounts can be exclusive and warlike in their focus on human heroes (Star 
1991). In response, later studies included more points of view such as taking the point of 
view of an electric train (Latour 1996). Furthermore, it is difficult to decide what is in and 
what is out of a network (McLean & Hassard 2004). The treatment of nonhumans also runs 
the risk of emptying humans of many qualities such as the capacity for emotion (Laurier & 
Philo 1999) and of raising the place of things above people (Collins & Yearley 1992).  
 
Some of these criticisms have been discussed (Latour 1991). Perhaps the most difficult to 
defend is the idea that ANT is grounded on a mischaracterisation of SSK’s ‘interests’ and is 
largely indistinguishable from SSK except for where ANT is confusing and unworkable (Bloor 
1999). Similarly, the most damning is the accusation that ANT is a backward step in 
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understanding science as it is founded on naïve realism (Collins & Yearley 1992). In Section 
2.4 I map out my position regarding realism in this thesis.  
 
There were two additional problems with using ‘early’ ANT for this study. As I have already 
argued, ‘translation’ is used in ANT in multiple ways to capture the way people and things 
become enrolled into networks. It would potentially have proven confusing for multiple ANT 
‘translations’ to be combined with the multiple empirical meanings of translation. A thesis on 
translational research replaced the ANT term translation with “transformation” (Rushforth 
2012). This is itself a ‘betrayal’ as the metaphor of transformation does not have the 
linguistic connotations or conceptual flexibility as translation (see Chapter 1). In this thesis, I 
do not employ early ANT ‘off the shelf’, but instead I borrow some of methodological 
concepts proposed by Latour and other writers, including Bloor.  
 
Secondly, this project was not concerned with establishing scientific facts, their resolution 
and the ‘representation of nature’. The thesis is concerned with the constitution of 
‘translation’. This means the study is dealing with two concepts that are, at present, unstable 
– synthetic biology and translation – and therefore required a framework that could deal with 
this as early ANT explains facts as ‘stable’ networks. As I further explain in Section 2.4, later 
contributions following from ANT do attend to fluid and protean objects like translation and 
synthetic biology. Indeed, they have “succeeded in washing away a single crucial 
assumption: that successful translation generates a single coordinated network and a single 
coherent reality” (Law 2009, p.152).  
 
 
Processes of co-production: accommodating nature and making doable work   
 
The idea of co-production was proposed as an attempt to unify two broad strands of STS 
research (Jasanoff 2004). Research in the constitutive strand of STS includes ANT and 
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translations discussed above, theoretical work on agency and the emergence of science 
practice and knowledge over time. It is concerned with the way science makes new things in 
the world. The interactive strand is the way science and other institutions, especially politics, 
influence one another and can be represented by the strong programme and scholars such 
as Fox Keller and Haraway who critique science through gender. 
  
Briefly stated, co-production is shorthand for the proposition that the ways in which we 
know and represent the world (both nature and society) are inseparable from the ways in 
which we choose to live in it. Knowledge and its material embodiments are at once 
products of social work and constitutive of forms of social life; society cannot function 
without knowledge any more than knowledge can exist without appropriate social 
supports. Scientific knowledge, in particular, is not a transcendent mirror of reality. It both 
embeds and is embedded in social practices, identities, norms, conventions, discourses, 
instruments and institutions – in short, in all the building blocks of what we term 
the social. The same can be said even more forcefully of technology.  
(Jasanoff 2004, p.3) 
 
Within the “idiom” of co-production there are four overlapping themes: emergence and 
stabilisation of phenomena; the resolution of controversy; the intelligibility and portability of 
knowledge; and the cultural practices and legitimation of what counts as science (Jasanoff 
2004). Similarly, there are four overlapping sites of analysis: identities, discourses, 
institutions and representations. I did not use these categories in my analysis directly, 
because I was interested in actors’ processes. However, whereas some ideas of ‘making 
science relevant’ imply a readymade society, following the co-production line, I take it that 
society is made relevant to science at the same time, and the processes produce both 
science and society.  
 
The work of ANT was meant to undermine the ‘modernist’ viewpoint – that culture and 
nature were somehow separate. Analytically, non-ANT studies of the process of science 
often emphasise one of these two determinants. For instance, scientists’ work involves 
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material interactions. Scientists plan their activities, build machines to do them, and respond 
to the results of their experimentation.  
 
As active, intentional beings, scientists tentatively construct some new machine. They 
then adopt a passive role, monitoring the performance of the machine to see whatever 
capture of material agency it might effect. 
(Pickering 1995, p.21) 
 
Pickering names these alternating processes accommodation of actors’ concepts and the 
resistance of nature, and coins the term “the dance of agency” to capture the way both 
humans and material world act towards each other (Pickering 1995, p.22). Pickering’s 
overall metaphor is that reality is produced in ‘the mangle’ between social and material 
agency (Pickering 1995).  
 
Pickering also draws a distinction between culture and practice:   
 
"culture" denotes the field of resources that scientists draw upon in their work, and 
"practice" refers to the acts of making (and unmaking) that they perform in that field. 
"Practice" thus has a temporal aspect that "culture" lacks, and the two terms should not 
be understood as synonyms for one another: a hammer, nails, and some planks of wood 
are not the same as the act of building a dog kennel – though a completed dog kennel 
might well function as a resource for future practice (training a dog, say). 
(Pickering 1992, p.3) 
 
While there are differences here, Pickering’s focus is on material, technical practices of 
knowledge production (Pickering 1995; Pickering 1992). Thus, in terms of co-production, ‘the 
mangle’ focuses on one determinant – the real-time interaction with nature.  
 
Since science does not get done outside of society, actors make their work relevant to other 
social domains. One way to understand this achievement is that, rather than choosing to 
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undertake experiments that are just technically doable, researchers actively align their 
experiments with social worlds beyond their laboratories (Fujimura 1987).  
 
Scientists achieve alignment by articulating – considering, collecting, coordinating and 
integrating – tasks between these levels of work organization. That is, they make 
problems doable through the seemingly mundane processes of organizing and 
reorganizing their work. 
(Fujimura 1987, p.258) 
 
The problems which scientists address are constructed through articulation. The patterning 
of tasks appears to be a mundane aspect but is an integral part of doing scientific problems. 
So, scientists (and non-scientists) have to actively re-organise their projects as knowledge 
changes and time passes. In her analysis, Fujimura (1987) considers three levels of 
organisation – the experiment, the laboratory and the social world. Using an example of a 
genetics project, she argues that, in order for an experiment to be done actors must 
organise equipment at the laboratory level. An experiment may require a centrifuge, and 
there may be one for ten people in the laboratory. Thus, there needs to be a system at the 
laboratory level to organise how people can co-ordinate access to the centrifuge. On the 
broader scale, laboratory work needs to be aligned with the social world in order to be 
relevant. This can involve changing the emphasis on research to, in her example, focusing 
on an interim target of a diagnostic test in order to preserve the company’s interest in the 
project. Figure 6 below shows a model of this theory using overhead projector acetates to 
stand in for the different levels.  
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Figure 6. Articulating a doable problem (Fujimura 1987, p.259) 
 
The reorganisation of work can take different forms. It might, for example, be the way that a 
contemporary scientific method was constructed by creating distant witnesses (Shapin & 
Schaffer 1985). The process of science is very much a social, historically contingent 
exercise that involves adaptations to forces in what might be termed the social domain. 
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Furthermore, this adds to the idea from Section 2.1 – attaining relevance is something that 
requires material as well as rhetorical work. I modified these ‘levels’ to fit with the data I 
generated in this project – Part II considers alignment and demarcation at the levels of state 
and science, domains of academia and industry, and the level of the laboratory.  
 
A second use of articulation is from a small body of literature that does not reference 
Fujimura. Here, articulation is a rhetorical device which actors use to give meanings to their 
projects and argue their research is relevant (van Lente & van Til 2008; Bos et al. 2014).  
 
Thus, ‘umbrella terms’ in policy (Rip & Voß 2013) like “sustainability” and “translation” are 
made into specific attributes of projects (Bos et al. 2014). In the sub-discipline of 
nanocoatings, sustainability: 
 
may refer to the coating itself or the product with its enhanced properties due to a coating. 
In our case ‘sustainable’ has been specified as (i) higher energy efficiency, (ii) higher 
quality, (iii) less material, (iv) reduced toxicity, or (v) higher durability.  
(van Lente & van Til 2008, p.975) 
 
Thus, articulation of relevance to sustainability can be different things even within a single 
project. This means that overall policy agendas can be interpreted and specified in different 
ways even in the same field of research.  
 
In sum, scientific knowledge is produced in dialogue with both the social and the material, 
depending on the emphasis of the critique. John Law (1993) introduced the term 
heterogeneous engineers to capture the way that engineering practices deal with the 
mechanical or material and also shape the social. Engineering involves arranging people 
and things and meanings. More recently, Jane Calvert reflected on her involvement with 
synthetic biology and argued that the iGEM competition was a particularly clear example of 
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synthetic biologists engineering, not just a biological order, but also the social order (Calvert 
2013, p.416). 
 
A starting assumption for the present thesis is that organising the social order and the 
production of knowledge are deeply intertwined. Throughout this thesis I use a broader 
definition of culture than Pickering and suggest that scientific practice is much more than 
technical work and organisation – scientists labour to make their research relevant and draw 
on a variety of cultural resources to do so. This thesis is concerned with both articulation in 
terms of organising work and with accommodation as scientists go about interacting with 
nature.  
 
The aim of this section was to locate this thesis within a general overview of STS 
methodology. STS tends to look for complex socio-materiality, and to be qualitative and 
descriptive (Jasanoff 1996). Throughout the thesis I employed a hybrid methodology that 
draws on early ANT and the ethnographic approaches that are found in Pickering and 
Fujimura’s analyses.  
 
 
2.4 Objects and Ontology   
 
The previous section discussed how to go about researching science, before moving on to 
ideas about scientific practice. Underlying those points, largely unsaid, was the question of 
how “reality” is understood by different STS researchers. The strong programme was 
relativist and focused entirely on social factors. By contrast, ANT was materialist and treated 
humans and nonhumans with the same vocabulary, at least at the outset. However, neither 
is incompatible with realism (Bloor 1999; Latour 1987; Williams & Edge 1996). I want to 
outline the key ideas that frame how objects and reality are treated in this study, which 
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stems from my rejection of the notion that science and technology are separate (Russell & 
Williams 2002b, p.51). This section lays the groundwork for the discussion in Section 7.2 by 
focusing on literature important to the overall conceptual framework for the thesis. Here I 
cover concepts of objects using examples ranging from a ball game through to more 
abstract and tricky objects like medical diseases.  
 
 
Material-semiotics  
 
The book We Have Never Been Modern (Latour 1993b) laid out the underpinning philosophy 
of ‘early’ ANT. Latour draws on the notion of quasi-objects, an idea Serres (2007) explains 
using the example of a ball in team sports. In his description the ball is a material entity, but 
that is not the totality of the object.  
 
A ball is not an ordinary object, for it is what it is only if a subject holds it. Over there, on 
the ground, it is nothing; it is stupid; it has no meaning, no function and no value. Ball isn’t 
played alone.  
(Serres 2007, p.225) 
 
There are two points here. The first is that the quasi-object gains meaning only when it is 
contextualised by a subject. The second is that the context, here a game, is social. The ball, 
in Serres’ example, has corporality and meaning. It moves around during the game and can 
mean different things – a good team passes the ball quickly; one who hogs the ball is a poor 
player; one with the ball is attacking. However, the ball can slow a player down; it is 
cumbersome and difficult to run with it. It also marks out the possessor as the one who may 
be tackled. Paradoxically, that makes the player both an attacker and a victim (Serres 2007). 
In the practice of playing the game, the ball and the players inscribe one another with 
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meaning, all be it temporarily. The ball fits somewhere between the ‘poles’ of the physicality 
of nature and the meanings of culture. In Latour’s words:  
 
Quasi-objects are in between and below the two poles, at the very place around which 
dualism and dialectics had turned endlessly without being able to come to terms with 
them. Quasi-objects are much more social, much more fabricated, much more collective 
than the ‘hard’ parts of nature, but they are in no way the arbitrary receptacles of a full-
fledged society.  
(Latour 1993b, p.55) 
 
A general theory of objects needs to account for all things, not just manmade articles. 
Considering synthetic biology for a moment, its status as an object is not clear. It is complex, 
and composed of practices. It is more complex and heterogeneous than a ball. Or even a 
ball game. So there is still work to do to begin conceptualising synthetic biology.  
 
 
Hybridity 
 
The world seems to be populated by individual objects, human and nonhuman. This is the 
modern perspective, so argue ANT theorists, which sees the world as made up of discrete 
and separate objects. Instead, says Latour, the world is made of “hybrids” constituted by 
their relations. The world is a “parliament of things” (Latour 1993b, pp.142–145). To see the 
world otherwise, as filled with independent entities, is a trick of perception that depends 
upon two processes: translation and purification (Latour 1993b, p.11). See Figure 7 below.  
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Figure 7. Purification and translation in actor-network theory (Latour 1993b, p.11) 
 
Translation is a way we come to see networks of relations as individual isolable objects. As 
an example, the technique of vaccination was not a separate object as a technique waiting 
to be discovered and circulated throughout society. Instead, vaccination depended on 
‘capturing the interests’ of hygienists, farmers, microbes and equipment and on ‘a theatre of 
proof’ that established its efficacy (Latour 1993a). Purification is the subsequent process by 
which categorises individual objects into humans and nonhumans, culture and nature. A 
related idea is explored in the metaphor of people as cyborgs – networks of humans, nature 
and machines (Haraway 1991). Hybrids or cyborgs, the outcome is that objects are better 
understood as products of relations.  
 
 
Fluid networks  
 
In ANT, every entity or actor is a network of relations. One of the ways that stability of 
networks can be achieved is through the circulation of special objects that can be 
transported with little deformation. These are termed immutable mobiles (Latour 1986). 
Making Research Translatable: Connections 
 
	80 
Objects are “a more or less stable network of associations” (Law & Singleton 2005, p.335). 
For example, the printing press allowed ideas, which up until then had been transmitted 
verbally and changed as they went from person to person, to be concretised in text. Printed 
on paper, ideas could flow with more stability (ibid. 1986). There is a further example from 
the period of European imperialism where the success of the navies depended upon stable 
objects, ships, which could circulate unchanged (Law 1986). Should the ships become 
deformed, in other words wrecked, they would be no use and could no longer contribute to 
success. This example also highlights the labour that goes into maintaining an object. In its 
lifetime, a ship might have all its masts, sails and timbers replaced, new commanders and 
crew, yet will still go by the same name (Blackburn 1999). ANT considered networks as 
relatively stable though in no way permanent. Stability is therefore the result of continuous 
labour.  
 
A later study took the immutable mobile concept and showed it was possible to understand 
apparently stable technologies to be more changeable, more fluid, than proposed by earlier 
ANT studies. Taking a Zimbabwean bush pump as their object of analysis de Laet and Mol 
(2000) argue that the technology is not fixed. The bush pump is a mechanical tool, which 
can be repaired, but it is also a community device and a nation-builder. Each of these 
identities has a different boundary. And, the success of the pump has many dimensions, too: 
it may give water, but not improve health; it may not help larger communities connect; it may 
develop a mechanical fault. The pump is fluid in the sense that the network sustaining it, the 
association of people and things, does not remain stable but the constituent parts and 
meanings, like the ship above, are slowly replaced depending on the context.  
 
So far, I have largely left it unsaid that objects are made and stabilised in practices. I now 
develop this further.  
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Objects multiple  
 
I have moved towards a view of the world constituted as dynamic networks. This means, for 
the purposes of this thesis, I assume there is a relational ontology. Immutable mobiles and 
their ‘ecological’ counterpart boundary objects (mentioned in Section 2.1) seem to occupy a 
key role in sustaining networks because of their interpretative flexibility. This leads to the 
idea, close to the alleged naïve realism of ANT, that these kinds of objects are an 
assemblage of various interpretations with a reality ‘behind’ them.  
 
It simply means different things to these different groups. Looked at in this way, then, 
messy objects are interpretatively complex objects, and if we want to understand them we 
need to take this into account. We need to explain (and in some cases explain away) the 
different perspectives, and so retrieve the real object behind the interpretations. 
(Law & Singleton 2005, p.334) 
 
In contrast to this position, post-ANT theories are ontological, say Mol (2002) and Law and 
Singleton (2005), because they consider the constitution of objects, rather than 
interpretations of objects:   
 
The move, then, is away from epistemology. Epistemology is concerned with reference: it 
asks whether representations of reality are accurate. But what becomes important if we 
attend to the way objects are enacted in practices is quite different. Since enactments 
come in the plural the crucial question to ask about them is how they are coordinated. In 
practice the body and its diseases are more than one, but this does not mean that they 
are fragmented into being many. 
(Mol 2002, p.vii) 
 
The metaphor of construction – and social construction – will no longer serve. Buyers, 
sellers, noticeboards, strawberries, spatial arrangements, economic theories, and rules of 
conduct – all of these assemble and together enact a set of practices that make a more or 
less precarious reality. 
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(Law 2009, p.151) 
 
This ‘performativity’ or ‘enacted’ version of objects interprets objects as being composed of 
multiple practices rather than as social constructions (Law 2009; Law 2002).  
 
Possibly, the most well-known example of this move away from constructionism, 
epistemology and representationalism comes from a study of atherosclerosis (Mol 2002). 
Mol follows various patients, doctors, nurses, pathologists and physiotherapists and charts 
what they do when they practise the disease. She finds that the different groups do the 
disease in a different way and this, she concludes, means the object is singular in theory, 
but multiple in practice. It is an object multiple (Mol 2002). Patients practise atherosclerosis 
in a different way to physiotherapists, who do it in a different way to surgeons, who do it in a 
different way to pathologists. A patient may complain of pain in their legs and may (or may 
not) struggle to walk. A physiotherapist measures a patient’s ability to walk a given distance. 
A surgeon may remove a bloody artery. A pathologist looks down a microscope at an 
occluded blood vessel prepared on a slide. In fact, some of the practices of atherosclerosis 
cannot be done at the same time:  
 
The practices of enacting clinical atherosclerosis and pathological atherosclerosis 
exclude one another. The first requires a patient who complains about pain in his legs. 
And the second requires a cross section of an artery visible under the microscope. These 
exigencies are incompatible, at least: they cannot be realised simultaneously.  
(Mol 2002, p.35) 
 
Two ‘strange consequences’ of the turn to enactment are multiplicity (Law 2009), and the 
types of contradictions described by Mol above.  
 
Furthermore, the turn to performed objects draws attention to how divers things appear to 
‘hang together’. Objects can be held together in co-ordination work (Mol 2002). Mol argues, 
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with reference to medical testing in atherosclerosis, that object features such as test results 
are added up, or hierarchically stacked if they conflict with one another, to form a composite. 
Secondly, test results can be translated into one another. Thus,  
 
The possibility to negotiate between clinical notes, pressure measurement numbers, 
duplex graphs, and angiographic images only arises thanks to the correlation studies that 
actively make them comparable with one another. The threat of incommensurability is 
countered in practice by establishing common measures. Correlation studies allow for the 
possibility (never friction free) of translations…  
(Mol 2002, pp.83–84) 
 
This means that, for an object like atherosclerosis, there is labour involved in keeping the 
parts together, through organisational work.  
 
Law and Singleton (2005) develop this notion even further in their consideration of alcoholic 
liver disease. They argue that the metaphors for objects reviewed so far: of as volumes in 
space, as networks and as fluids, do not account for an object multiple. They propose the 
metaphor of fire. Not a domestic fire but, following the fluid bush pump in an unremarked 
connection, a bushfire. Here is an extended quote explaining the concept with respect to 
alcoholic liver disease:  
 
So we have three fire objects, three versions of alcoholic liver disease. Each is made in a 
series of absences, but (and this is crucial) each is made differently. In the hospital, it is a 
lethal condition that implies abstinence. In the substance abuse centre, it is a problem 
that implies regulation and control. In the GP’s surgery, it is a reality that is better than 
hard drugs. Each includes and relates to a different set of absent presences. Each is 
transformative and generative. Each moves the patient and the patient’s body on: to 
abstinence; to family life; to alcohol rather than drug use. But this means that the pattern 
of absent presences over the three locations is itself a pattern of absent presence, of 
necessary otherness…  
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… Alcoholic liver disease becomes an object that jumps, creatively, destructively and 
more or less unpredictably, from location to location. It is an object in the form of a 
dancing and dangerous pattern of discontinuous displacements between locations that 
are other to (but linked with) each other. 
(Law & Singleton 2005, pp.346–347) 
  
Law and Singleton conclude that it is the multiplicity of alcoholic liver disease that makes it 
difficult to manage in medical administration. The quote above also draws out another 
important feature in these versions of objects. They are composed of things which are there, 
and things which are not. At the same time certain absences are made explicit, and others 
are not.  
 
It is possible to conceptualise synthetic biology as a fire object. It is composed of different 
practices from different academic disciplines and those of non-scientific actors like 
administrators and policymakers. The post-ANT version of multiplicity therefore seems like a 
useful place to start conceptualising synthetic biology. Furthermore, patterns of absence and 
presence are, methodologically, also a starting point for the thesis.  
 
Presently, this is as far as post-ANT thinking goes. Reality is performed by practices. 
Multiple practices in different sites perform complex objects. Objects create and destroy. 
There is, however, another line of scholarship that occasionally references the work above, 
but tends to focus on the ‘technical’ objects of knowledge and their role in science and 
technology.  
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Post-social theory  
 
Knorr Cetina argues there is a “massive expansion of object worlds in the social world” 
(Knorr-Cetina 2005b, p.585) by which there is a proliferation of all kinds of technology, 
knowledge objects and information.  
 
What postsocial theory offers in the stead of the scenario of simple “desocialization” is the 
analysis of alternative forms of binding self and other, changes in the structure of the self 
that accommodates these forms, and forms of social imagination that subordinate 
sociality to new promises and concerns.  
(Knorr-Cetina 2005b, p.586) 
 
According to post-social theory, objects result in new forms of sociality. Objects of 
knowledge, such as scientific concepts, computer programmes and technical equipment, are 
increasingly important as ‘glue’ that coheres the self and society.  
 
When I use the term objects of knowledge I am paraphrasing another idea – epistemic 
objects. The concept of epistemic objects began to emerge with an historical analysis in the 
biological sciences in which experiments were comprised of two types of objects: epistemic 
and technical or technological objects (Rheinberger 1992; Rheinberger 1997). These are not 
fixed categories – an epistemic object in one experimental system maybe a technical object 
in another. A scientific or epistemic thing:  
 
… is not and cannot be fixed from the beginning, it represents itself in a characteristic, 
irreducible vagueness, which is inevitable since it translates the fact that one does not 
exactly know what one is looking for. 
(Rheinberger 1992, p.310) 
 
Making Research Translatable: Connections 
 
	86 
Epistemic things “are in the process of being materially defined” (Rheinberger 1992, p.310) 
and as such they are not stable but pick up and lose characteristics. Knorr Cetina (1997) 
begins to refer to partial objects at the end of her article, broadening the concept beyond 
science.  
 
Partial (epistemic) objects can be understood as having three features (Knorr-Cetina 2005a, 
p.193). 1) The unfolding character is the way objects are dynamic and continually ‘opened 
up’. An example might be the understanding of the gene. As the human genome proved not 
to be as readable, predictable and deterministic as first thought, questions were raised about 
the milieu in which DNA sits. Then, as knowledge about epigenetics developed, what was 
understood as individual and deterministic “gene action” gave way to more integrated and 
responsive concept “reactive genomes” (Fox Keller 2014). Different sets of questions and 
lines of investigation arise with this new understanding: the genome unfolds. 2) The 
dispersed character is the way epistemic objects are constituted of other objects, some of 
which are themselves unfolding. Finally, 3) the signifying characteristic is the way that 
researchers identify lacks in their knowledge about the object, and this generates questions 
for further investigation, which produces new presences and new absences. A ‘lack’ of 
knowledge about an object results in new questions being asked. In turn, this generates 
more present knowledge, and further lacks. This is rather like the absence-presence in post-
ANT (Law & Singleton 2005), and accommodation in ‘the mangle’ (Pickering 1995) that I 
mentioned in Section 2.3.  
In terms of suggesting how these objects bind society, then, Knorr Cetina draws on 
psychoanalytic theory (Knorr-Cetina 2005a; Knorr-Cetina 1997) and uses a language similar 
to post-ANT. She argues that, as above, actors identify particular absences in objects. 
Actors then do work to ‘fill in’ these absences, which make realities. These then provide lines 
of extension, or ‘chains of absences’ that the actor identifies and which the object has had a 
part in signalling. This theory is explored with respect to ‘the market’ (Knorr Cetina & 
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Bruegger 2000). A financial market can operate as a binding object. Firstly, traders identify 
lacks in the market that they can exploit, earn status, and realise their own identities – to be 
successful and wealthy, for instance. Secondly, the traders operate at computer terminals 
that synchronise global participation in the market by their connection to one another. Thus, 
market provides a place to embed the self and coordinate society (Knorr Cetina & Bruegger 
2000). This provides a different explanation to Mol’s (2002) co-ordination work in how 
objects ‘hang together’ in that the self is intimately bound up in the extension of an object.  
 
As I have argued, objects are not stable. One study, that took inspiration from the above 
‘object theories’ (Engestrom & Blackler 2005; Star & Griesemer 1989; Knorr-Cetina 2005a; 
Rheinberger 1997), examined the life of an object in translational genetics (McGivern & 
Dopson 2010). The authors report of an ‘inter-epistemic’ battle between medical academics 
and government administrators in a genetics network. The academics were producing 
research and publications within their own domain, but this was not satisfactory for the 
administrators who closed the network by cutting funding. Following the closure some 
medical academics were able to “reincarnate” the object to create a genetics test that 
became a diagnostic technology in NHS practice. This specific study reveals some of the 
ways that institutions create certain type of objects. Here, the object is transformed from an 
epistemic object to a technical one. 
 
What we find in these accounts is similarities and differences. Objects can be understood as 
generative, multiple and unfolding. This final section raises awareness of how objects can be 
transformed as they move from place to place. Or, as they are translated from one domain 
to another.  
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A turn to ontology?  
 
The discussion, particularly in relation to the ‘objects multiple’ sub-section above, generated 
debate in STS over whether ontological questions have replaced epistemological questions, 
including a Social Studies of Science special issue (Law & Lien 2013; Woolgar & Lezaun 
2013; van Heur et al. 2012; Mol 2013; Brives 2013; Marres 2013; Lynch 2013). There are 
two identifiable trends to studying ontology. The first is to understand objects as multiple 
realities proposed by post-ANT and the second is to study how identity and difference is 
done in specific cases (Lynch 2013). One option would be to call an empirical examination of 
things by a different name – ontography (Lynch 2013). This would mean, according to 
Lynch, that the analyst would not make an a priori decision that reality was composed of 
multiple objects. Instead, the analyst would approach the subject and decide whether 
ontology was an important aspect.  
 
Furthermore,  
 
it remains unclear how claims about the ontological composition of the world differ from 
more conventional propositions about the social construction, co-production, or 
performative constitution of a certain reality. 
(Woolgar & Lezaun 2013, p.323) 
 
Here, the reformulation of questions to be about ‘ontologies’ needs to be more clearly 
separated from other theoretical trends. The claims to greater political inventions have not 
been clearly demonstrated in the discussions (Woolgar & Lezaun 2013). An overall ‘turn’ 
seems unlikely since, although the use of the word “ontology” has increased, usage appears 
in disconnected discourses with different meanings (van Heur et al. 2012). The apparent 
shift to ontology is perhaps an outcome of the particular types of argument used by some 
researchers.  
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In approaching this research project, partly because I came from a positivist natural science 
background, I wanted to understand the objects that I had chosen to study within an STS 
framework. An important way to achieve this was to articulate them with theories of objects. 
So, my approach began somewhere in between ontology and ontography. On the one hand 
I was interested in the idea of a multiplicity and absences. On the other, I wanted to know 
how people defined and did synthetic biology, as the object to be translated, and how they 
defined and did translation. I therefore considered ontology as a ‘sensitising concept’ 
(Blumer 1986) in that I was aware of it as a possible line of analysis.  
 
The aim of this section has been to outline the ontological position of the project. This is that 
an analysis of practices can yield insight into the constitution and roles of objects and 
associated concepts such as identity and institutions. From this perspective objects are 
material-semiotic, performed, multiple and generative. Section 7.2 returns to this literature to 
conceptualise synthetic biology as an unfolding multiple before discussing the ‘absence’ of 
translation.   
 
 
2.5 Research Questions  
 
First I give a brief conclusion before I state the research questions. Synthetic biology seems 
to throw into relief some of the trends and concerns that have emerged in contemporary life 
science. Section 2.2, while mainly focusing on the case of the UK, has covered some of the 
main themes identified in social research. Synthetic biology practices change the meaning 
and doing of biology and biological work; it raises awareness about ethical issues regarding 
the capitalisation and governance of designed life; and shows how promises and 
expectations can be realised in material and organisational ways. Thus, as actors translate 
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synthetic biology, there is a strong foundation of social research on which to build. At the 
same time, translation has been studied predominantly with cultural analyses relating to 
credibility, professional identity and the boundaries between laboratory and clinic. Therefore, 
there seems conceptual space to approach translation as an ‘absence’ in synthetic biology 
that different actors work towards addressing. This is a starting assumption. The STS 
concepts I have reviewed, analytical, methodological, epistemological and ontological, give a 
philosophical and empirical background to the remainder of this thesis.  
 
The overall aim of this thesis is to understand how actors make synthetic biology 
translatable. This aim will be investigated by asking the following research questions: 	
1. In what activities do researchers, administrators and policymakers engage to 
address “translation” in synthetic biology? 
2. What connections do researchers, administrators and policymakers make and 
unmake as synthetic biology emerges as a ‘translational science’?  
3. How does attending to translation shape the emergence of synthetic biology in the 
UK and, reciprocally, shape understandings of translation?  
 
In the next chapter, I outline the processes I took to answer these questions and thus 
explain how I addressed the overall aim.  
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Chapter Three  
 
Performing Research 
 
 
 
In order to answer the research questions I took a qualitative research approach because 
my central concerns in this thesis are with actors’ understandings, practices and ideas 
regarding translation. I planned to ‘get a feel’ for translation by conducting observations and 
reading documents, and further explore some points through a process of interviewing. I 
conceived of translation as an “umbrella term” (Rip & Voß 2013) that was flexible and 
enacted in local practices in different ways (Rushforth 2012; Bos et al. 2014; van Lente & 
van Til 2008; Mol 2002; Law & Singleton 2005). But things did not always run according to 
my plan and the research process was “messy” (Strauss & Corbin 2008, p.32). In this 
chapter I describe how I went about conducting the research, making decisions, generating 
and analysing data and, finally, writing an account.  
 
The chapter title includes the idea of ‘performance’. I use the word in its double meaning of 
both doing and presenting. This is consistent with the theoretical STS framework that I 
outlined in Section 2.4, and continue to develop throughout this thesis. The chapter is the 
presentation of some of the decisions I took while doing the research process and is an 
attempt to detail some of the experiences with which the reader might identify. For ease of 
explanation it is semi-chronological. It is also not possible to recount every consideration. I 
have taken a variety of strategies to try to explore selected issues in detail. These include 
taking illustrative moments and extreme cases (Flyvbjerg 2006) to probe some of the 
matters that emerged during this project. The issues that I raise in this discussion do not 
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necessarily have resolutions but they raised further questions and sensitised me to other 
situations during the research. I include them because they are important details of how I 
conducted the research. I narrate how the project took shape and how, by articulating and 
accommodating my research problem, I made my project doable (Fujimura 1987; Pickering 
1995). In so doing, I aim to be transparent about the research process (Jenkins 2002). This 
is an important part of ‘responsible speech’ in sociology (Bauman & May 2001, p.8). This 
account is of how my performance of research practices, including writing, extended 
‘translation of synthetic biology’.  
 
 
3.1 Action and Practice  
 
I want to begin by adding a little practical detail to the ontological points I made in Section 
2.4. Of key ontological importance in this study is my focus on action and practice. As 
reviewed in the Section 2.1, STS scholars have explored the ways scientists, laboratory 
technicians and assistants make decisions and articulate their findings with other scientists 
(Knorr Cetina 1983, p.169), with broader social worlds within and beyond science (Fujimura 
1987) and with instruments and nature (Pickering 1995). More widely, social theorists and 
social researchers have become increasingly interested in practice in what has been called 
‘the practice turn’ (Schatzki 2005). In some forms of ethnography, for example, action rather 
than belonging and biography has become the main question (Baszanger & Dodier 2004, 
p.21). Thus, my interest in action reflects a wider trend than just an STS imperative. In this 
thesis, I focus on the tasks, activities and practices that actors and I relate to translating 
synthetic biology. 
 
Literature on ‘practice theories’ has emerged in philosophy and in studies of consumption 
(Schatzki 2002; Schatzki 2003; Reckwitz 2002; Shove et al. 2007; Hand & Shove 2007; 
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Hand et al. 2005). On these accounts, an overall practice is composed of all the specific 
instances of each performance. Each instance of a practice is specific and unique e.g. 
hammering a nail, taking a shower but together they constitute ‘the practice’. There are then, 
according to Schatzki, two related concepts of practice: the overall practice and each 
instance of a practice as it is performed (Schatzki 1996). I have already argued, following 
Mol’s (2002) case of atherosclerosis, that performing practices produces objects that can be 
understood as multiple in practice. Thus, an overall practice can be multiple. This allowed 
me to conceptualise translation in synthetic biology as a ‘practice multiple’ that did not 
privilege scientific work. This meant that various practices including research administration 
and policymaking could be relevant to translating synthetic biology.  
 
Furthermore, a consequence of performance is that attributes are not an essential property 
of a thing, but are repeatedly enacted (like gender identity) (Butler 2010). This means that as 
new practices loop through and others fade out of an object, like synthetic biology, the 
properties of the object can change. Whereas ‘social construction’ implies building stability, 
the notion of performance lends reality a contingent and precarious existence (Law 2009). 
Specific properties of reality are attributed in specific reconfigurations, which can exclude 
other properties (Barad 2003; Barad 2007). Arising from this is the idea that reality is both 
dependent on the methods used to find out about it, and is inherently indeterminate (Law 
2004). Thus, whatever methods I choose will generate some characteristics of synthetic 
biology and may exclude the possibility of knowing others. Focusing on actions of different 
social groups’ practices will produce an ‘object multiple’, and may exclude possibilities of 
producing other characteristics of synthetic biology. But, because of the inherent ‘mess’ of  
(social) reality (Law 2004), it is not necessarily possible to know the specifics of these 
exclusions because it is not possible to isolate phenomena to make claims in the same way 
as with natural science. It is, however, my stance on how methods perform properties of 
objects.  
Making Research Translatable: Connections 
 
	94 
 
In the introduction I quoted Strauss and Corbin’s notion that research is messy. However, 
mess can apply to reality, rather than just research. John Law, in his ‘attack’ on social 
research methods (courses), argues for a discourse around teaching methods: 
 
that is broader, looser, more generous, and in certain respects quite different to that of 
many of the conventional understandings 
(Law 2004, p.4) 
 
because:  
 
‘method talk’ connotes something quite different – that is a particular version of rigour. 
This is the idea that it is important to obtain the best and technically robust possible 
account of reality, where reality is assumed… to be a pretty determinate set of 
discoverable entities and processes. That such is what the world is: a set of possibly 
discoverable processes. 
(Law 2004, p.9) 
 
He goes on to challenge reality’s independence, anteriority, singularity and definiteness 
arguing throughout the book that reality is multiple, indefinite, in flux and constituted at the 
point of performance.  
 
A good example of dealing with mess is with Law and Singleton’s (2005) methodological 
discussion of alcoholic liver disease (detailed in Section 2.4). In the article, the authors 
conclude that problems with researching alcoholic liver disease mirrored those of health 
administrators struggling to manage provision. As a messy object, the disease was different 
in different sites and slipped in and out of focus and morphed into other objects (Law & 
Singleton 2005). This was an effect I experienced in trying to fix on translation and, at times, 
synthetic biology. These comments foreshadow the discussion in the Section 7.2 where I 
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outline the concept of unfolding multiples and conceptualise translation, finally, as patterns 
of absences.  
 
In terms of designing a project, it might be tempting to think of method in a messy manner, 
but this is not the case. I have, instead, taken the position that methods need to be 
explained systematically and the apparent mess justified and to some extent ‘cleaned’ for 
the reader, albeit through this semi-chronological narrative.  
 
In sum, action and practice imply attendance to what people do and say, and the written and 
material paraphernalia required for these things. Multiplicity allows for various practices to 
count as, and constitute, a particular object. I discuss the reflexive and theoretical 
implications for this in Section 3.5 and Section 7.2. Methodologically, I needed to deploy a 
variety of data generation and analytic strategies to try to understand translation in synthetic 
biology. Finally, the specific methods perform specific characteristics of synthetic biology, 
and exclude other (unknown) possibilities.  
 
Next, I begin to narrate how the project took shape. The contributions I have incorporated 
into the methodology, following the discussions in Section 2.3 are the ANT notions of 
following the actors, symmetry and the assumption of hybridity. I discuss these points with 
respect to doing the research in the next two sections.  
 
 
3.2 Actor Networks  
 
My PhD was funded by the ESRC. I was a member of the ESRC White Rose Doctoral 
Training Centre network “Rethinking the social production, locus and impact of bioscience”, 
which consisted of three PhD students and their six supervisors. However, during the first 
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couple of months I was invited to join another PhD network called “synthetic biology for 
human healthcare”.  The core of this network comprised one other social researcher and two 
candidates with molecular biology backgrounds. The initial supervisory structure of the 
network was the same as the WRDTC one I had already joined. However, over the coming 
years, additional people came and went. Postdocs and other supervisors dropped in for 
different meetings. Several other PhD students from chemical and biological engineering 
were regular visitors. My affiliation with the synthetic biology network was a springboard for 
this project as it facilitated my access to laboratories as research sites. Furthermore, in 
2014, five of us from the network collaborated to recruit undergraduates to form an iGEM 
team for the 2014 competition (more about this later).  
 
There were a range of synthetic biology projects in the network – creating biological fuel 
cells, pathogen detection systems, and a collaboration aimed at destroying biofilms. I was 
particularly interested in one project tackling problems in skin-graft surgeries. There were 
two sister projects – a PhD project and a postdoc project, that were funded by the institution 
and BBSRC, respectively. The project appeared to have some of the elements I was looking 
to explore. Although the project was not explicitly funded as a ‘translational’ one, the aim 
was to use synthetic biology techniques to produce a novel protein for tissue engineers to 
improve the adherence of skin cells in grafts or surgery. This meant that it was a) positioned 
as synthetic biology b) concerned with moving knowledge between disciplines c) innovation 
and market orientated d) easy to negotiate further access as I was already partially 
integrated e) nearby and convenient. Bearing in mind the literature reviewed in the previous 
chapter, it seemed like a conceptually rich site to investigate the topic. The laboratory 
spaces of the student and postdoc became key field sites. This project is the focus of the 
analysis in Chapter 6. 
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In some senses, because I had already been invited to an academic network and I was 
already regularly interacting with actors in synthetic biology since November 2012, 
negotiating initial access was unproblematic. The laboratory observations mainly involved 
visiting laboratories and snowballing other data sources. I visited three laboratories in two 
departments and shadowed researchers at their benches, computer stations and 
lunchtimes. During this time I identified a range of relevant workshops and conferences and, 
while I did not ‘follow the actors’ from the network to these events (since I think of my 
method as ‘following translation’), I saw at least one (usually more) at each site.  
 
Curiously, although in its infancy, synthetic biology had an ambivalent status at the 
institution. The institution had hosted one of the first seven BBSRC funded Networks in 
Synthetic Biology (NSBs). Yet, momentum seemed to be stalling. One administrator 
commented on difficulties in securing further funding for synthetic biology:  
 
But there is kind of an overall feeling… that we’ve kind of missed the boat a little bit in that 
area. BBSRC have just awarded three research centres in synthetic biology, um, we 
didn’t go into that call first time. We’re hoping to look to develop it for a second call. 
(Research administrator 2 interview, 18th February 2014) 
 
The institution did submit a proposal to the second call for SBRCs. It was unsuccessful. So 
too was a collaborative proposal for a doctoral training centre in synthetic biology. The idea 
that the institution was not at the centre of developments in synthetic biology was put in a 
different way by another researcher:  
 
something that had always been interesting is the peripheral status of this institution in 
the development of the field. So, [X] is reasonably well known. And is one of the relatively 
few proper, in scare quotes, engineers involved in it. So [they’re] actually quite important. 
To the field. Nationally… But but for some reason [the institution is] actually excluded 
from a lot things. [The institution is] definitely not in the core… very much in the periphery.  
(Social researcher 2 interview, 2nd July 2014) 
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This quotation is an example of a local sense of exclusion. The institution is portrayed as 
having a good record of research in synthetic biology and that it believes itself to be of 
import given the expertise of one its key players. Although these seem to qualify the 
institution to be central to developments in UK synthetic biology, actors felt they did not hear 
about some key decision-making meetings.  
 
On the other hand, the institution funded the PhD network. It has also hosted researchers 
who have moved on to take up prestigious places in synthetic biology at other institutions. 
This suggests that, in some ways, synthetic biology was and had been well supported. 
Furthermore, following the initial NSB funding, there were good collaborative relationships 
between social, biological and engineering researchers. This had been a main goal of the 
NSBs (Molyneux-Hodgson & Meyer 2009). The ambivalence, while not central to the 
analysis in Chapter 6, does give some important background in terms of other factors that 
may influence the projects I describe.  
 
 
Community membership  
 
Due to my involvement on the network, I was invited (and expected, I think) to get involved 
with iGEM. This extended my time in the field beyond what I had originally planned by about 
two months. Discussions about recruiting undergraduates for iGEM took place from 
Christmas 2013, with recruitment in the spring. The project ran through July and August 
2014. This culminated with trip to Boston, MA at the end of October 2014. While this was not 
a core part of my data collection, the supervisory role, development of the project and trip to 
the iGEM Giant Jamboree in Boston were all informative and helped develop some of the 
general feel for synthetic biology.  
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Importantly, though, there were ways in which it was possible to gain trust in the different 
sites I visited. One way that I was able to build trust was through demonstrating competence 
in laboratory techniques that I had learned as a biomedical scientist at university. When we 
were training the iGEM team the microbiologists set up a small test to check the students’ 
ability to pipette liquid. The aim was to pipette two samples of distilled water into two 
Eppendorf tubes and weigh them to see if there was a difference in mass. I rolled up my 
sleeves, flexed my thumb and relied on the thousands of similar actions I had performed 
over a decade ago. After we did the test, one of the microbiologists used my masses as an 
example of accuracy and precision. By demonstrating my technical ability, I felt I was able to 
gain a little credibility in the field. This is a rather specific example. The effect likely extended 
more generally into the language and ‘way to be’ in a laboratory setting. Thus, although I did 
not conceive of my involvement in iGEM as key to my interest in translation, I felt it was 
important to my role as a researcher (see Section 3.5).  
 
There is debate in social research about the effect of a researcher’s membership of the 
communities they study. Sharing some social experiences and a common language can be 
ways of understanding membership and there is a possibility, in this way, to generate 
material of greater depth because participants may share more with the researcher (Adler & 
Adler 1987). From this position, being an insider to a community has certain advantages. On 
the other hand, researching as an outsider, such as Latour and his naïve, “anthropological 
probe”, may sensitise the researcher to elements of their research site. Elements an insider 
may overlook.  
 
The insider-outsider formulation seems the type of dualism that poststructuralist and 
postmodernist scholarship has challenged. One way to treat this dichotomy is to focus on 
the hyphen as a space in which researchers can be both inside and outside (Corbin Dwyer & 
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Buckle 2009). In the idiom of this thesis, these boundaries are performed. To the reader, I 
typically refer to participants as “actors”. When I talked with participants, or presented to 
them, I typically said “we”, including myself. Thus, I did the boundary of inside and outside at 
specific points (Gieryn 1983).  
 
 
Observations 
 
There were three issues that arose during observations that I want to discuss. The first is 
what can happen when a researcher intervenes; the second is what can happen when a 
researcher is already familiar with their site; the third is what can happen when a researcher 
discovers that access is limited, in my case, by time. What I do not have space to explore 
here is the huge amount of relational groundwork done by other researchers, and the 
emotional labour (Hochschild 2003; Wharton 2009) that goes into maintaining research 
relationships.  
 
Reactivity. I was visiting an engineering department. I had been talking to a researcher in 
her ground floor laboratory (Field notes, 28th January 2014). She was preparing cell culture 
media. This involved collecting and weighing small masses of various salts and checking her 
calculations and previous mixtures in her lab book. Then noting down what she was making 
on this day. After this, we climbed back up the stairs to the PhD room in the building. A 
whole cross-section of biotechnology, bioengineering and molecular biology PhD candidates 
had their desks there. About thirty or so.  
 
This particular lunchtime, the room was quiet. Some had gone to buy their food, or moved to 
one of the building’s more public spaces to eat. There were four of us left. Two of the others 
dashed to the windowsill to grab a mini fuss-ball table. One shouted, first to three! They 
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quickly scored the goals. Afterwards, one of the candidates commented, it’s not always like 
this when you’re not here. Yeah, said another, we seem to be more chatty when you’re in.  
 
Entering or leaving the field are perhaps the largest interventions a researcher can make 
(Burawoy 1998). The ‘novelty effect’ is a form of reactivity that can mean the presence of a 
researcher can produce untypical results (Bryman 2012, p.715). Although I had anticipated 
that my presence as a researcher would have an effect, it came as a surprise that  
participants, some of whom were of no direct interest to my project, would perform ‘fun, 
exciting science’. Furthermore, the participants were aware of my presence and reflexively 
commented on their behaviour. As this happened at a relatively early stage in the research I 
was more aware of my presence in future situations, particularly during later interviews, 
participation at events and visits to other field sites.  
 
Familiarity. When I was at conferences and meetings I was able to sit and make notes. Most 
of the other delegates did the same. At other times, for example, during refreshment breaks, 
I was able to have conversations with other actors and, later on, record these in my 
notebook or type them into my tablet.  
 
In contrast to the flow of recording at these field sites, field notes for the laboratory visits 
were more problematic. Physically, I was always moving out of the way of researchers, or 
trying to find a space they were not using. It was difficult to rest my notebook anyway as the 
benches were filled with apparatus and running experiments. More importantly, I found it 
difficult to ‘see’ translation, so I was not sure where to look. As I followed the researchers 
carrying racks of Eppendorf tubes and well plates from bench to bench and, in some cases, 
between laboratories, I was not sure of the overall relevance of these activities to 
‘translation’. They had something to do with it, but the connection was unclear. This was 
coupled to my own history of being at the bench: I had spent two years doing this form of 
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work and had seen colleagues performing these techniques. My sense was that my field 
notes were somehow missing the point, that my “familiarity may be in tension with 
inquisitiveness” (Bauman & May 2001, p.10). Would a researcher unfamiliar with laboratory 
science have felt the same? I was, however, able to interpret my laboratory field notes in a 
meaningful way after I had generated some analytical insights from the interviews and other 
observations. The final conclusion to Chapter 6, explicitly linking time and skills to points in 
earlier chapters, came late in the writing.  
 
A dead end? A comedic yet disappointing development concerned the skin graft project’s 
timespan. The network to which I had been invited consisted of three doctoral projects 
funded from 2012 to 2015, with submission slated for sometime in early 2016. I never 
specifically asked about the length of the postdoc component.  Then, in November 2013, I 
recall a comment to the effect of, “you should catch so-and-so before they leave after 
Christmas”. Leave? I remember thinking. I was completely unprepared for a part of the 
project to end. Despite this surprise, I was able to organise an interview. Also, the final 
meeting for that element of the project, which took place in January 2014, proved to be a 
very useful point as it involved a presentation of the overall project and much discussion of 
the project work, the current status and possible next steps. Perhaps, because it was my last 
chance, I was also particularly alert. It therefore ended up being a crucial series of events for 
that particular site, even if they appeared to come prematurely.  
 
In reconstructing these events, the experiences of doing observations appeared to catalyse 
two things. First, I decided that I was not getting at translation on these laboratory visits. I 
wondered if it was something that emerged in a different organisational or practice-context. 
Had I wasted my time? Second, I set about writing up my observations and experiences and 
generated a chapter. But it did not work. I dismantled it and peppered rewritten paragraphs 
throughout this thesis. While it had always been my plan to interview actors, and the 
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observations were crucial to identifying actors to interview and deciding what kinds of 
questions I might ask, I found the experience of trying to write desperately frustrating. It was 
only after beginning to analyse the interviews that I felt I was able to ‘read back through’ the 
observational data and interpret it what I felt was a more satisfying and convincing way.  
 
 
3.3 Hybridity and Mess in Practice  
 
An artefact of the narrative so far implies that I ceased observing, attempted writing and then 
began the process of interviewing. It was not nearly so tidy. By April 2014, I had conducted 
four formal interviews (in that I had prepared questions and digitally recorded them). I had 
also made numerous field notes of conversations from my observations, visited several 
events and made notes regarding Internet sites, films and publications. From my initial 
analyses of observations in laboratories and at events I had some ideas to pursue in the first 
interviews.  
 
 
Interviews  
 
The main interview stage took place through the summer of 2014. I began creating a list of 
possible interviewees in May and had a total of twenty-eight interviews by 2nd of September 
2014. I prepared a set of questions so that I could guide each interview – they were semi-
structured.  
 
I selected interviewees via a variety of mechanisms. My initial strategy was to identify 
interviewees by getting referrals and suggestions from the synthetic biology network 
contacts. Using this method, I conducted interviews with two research administrators, two 
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postdocs, a PI as well as informal interviews with various academic participants during lab 
visits. Through attendance at conferences and general reading of policy and scientific 
literature I identified a range of further potential participants. A number of them were named 
co-investigators on the grant application for the Innovation Knowledge Centre for Synthetic 
Biology – The Synthetic Biology Commercial and Industrial Translation Engine (SynbiCITE). 
The SynbiCITE proposal was important for two reasons. Firstly, it was funded as an 
institution that contained “industrial translation” in its name. Secondly, it was a large proposal 
in terms of the number of co-investigators. The proposal listed thirty co-investigators and 
twenty-eight ‘other partners’ (academic and commercial institutions) (Engineering and 
Physical Sciences Research Council 2015a).  
 
After Easter 2014 I had assembled a list of interviewees from around the UK and contacted 
them. I had a regimen of: email approach, telephone call, and follow up emails or calls. I was 
surprised at the conversion rate – my experience in marketing and business environments 
did not prepare me for ‘yeses’ to come quite so quickly. From my list of potential participants, 
I selected the final sample by their agreement to participate. The interview sampling was 
therefore, at various times, different combinations of:  
 
• Theoretical sampling when looking for cases where I could test ideas  
• Purposive sampling, for example, to select interviewees who would be able to 
‘articulate’ translation because they were associated with it 
• Snowball sampling where sources such as interviewees or documents refer to 
further sources  
• Opportunistic sampling such as being directed from one interview to another 
potential participant ‘down the hall’ 
(Miles & Huberman 1994, p.28) 
 
Before the interviews I planned a set of questions. There were around twenty prompt 
questions on various themes, which were related to the research questions and which I 
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could tick off during the interview. A single question would often result in a conversation that 
covered multiple prompts. Also, the interviews tended to come in bunches, often because 
they were organised around a visit or event. This meant that, although I prepared a set of 
questions unique to a particular participant, the ones in each bunch tended to be more 
similar. In small font in the top right corner of the question sheet I typed core theoretical 
concepts and themes generated from recent analyses typed. These were part of my 
preparation and a way of checking that my questions were relevant rather than anything I 
actively referred to during the interview.  
 
The interviews took multiple forms (see Figure 8 below). I attended many sites in person. 
Often, these included some kind of tour – I was ‘shown around’ RCUK in Swindon and parts 
of the Universities of Newcastle and Sheffield. However, in order to access some 
participants more quickly and cheaply, I agreed to some interviews over the Internet and 
telephone.  Five of the interviews took place via online video, though one was sound only, 
and two were on the telephone (though these were with the same participant). Several of the 
interviews took place during other events – a meet-up for iGEM, a launch event for an 
academic network. I recorded twenty-four interviews on a digital voice recorder.  
 
Figure 8. Table of interviews 
Participant Code Interview date  Mode of interaction  
Academic Researcher 2 28th July 2014  In person; unrecorded 
Academic Researcher 4 4th December 2013  In person 
Academic Researcher 5 7th May 2014  In person  
Academic Researcher 6 5th February 2014  In person  
Academic Researcher 7 28th July 2014 In person  
Academic Researcher 9 28th July 2014 In person  
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Academic Researcher 10 1st September 2014 In person 
Academic Researcher 11 29th August 2014 In person 
Academic Researcher 12 15th July 2014   Telephone  
Academic Researcher 14 19th August 2014   Video internet call  
Academic Researcher 15 28th August 2014  Video internet call 
Academic Researcher 18 28th July 2014  In person  
Academic Researcher 19 28th July 2014   In person; unrecorded 
Social Researcher 1 1st July 2014  Video internet call 
Social Researcher 2 2nd July 2014 In person  
Research Administrator 1 19th August 2014 In person  
Research Administrator 2 18th February 2014  In person 
Research Administrator 3 3rd March 2014   In person 
Research Administrator 4 16th July 2014  Voice internet call  
Research Administrator 6 19th August 2014 In person  
John Collins 3rd July 2014  Video internet call  
Research Administrator 10 18th August 2014 In person  
Research Administrator 12 19th August 2014 In person  
Research Administrator 15 19th August 2014 In person  
David Willetts 2nd September 2014   In person  
Industry representative 1 1st September 2014 In person  
Industry representative 2 10th September 2014  In person; unrecorded  
 
The process of interviewing raised some important issues in the production of knowledge 
and below I consider rapport and power.  
 
Rapport. One of the aspects of being in the field is that I wanted to develop relationships 
with participants so that they would be at ease and feel free to answer questions, and thus 
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generate higher quality data. One way to approach building rapport is for researchers to be 
aware of the characteristics of both actors in the interview (Aldridge 1993). Aldridge notes 
that, in his research with Anglican clergy, because the appointment of women to the Church 
was a concern at the time, gender was a particularly important consideration. In my research 
many of the actors I spoke to already had further degrees, making them academically ‘elite’. 
Indeed, many were in positions of authority, too. There was then an interesting dynamic 
between me as a PhD candidate and their having passed through an academic system and, 
in some cases, moved into administration. However, because of my interest in translation I 
seemed to be asking questions that appeared timely to many actors. Several participants, 
for instance, had experienced research in academia, industry and worked in administration. 
So, my tactic of preparing individual interview schedules for each person in each role was 
one way of being aware of the participants’ relevant features.  
 
When I was transcribing the recordings (see Section 3.6) I was able to identify my laughter 
in a lot of the dialogue. For the most part I thoroughly enjoyed being in the interviews and I 
think this had an impact on how ready people were to talk. A problem follows from this, 
though. In particular, one of the early interviews ran for an hour and fifteen minutes and I 
found it difficult to end it. This was for two reasons. One, it was early in the research process 
and so I had not begun to refine what was important. Two, I wanted the participant to feel at 
ease and, even when they were talking about things that seemed irrelevant to my research 
questions, I let them run with their own line of thinking. Sometimes, this felt like they were 
reassuring themselves of their own worth: arguing for their own expertise (academic 
researchers 4 and 6). The steering and ending of interviews therefore presented a problem 
for maintaining rapport.  
 
Also, I noted a difference in how it felt to conduct interviews face to face in comparison to 
telephone or video. There are a range of differences when interviewing in different modes 
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including: interruption, topic control, lack of visual communication, articulation, holding the 
telephone, bringing preparatory materials, recording the interviews (Stephens 2007, pp.209–
211). In some cases, interviews using telephones do not generate different findings to 
interviews conducted face-to-face (Sturges & Hanrahan 2004). That said, my experience 
was that there was a qualitative difference between the interview modes. This is by 
comparison of the ‘feeling’ of conducting interviews face-to-face, via video conferencing with 
and without pictures, and via the telephone. I found it more difficult to maintain rapport in the 
absence of physicality and images. This is because microphones often transmit more 
background noise and there are no ways to communicate nonverbally. In fact, in one 
interview, the participant said they could not use the video because they were using their 
tablet. I got the sense they were referring to official documents as I was asking questions 
(research administrator 4). Another, who also opted for sound only, then proceeded to make 
coffee away from the microphone and then, I think, repeatedly bang a paperweight on the 
desk (academic researcher 14). The recurring jarring knocks, extra loud in the headphones, 
made transcription a painful experience. In this project rapport, access and data quality were 
all bound together.  
 
Power. Two interviewees, who were senior research colleagues, agreed to have lunch with 
me but suggested that I would not get ‘good data’ if I recorded them. As they were more 
senior, and I wanted to maintain rapport, I accepted. We dined in a café and I struggled to 
change between my pen and fork quickly enough. After lunch, I scribbled as much as I could 
recall as I was waiting for the next interview. I was conscious of their unease, my desire to 
make notes and my own need to act in a polite manner at the dinner table. Thus, I felt that 
resulted in a much lower quality of data, mainly because I had not felt able to defend my 
need to record them.  
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A related point arose from my interactions with government. I decided, because of his 
connection to synthetic biology, it would be relevant and interesting to attempt to recruit 
David Willetts to the study. He had been minister of state for universities and science from 
May 2010 to July 2014. Surprisingly, he agreed. Despite some difficulties with scheduling, 
including a rearrangement, it so happened that we were able to find a date that was the day 
after two other interviews and an iGEM meeting in London.  
 
I was nervous about the interview and had attended a daylong research course “conducting 
elite interviews”. I also sought advice from a scholar in the Politics Department for whom 
interaction with ministers was commonplace. My anxiety began to increase during the trip 
across London from the conference to the Houses of Parliament. This was exacerbated by 
the police presence at the gate where there was a jarring contrast between modern security 
technologies and the 14th century roof. I was directed to a high-ceilinged antechamber to 
wait. I was half an hour early. I watched people rush around and greet one another and loiter 
on the uneven stone floor. Later, in a clip on YouTube of a BBC interview, I saw the 
comedian Russell Brand make a comment that stuck in my mind:  
 
What I noticed when I was in the Houses of Parliament... it's decorated exactly the same 
as Eton, it's decorated exactly the same as Oxford, so a certain type of people go in there 
and say 'this makes me nervous' and another type of people go in there and go 'this is 
how it should be'. 
(Brand 2013)  
 
The process and environment were nerve-wracking. I came away from the interview and 
could not recall any words we had exchanged. Only that at one point I had completely lost 
my train of thought mid-sentence and the minister had reassured me. Yet I can still recall his 
restless fidgeting in the first part of the interview, and our walk to the London underground 
exit. I felt deeply embarrassed and delayed transcribing the recording.  
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When, several days later, I listened to the audio recording I was struck by how quickly David 
Willetts was satisfied with his answers. Most of the other interviewees talked around their 
subjects, almost circling points. He, however, gave an answer quickly and precisely. This 
gave the interview a real pace that I had not experienced – all the others seemed leisurely in 
comparison. Listening back I was also able to identify the point at which he relaxed – as I 
was explaining how, in my research, the Roadmap (Technology Strategy Board 2012b) 
seemed to have a broadly positive image. At this moment I remember he leaned back on his 
sofa. I got the feeling I was not a threat.  
 
This extreme example highlights some key elements of power in elite interviews, partly 
“because the typical or average case is often not the richest in information” (Flyvbjerg 2006, 
p.229). This case then is a discussion of issues that were present in different forms in other 
interactions, including nervousness, the buildings and environment, my thoughts about the 
other’s status, approaching the recordings and reinterpreting the situation during 
transcription.  
 
My aim in this section has been to give a sense of the process of observing and interviewing 
people in the course of this project. These points and considerations are made as adjuncts 
to the arguments regarding integrity, validity and ethics in Section 3.4. I found the processes 
of data generation to be frustrating, fun and even physically painful.  
 
 
Documents and Websites  
 
I aimed to collect various documents and representations of ‘translation’. I used a computer 
to generate data from my desk. This included searching for “translational research” and 
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employing other terms and Boolean operators to explore documents and websites with 
related terms. This yielded a lot of data on how translational research was discussed in 
biomedical and medical science and formed the bulk of my initial reading. I began narrowing 
searches of “translation” with “synthetic biology”, “UK”, “government”, “funding” among other 
terms. Perhaps the first piece of ‘grey literature’ was the policy-informing A Roadmap for 
Synthetic Biology in the UK (Technology Strategy Board 2012b). This was reassuring in the 
sense that the word “translation” occurred several times in the text. Furthermore, several of 
the searches specific to synthetic biology produced the same documents as the 
“translational research” searches. The Roadmap has an interesting status in this project as 
several of my participants had contributed to its text.  
 
When I was attending field sites, such as interviews and meetings I gathered other 
documents. This was opportunistic. I filed conference programmes after attendance. I also 
found that various website searches would yield interesting publications, by TSB and RCUK, 
or by BIS and other government departments. Three particularly interesting documents, 
other than the Synthetic Biology Roadmap, are worth mentioning.  The Bioengineering 
Report (House of Commons Science and Technology Committee 2010), the Bridging the 
Valley of Death: Improving the Commercialisation of Research (House of Commons Science 
and Technology Committee 2013) and Emerging Biotechnologies: Technology, Choice and 
the Public Good (Nuffield Council on Bioethics 2012). Each came about by a different search 
– one on the government website, one in Google and one from a participant interview.  
 
Websites also turned out to be a useful source of information, particularly for checking 
funding details of projects such as the NSBs or SynbiCITE. Moreoever, they formed 
important sites for testing ideas because I could easily find them during the interview 
analyses, a point I return to in Section 3.6.  
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Multiple and hybrid sites 
 
What I hope is apparent from the discussion so far is that I was collecting various forms of 
data by being involved with different, heterogeneous communities. This study is not an 
ethnography in the anthropological sense in that I have not committed to generating 
accounts from only the participants’ viewpoints. Indeed, ANT-inspired studies are not 
typically ethnographic (Bruni 2005). Researching ‘translation’ I also had in mind that I would 
attend different sites. So, although a traditional, dominant form of ethnography locates 
research at a single site there is an increasing tendency towards “multi-sited ethnography” 
(Marcus 1995). Marcus, following Latour, suggests there are different ways of making 
different objects central to multi-sited ethnography by “following people, things, metaphors, 
plots, biographies and conflicts” (Marcus 1995, pp.106–110). At some points I followed 
actors. At others, I followed the absence of translation, a ‘chain of absence’ (Knorr-Cetina 
2005a) dictated partly by my own plans, partly by disciplinary and methodological affiliations 
and partly by what the world allowed me to do.  
 
Multiple sites are not necessarily different geographical locations. They also imply multiple 
forms of data, for instance, analogue and digital. A “virtual ethnography” is both almost 
ethnographic and takes place both online and offline (Hine 2007). The contemporary 
pervasion of internet and mobile communication meant that I was able to research via 
websites, internet searches, contact people via phone and email and so on. One example of 
a ‘hybrid’ research site in this study was a webinar launch of new funding stream. I was in 
virtual attendance, while others were present in a room in London, and I had the facility to 
conduct ‘chats’ with other online observers via instant messaging.  
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Multiplicity also took a temporal form regarding the SB 6.0 conference, held at Imperial 
College, London. I attended the conference 9th – 11th July 2013. Later, the organisers 
published videos of the main sessions (BioBricks Foundation 2013). I was therefore able to 
‘revisit the past’ in a way that I was not expecting – it was not a recording I had planned or 
made. This meant I was able to transcribe specific talks that I knew were of interest.  
 
One of the features of practicing multi-sited research is that it makes connections between 
various individuals, organisations and entities. In its process, multi-sited research makes a 
new space:  
 
The multi-sited ethnographer can be viewed as an embodiment of the middle range: it is 
not that the study contributes to bridging a pre-existing middle range, as much as that 
ethnographers bring it into being through the territory they map out whilst attending to the 
diverse accountabilities which they experience. Multi-sited ethnographers craft field sites 
with an eye to producing appropriate accounts for heterogeneous audiences comprising 
diverse sets of peers, policy makers, funders, bosses and research contacts… the 
ethnographer seeks out resonances, finding audiences for whom the study will be 
recognized as having an adequacy to connect with their concerns. Rather than being 
inherently recognizable as timely, a study finds an audience through a much more active 
process.  
(Hine 2007, p.657) 
 
By travelling to different participants I was making an audience for my findings (see also 
Section 3.5 for how the findings might travel beyond the project). Perhaps others had not 
thought of translation as something that would, or could be, a topic of sociological research. 
This study highlighted ‘translation’ for some of the participants. More importantly, I was 
performing my own research object of translation. I was asking questions and following lines 
of questions that unfolded translation, and synthetic biology. 
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3.4 Doing Ethical Research  
 
In this section, I deal with ethics in the broadest sense – not only to participants, but to 
funders, the academic community and wider society (Berg 2001, p.39). Thus, doing ‘good’ 
research has broad implications for practicing and communicating research (Jenkins 2002, 
p.13). As such, I cover the ways that I related to the participants and the ways I aim for this 
to be quality research for social researchers and wider society.  
 
There are a variety of ethical considerations when approaching research. These are both 
“consequentialist”, in ensuring that participants are protected from harm and that research 
promotes some benefit, and “deontological” in the sense of ensuring others’ rights to equal 
and respectful treatment (Murphy & Dingwall 2007, p.339). Though, as Murphy and Dingwall 
(2007) go on to point out, these conceptions are problematic as they exist in a specific time 
and place (now, in Western society) and their specific enactments may create particular 
issues. With their caveat in mind, I now discuss how I designed and did ethical research in 
this project.  
 
In Western society there has been a proliferation of guidelines and laws regarding the 
generation and use of personal data (Berg 2001, p.39). These include guidelines such as 
the ESRC Framework for Research Ethics (Economic and Social Research Council 2012) 
and the Statement of Ethical Practice (British Sociological Association 2002) and laws such 
as the Data Protection Act (1998). Furthermore, the research project was formally granted 
ethical approval by Department of Sociological Studies, University of Sheffield (see 
Appendix II). This project adheres to these various stipulations.  
 
In terms of approaching and recruiting participants I provided an explanation of the project 
and a participant information sheet for them to read. I would then ask participants if they had 
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any questions and, when that had been addressed, asked them to sign a consent form (see 
Appendix II for information sheet and consent form). All except one of the participants were 
either studying for or had been awarded postgraduate degrees and none of the participants 
would normally be considered vulnerable in this context. The conversations could be on the 
phone, email or in person. Signed hard copy consent forms were stored in a lockable 
cupboard in the department to which only the department manager and myself had keys. 
The electronic versions were stored, as with all the digital recordings and transcripts, on the 
University’s password-protected ‘cloud’.  
 
Following the guideline documents above, I take the view that ethics operates beyond 
bureaucratic procedures and formal structures. In some indigenous communities, research 
ethics means making meaningful, mutual and requited relationships (Smith 2005). This 
model places the emphasis on process, maintenance and care. For me, outside of the ethics 
forms and ethics committees, I worked to establish a respectful rapport and I followed up 
meetings with thank you emails with the hope of initiating future contact to share findings. I 
also aim to write in a style that is accessible, yet still expresses the details of the field 
research and nuances of theory I cover (Jenkins 2002, p.13). For more on the production of 
this thesis, see the final Section 3.7: A Genre Account.  
 
Two points require further mention. First, one participant, to whom I had been directed, 
seemed edgy in the interview. I realised this when I produced the digital recorder and they 
were unusually hesitant. We agreed that any quotes I used would be sent them for 
agreement and all data would be destroyed at the end of the project. This was despite the 
steps taken for anonymity. After I left the interview and puzzled over the issue I came to the 
conclusion that a factor had been an assumption I had made. Because of the route of the 
referral and the actor’s position I had thought they would be familiar with social research 
techniques and strategies, such as recording. I now think that they were taken somewhat 
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off-guard by my whipping out of a digital recorder. With the remaining few interviews I was 
mindful not to make assumptions regarding interview practices.  
 
The second point involves the style of writing, to preserve anonymity and communicate 
clearly. Chapter 6 focuses on the ‘bioglue project’. This was a small project and so there 
were a small number of key actors. I have had to take care in use of quotes and descriptions 
to ensure that the small number of people could not identify one another. Thus, the ethical 
approach has had an impact upon the final shape of this report.  
 
 
Integrating methods 
 
The ontological and epistemological position described in this chapter meant study design 
needed to attend to heterogeneity, practice, multiplicity and complexity. As such, I opted for 
using multiple techniques to generate data. Using multiple methods brings to the fore how 
different methods are validly integrated.  
 
Validity, for the purposes of this discussion, means the soundness of the project, its 
coherence. There is a central problem of validity in interpretivism – we cannot know for 
certain what happens in another person’s mind. However, there are alternatives to ensuring 
validity of a study such as conducting sensible, comprehensive, transparent and sceptical 
research (Jenkins 2002, pp.98–104). I think of this as producing coherence (see Section 7.3 
for how coherence of a multiple object can be achieved with narrative work).  
 
There are different ways to ensure valid integration of research methods. One way is to 
check that there is ‘complementarity’ between the ontologies and epistemologies facilitated 
by the different methods (Mason 2002, pp.35–6). I have taken care to outline the ontological 
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and epistemological foundations of this project in Sections 2.1, 2.2 and throughout Chapter 
3. I applied this throughout as a form of theoretical integration. Furthermore, the notion of 
symmetry means that all materials can be treated the same in the first instance, be they field 
notes, transcripts or documents. Indeed, ANT-type studies acknowledge that objects are 
partly constituted by discourse (Sismondo 2010, p.150), though in this project I take 
discourse to include material as well as textual practices (Barad 2003). There is no internal 
conflict between using observations, interview and documentation in terms of giving an 
account of the constitution of translation. Indeed, it would be difficult to generate data on 
specific people’s thoughts and beliefs without some method directed at soliciting information 
from people regarding their perspectives (e.g. interviews). Likewise, data on organisational 
representations of ‘translational’ would be challenging to acquire in the absence of websites 
and documentation. The treatment of objects, and how to find out about them within a messy 
world, is consistent throughout all the work in this research. In other words, the project 
methods were aligned in terms of their ontological and epistemological assumptions.  
 
A second way, relevant to qualitative research, is to be flexible in the process of the doing 
the work to make sure the methods are sensitive to the context (Mason 2002, p.3). 
Research methods, to be coherent with the philosophy I have laid out, need to adapt to the 
unfolding nature of the world and the object of study. Unlike quantitative research, where the 
method is structured for the purposes of representative generalisation, flexibility, here, 
allows for ‘depth’. This is a part of Latour’s dictum to ‘follow the actors’ (Latour 1987). The 
ability to be flexible was built into the project because I was able to respond to different 
avenues throughout the investigation. It is the case with semi-structured interviews, too: 
while I had prepared questions and themes to follow, there were several times when the 
interview was outside of my topics but I followed the interviewee to see where they went. 
Sometimes this was fruitful, sometimes not.  
 
Making Research Translatable: Connections 
 
	118 
A third way to integrate methods is to ensure they ‘mesh’ in explanations. This means 
attention to the style of argument. In terms of offering a convincing argument, I draw on data 
generated from the multiple methods throughout the thesis. I do not, however, offer 
generalisations based on representation. The argumentation is based on evoking and 
illustrating elements of translation in synthetic biology. In giving an account of a messy, 
decentred object one needs to deploy different metaphors and conceptual apparatuses (Law 
2002). As I said at the very start of the thesis, I use a variety of concepts to analyse the data. 
In giving the account, then, I follow Jasanoff in that I am “against reductionist story-telling… 
causes are heterogeneous and hard to pin down” (Jasanoff 1996, p.413). It is possible to 
enact the complexity of the social world by using data from different methods and connecting 
them with various concepts in the explanations.  
 
This brings me, finally, to the issue of interpretive validity. This means that the interpretation 
I offer is convincing. As well as using theory generated from other research, I concentrate 
my claims to interpretive validity on reflexivity (see Section 3.4) and transparency.  
 
The basic principle here is that you are never taking it as self-evident that a particular 
interpretation can be made of your data but instead that you are continually and 
assiduously charting and justifying the steps through which your interpretations were 
made. If you do this effectively, it should enable you to show both that you have 
understood and engaged with your own position, or standpoint, or analytical lens, in a 
reflexive sense, and also that you have tried your best to read your data from alternative 
interpretive perspectives. 
(Mason 2002, p.192) 
 
I have demonstrated a clear engagement with the theoretical lens(es) through which I have 
generated interpretations. I have detailed in Section 3.6 the analytic processes by which I 
have come to conclusions. It is through this practice of ‘laying out in detail’ that I aim to 
create a convincing argument.   
Performing Research  
 	 119  
A study for others   
 
This thesis is, in part, concerned with academic research and the production of knowledge 
with ‘impact’. Here, I describe two points about the way I intend that this research might be 
transferrable to other sites and cases. One of the ways to achieve this is through detailed 
description of the empirical sites. In this mode, it is for others to decide the value of the 
account in understanding their matters of concern (Hammersley & Atkinson 2007).  
 
A more satisfying contribution for me is to be able to make a theoretical contribution. This 
means creating abstractions. Abstractions are mobile. Indeed, abstractions are the key to 
sociological inquiry (and human society, more generally) and as such there “isn’t a no theory 
option” (Jenkins 2002, p.32). So, creating theory is a way to abstract from this project and 
suggest that phenomena may be a part of a pattern outside of the specifics. My overall 
strategy of multi-sited ethnography was meant to attend to generalisation and the concepts I 
have developed are likely to be mobile because of extended case study design (Burawoy 
1998) where I have connected translation in synthetic biology to other entities. Furthermore, 
I chose the skin graft project because it incorporated many of the issues that I hoped to 
explore (Flyvbjerg 2006), and that were already noted in other literature, which I highlighted 
in Section 3.2. Thus, I made theory at a local level, in the laboratory. But I also made 
connections between that data, interviews, national policy, and what other actors did and 
said at other points. Therefore, I contend that I offer ‘connected concepts’ that other 
researchers, and some of my participants, may be able to apply to their own situations.  
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3.5 Reflexivity    
 
I have been emphasising that this research project was done by me, so this is an 
appropriate time to bring up reflexivity in this thesis. The idea of reflexivity is related to the 
capacity of people to be both subject and object of action. In the sentence, “I free myself”, 
the speaker is the subject and the object of the verb. When this point is extended to social 
research, in that people can refer to and be aware of themselves and their relationships, it 
has implications for conduct in the social sciences and especially studies of science and any 
interest in the co-production of knowledge. It can be a way to develop convincing arguments 
and perform ethical research (see Section 3.4).  
 
In this study, I followed the actors through their everyday working life. As I did this, and they 
interpreted the world, I interpreted their actions and their interpretations. This produced 
information, but “what we call our data are really our own constructions of other people's 
constructions of what they and their compatriots are up to” (Geertz 1973, p.9). Giddens calls 
this “the double hermeneutic” (Giddens 1984). The thoughts and theories that I have, and 
share with actors or disseminate at a later date, then can ‘loop’ back into actors’ 
understandings of the world and alter their practices and their understandings of their own 
positions (Hacking 1995). An example of this is Merton’s (1948) self-fulfilling prophecy 
whereby unfounded claims about the weakness of a bank resulted in depositors withdrawing 
their monies and the bank getting into financial difficulty. The upshot is that, as a researcher, 
I need to be aware of my own position within a “research assemblage” (Fox & Alldred 2015).  
 
Reflexivity, for some writers, is a key part of STS scholarship (Jasanoff 1996). However, 
certain positions do receive critique. Quite rightly, and in keeping with the positions taken 
elsewhere in the thesis, reflexivity is neither a special academic virtue nor does it facilitate 
privileged knowledge (Lynch 2000). The reflexivity of this thesis rests on the notion that 
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integrity and quality can be achieved by demonstrating how the position of a researcher 
affects the knowledge production process.  
 
With these points in mind, I attempted to address the issue of reflexivity in various ways. I 
discuss the specifics in the research processes throughout this chapter and how, possibly, I 
affect/effect the findings of this study. To be theoretically reflexive, I applied the concepts I 
generated back into this study. This aided my own understanding of the research process 
and role in extending an object and I describe this in the self-test subsection coming up. 
Finally, I wrote a brief account of my own history and considered how this may have 
implications for my research practice. This comes next. 
 
 
A partial presentation of self  
 
Work in STS has emphasised science as a local achievement – specific material cultures 
that produce facts – rather than finding universal truths.  
 
Relativism is the perfect mirror twin of totalization in the ideologies of objectivity; both 
deny the stakes in location, embodiment, and partial perspective; both make it impossible 
to see well. Relativism and totalization are both "god tricks" promising vision from 
everywhere and nowhere equally and fully, common myths in rhetorics surrounding 
Science. But it is precisely in the politics and epistemology of partial perspectives that the 
possibility of sustained, rational, objective inquiry rests. 
(Haraway 1988, p.584) 
 
What Haraway argues for is an epistemology where all knowledge is understood as located 
in specific times, places and practices. Barad has extended this possibility of partial 
knowledge to the idea that knowledge is created by intra-action between phenomena (Barad 
2007). In other words, partial knowledges cannot be aggregated to some complete whole. 
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Instead, knowledge is created by specific configurations of materials and meaning. People, 
as phenomena, produce knowledge in locations. In light of this, I introduce myself as a 
‘partial connector’ – a specific person who intra-acts with other phenomena through different 
practices at different locations and who enacts a partial self, and partial knowledge, at each 
site:  
 
I was born in Leeds, UK to a teacher and doctor. We moved to Manitoba. Later, we settled in 
a large village on the border of Buckinghamshire and Oxfordshire. Formally, I hold a degree 
in Biomedical Science and a certificate and a diploma in Education. I have worked as a 
research assistant in a bioscience laboratory, as a teacher of science, as a confectioner 
making sweets for customers’ entertainment, as an account manager for a marketing firm.  
 
There are a couple of points I want make about this biography. One, people can be struck by 
my accent – I pronounce “castle” with a flat “a”, yet to some people I sound posh. I play on 
this a little and normally introduce myself as “born in Leeds, raised near Oxford”. Thus, I can 
be from the North and South of England. As a general rule, I give a narrative in a way that I 
hope people will find something that they connect with. Also, I present some information and 
explicitly omit others – gender, race, age.  
 
Two, I began to address the issue of access and trust in Section 3.2. My bioscience training 
meant I was able to gain credibility and trust by demonstrating a technical competence – 
pipetting. As I said, this small example may reflect a larger effect of professionally working in 
science and having an idea of how academic research proceeds. However, this meant that 
access was bound up with participation.  
 
One typology of researcher roles outlines a spectrum of four different roles (Gold 1958). At 
the one end of the spectrum, complete observer, there is no interaction between researcher 
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and participants. The other roles, observer-as-participant participant-as-observer and 
complete participant, involve progressively more interaction and immersion in the research 
sites. Although this relies on an unfortunate dualism, between researchers and researched, 
it does offer me a place to acknowledge the multiplicities of ‘presenting the self’ (Goffman 
1959). As I moved among the different sites I took on different roles, different levels of 
participation. I transitioned from complete participant (peer/colleague) in the PhD network, to 
participant-as-observer in the laboratories and conferences, back to complete participant (as 
iGEM advisor) and to observer-as-participant during interviews. I wanted to be seen as a 
competent and sensitive social researcher and also, as part of the network and iGEM team, 
as a hard-working contributor. However, this seemed to be an effective strategy to maintain 
access, at least to the synthetic biology laboratories and iGEM. 
 
The idea of roles extends to my participation in STS communities. Reading about the 
development of ANT is a route that, retrospectively, allowed me to gain in confidence and 
legitimise my increasing participation in academic STS (Lave & Wenger 1991). The 
development of ‘super symmetry’ to include objects, the critiques with respect to ‘flattening’ 
and power, and the emergence of what is sometimes called post-ANT, gave me an 
understanding of how STS had developed and kinds of critiques that had been historically 
successful, and the shift in emphasis from epistemology to science and society. In terms of 
‘getting’ STS, the knowledge of ANT’s key papers gave me access to community in-jokes, 
including the tongue-in-cheek use of hyphens after Latour’s critique where he problematized 
“the word ‘actor’, the word ‘network’, the word ‘theory’ and the hyphen!” (Latour 1999, p.15).  
 
For me, knowledge of ANT facilitated my increased participation in several ways. It gave me 
a conceptual tool that challenged my assumptions about the structure of the world, a case 
study of how STS academics critique and develop theory, and a point of reference to talk to 
members of the community, a ‘language’. Thus, the participatory roles I took through the 
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research had implications beyond the project itself (see Appendix III for how my participation 
in academic communities increased over the course of the PhD).  
 
 
Self-test  
 
The strong programme (see section 2.1) advocated a reflexive approach in that “its patterns 
of explanation would have to be applicable to sociology itself” (Bloor 1991, p.5). One 
criticism levelled at the strong programme was that its style of explanation did not 
accomplish reflexivity because the programme did not treat its own explanations 
symmetrically (Woolgar 1981). In other words, in parallel to the ways that scientists construct 
elements of the natural world, social studies construct elements of the social world. The ANT 
version of symmetry was one attempt to remedy this problem. In this study, I systematically 
applied the emerging concepts to the study itself. For example, the notion of the unfolding 
multiple (Section 7.2). This study performs multiplicity and is a part of the ‘unfolding’ of 
translation and of synthetic biology.  
 
Whereas one thesis is a construction (Meyer 2006), this one is a reflexive performance.  
 
 
3.6 Analysis  
 
The act of breaking up concepts, ‘loosening’ them, and subsequently ordering them is a 
means of describing components in a logical way. One of the problems with doing this, 
though, is that it can make the process appear sequential. I cannot stress enough that this 
was not the case with this project, and often is not the case with qualitative research more 
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generally – making sense of a messy world is a messy process (Law 2004). As such, I did 
analytical work throughout the project and the loosening up took different forms.  
 
A second point is that this is a PhD thesis. I placed emphasis on my own development. I 
approached the project with an ethic of experiential learning. I had to do research. I could, 
and indeed did, err. The analytical systems emerged through doing. The practice of analysis 
and synthesis was perhaps where the greatest practical learning occurred. It is where many 
of the concepts and terminology discussed in Chapter 2, and some of the methodological 
theory discussed above, came to mean something. Sometimes this led to ideas that faded 
away. For example, most of the diagrams depicting translation involve a linear diagram 
usually progressing from science on the left of a page towards market, product or society on 
the right of a page. Early on, I felt that I wanted to challenge these diagrams. Then to say 
that the models were performed in the way that institutions were funded. However, as I read 
literature regarding linearity, I felt it would be difficult to say challenge this in a novel way 
(Godin 2013; Godin 2006; Edgerton 2004; Balconi et al. 2010; Williams & Edge 1996; 
Sorensen & Williams 2002). Indeed, the appearance of linearity is the product of a multi-
authored innovation story (Deuten & Rip 2000). Over time, as I was able to refine concepts 
in writing, the thesis emerged. Therefore, the process of analysis was laborious as it 
involved both learning to do and doing.  
 
 
Transforming data  
 
The human senses focus on specific ranges of the world in terms of wavelengths of light, 
frequencies of sound and so on. Our perception is already concentrated on certain types of 
events at particular scales so that we can make sense of our environment. The very act of 
‘sensing’ data involves a reductive transformation. Collecting data for others, by writing or 
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recording in some way, eliminates further elements of the world. This section explains some 
of the transformations that the data underwent in this project.  
 
The process of qualitative analysis can be broken down into reduction, display and 
conclusions (Miles & Huberman 1994, pp.10–12). Furthermore, the process of analysis is 
intertwined with the way data is managed (Miles & Huberman 1994). My data consisted of 
documents, handwritten notes, typed notes on a tablet, and a computer, recorded 
interviews, videos of speeches, photographs and so on. One transformation is the data 
undergoes ‘processing’.  
 
The raw data requires some sort of organizing and processing before it can actually be 
analyzed. Field notes, for example, may fill hundreds of pages of note books or take up 
thousands of megabytes of space on a computer disk. These notes need to be edited, 
corrected, and made more readable, even before they can be organized, indexed, or 
entered into a computer-generated text analysis program file. Recorded interviews must 
be transcribed (transformed into written text), corrected, and edited… 
(Berg 2001, p.34) 
 
In order to demonstrate the kinds of work that gets done in ‘cleaning up’ data, and in keeping 
with the overall epistemology of the thesis, I have chosen to focus on the details of acts of 
transcription. I experienced comparable processes and effects to the ones described below 
in generating and readying field notes, diagrams and videos.  
 
In this project I decided to transcribe the interviews myself. This was to revisit, recall and to 
become more familiar with the interview data. The process of transcription is an active part 
of the research process, with interpretive and analytic decision-making (Tilley 2003). 
Transcription is also an iterative process that facilitates an engagement with data 
construction where “analysis takes place and understandings are derived through the 
process of constructing a transcript by listening and re-listening, viewing and re-viewing” 
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(Lapadat & Lindsay 1999, p.82). I had found that steering the interviews meant that I 
focused on guiding the conversation to topics that I wanted cover. I made a few notes, but 
relied on the ‘memory’ of the tape recorder. Through re-listening, and typing, I returned to 
the sites of interviews, albeit in digital form. This is in contrast to many events during the 
observational data collection that I could revisit only by reading my scratch notes. As 
explained in Section 3.3, the SB 6.0 conference was a notable exception as the organisers 
subsequently posted videos online.  
 
Listening to some sections of recordings over and over, the interviews became much longer 
and more nuanced. Instead of a forty-minute conversation, progressing through time, I also 
used a media player to slow the recordings to about 30% so I could closer match my typing 
speed. Thus, rather than technology facilitating a compression of spacetime, the process of 
transcription expanded the object (Engestrom et al. 2003). Transcribing changed my sense 
of time of the interview, extending and drawing out the experience and interaction.  
 
I went over and over certain sections in recording, usually because it was difficult to hear the 
exact words for some reason. One interview took place in a café (industry rep 1, 1st 
September 2014). The repeated hissing of an espresso machine was very disruptive to the 
mic’s pickup. I tried to transform the recording using a computer program to limit background 
noise and focus on human speech. This meant I was able to transcribe some words warped 
by the interference.  
 
There are, then, many choices to make during transcription (Hammersley 2010). At one 
point, for example, I experimented by reformatting some of the transcripts into screenplays 
to enhance the notions of performances and actors. Initially, I opted for as naturalistic a style 
as I could. I also chose to type the mutterings, stutters, repeats and other non-speech 
elements. I tried to punctuate little and included as many vocal noises as possible – we give 
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off signals intentionally and unintentionally, and both can be ‘received’ differently in 
interaction (Goffman 1959). Occasionally, I added relevant comments on gesture or 
expression. All these different processes and different choices mean that the “transcription 
of tapes can be done in many ways that will produce rather different texts” (Miles & 
Huberman 1994, p.9). As I was writing up, though, I began adding punctuation and, by using 
square brackets, correcting quotations to make it easier for the reader to understand them. 
The interview data were transformed right up to the last.  
 
 
Coding  
 
The generation of codes is one way to compare ‘horizontally’ between different sets of data 
(Mason 2002). There are different ways to approach coding so I will describe the way I 
coded the transcripts. In an analogous way, I wrote memos and notes with respect to 
observations and emerging findings. I have chosen to keep this discussion to the interviews 
to be consistent with the previous section on transcriptions and explore specific processes in 
more depth.  
 
The first interview I analysed line by line with no prior categories. This closely resembles 
‘open coding’ (Strauss & Corbin 2008). My aim was to begin to generate ideas directly from 
the data with the aim of refining them later, both in comparison with other data and with the 
literature. This generated a lot of themes. As I coded subsequent transcripts I referred to, 
and adapted, the categories from the previous ones (Glaser 1965). Many of these categories 
were irrelevant to my research questions. In the later transcripts, I generated codes that 
were more descriptive and contained more data.  
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I copied text into new documents with theme headings. This generated eighteen new 
documents. The sections of transcripts that covered multiple themes were present in the 
new documents – some sections doubled and tripled. Some of these documents such as 
“defining Synthetic Biology and Translation” were comparatively large – more than ninety 
pages. “Scientific scepticism” turned out to be only a page long. By reading through these I 
then generated new documents by writing brief statements about what each segment 
covered. I highlighted these with different colours to create what I imagined were going to be 
four discussion chapters.  
 
What emerged from coding the interviews were theories about performances of translation. I 
tested these by comparing between interviews codes and memos on the field notes and 
documents. What then came from coding and memo writing was still not finalised. As the 
next Section 3.7 explores, the act of writing was an important part of the analytical and 
research processes as it formed a way, albeit temporarily, to crystallise the findings.  
 
 
3.7 A Genre Account  
 
The process of doing academic social research is, like laboratory life, very much about 
producing texts. As Latour writes:  
 
See? That’s again why I dislike the way doctoral students are trained. Writing texts has 
everything to do with method. You write a text of so many words, in so many months, 
based on so many interviews, so many hours of observation, so many documents. That’s 
all. You do nothing more. 
 (Latour 2005, p.148) 
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The requirements of the final text, in this case a thesis, function as a method as it limits and 
facilitates what can be described and explained. The university faculty suggested the final 
thesis should be 75 000 – 100 000 words noting that “brevity achieved without sacrifice of 
clarity is a virtue much appreciated by examiners” (The University of Sheffield 2015). The 
thesis also needs to be so many chapters and to address certain issues. This forces the 
writing into certain conventions, such as divided sections. In this thesis, writing was 
constitutive and I now explore how writing as method influenced the analytic and concluding 
processes.  
 
In order to make some decisions about academic writing, and presentation of data, I read 
Clear and Simple as the Truth (Thomas & Turner 2011). The authors argue that “even the 
best educated members of our society commonly lack a routine style for presenting the 
result of their own engagement with a problem to people outside their profession” (Thomas 
& Turner 2011, p.10). It is to meet this need that clear prose in ‘classic style’ was developed.  
 
I chose not to use ‘classic prose’ throughout the thesis because it explicitly ‘hides labour’ 
(Thomas & Turner 2011, pp.194–5). In a practical writing exercise, the authors explain how 
to hide the labour of observation and begin adding inference to a perceptible observation. By 
presenting an interpretation as ‘transparent’ it hides the action that goes into interpretation. 
In contrast, what I find particularly attractive about the Latourian approach – the explicit and 
playful use of metaphor – is that it facilitates ‘obvious’ reinterpretation. The labour is laid out 
for the reader. A second reason was because ‘classic prose’ assumes “thought precedes 
writing” (Thomas & Turner 2011, p.11). To follow a ‘classic’ course of presentation would 
therefore be at odds with one of the fundamental assumptions of this thesis. That is, 
dualisms like thought and action are ways to understand a problem that already rest on 
processes which mask hybridity (Latour 1993b).  
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Rather than present this thesis in ‘classic prose’, I used it as an analytical stratagem. When I 
struggled to write about something I would try to approach it with the ‘plain for all to see’ way 
of describing. This ‘loosened up’ my writing, and often allowed me begin writing about my 
research without trying to use STS concepts.  
 
The first attempt at writing an empirical chapter resulted in me concluding I did not 
understand ‘translation’, at least in the laboratory. But it was an important process to go 
through, and much of that attempt has found its way into other sections, particularly 
Chapters 1, 3, 6 and 7. Even towards the end of drafting the thesis, I was still developing 
new connections, new points of coherence. In so doing, I was doing more ‘cleaning’. These 
exploratory writings were a form of research, discovery and analysis where:  
 
I made accidental and fortuitous connections I could not foresee or control. My point here 
is that I did not limit data analysis to conventional practices of coding data and then 
sorting it into categories that I then grouped into themes that became section headings in 
an outline that organized and governed my writing in advance of writing. Thought 
happened in the writing.  
(Richardson & St. Pierre 2005, p.970) 
 
I have been over and over the writing in the thesis. Editing, rephrasing, deleting and 
substituting different words and paragraphs. Over time, the final argument, the final 
connections emerged. For Glaser (1965), writing comes after theory. I think of writing as an 
analytical, iterative process of ‘layering’.  
 
Some scholars have commented on how some sociological scholarship is poorly written 
(Richardson & St. Pierre 2005; Becker 2007; Wright Mills 2000; Jenkins 2002). There are 
non-academic influences on my writing, particularly minimalism, which influenced my style in 
Chapter 7. Minimalism is a sparse style of writing that encourages the reader to slow down.  
I use minimalism to recall the earlier points throughout the thesis and create a synthesis:  
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In minimalism, every story is a symphony, building and building, but never losing the 
original melody line. All characters and scenes, things that seem dissimilar, they all 
illustrate some aspect of the story’s theme.  
(Palahniuk 2004, p.143) 
 
I think it may be suited to some sociological description and analyses in order to limit longer 
sentences and sensitise the acts of both reading and writing on representation. Furthermore, 
minimalism seems an appropriate style with which to describe “a fractionally coherent 
subject or object” (Law 2002, p.3) (see Section 2.4) because minimalism is additive – each 
element adds to the whole. Chapter 7 is my first experiment in a writing style that might be 
termed “academic minimalism”.  
 
It is sometimes difficult, however, to balance minimalist sentences with the detail and depth 
required by some academic explanations. Therefore, I instituted a set of mediating 
principles. In 1946, George Orwell suggested some guidelines for writing accessibly and 
without ambivalence. I often think of these when writing academically because they are 
concerned with ethical communication in politics:   
 
1. Never use a metaphor, simile or other figure of speech which you are used to 
seeing in print. 
2. Never use a long word where a short one will do.  
3. If it is possible to cut a word out, always cut it out.  
4. Never use the passive where you can use the active.  
5. Never use a foreign phrase, a scientific word or a jargon word if you can think of 
an everyday English equivalent.  
6. Break any of the rules sooner that say anything outright barbarous.  
(Orwell 2004, p.119) 
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Although these rules are formulated for writing in general, I have tried to produce a thesis 
that is readable and clear in style. That is my hope – that the thesis is a convincing account, 
but one that reminds the reader it has been crafted.  
 
Indeed, the final thesis is a ‘cleaned up’ representation of the process of research. In so 
doing, I aim to connect my thesis with a broader research ‘genre’ in STS where: 
 
… the approaches taken by SSK scholars, and by science studies more generally, have 
tended to be qualitative rather than quantitative, thickly descriptive rather than thinly 
reductionist or model-dependent, deconstructive rather than paradigmatic, and self-
consciously, often ironically, narrative. 
(Jasanoff 1996, p.411) 
 
These four points form a framework to summarise this chapter and connect this research 
project to some of the common features of STS scholarship. This includes some general 
comments about the methodological, sociological, anthropological and postmodernist 
influences that have inspired the shaping and concerns of this project. I have not ‘blindly 
followed’ other scholars so I will say a little more about how I take each of these points and 
justify their use in the research.   
 
 
Qualitative and descriptive research  
 
Science tends to present its method in a way which removes the complexities, difficulties 
and realities of practice (Latour & Woolgar 1986). In contrast, STS researchers often tend to 
give accounts of science in the anthropological mode of ‘thick description’ (Geertz 1973). 
This is an account whereby the words and terminology used to describe action also work to 
frame the context of that which is being described. For example, to describe someone as 
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hitting a small wooden ball with a wooden stick through metal hoops on a patch of grass is 
‘thin’ compared to saying someone is playing croquet on a lawn (Maxwell & Mittapalli 2008, 
p.880). This is particularly the case in my use of acronyms and biological terminology (in 
Chapter 6) and so I have included a glossary of terms to aid the reader.  
 
However, any description is already interpreted:  
 
A purely objective description is not possible, because the social world is always already 
interpreted and because what we see is shaped by how we see it.  
(Mason 2002, p.149) 
 
This means that every description and methodological choice is ‘doing work’ to interpret the 
world and is not a reflection of an external reality. However, this interpretive labour is a way 
to explore a phenomenon, or case, in depth.   
 
The questions that I presented at the end of the literature review are concerned with 
changes. Changes in qualities. It is not, for the most part, concerned with numbers and 
measuring. Indeed, this is a problematic and artificial distinction, not least because 
quantitative data are based on categories qualitative in nature (Douglas 2002). Broadly 
speaking, qualitative research aligns with an interpretive epistemology, constructionist 
ontology and inductive theory-making (Bryman 2012, p.380). There are caveats to these 
broad-brushstrokes. As I have detailed, there is not necessarily a clear distinction between 
deductive and inductive research. Although this thesis has produced some theory in an 
inductive way, I have used other social theory to guide this research. This has aided the 
interpretation of some of the data in that I used other theories as “sensitising concepts” 
(Blumer 1986). These are concepts marked by an absence of clear specifications and 
benchmarks. Instead they offer general suggestions of content. For instance, articulating 
alignment became an important analytical framework during the writing process. However, 
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other notions, particularly the ‘imaginary’ first outlined in Section 4.3 and the ideas of 
‘contours’ described in Section 5.2 were more inductive.  
 
 
Deconstructive narrative   
 
Narratives are ways of telling a story. This involves putting together an account to connect 
elements in the account. They can, but do not have to be, chronological. It is possible to see 
the overall shape of the thesis as a narrative funnel guiding the reader from a nation state 
perspective to the view from the laboratory bench. An example of self-conscious narrative 
description concerns the way researchers embody protein structures (Myers 2008).  
 
Furthermore, my narrative attempts to convey complexity by being deconstructive. This is an 
approach to analysis most associated with Jaques Derrida. There is a problem with trying to 
give a brief account of deconstruction that is well articulated in the ‘deconstruction’ entry in 
the Sage Encyclopaedia of Research Methods:  
 
An encyclopedia is designed to enclose, encapsulate, reduce, and simplify its subject 
matters, whereas deconstruction is oriented toward opening, expanding, amplifying, and 
complexifying them. 
(Gough 2008, p.203) 
 
Gough goes on to offer a ‘performed’ entry – rather than explaining deconstruction, he does 
it for the reader. Deconstruction reverses the common-sense idea that signs represent an 
objective reality and treats the iterative use of signification as the cause of belief in, rather 
representation of, an objective reality (Carspecken 2008, p.171). Theory associated with 
STS has broadened deconstruction from a focus on language and text to material matters 
(Barad 2007; Barad 2003; Pickering 1995; Pickering 1992).  
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Furthermore, one of the central projects of STS is to suggest that ‘things could be otherwise’ 
by showing the contingent nature of reality, even its singularity (Woolgar & Lezaun 2013). 
One way is to offer a different account that runs against the expected, or assumed, (grand) 
narrative.  
 
The alternative is to imagine, reflexively, that telling stories about the world also helps to 
perform that world. This means that in a (writing) performance reality is staged.  
(Law 2002, p.6) 
 
Thus, the accounts I present in this thesis participate in the world (Law 2002, p.6). I aim for it 
to participate in STS, too. Woolgar (2014) gave a lecture on provocation and irony at the 
Centre for Science, Technology, Medicine and Society at UC, Berkeley. He argues, among 
other things, that irony is subversive and is performative because it potentially splits its 
audience into those who get the joke, and those who judge the representation to be sincere. 
Thus, in retelling the data collection and analysis in a narrative style, I aim to perform an 
STS version of irony, and account for the complexity of doing research.  
 
To summarise – in the project I am interested in exploring quality rather than measurement, 
emphasising depth of investigation, opening up and complexifying and, lastly, proposing 
alternative accounts of ‘translation’.  
 
 
3.8 Conclusion  
 
In this chapter I have outlined the process and considerations for performing this research 
project. Ontologically, I have assumed a position of relativism in the sense of ‘non-absolute 
realism’ or ‘relativist realism’ (Bloor 1999) in which reality is not entirely singular, antecedent, 
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definite or independent (Law 2004). This means, epistemologically, that reality is produced 
and known through specific ‘intra-actions’ between phenomena, which include interpretive 
schema, research methods, material tools, natural and manmade materials (Barad 2003; 
Barad 2007; Law 2004). The upshot of this is that there is no complete knowledge. Instead, 
partial knowledge in the double sense of incomplete and biased (Haraway 1988) is 
performed and inscribed at specific points. Methodologically, I have selected an approach 
that will capture performances of making synthetic biology translatable in different sites. 
Thus, I followed (Latour 1987), observed and ‘interrogated’ human and nonhuman actors in 
a multi-sited ethnography (Marcus 1995; Hine 2007). I have explained the ontology, 
epistemology and methods and described how they are all interrelated in theory and 
practice. The matter of ethics is related to writing and representation as well as the conduct 
of research, as well as the self. In so doing, I have articulated the alignment of this thesis 
with STS communities, research participants and wider society. In the next three chapters I 
describe the analysis and findings I created in the approach I have outlined.  
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Chapter 4 
 
States of Synthetic Biology 
 
 
 
In this chapter I explore how actors align synthetic biology with other entities. The level is 
similar in scope to the “social world” beyond the laboratory (Fujimura 1987, p.258) that 
includes the work of research administrators, scientists and policymakers. In Section 4.1, I 
detail how synthetic biology is performed as a precarious yet potent solution to state 
economic recovery. Proponents of synthetic biology, actors from various academic 
disciplines, biotechnology industries, government and research funding, make synthetic 
biology into an entity that can realise the UK state’s identity as a global leader of bioscience. 
However, there is much debate as to what constitutes synthetic biology and what novelty 
synthetic biology offers. In Section 4.2, I explore the messy and local processes of 
demarcating synthetic biology from other biotechnology and bioengineering. I situate this 
discussion in the context of actors attempting to preserve their access to resources, 
particularly funding. Finally, in Section 4.3, I analyse the way actors cite various influences 
that shape the establishment of a UK synthetic biology industry. I argue that a particular kind 
of industrial manufacturing is imagined and this affects how synthetic biology is emerging: a 
particular commercialisation narrative enables some actions while constraining others 
(Deuten & Rip 2000).  
 
 
Making Research Translatable: Articulations & Contributions 
 
	142 
4.1 Towards Global Leadership     
 
UK science, health and wealth: policies and reports 
 
In this section I show how a range of governmental reports describe the UK research system 
as globally competitive in terms of fundamental science yet lacking an ability to turn these 
into applications and economic gain. I situate this narrative in relation to the promises and 
potential of synthetic biology and argue that these technological promises of the field are 
turned into organisational responses. I begin with three documents, selected because of 
their importance to UK policies relating to bioscience research. These are a Review of 
Health Research Funding (Cooksey 2006), The Life Science Strategy for the UK 
(Department for Business Innovation and Skills 2011) and a government report into different 
biotechnologies called Bioengineering (House of Commons Science and Technology 
Committee 2010). Each of these documents adds to setting a scene in which synthetic 
biology can realise its translational potential.  
 
The UK government has produced policies to lay out the future of research investments and 
commissioned various reviews of publicly funded bioscience research. The Cooksey Review 
(Cooksey 2006) focused on health research in the UK and claimed that the UK has a history 
of notable biomedical science.  
 
The Review found that the UK Health Research system has many strengths. It has a long 
tradition of producing excellent basic science, with the Medical Research Council (MRC) 
funding 27 Nobel prize winners since its establishment in 1913. The quality of the health 
research base, combined with a national health service, creates a major selling point that 
attracts R&D investment from the pharmaceutical and biotechnology industries, which 
form a major part of the UK knowledge economy. 
(Cooksey 2006, p.3) 
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The report draws explicit links between the state’s economy, bio-industry and scientific 
knowledge. According to the review, the National Health Service (NHS) is a specific feature 
of the UK that combines with the research activities and appeals to industrial investors in 
biomedical sciences.  
 
Despite this history and these features, the Cooksey Review concludes that there is not 
enough conversion of biomedical knowledge to health and wealth benefit and that:  
 
…the UK is at risk of failing to reap the full economic, health and social benefits that the 
UK’s public investment in health research should generate. There is no overarching UK 
health research strategy to ensure UK health priorities are considered through all types of 
research and there are two key gaps in the translation of health research:  
• translating ideas from basic and clinical research into the development of new 
products and approaches to treatment of disease and illness; and  
• implementing those new products and approaches into clinical practice 
(Cooksey 2006, p.3) 
 
The report recommends the “the government should seek to achieve better coordination of 
health research and more coherent funding arrangements to support translation” and that 
“other institutional changes are necessary to maximise the economic and health benefits 
arising from a single health research budget” (Cooksey 2006, p.4).  
 
The government, in one response to the Cooksey Review, created the Office for Strategic 
Coordination of Health Research (OSCHR) which was tasked with setting the health 
research strategy and coordinating the budgets for DH and MRC. The MRC website states 
the OSCHR:  
 
… has demonstrated a powerful capacity to work across government through 
collaboration, addressing many of the issues required to ensure a comprehensive health 
research environment and leading to improved health outcomes and economic growth. 
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The OSCHR process has helped to focus on the development of better NHS electronic 
data capabilities for research; create a research programme for public health and greatly 
enhance translation science.  
(Medical Research Council 2015b) 
 
In the view of MRC, the Cooksey Review of health research resulted in successful 
institutional change and new funding arrangements that prioritised translational science. In 
this way, the MRC also constructs the view that the UK is ‘good’ at basic science but ‘bad’ at 
creating clinical applications and that what was required was “cultural change among public 
funders of health research to address the barriers to research collaboration and to support 
the application and translation of basic research” (Medical Research Council 2015b). These 
comments legitimise the institutional and cultural changes meant to ensure the realisation of 
health and wealth benefits.  
 
The UK contribution to global bioscience is also a feature of the Introduction to the Strategy 
for UK Life Sciences (Department for Business Innovation and Skills 2011). In contrast to the 
Cooksey Review, where the conversion of ‘basic’ science to clinical application is identified 
as being deficient, the ministerial foreword to the Strategy suggests the UK is a place that 
can support discoveries that turn out to be medically beneficial.   
 
The UK has long been a world-leader for innovation in life sciences. That is why many of 
the most talented scientists from other countries come here to research and develop 
innovative drugs and technologies. It is also why so many of the great breakthroughs in 
this field – like Sir Alexander Fleming’s discovery of penicillin and the discovery of the 
structure of DNA and antibody therapies – have happened here. 
 
We want that enviable record to continue into the future, strengthening our life sciences 
industries and helping to build a sustainable economic recovery. 
(Lansley & Willetts 2011, p.2) 
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The above quotation connects scientific discovery, industry and state economy. The UK is 
presented as a place for advancing basic science and that successful conversion of 
knowledge will produce income for the country. Towards the end of the document there are 
two and a half pages of ‘actions’. The first two actions are:  
 
• We will invest £310m to support the discovery, development and 
commercialisation of research. This covers £130m for Stratified Medicines and 
£180m for a Biomedical Catalyst Fund.  
• We will commission an independent panel to develop a technology roadmap that 
will propose actions required to establish a world leading synthetic biology 
industry.  
(Department for Business Innovation and Skills 2011, p.31) 
 
The Strategy mobilises a history of successful innovation to justify spending on developing 
technologies and industries in order to support the UK economy. In particular, the Strategy 
publicly announced the process of changing funding arrangements (see Section 5.1 for a 
detailed description of Catalyst funding) and for developing synthetic biology within the UK to 
become a world leading industry.  
 
In 2010, The House of Commons Science and Technology Committee produced a report 
into three areas of bio-scientific innovation – GM crops, stem cells and the ‘emerging’ field of 
synthetic biology. In constructing the report, called Bioengineering, the committee solicited 
evidence from a wide range of stakeholders, including representatives from academia and 
industry. The executive summary reads:  
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We found that the UK has an excellent research base but is still failing to maximise its 
potential by translating research into wealth and health. Considering that the UK is 
emerging from a recession and a difficult economic climate still prevails, this is worrying. 
The road to economic recovery will depend, in part, on exploitation of the UK’s research 
base, which in turn requires efficient translation to generate returns on investments. 
(House of Commons Science and Technology Committee 2010, p.3) 
 
The report emphasises the recessive state of the UK economy and argues that translation is 
“still failing”. Basic life science or knowledge is seen as a state resource generated by public 
funding and which can be converted to a financial surplus. This, according to the report, 
requires improvements in the processes by which science is converted to profitable and 
marketable products and services.  
 
These documents do a number of things. They connect the production of knowledge to state 
economic benefits, a particularly salient argument within a narrative of austerity and 
recession. They present the UK state as a space for world-leading bioscience and that this 
should continue. In this way, they perform the notion that “the modern state is a scientific 
state” (Sismondo 2010, p.191). They identify cultural and institutional changes as key to 
realising the promise of bioscience. They prioritise technological development in the name of 
economic recovery and health benefits. Thus, some areas of research are selected as more 
important than others. Finally, the arguments presented in the documents make connections 
that serve to legitimise some kinds of activities and investments in bioscience and de-
prioritise others. This will be further explored in the upcoming sections.  
 
While much STS work has argued for an integrated and networked understanding of the 
character of production of knowledge (Knorr Cetina 1981; Latour 1987; Gibbons et al. 1994), 
the policies described above appear to argue that individual discoveries can be located 
within the borders of the UK: a discrete space for science. It is onto this stage, of a UK 
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absence of or weakness in translational bioscience, which synthetic biology and its 
proponents have stepped.  
 
 
Funding potential  
 
Some of the research councils responsible for administering public funds for research made 
synthetic biology a funding stream in 2007 and funded seven academic networks that ran 
between 2008 and 2011. Five networks were in single universities (Bristol, Edinburgh, 
Nottingham, Oxford and Sheffield) and two were collaborations, one between the 
universities of York and Durham and one between Birkbeck College and University College 
London (UCL). The funding for and interest surrounding UK synthetic biology increased. In 
2010, RCUK awarded Imperial College a 5-year grant for the Centre for Synthetic Biology 
and Innovation (CSynBI).  
 
As explained above, the Bioengineering report solicited information from a range of 
stakeholders in bioscience and innovation. Evidence submitted by CSynBI presents 
synthetic biology as having revolutionary potential. The memorandum is worth quoting at 
length because of the way CSynBI connects the potential of synthetic biology to the 
realisation and failure of other technologies.  
 
The last half of the 19th century and the first years of the 20th century saw scientific and 
technological discoveries that created the basis of wealth generation by means of major 
new industries— petrochemical, automotive, aircraft, electronics etc. SB [synthetic 
biology] has the potential to create another group of major new industries with profound 
implications for the future of the UK, Europe and other major economies…  
 
Unlike synthetic chemistry in the 19th Century, the UK essentially “missed the boat” on 
the commercial potential of the microchip revolution and lost the opportunity to participate 
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in any significant, commercial way in what is now a major global industry. The UK writes 
significant amounts of commercial software, but the US dominates the sector (eg 
Microsoft and Google). In the opinion of The Royal Academy of Engineering Inquiry into 
Synthetic Biology’s working party, one of the key reasons for the UK’s relative failure was 
because the UK professionals did not undertake an effective campaign to inform decision 
makers about the potential significance of the microchip…  
 
If the promise of SB is realised, it could form the basis of a new industrial revolution 
based on the confluence of biology with engineering. The UK has little in the way of 
natural resources but a major asset is human resource in terms of a strong science base. 
It is therefore important to build the capacity to exploit the science base in SB to create 
the new technology and companies that can create employment and economic benefits to 
the UK. 
(House of Commons Science and Technology Committee 2010, p.Ev 1) 
 
CSynBI’s evidence to the committee positions synthetic biology as having an economic and 
technological potential similar to some of the most recognisable and commonplace 
industries in contemporary society – planes, cars, computing and so on. CSynBI argue the 
UK ‘lost out’ during the computing revolution, partly because proponents did not make their 
case for support clear. Finally, the human capital of the UK, rather than its natural capital, is 
suggested as a key area for building capacity to build a profitable technology. The 
expectations of synthetic biology are equated with a history of successes and failures of 
other more well-known technologies. By presenting synthetic biology in this way, the 
memorandum aligns synthetic biology with other technologies, and a ‘fear of loss’. It also 
argues that the new technology could produce various benefits to the UK economy. Thus, 
the quotation performs an alignment of synthetic biology with UK needs as identified by 
government.  
 
The idea of an industrial revolution invokes ideas of moving from craft production to 
standardised systems. Professor Freemont, co-director of CSynBI with Professor Kitney, 
said:  
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Before the industrial revolution most items were made by hand, which meant that they 
were slower to manufacture, more expensive to produce and limited in number. We are at 
a similar juncture in synthetic biology, having to test and build each part from scratch, 
which is a long and slow process. We demonstrate in our study a new method that could 
help to rapidly scale up the production and testing of biological parts. 
(Freemont & Kitney quoted in: Smith 2013) 
 
Ad-hoc building is time-consuming. The acceleration of testing and development is one of 
the promises of the synthetic biology approach. This quotation argues that the work being 
done to improve the speed of scaling up and testing of new parts will mean that 
manufacturing can happen more quickly. Overall, the idea is that investment in synthetic 
biology will speed up translation of science to the bioeconomy. 
 
In 2012, the Chancellor of the Exchequer George Osborne gave a speech at the Royal 
Society. He spoke of how science was a driver of economic growth. He made several 
announcements, including additional funding for UK space technology and the publication of 
A Synthetic Biology Roadmap for the UK (Technology Strategy Board 2012b). In his speech, 
he used some of the hopes of synthetic biology to justify increasing government investment 
in the field:  
 
Synthetic biology has huge potential. Indeed it has been said that it will heal us, feed us 
and fuel us. The UK can be world-leading in this emerging technology. That is why we are 
backing it with further investment today. 
(Osborne 2012) 
 
The chancellor pointed out that synthetic biology offers something else to the state besides 
improvements in medical, food and energy technologies. The state can establish itself as a 
world leader. This connects the way that synthetic biology is funded, the types of research 
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avenues that might be pursued, and the way the UK state imagines itself within global 
bioscience.  
 
The proponents of synthetic biology are active in creating grand expectations. In these 
documents and speeches “the future is mobilised in real time to marshal resources, 
coordinate activities and manage uncertainty” (Brown & Michael 2003, p.4). However, 
particular kinds of futures are invoked. The overall goal of making biology an engineering 
discipline is reinterpreted in these examples to align synthetic biology with state needs and 
legitimise government backing of the field.  
 
Before moving on, I want to acknowledge that the promises of synthetic biology are not 
necessarily orientated to health and wealth. There are high-profile researchers in synthetic 
biology who emphasise the transformation of biology into an engineering discipline rather 
than focus on state economic benefits. One researcher pointed out that synthetic biology is 
founded upon epistemic, rather than commercial, principles:  
 
The idea of synthetic biology is not driven by “we need to build these foundations to have 
innovation”, I mean, that’s it’s sort of a given that that will happen… It’s more we need 
build these foundations so that the experiments and the building and doing becomes 
much more routine and quicker and faster. Scalable. Predictable. Modelling. Just to take 
away the huge amount of time and money that is spent on experiments that basically 
don’t go anywhere.  
(Academic researcher 10 interview, 1st September 2014) 
 
The quotation illustrates how some researchers are orientated towards innovation: the main 
goal for this researcher was to improve the engineering of life and to make biological science 
generate more verifiable knowledge per unit investment. If biology is made easier to 
engineer by applying the design principles of abstraction and modularisation and 
standardisation then that will somehow, inevitably, produce innovation.  
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This epistemic focus on synthetic biology does not appear to be the case for some of the 
more public proponents and supporters in the UK. They argue for funding and infrastructural 
support to realise the promise of innovation, rather than of engineering. In the science 
funding narratives described above, the UK is a state with a good science base, but a state 
in which technological innovation is precarious and vulnerable to failure because of lack of 
support from the state or lack of coordinated action from proponents. With support, so the 
story goes, synthetic biology can flourish to address state needs.  
 
 
Realising promises by funding re-organisation    
 
Synthetic biology is presented as having the potential to deliver a return on life science 
investment, which would see benefits for the UK. RCUK has continued to invest in Synthetic 
biology following the initial networks and research centres such as CSynBI. The funding has 
come predominantly from a pair of the quangos that make up RCUK: the BBSRC and the 
EPSRC, reflecting the disciplinary combination of biological and engineering research. Other 
councils, including AHRC, ESRC, MRC and NERC have also made contributions to greater 
or lesser degrees to various forms of grants and other forms of support. However, towards 
the end of the NSB funding period the government became increasingly involved in the 
emergence of synthetic biology. This included synthetic biology being one of eight 
technological areas highlighted by the chancellor during his talk at the Royal Society in 2012 
(Willetts 2013a, p.9; Osborne 2012).  
 
The links between RCUK, UK government and synthetic biology were then particularly 
visible at SB 6.0, the sixth international conference of synthetic biology. This was held in 
2013 at Imperial College, London. There were over 750 delegates from around the world. 
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Predominantly, the audience consisted of synthetic biology researchers. The three-day 
conference was structured into four main sessions each day. Three of the four daily 
sessions were plenaries held in The Great Hall and featured a panel of speakers.  
 
One morning David Willetts, then minister of state for universities and science, was invited to 
address the whole conference audience at the beginning of the Translating technology, 
transcending industrialisation track. Professor Kitney, a director of CSynBI, used the 
opportunity to highlight the minister’s endorsement of synthetic biology.  
 
We are particularly pleased that David has been able to come this morning because he 
has been a great supporter of synthetic biology in the United Kingdom as I’m sure he will 
tell you in a very modest way. 
(Kitney, 11th July 2013) 
 
In Willetts’ speech at the synthetic biology conference, he explained that the chancellor’s 
analysis of emerging technologies had taken a strategic view to invest in those that some 
think will have worldwide significance and in which Britain already had strength. Willetts 
stated that the current policy was to “reinforce academic work with practical measures to 
help take it further” and that the Eight Great Technologies report had prompted the 
Chancellor, George Osborne to announce an extra £600m government investment in those 
areas of technology (David Willetts speech, 11th July 2013). Of that, £50m was to be 
invested in synthetic biology over the coming two years. This was in addition to the on-going 
RCUK investments.  
 
Willetts had previously argued that there was a particular role for government in making 
strategic decisions regarding science funding:  
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One reason science in Britain is so excellent is that Ministers do not interfere in the 
allocation of funds for particular science programmes – the Haldane Principle. This 
principle covers current expenditure science which is within the ring-fenced £4.6bn 
annual resource budget. Governments do however have a more direct role in deciding on 
the allocation of major science capital spending. And there is also a role for government 
in deciding broad areas of technology to support through the Technology Strategy Board 
before they have reached full commercialisation. 
(Willetts 2013a, p.8) 
 
The document states that approximately a third of the science research budget comes from 
government, a third is allocated through RCUK and universities allocate the remaining third, 
after they have received their block grants from HEFCE and its devolved counterparts. 
Accordingly, government can make an impact in steering capital investment and support for 
commercialisation without contravening the Haldane Principle (for a discussion of The 
Haldane Principle and its shaky historical grounds, see Edgerton 2009). During an interview 
conducted for this research project, Willetts said:  
 
Politicians tend to get involved more when there is a big new capital decision to be taken. 
Those are the strategic kind of things are legitimately for ministers. I think that with 
synthetic biology, increasingly, the need will be for larger scale plants. Kind of places 
where you can produce on a sort of intermediate scale and show the process can deliver 
tonnes for that product. So I think there will be more [of those] types of decisions.  
(David Willetts interview, 2nd September 2014) 
 
The role of government, then, is to make larger, strategic decisions regarding the allocation 
of public funds in science and technology. In other words, government can steer the overall 
direction of the state’s research programme by earmarking portions of finite resources. 
Government has specifically backed infrastructure for fundamental research and translation 
of synthetic biology. According to David Willetts, the next phase in translation is for 
academia and industry to negotiate and agree on how to establish a synthetic biology 
manufacturing industry. This positions responsibility for translating synthetic biology outside 
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of government. I return to how responsibility for translation comes to academics, and explore 
it in more detail, in Section 4.3, Section 5.1 and Section 5.3.   
 
During his conference address, the minister gave a narrative for the way he had become 
involved in synthetic biology and some of the organisational developments that had 
occurred.  
 
It began with a roundtable I chaired back in October 2011 considering the possible role 
for government in providing more support for synthetic biology. That resulted in the 
formation of a working group chaired by Lionel Clarke of Shell that produced a Roadmap 
for synthetic biology in the UK and I pay tribute to Lionel’s work and this roadmap has 
been an invaluable guide to public policy since it was produced. We’ve now created a 
leadership council on synthetic biology co-chaired by Lionel Clarke and myself which 
brings together both representatives of the academic community and from the business 
community as well.  
(David Willetts speech, 11th July 2013) 
 
This brief account of the developments gives a sense of growth to synthetic biology. The 
discussions started ‘around a table’ and produced a document for technological 
development, which has informed research funding. The Roadmap (Technology Strategy 
Board 2012b) included five recommendations for state policy:  
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Figure 9. Recommendations from A Roadmap for Synthetic Biology in the UK  
(Technology Strategy Board 2012b, p.5) 
 
These recommendations, as discussed throughout this thesis, serve as an important guide 
to the dimensions of the emergence of UK synthetic biology.  
 
The synthetic biology leadership council (SBLC), identified in the fifth recommendation, had 
its inaugural meeting in November 2012. The SBLC, as explained in Willetts’ quotation 
above, was originally co-chaired by the minister and Lionel Clark, an industry representative. 
The SBLC included various invited members of academia, industry, RCUK and other 
institutional stakeholders. The SBLC was set up as a steering group for synthetic biology in 
the UK and, with the co-chairing arrangement and non-elected council members, also 
enacted a relationship between academic synthetic biology, UK industry and the UK 
government. The formation of the SBLC institutionalised ministerial and industrial 
involvement in the steering of UK synthetic biology.  
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As well as acknowledging the roadmap and SBLC, Willett’s SB 6.0 speech included a series 
of funding announcements relevant to the other four recommendations and signalled the 
“start of a new wave of investment supported by the British government in translation of and 
research in synthetic biology” (Willetts, 2013). In the order of the speech these were to:  
 
• Contribute to the world effort in synthetic biology by creating an innovation 
knowledge centre (IKC) to bring together academics and people focused on 
applications of synthetic biology with the aim to accelerate the translation of 
research to application. This was to be based at Imperial, led by Professor Kitney, 
with a five-year grant of £10 million 
• £1 million to collaborate with USA, China and India on a project aimed at producing 
a fully synthetic yeast genome. The UK component was to be led by Dr Tom Ellis 
and Professor Paul Freemont  
• £20m for synthetic biology research centres (SBRCs) to generate research relevant 
to one or more industrial sectors  
• £10m synthetic biology seed fund for companies and pre-companies “to help bridge 
what’s called the Valley of Death between pure research and commercialisation”   
• £18 million for DNA synthesis technologies 
• £2 million to train young academics  
• This was in addition to £65 million already committed by BBSRC and EPSRC  
 
These commitments perform how the promises of synthetic biology are to be realised in 
institutional ways. The synthetic biology IKC, called the Synthetic Biology Innovation and 
Commercialisation Industrial Translation Engine, was funded in 2013. This long title has 
been abbreviated to SynbiCITE (pronounced “Syn-bee-city”). The establishment of six 
SBRCs, SynbiCITE and the seed fund divide the labour of innovation into different 
institutions. The SBRCs are to generate industrially relevant knowledge. SynbiCITE is to 
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identify opportunities from synthetic biology research and match them to industrial partners 
or back the formation of new companies with support from the seed fund. The international 
projects are a ‘signal’ of the UK’s commitment and leadership, underlined by the 
announcement being made at the international conference. Many of these developments are 
discussed in more detail in Section 5.3.  
 
For the purposes of this argument, the alignment of the expectations of synthetic biology 
with UK state needs legitimised government investment and facilitated actors’ access to 
increased commitments. Public and ministerial announcements are a mixed blessing: they 
simultaneously raise the stakes for innovators while making it more difficult for funders to 
renege on their commitments (Deuten & Rip 2000, p.80). Furthermore, Schyfter and Calvert 
(2015) have begun to explore the way the expectations of synthetic biology have been 
realised in different institutional formations in the UK and USA. They argue that some of the 
organisational developments ignore the infrastructural requirements needed to realise the 
promise of an engineering discipline. In other words, there is a tension between realising 
economic gains and realising engineering benefits. Whether or not this turns out to be critical 
tension, synthetic biology is an academic field where governmental and industrial affiliations 
are presently realised in institutional formats.  
 
 
A global synthetic biology leader  
 
In 2010, the UK was presented as a world-leader in synthetic biology basic research. 
Professor Richard Kitney is quoted as saying, “as far as the academic research side of 
synthetic biology is concerned we are number two in the world at the moment, the US being 
the leader” (House of Commons Science and Technology Committee 2010, p.13). The 
roadmap recommended the UK “assume a leading international role” (Technology Strategy 
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Board 2012b, p.32).  The earlier quotations from policy documents present a history of 
world-class bioscience and innovation from the UK. This is nuanced as actors make 
international comparisons and shape the global leadership that the UK could achieve.  
 
Although the UK is second to the US in terms of research output, the UK is a leader in terms 
of funding in Europe.  
  
So the UK has really taken a leadership role in that aspect and we’ve also funded an 
awful lot of synthetic biology so when you look at the portfolio of funded grants, for 
example, between the UK and the the rest of Europe, the UK makes up maybe about a 
third of the funded portfolio. So we’re quite considerably ahead of the next highest funder 
of synthetic biology in Europe, which I think is Switzerland. 
(Research administrator 4 interview, 16th July 2014) 
 
Establishing UK synthetic biology means the state can be enacted as a leader of some form. 
Although the US is a leader of research output, there is a sense that the UK was leading the 
US in some of the practices that were being undertaken. The Roadmap, in particular, seems 
to be a part of a strategy that the UK is pioneering, which participants felt is recognised by 
actors in Europe and the US.  
 
It’s quite nice now that you know people all over Europe and other countries are saying 
well wow look at the look at what the UK are doing in synthetic biology, isn’t it great? We 
need to do that. We need a roadmap. So one of the recent talks I was at, there was 
someone from the NSF in America [who] was giving a presentation and her finishing slide 
actually was: So now we’re quite agreed in America that what we need is an American 
roadmap. And they had a picture of our roadmap with the UK crossed out and USA 
written on it. And bearing in mind that that’s the country where synthetic biology really 
started. It’s quite cool, actually, that everybody’s looking to the UK and they think that 
politically and organisationally and funding wise we’ve kind of got all that done. 
(Research administrator 10 interview, 18th August 2014) 
 
States of Synthetic Biology  
 	 159  
Here, the administrator acknowledges a playful rivalry between the UK and US. This is 
coupled with the sense that the UK ‘does better than it should’ in biological research output, 
given its size:  
 
I think the UK punches, probably punches above its weight in terms of the number of 
academics here. Probably perhaps. Biology. So it’s somewhere where we can take the 
lead… And the US, the US are definitely um, not jealous but they look to us, I think.  
(Research administrator 6 interview, 19th August 2014) 
 
Thus, the UK is a successful place for synthetic biology. The notion that the UK has 
successfully organised synthetic biology plays out in the Roadmap, which envisions the kind 
of leading role the UK might take:   
 
Whereas the UK is considered to lead synthetic biology in Europe, our total research 
funding is significantly lower than in the US. On the other hand, overall research effort 
across Europe including the UK is comparable to the US, placing the UK in a prime 
position to continue its leading international role, for example in helping to establish 
international standards, both technical and regulatory. 
(Technology Strategy Board 2012b, p.32) 
 
In interview, David Willetts presented the UK as a leader in standards and regulations 
because there are difficulties in innovation funding and in how much scientists value their 
work.  
 
I think we can innovate in other ways. I mean, I accept that shifting to mass production is 
something that we find tricky in the UK. Because science overestimates it’s significance 
and there isn’t public funding. But there are other forms of innovation that we may be 
better at. For example innovation in standards and regulation. 
(David Willetts interview, 2nd September 2014) 
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The differences alluded to here, between academia and industry, are covered in more detail 
in Section 5.2. However, this perceived position as a leader of European research policy has 
been enacted by the UK’s principle role in developing the Strategic Vision for the European 
Research Area in synthetic biology (ERASynBio 2014). This document bears striking 
resemblance to the Roadmap in terms of the themes and development opportunities. The 
point here is that, the perceived successes in policy may generate work in other policy 
areas.  
 
While the Roadmap appears to be particularly important it is not the only work that 
contributes to the UK as a policy leader.  
 
The UK is really leading the world in some of the policy aspects. So, the UK did the 
synthetic biology dialogue. We published a report on the social and ethical implications, 
erm, we published the UK synthetic biology roadmap. So we’ve been involved in a whole 
range of different policy activities and yeah, even the US is now getting to the point where 
its starting to want to do some of those activities. 
(Research administrator 4 interview, 16th July 2014)  
 
Both the report, the Synthetic Biology: Social and Ethical Challenges (Balmer & Martin 2008) 
and the reported findings from public workshops of the Synthetic Biology Dialogue (TNS-
BMRB 2010) contribute to the performance of the UK state as a global policy leader.  
Broadly, while the US is understood to have the highest national investment in synthetic 
biology in this narrative, the UK is thought to be in a position that it could lead the 
international policy developments and shape the biological and innovation standards 
concerning synthetic biology. Thus, it connects some kinds of policy work in synthetic 
biology with the status of the UK State.  
 
This section has explored how the promises of synthetic biology – that it could form the 
basis of an industrial revolution and support the UK economy and society – have been 
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turned into funding commitments to support certain kinds of institutional developments. The 
alignment of synthetic biology and the UK state has involved the creation of various 
organisational structures including the SBLC, the SBRCs and SynbiCITE. These 
relationships bring with them pressures and uncertainties. They also perform the UK, not as 
a global research leader necessarily, but as a leader of standardisation and policies. I have 
shown how the alignments and connections between state and science are contributing to 
the shape of synthetic biology in the UK. The next section begins to explore the importance 
of, and labour that goes into, maintaining synthetic biology as a new field capable of novel 
contributions.  
 
 
4.2 Demarcating Synthetic Biology  
 
The above discussion appears to treat synthetic biology as a single object. However, as I 
explore in this section, synthetic biology is generally understood as a range of approaches 
and techniques rather than as a single thing. The appearance of an identifiable object, 
synthetic biology, is achieved in local specific contexts. Furthermore, how synthetic biology 
is demarcated conceptually and in practice has implications for the way resources are 
allocated and for what might count as translated research. That is, what counts as 
successfully commercialised or industrialised synthetic biology. This section examines 
demarcation as a sister process to articulating alignment. Alignment, so far, has been 
concerned with connecting entities and tinkering by reorganising institutions. Demarcation, in 
this section, is mostly concerned with dissociating and distancing.  
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Defining synthetic biology  
 
There is not a single and unanimously agreed-upon definition of synthetic biology. The 
definitions of synthetic biology are multiple and contested (see Section 1.2). Actors do 
identify synthetic biology practices, as multiple as they can be, and these form local 
boundaries around what synthetic biology is, and what it is for. For many actors, the moves 
towards commercialisation and markets bring to the fore particular kinds of statements about 
what synthetic biology is. Statements about what constitutes ‘proper’ synthetic biology.   
 
Actors including researchers and administrators talk about synthetic biology as a diverse 
field composed of various subtopics and research interests. Synthetic biology was referred 
to as a “broad church” (academic researcher 4, 4th December 2013) and was described as 
“many things to many people” by one primary investigator (academic researcher 15, 28th 
August 2014). Smirking, one participant said, “I expect you’ll spend the first few chapters of 
your thesis trying to define synthetic biology… which there’s a lot of debate about at the 
moment” (industry rep 1, 1st September 2014). In other words, it is not contentious to say 
that synthetic biology is not singular since the actors are well aware of how contested the 
definitions are; there is already awareness of non-unity and diversity in synthetic biology. 
These points also form a starting place for the argument in Section 7.2.   
 
There are a number of schematic representations of synthetic biology that circulate in 
academic and policy discourse. The Roadmap, for example, includes a diagram showing 
how synthetic biology is translational. Academic disciplines contribute to understanding; 
synthetic biology then converts the knowledge into industrial and market applications (see 
Figure 10 on the next page).  
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Figure 10. Synthetic biology as a translational field of science  
(Technology Strategy Board 2012b, p.13) 
 
The diagram is a representation of the diversity of synthetic biology. Here, synthetic biology 
is positioned above of academic disciplines and below market sectors. Various mathematical 
and biological sciences and different scales of investigation are orientated to different market 
sectors. It draws a boundary around synthetic biology by showing which disciplines are 
legitimately involved and the kinds of process that convert knowledge to application.  
 
Administrative practices are also an important set of activities that produce versions of 
synthetic biology. For instance, in funding decision-making, defining synthetic biology can 
take a different form than a diagrammatic representation. I briefly describe how these 
funding processes contribute to forming synthetic biology.  
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One way researchers can get money is by applying to RCUK for grants. RCUK has two main 
streams of funding. Responsive mode is the standard route for gaining funding while a 
parallel mode, special opportunities, can include ‘hot’ areas of science, strategic longer 
larger awards (SLoLa) for experienced academics, career development grants, business 
opportunities and so on. A researcher, or group, fills out a proposal form online and submits 
through the Joint Electronic Submission system (Je-S). Application forms include mundane 
criteria such as selecting a research council to which to apply, the type of scheme and 
completing the form correctly. These are submitted by a deadline and are sent for review by 
an expert panel of peers – ‘excellent science’ is the main criterion for RCUK. The proposals 
are ranked by the panel and monies distributed accordingly.  
 
At the time of the interviews, synthetic biology was a funding priority for RCUK and so there 
was a specific allocation for proposals. This means a particular area of science has a 
specific funding code. The administrator quoted below decides that because synthetic 
biology has its own funding code, RCUK understands it as a discipline.  
 
I think I do see it as a as its own scientific discipline but there’s definitely something that… 
So when [RCUK] code grants there’s definitely an approach that we look for. So does it 
have an engineering spirit? Is it using mathe-model, math, you know, modelling to ensue, 
to inform the biology that they’re going to influence? All of the, is it modular? 
... in terms of [RCUK] I don’t think we really don’t define it… But I mean we code it. So 
when we get all of our responsive mode grants in we then go through and and we code 
the grants according to what scientific areas they fall in. And synthetic biology is one of 
those so we obviously see it as a discipline in its own right.  
(Research administrator 10 interview, 18th August 2014) 
 
The blurry line between discipline and approach is captured by the quote. Synthetic biology 
in funding administration, is text and diagrams on a form, written by an academic, that can 
be identified on an application by administrators, and coded so it goes to the correct panel 
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for review and funding is allocated from the correct stream. This is a set of practices from 
which laboratory work is absent. Instead, it is a bureaucratic object that can be used to 
contain applications and is transported between researchers, administrators and review 
panel.  
 
These practices function to assign some projects to synthetic biology, and not others, and 
therefore contribute to synthetic-biology-as-a-thing. The object of synthetic biology is done 
differently by different groups (Mol 2002). This means the synthetic biology is shaped by the 
way funding bodies process grant proposals as well as the way researchers align their work. 
Furthermore, the way industry define synthetic biology has implications for what counts as 
translated synthetic biology and for the way synthetic biology is treated outside of the 
academe.  
 
 
The stakes  
 
In the summer of 2014 the international company Ecover, a ‘green’ producer of soaps and 
detergents, announced they were replacing palm oil in their products with an oil produced by 
algae. It quickly emerged that the algal oil was produced by a San Francisco biotech 
company called Solazyme. This led to a “furore” including reports in national newspapers 
like The Guardian (UK) and The New York Times (USA) (Ginserg 2015).  
 
One participant suggested what the implications could be of defining synthetic biology in 
different ways.  
 
I think the problem as I just alluded in synthetic biology is two, really. One, is there’s a bit 
of stress at the moment between academics particularly in the UK who want to be very 
very broad in the definition of synthetic biology so they slip under the funding wire. On the 
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other hand, industry who are being attacked by activists who want largely want to rerun 
the GM debates, which again I participated in when I was in industry. They want [the 
definition] to be incredibly tight so they don’t fall under the wire. So there’s this kind of odd 
dichotomy of people being very specific. As [in]: oh, of course my my molecular biology is 
a synthetic biology. I made these oligos, didn’t I? And, yeah, and you get kind of 
companies who have effectively built an organism from scratch who say, oh no no no no 
no no no no no. And I didn’t use engineering principles. We just damn well did it. And so, 
you know, there’s a there’s a difference there.  
(Research administrator 12 interview, 19th August 2014)  
 
This quotation is about how synthetic biology is interpreted and used. Academics want to be 
able to apply for grants and so the broadest definition works for them because it is the most 
inclusive. Meanwhile, industry want a restricted definition so they can control whether they 
align themselves with synthetic biology or not. This point was made in The Guardian by the 
ETC group arguing that Ecover exploited the confusion of what constitutes synthetic biology 
to claim they were not using novel biotechnology (Thomas 2014). This highlights how 
difficult it might be to anticipate what will happen as synthetic biology moves from academic 
science to industry. What counts as synthetic biology may change as it is translated from 
one domain to another one.  
 
These sections have described some examples of the material practices involved in 
‘bounding’ synthetic biology (Meyer 2006). In the next section, which explores boundary-
work as a rhetorical practice of demarcation (Gieryn 1983), proponents attempt to separate 
synthetic biology as a novel contribution to science.    
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Beyond craft science  
 
For many involved in bioscience, the difference between synthetic biology and other 
contemporary biologies, comes down to purpose. For them, synthetic biology is about using 
microbiology techniques to create a system, device or biological part that would solve an 
identified problem. One PhD student referred to this as doing “closed” as opposed to “open” 
science (field notes 13th January 2014). Another PhD student contrasted their “discovery-
based project” generating knowledge about algal communities with, perhaps only half-joking, 
the “saving the world” synthetic biology project of their colleague (field notes 13th January 
2014). These statements enact a boundary between applied synthetic biology and basic 
science, though “basic” research is produced in various contexts with an array of meanings 
(Calvert 2006).  
 
One of the ways that synthetic biology is distinguished from other bioscience is by 
articulating microbiology as a ‘craft’ science that is inconsistent from context to context. For 
some actors biology is not reproducible because “it can be demonstrated on occasion in the 
lab… 85% of all biological research reported is not repeatable” (John Collins, SynbiCITE, 
interview 3rd July 2014). They also argue that as biological properties change at increasing 
size, there are problems with scalability. These two points, reproducibility and scalability, can 
be seen as heuristics that are imagined to guide the application of an engineering approach. 
This means standardisation is an integral activity that would solve some of the problems 
actors identify with other bioscience.  
 
Metrology and standards are central to the project of synthetic biology and apparently crucial 
to the coordinated industrial commercialisation of biological knowledge. From this point of 
view, synthetic biology solves issues based on manufacturing since biological functions 
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need to be repeatable. The lack of reproducible results also has an impact on the acquisition 
of funds for ‘translational’ projects:  
 
The trouble is, you look at the returns of VC industry in this sector and it’s extremely poor. 
I mean, who would put the money in? It’s extremely high risk. The attrition is very high. 
Oh, did I say that you know that ten per cent of biological research is reproducible? No 
wonder it’s high. 
(Industry rep interview, 1st September 2014) 
 
(Transcript note: earlier in the interview they say, “it’s estimated that only 10% of that 
work is reproducible” and this quote has been edited to fit with their own and other 
circulating numbers.) 
 
The industrial representative argues that investment is problematic because the 
reproducibility of biological results is poor. Knowledge, on this view, cannot be increased if 
the results of experimentation cannot be repeated and so investors are unlikely to come 
forward because of the risk. The role for synthetic biology, and for the participant’s company, 
is to increase the reproducibility of biological research.  
 
The commercial director of SynbiCITE made the point that turning biology into a 
reproducible science was a way to enable translation to industry and create wealth:  
 
Effectively [to] use different tools or different toolkits with the same design to produce the 
same output, and you can verify, that you corroborate, you can model it. You can 
simulate it and you can reproduce it. But it sounds easy. But actually that’s what 
translation is. Reproducibility. Sustainable reproducibility. And ultimately profitable 
reproducibility.  
(John Collins interview, 3rd July 2014) 
 
These comments present synthetic biology as the solution to commercialising biology in 
different ways. They draw on the epistemological goals of synthetic biology and argue that 
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they facilitate gains, not just in knowledge production, but also in creating industrial 
applications from biology. This is in addition to the way that synthetic biology ‘fits’ with 
ownership regimes that appeal to industry (Calvert 2012). Demarcation draws on problems 
actors identify in biology and argue that synthetic biology will be able to convert knowledge 
to products by changing the reproducibility of biological experiments, which will facilitate 
manufacturing and increase confidence for investment.  
 
 
Cynical alignment   
 
An overall project for some synthetic biologists is to work towards the standardisation of 
biological parts. Standards are a key point of differentiation in the argument for a distinct 
synthetic biology. Standards are therefore a key resource for articulation and demarcation. It 
is through standardisation that reproducibility is to be achieved. This section explores how 
proponents of synthetic biology argue that some researchers are ‘re-labelling’ their existing 
work. Then, in the following section, I show how researchers, particularly molecular 
biologists, suggest that synthetic biology is merely a ‘re-badging’ of their established 
research programmes. Cynical alignment can work in both directions.  
 
Standardisation is both a key defining feature of synthetic biology and essential to fulfilling its 
promise. One research administrator said:   
 
There are certain things you can standardise easily like data and the way you work with 
the data. More difficult is actually when you talk about standardising life, so making a real 
toolkit of biological parts. And that is incredibly difficult but it’s really essential if yeah, if 
synthetic biology [is to] fulfil its potential then there’s a whole load of activities that really 
need to be standardised. And that is a giant technological problem. Which no one has 
really worked [out] a solution to yet. And that’ll require, not only investment in  
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infrastructure, but also just for the scientific community to sit down and say, you know, 
what are, what’s gonna be our standards and how we’re gonna work in the future. 
(Research administrator 4 interview, 16th July 2014) 
 
This quotation illustrates the notion that standardisation is not a purely technical problem. It 
involves social changes, too. This is despite standardising and modularising life being 
problematic in that advancing engineering often requires bespoke rather than standard parts 
(Calvert 2013). Consensus about the kinds of biological tools that will be in the kit also 
means people agreeing to standardise the ways synthetic biology work can be done. This is 
the central goal of the Flowers Consortium, a group of five UK universities attempting to 
create an infrastructure in the form of standards for synthetic biology (The Flowers 
Consortium 2015).  
 
The fundamental work in synthetic biology can be understood as the construction of 
standards, modules and registries. For instance, the iGEM competition has a track for 
“fundamental advance” (field notes, iGEM, 1st November 2014). This still leaves applications 
that need to be developed and translated; there is a balance between developing standards 
and generating new products:  
 
The scientists at [X] were kind of really annoyed because [another institution] were not 
doing proper synthetic biology… they were going for the low hanging fruits of application. 
Commercial application. So, for example, [another] centre was considered to be one 
where they were just doing industrial biotechnology or biofuels or whatever just because 
that would be a quick win. That when people who are trying to do proper synthetic 
biology, trying to develop standardised parts which can be used in many different 
contexts, were penalised because of their lack of kind of speed of application.  
(Social researcher 1 interview, 1st July 2014) 
 
Here, a boundary is established between “proper synthetic biology” and scientists doing 
“quick win” work which does not contribute to the community ethos of standardisation. For 
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some researchers, there is a distinction within synthetic biology: the ‘fundamental’ work 
being the creation of standards and parts, orthogonal DNA and so on, while the ‘applied 
side’ is about developing the specific product or service. Yet, some funds go to groups who 
are not in the core group of scientists, and sometimes these researchers are seen as not 
contributing to the overall programme of synthetic biology. This means those researchers 
working on ‘fundamental’ projects can feel as though they are punished because the 
creation of infrastructure is time-consuming. Thus, by promising speedy applications, other 
researchers were thought to be able to access resources and reduce core funding.  
 
The demarcation of synthetic biology is far from straightforward. Actors who were particularly 
invested in the success of synthetic biology raised the issue of ‘rebadging’. For them, people 
who were realigning their work without making significant contributions were risking the 
whole project:  
 
If you then open the door and welcome in things that were existingly done, that were not 
taking into account any of those standards and not putting any efforts into modularisation, 
and building the foundations, then it kinda dilutes the whole thing. It’s like, I dunno, having 
a Lego set and then allowing your friend to come along with Meccano and… It’ll end up a 
mess, right?  
 (Academic researcher 10 Interview, 1st September 2014) 
 
This suggests that synthetic biology needs borders to preserve the founding principles. This 
is in direct tension with research administrator 12’s thought that academics want a ‘loose’ 
definition (see subsection The stakes). According to academic researcher 10, if anybody can 
get funding for synthetic biology work then there is a possibility that this will result, not in a 
standardised approach to biological engineering, but in an ad hoc discipline. In this view 
synthetic biology, as a codified and systematised science, is vulnerable if funded research is 
not committed to contributing to the specified engineering approach. This version of the 
rebadging argument puts synthetic biology itself, all its potential, on the line.  
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However, any separations between basic and applied bioscience can be problematic. In 
their introduction to their overview of STS, Bauchspies et al. say:  
 
We can already see in fields like biotechnology that the distinctions between pure and 
applied science and between science and technology are no longer viable  
(Bauchspies et al. 2006, p.9).  
 
For the case of synthetic biology, it is not so much that these distinctions are not viable so 
much as they are remade and enacted at specific points. They are also dependent on the 
perspective of the observer – fundamental synthetic biology to one person might be 
another’s applied molecular biology.  
 
 
Resisting a Revolution  
 
While synthetic biology attempts to distinguish itself from other biological sciences (it does 
not appear to need to be distinguished from, say, engineering or mathematics), there is a 
trend among ‘classical’ microbiologists to view synthetic biology as offering nothing new. 
This could occur in different ways and these are explored below.  
 
RCUK and UK government funding policy identified industrial biotechnology as an area of 
investment. Thirteen networks in industrial biotechnology and bioenergy (NIBBs) were 
funded in 2014. I ‘followed’ synthetic biology researchers to a launch event for one of the 
NIBBs. The event was a two-day meeting which involved various sessions and 
presentations aimed at fostering collaboration. (A more detailed description can be found in 
Section 5.1.) On the first morning I was one of the first people to enter the conference room. 
There were large round tables, around ten chairs each, and a projector screen at the far 
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end. A couple of event organisers handed out name badges. I sat down and introduced 
myself to neighbours as the room filled up. A senior academic scientist joined me. When I 
explained I was interested in synthetic biology, she leant over to me and, in a hushed yet 
forceful tone, explained synthetic biology was ‘just molecular biology’ (field notes 9th 
September 2014). Despite synthetic biologists being at the meeting, synthetic biology was 
not a high profile feature of the event. The main references were during a plenary where a 
“synthetic biology type approach” was written on a whiteboard as part of a cluster of ideas 
aimed at solving particular problems. This had the effect of reducing the status of synthetic 
biology, graphically making it one of a number of allied approaches in industrial 
biotechnology, despite the claims that synthetic biology could create an industrial revolution. 
 
Similarly, another senior researcher found synthetic biology to be something which had a 
long history under other names. They concluded that the name is irrelevant and that the 
outcome is key.  
 
I argue again that actually that sort of things been done under different badges for many 
many years. So as you can see I’m slightly more regressive in terms of synthetic biology 
and you know, at the end of the day, the important thing is the outcome, whether there is 
an improvement in our understanding of processes… or whether you end up with a strain 
that has improved industrial performance, ok? So the net result is the same. 
(Academic researcher 18 interview, 28th July 2014) 
 
Here, the process, whether synthetic biology or otherwise, is less important than the 
outcome. However, as alluded to previously, even though formal definitions and 
representations of synthetic biology circulate participants often commented on the difficulties 
of defining synthetic biology.  
 
One of the issues, then, concerns novelty. One administrator working in innovation said:  
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I think for me, for my definition of synthetic biology is, is new biology. You know, is it a 
biological system [that’s] fundamentally new? Not rearranged in a way that would achieve 
in a, it’s something fundamentally new.  
(Research administrator 12 interview, 9th August 2014) 
 
This type of novelty, voiced primarily by those with microbiology training in interviews and 
meetings leads to the conclusion that synthetic biology is not new. Synthetic biology uses 
the same techniques as ‘classical microbiology’ and some of its products are so similar that 
the two are indistinguishable when using the definition “making new forms of life”. Academic 
researcher 15 described how they had been working on protein synthesis for years and now 
their research seemed to align with some of the “synthetic biology from the USA” (Academic 
researcher 15 interview, 28th August 2014). Thus, different participants granted synthetic 
biology more or less novelty.  
 
A second way the novelty was challenged was related to the idea that synthetic biology is an 
extension of other techniques. Academic researcher 4 described their synthetic biology 
project as using “classical microbiology” techniques (interview 4th December 2013). 
However, they found it very difficult to explain how the synthetic biology project they were 
involved in could be distinguished from previous work they had done in microbiology. In 
other words, synthetic biology, for some researchers with micro and molecular biology 
training, is simply a rebranding of biological techniques that were already well developed.  
These resistances connect synthetic biology to this history of microbiology. Microbiology has 
long employed the techniques that the actors feel are appropriated by synthetic biology.  
This could be seen as a form of boundary work based on intra-scientific inclusion rather than 
expansion, expulsion or protection of autonomy (see Section 2.1). This is because it negates 
the idea that synthetic biology is new and may work to retain access to some of the 
resources that actors feel are being diverted to synthetic biology. 
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Synthetic biology is constructed as the solution to the UK bioeconomy, given that it aims to 
improve the reproducibility of biological research. To highlight ‘trial and error’ methods of 
biological research as being irreproducible happens to be the inverse of the way that, in 19th 
century England, John Tyndall separated science from mechanics:  
 
Scientists acquire knowledge through systematic experimentation with nature; because 
mechanicians and engineers rely on mere observation, trial-and-error, and common 
sense, they cannot explain their practical successes or failures. 
(Gieryn 1983, p.786) 
 
The argument made here about mechanicians, particularly the ad hoc and iterative nature of 
engineering, are almost exactly how actors in synthetic biology criticise other biological 
science. On the other hand, engineers are not interested in explanation and are ‘happy if it 
works’ (field notes, iGEM meet up, 18th July 2014). The contributions of synthetic biology, 
and problems of biology, are deployed in ways to discredit claims to novelty or to justify 
support for different areas of science. Since “novelty is a requirement for marketability in 
science” (Fujimura 1987, p.282), this affects how actors can make their research relevant 
and secure access to resources.  
 
This section has explored the ways in which the boundaries of synthetic biology are 
performed with respect to other biology, and that even the notion of basic and applied 
knowledge exists within the ‘translational’ field of synthetic biology. Establishing synthetic 
biology’s boundaries is a messy process with actors deploying engineering principles as 
distinguishing features. On the other hand, some actors dismiss synthetic biology because it 
relies on well-established biological techniques. The credibility of synthetic biology, and 
proponents’ access to resources, are at stake. The next section charts another strategy for 
enhancing credibility – creating a plausible future.  
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4.3 Imagining an Industry    
 
This section explores the ways that a future synthetic biology industry is being shaped in the 
present.  
 
 
Supporting Industry Creation 
 
One institutional enactment of the roadmap’s recommendation “to invest to accelerate 
technology to market” has been the establishment of SynbiCITE, the synthetic biology IKC. 
There are currently seven IKCs in different technological areas. These are centres of 
expertise and:  
 
Are a key component of the UK’s approach to the commercialisation of emerging 
technologies through creating early stage critical mass in an area of disruptive 
technology.  
(EPSRC 2015) 
 
The case for an IKC is usually created following consultations with stakeholders. The act of 
establishing an IKC in synthetic biology aligns synthetic biology with other emerging 
technologies.  
 
The purpose of SynbiCITE is to support the establishment of commercial technology. One 
research council administrator said:  
 
And my view on why we have an IKC rather than just say the TSB [technology strategy 
board/Innovate UK] doing a call is that the businesses based on the technology are not 
established enough to collaborate in that way… they need other types of support as well 
and there isn’t an established industry and they may be facing particular challenges in 
obtaining funding. So, you know what catapult centres are, I presume, but they’re much 
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more industry led. [In the case of] the IKCs I don’t think the industry has developed to a 
point where they can lead… the TSB and BBSRC are looking for a new industry coming 
of this not, not an incremental innovation, although that may happen. I think… we’d be 
underwhelmed if, you know, we improved process efficiency by 5% in an existing 
industry…            
(Research administrator 1 interview, 19th August 2014) 
 
SynbiCITE has been funded because there is not yet a UK industry. In its absence there 
needs to be some kind of work that creates the shape of an industry. The expectation of 
some funders is that a synthetic biology industry would offer something more profound than 
‘an efficiency increase’ to current production lines.  
 
The government’s support for synthetic biology has had an impact on the way decisions 
about the allocation of funding are made, and the identification of organisational needs. 
There are currently seven IKCs in the UK. All of them, except for IKC for synthetic biology, 
have been created following consultation with industry and academic experts.  
 
I think the one thing that I’d just mention and it may make may not be relevant to you at 
all… but is on my mind… is that for synthetic biology IKC is the first IKC that we’ve 
awarded in a top down way. So, but it was, we want an IKC in synthetic biology and it’s in 
the roadmap… but previous IKCs have all been as a result of an open call where people 
came in and said, you know, you could have an IKC in this area or this area or this area 
so we’ve been choosing between different areas… So, you know, when I talked about 
panel meeting we were looking at three IKCs in synthetic biology. Previous panel 
meetings have um… been reviewing the case for the IKC as well as the ability to deliver 
it. If you like. 
(Research administrator 1 Interview, 19th August 2014) 
 
The case for SynbiCITE was not in competition with IKCs in other areas. For synthetic 
biology, there was going to be an IKC. The question was, “to whom would it be awarded?” 
rather than “does the UK need an IKC in this area?” Uniquely, SynbiCITE was awarded in a 
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‘top down’ way (research administrator 1 interview, 19th August 2014). The initiation of 
SynbiCITE is part of the process of creating a UK synthetic biology industry in the absence 
of companies with the ability to develop products and services into a market. In imagining an 
industry, actors refer to other entities to shape a future for synthetic biology. The next three 
sections consider the character of the future industry of synthetic biology.  
 
 
Science for the Public  
 
The public is frequently mobilised in discussions about the future of synthetic biology. One 
research administrator presented the public as the ones who would need to be satisfied by 
innovation:   
  
I think another big potential challenge for synthetic biology is around delivery. So, we 
spent a hundred and eighty million pounds on synthetic biology in the UK. When are we 
gonna see the, you know, when is the public gonna see a return of that on that 
investment?  
(Research administrator 4 Interview, 16th July 2014) 
 
‘The public’ is high on the agenda for funders and researchers alike. In interview, the 
commercial director of SynbiCITE said, “I think there’s gonna be a major hurdle with the 
public acceptance of this because too many have for too long tied it to GMO” (John Collins 
interview, 3rd July 2014). A related concern is that even the language used to describe the 
microbes – as ‘bugs’ – might put off the public and exacerbate ill feeling towards synthetic 
biology (field notes, 7th May 2014).  
 
Another participant put this in stronger terms (he was irreverent throughout our interactions – 
his choice of words seemed deliberately crude and comic):  
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I think one of the aims… of the synthetic biology community was to set things up so that 
they didn’t run into the same problems as genetic engineering did. So the lobby, the 
antigenetic engineering lobby in Europe is, to a greater or lesser extent, idiotic and 
caused by failure of the public to understand and lack of desire of the public to 
understand what’s really going on… I think people [supporting synthetic biology] are very 
keen not to repeat that mistake. 
(Academic researcher 14 Interview, 19th August 2014) 
 
Proponents of synthetic biology are consciously attempting to avoid their version of what 
happened with GM crops, in particular, a public rejection. The areas of genetically modified 
(GM) crops and organisms are known to be a significant feature in debates about the future 
of synthetic biology (Marris 2014). I argue that distinguishing synthetic biology from the 
history of GM decreases the possibility of releasing synthetic organisms outside of 
laboratories, perhaps related to concerns about cross-pollination between GM and non-GM 
crops.  
 
The interaction of science and the public can be imagined as some form of trial. A point 
when synthetic biology comes to the attention of the public.  
 
[Synthetic biology] hasn’t yet gone through its kind of Daily Mail moment where it 
achieves sufficient prominence that people start being worried about it. I think that will be 
the test and I hope, and part of what I was trying to do as a layman, was understand it, 
and prepare people for that moment. You know, Craig Venter will at some point say 
something so outrageous or claim to have done something so extraordinary that will be a 
reaction against it and that’s when synthetic biology will be most vulnerable… it hasn’t yet 
gone through that moment of challenge.  
(David Willetts interview, 2nd September 2014) 
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The minister uses ‘The Daily Mail moment’ as a synecdoche for a time in which the media 
reports negatively on a topic, which may contribute to a public rejection. There are risks to 
realising the benefits of synthetic biology.  
 
The conception of a single problematic public does get challenged. At the seventh SBLC 
meeting one proponent of synthetic biology said that it was important to educate the public 
so they respond to facts, rather than their own emotions (field notes, SBLC 27th November 
2014). This view was questioned during the following discussion and Professor Joyce Tait, 
director of the Innogen Centre, argued that the GM controversy was a complex 
phenomenon. She said that the debate and its outcome depended, not on a single public, 
but on a coalition of NGOs with diverse interests including groups with consumer, 
conservation and development interests complemented by sensationalist media reportage. 
The reason GM crops ‘failed’ was not because of a single public, but because of multiple 
concerns about food additives, genetic modifications finding their way into the environment 
and the global practices of large agri-tech businesses. As synthetic biology has attracted 
various types of scholars, there are signs of complexifying the institutional understanding of 
the public.  
 
Despite these conversations, however, GM is still an important entity which actors use to 
argue that synthetic biology is technologically more advanced.  
 
What synthetic biology is, it’s an extension of all the other technological (inaudible 4.04), 
but the tools are just now more precise… some people, who are let’s say not advocates 
of synthetic biology, have been calling it extreme genetic engineering… well actually it’s 
extremely precise genetic engineering. 
(Industry rep interview, 1st September 2014) 
 
States of Synthetic Biology  
 	 181  
Precision here implies control and safety: the capability to produce a specific effect. The 
participant suggests that synthetic biology is not dangerous or irresponsible because it is a 
defined and moderate technology.  
 
The dominant discourse configures the public as a single unit, and one that is a threat to 
realising synthetic biology’s potential (Welsh & Wynne 2013; Marris 2014). The idea of 
public acceptance of synthetic biology often includes references to a forerunner technology 
– genetic modification. Proponents tend to understand the possible connection to GM as 
problematic. They attempt to separate synthetic biology from GM in order, in their view, to 
create a more publicly acceptable science by presenting synthetic biology as more 
controlled and precise than GM.  
 
 
Regulation and Release 
 
There are other ways that a synthetic biology industry is being shaped with respect to 
releasable organisms.  
 
I think we recently alluded to the terms of commercialisation. I think you can make a 
broad division between things that you release into the environment and things that you 
don’t… the things that you release into the environment… there’s a huuugge number of 
regulatory issues that need to be addressed…  
(Academic researcher 14 Interview, 19th August 2014) 
 
This participant suggests that some regulatory structures can push new technologies down 
different trajectories. In this case, the quotation implies a move away from releasing 
organisms.  
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The perceived regulatory issues associated with developing a new technology can, 
according to some actors, inhibit technological innovation because of knock-on effects in 
other industries.  
 
Regulation as well is potentially a killer in that over-regulated environments destroy 
platform technologies and synthetic biology’s a platform technology. And with all platform 
technologies it’s possible to a spread them too thin or encapsulate them within regulation 
frameworks that prevents you from being able to manufacture. A case in point would be 
nanotechnology. We’ve been producing nanoparts for donkey’s years… they’re in your 
toothpaste, they’re all over, they’re in paint, they’re you know, we’ve got big industry [that] 
has produced them for a long time. Lloyds… will happily insure big industry that’s been 
producing these particles because they’re never called nanoparticules before. And then 
nanoworld was brought out. 
(John Collins, commercial director SynbiCITE, interview 3rd July 2014) 
 
The main concern here is that anxiety about a new technology can result in restrictive 
regulations, and that this can happen even to more established industries that rely on similar 
technology and that appear to have enjoyed a more relaxed regulatory structure. Following 
this line of argument, this means it may be difficult to insure a company against future claims 
and therefore it becomes challenging to develop technologies. The worry for some 
proponents is that a regulatory structure can inhibit innovation.  
 
Although synthetic biology relies on a range of technologies that are already widely used, 
such as cell culture and polymerase chain reactions (PCR), new rules could be brought in to 
regulate synthetic biology. One proposition is to describe a model for how synthetic biology 
might self-regulate.  
 
So, the question I ask everybody is… what’s novel and new about what you’re doing? Oh, 
yeah, I know that. Well, what potential hazards and risks may encourage? Oh yeah yeah. 
I do that. And then the question that always gets most people is, what does an early 
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warning look like? A-right? Because that presupposes that you’ve not answered the first 
two questions sufficiently well. Right. Something’s come in and you’ve missed. What does 
an early warning look like? The airline industry makes a big deal about early warnings… 
No whistleblowing, or anything. Everybody anywhere can say, look, you know, look at  
 
that. Because when a plane falls out the sky. Two hundred and fifty people die. And, I 
think it’s that kind of idea that we’ve got to get into people’s minds. 
(Industry rep 1 interview, 1st September 2014) 
 
The airline industry is highly regulated but, according to this participant, because it has the 
right approach to risk it can be made safe by the people working in the industry. There are 
already efforts to make synthetic biology an industry in which workers feel able to report 
concerns about risk and misuse. For instance, the iGEM Jamboree included a presentation 
by the FBI to encourage synthetic biologists to be ‘on the look out’ for wrongdoing and 
danger and to report incidents and suspicions (field notes, iGEM Jamboree, 2nd November 
2014).  
 
The regulatory structure for synthetic biology is being imagined and created alongside the 
industrial possibilities. The self-regulation of synthetic biology can be a possible solution to 
responsibility. It seems to address the questions arising from the UK Dialogue (TNS-BMRB 
2010) by creating a reflexive workforce. It also implies that externally created regulations, 
which may prove inhibiting to the development of the technology, can be avoided. Thus, the 
possibility of releasing synthetic biology organisms in the UK is further reduced.  
 
 
Contained bio-manufacturing 
 
Synthetic biology has the potential to produce compounds, be they existing drugs, novel 
medical applications, fuels, oils, rather than crops or other forms of unconfined life. Actors 
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articulate synthetic biology with other technologies to create a future for synthetic biology. 
This industry is located within a world running short of a key natural resource for fuels, oils 
and materials (Freemont & Kitney 2014, p.40). One plan is to use microbes as factories. As 
John Collins says:  
 
In our case its producing materials…so materials industries. Steel industry. Just the 
same… you look back through the history of the production… mass production, which is a 
slightly different process or the manufacturing at scale process which is like [the] steel 
industry. Materials are all manufactured at scale… Synthetic biology is no different. 
(John Collins, commercial director SynbiCITE, interview 3rd July 2014) 
 
Here, Collins makes a distinction in the way that industrialising synthetic biology is to be 
approached. Mass manufacturing is the production of units such as cars, machine tools and 
electrical goods. Manufacturing at scale is the production of homogenous materials such as 
chemicals and metals. Synthetic biology can fit into a manufacturing at scale paradigm by 
producing various chemicals at scale.  
 
The industrial revolution brought with it important changes in manufacturing processes. 
Developments in other synthetic materials have produced new techniques which has 
enabled the production of other technologies.  
 
…it was actually for industrial diamond and synthetic industrial diamond… which 
interestingly has lots of parallels with the production the manufacturing at scale which is 
different from mass manufacturing um of a material. In this case it was carbonaceous. But 
it was by a route that was the whole synthetic diamond industry is based on a process 
shouldn’t really be able to work… much as the same as lot of biology actually… Until 
diamond could be synthesised diamond tools were made from near gem diamond as it 
was called that was mined out of the ground which has its own ethical issues in its own 
right. As soon as you could start to synthesis diamond and you could make diamond grit 
for grinding tools or for compacting into diamond tools you could actually engineer 
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materials cost efficiently sufficiently well to have the cars and the planes and the light 
bulbs that we have nowadays. 
(John Collins interview, 3rd July 2014) 
 
John Collins aligns synthetic biology with industrial diamonds and the idea they have 
facilitated desirable yet mundane aspects of contemporary life. Synthetic biology, he 
suggests, may do the same for a future way of life. Chapter 6 explores in detail one project 
designed to use synthetic biology to produce novel biomolecules with the aim of moving to 
scaled-up production in future.  
 
A containment ethos was evident during the iGEM competition. Based on their interviews 
with industry, our student team reported on the reduced likelihood of uptake if they 
manufactured a technology based on a releasable organism. They had to change their early 
design to produce proteins and use a complex system of fermenters and filters in order to 
release a protein, rather than have the microbes functioning in the environment. In other 
words, technological solutions utilising synthetic biology need to secure engineered life 
behind screens and filters (field notes, iGEM project 2014).  
 
Aligning synthetic biology with commonplace manufacturing industries domesticates it in a 
way that appears to be aimed at reducing fears imagined to circulate in the public. The 
notion of “contained biomanufacture” is reminiscent of the USA’s sociotechnical imaginary of 
“containment” towards nuclear technology where “the central move was to create a newly 
manageable entity, the ‘‘atom for peace,’’ which converts nuclear energy from terrifying to 
benign form” (Jasanoff & Kim 2013 p121). Thus, by aiming for industrial production, actors 
attempt to produce a beneficial yet uncontentious imaginary industry.  
 
This imaginary iteratively cycles with human action: SynbiCITE has updated its webpage 
and currently displays examples of existing projects. Synthetic biology has been used to 
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create compounds for use in medicine, fuels and foods. However, agriculture and 
environmental applications are still ‘potential’. They have not been realised industrially. 
Thus, applications of releasable organisms have not been translated to production while 
those based on contained bio-manufacture have made Artemisinin (drug), 2,3-butanediol 
(fuel) and Nootkatone (‘natural’ flavour) (SynbiCITE 2015b).  
 
Innovating responsibly, according to the Roadmap, involves both attending to public 
concerns, albeit ones drawn from the GMO debate in the 1990s, and generating a regulatory 
framework. Societal benefit can be achieved because the public is thought to be more 
receptive to microbes that are not released while at the same time the regulatory structure is 
thought to be more amenable to contained microbes. By containing microbes actors may 
avoid public rejection based on fear and some forms of regulation. The ‘scorched earth’ of 
releasable GMOs in crops and food is to be avoided by containing any engineered 
organisms and using them as factories and sites for manufacturing. By imagining an industry 
based on contained bio-manufacturing, both synthetic organisms and the responsibility for 
regulations and safety are to be kept ‘in house’.  
 
 
4.4 Conclusion   
 
Articulating alignment and demarcation are two tandem processes of making synthetic 
biology a ‘doable problem’ (Fujimura 1987). Section 4.1 described how the actors associated 
with life science and synthetic biology articulated a problem-solution that could be addressed 
with synthetic biology. In other words, they aligned synthetic biology with state economic 
deficit and suggested it could be ameliorated in part by funding synthetic biology to translate 
bioscience in order to create a UK industry. Section 4.2 gave details of how actors use ‘an 
engineering approach’ to materially and rhetorically demarcate synthetic biology from other 
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biology to preserve access to resources. However, it is not a case of translating into ‘any old 
industry’. There are specific ways, explored in Section 4.3, of how a synthetic biology 
industry is being established. Successful translation depends on distancing other biology 
and creating a recognisable infrastructure.  
 
The UK state is performed as an innovative state, and one that needs to be capitalised upon 
in the post-2008 financial crash environment. One that has a strong history of life science 
innovation but a place where this transition is precarious. Synthetic biology is a site where 
the UK can be realised as a global leader, not in terms of research output, but in terms of 
leading on policy and standardisation. The UK government, RCUK, industry and academia 
are organisationally intertwined in the SBLC, IKC. The standardised and modularised 
approach to life is also coupled with a desire to see a successful translation to industries. 
This appears to require synthetic biology to be different from GMOs in that the engineered 
organisms of UK synthetic biology are to be used for manufacturing chemicals and 
compounds that are already in widespread use. The researchers themselves distance their 
technology from the ‘release’ of GMOs. Instead, by aligning synthetic biology with industrial 
manufacturing and controlled, mundane technologies, the field is presented as safe, capable 
of self-regulation and beneficial to society in the long-term. In other words, the synthetic 
biology industry is being directed at manufacturing, particularly niche chemicals, rather than 
forms of organisms that exist outside controlled environments. The imagined industry aligns 
synthetic biology with perceived public concerns and state needs.  
 
An analysis of the ‘GM controversy’ has been applied to suggestions about nanotechnology 
governance where the authors argue that awareness and openness of the purposes of 
technologies need to be cultivated:  
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The GM experience demonstrates the degree to which contemporary scientific research 
is informed by tacit visions and imaginaries of the social role of technology. Often 
explicitly utopic these tacit, technoscientific imaginaries form the basis upon which 
research priorities are negotiated and planned. Importantly, however, in the GM 
experience such tacit visions were never openly acknowledged or subject to public 
discussion and debate. 
(Kearnes et al. 2006, p.302) 
 
One aim of this chapter has been to address these tacit visions. In articulating promises, 
actors make present various absences and specify them to make translating synthetic 
biology into a ‘doable problem’ aligned with state needs, features of bioscience and 
perceptions of publics. In the next chapter, I shift to focus on the relationship between 
academics and industry and the importance of successful collaborations.  	  
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Chapter Five  
 
Universities and Industry  
 
 
 
Translation, commercialisation and industrialisation of research imply interactions between 
universities and industry. This chapter focuses on these entities, particularly on the 
performances of relations between them. I begin section 5.1 by showing how funders and 
universities identify collaborations as a key route to accessing resources and realising the 
impact of research. This, in part, justifies the additional resources that these actors deploy in 
an attempt to foster collaborations. A part of this involves circulating ‘collaborative success 
stories’. However, a central concern of the STS scholarship on ‘translation’ is that research 
cultures are different. In section 5.2, I explore how the differences between academia and 
industry were enacted during my fieldwork and narrated during interviews. Then, in section 
5.3, I argue that actors align synthetic biology with industrial commercialisation through two 
channels. Actors are in the process of embedding commercialisation in the new facilities and 
pedagogical practices of synthetic biology.  
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5.1 Collaborating to commercialise  
 
Collaborations: impact, resources and speed  
 
As I have already discussed, synthetic biology is a field with many hopes and promises of 
creating a better future. These promises are for synthetic biology research to deliver benefits 
in health, fuel and food, and for research to produce economic outcomes.  
 
There’s so much pressure on synthetic biologists to think of the market think of 
commercialisation, collaborate [with] companies, all these calls, the SBLCs and 
everything, they have this huge pressure on them to orient their research towards the 
private sector.  
(Social researcher 1 interview, 1st July 2014) 
 
Some of the funding allocation for synthetic biology is specifically attached to 
commercialisation and private companies (these are discussed in Section 5.3). A high profile 
set of RCUK investments has been to establish the multidisciplinary synthetic biology 
research centres (SBRCs). These were awarded over two calls. The first three SBRCs were 
awarded to Nottingham, Bristol and a Cambridge and John Innes joint project in 2014. The 
second call, which was announced in early 2015, was awarded to The Universities of 
Edinburgh, Manchester and Warwick. The industry involvement on these projects was not 
stipulated but was suggested to include “cash contributions, materials, access to equipment 
or facilities and staff participation in research or on a project management 
committee/scientific advisory board” (BBSRC 2013).  
 
In fact, RCUK is one institution that has identified collaborations as a key area for developing 
their own practices.  
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Partnerships and collaboration are essential to bring the benefits of our research to 
people, to drive economic growth and to deliver excellence with impact. Working with 
strategic partners we can continue to leverage additional funds to maximise the 
investment in UK research. We will continue to build on and enhance existing 
relationships with key partners both within and outside of the research sector such as 
HEFCE and the wider UK Funding Councils; the Technology Strategy Board (TSB); 
relevant charities and voluntary organisations; public sector bodies of various kinds; 
government departments; and businesses and industry. 
(Research Councils UK 2015c, p.3) 
 
RCUK connect collaborative working with realising benefits of research investments. 
Collaborations, for them, can also be a route to accessing more funding. The synthetic 
biology Roadmap identified the BBSRC and EPSRC as having successfully leveraged 
funding from the EU, Gates Foundation and NSF (Technology Strategy Board 2012b, p.16).  
 
Furthermore, RCUK identify collaborative working as a way to realise benefits in terms of the 
‘use of knowledge’. Some possible routes for realising benefits are outlined below.  
 
There are rich pathways by which the outcomes of our investments reach application. 
Pathways include direct academic collaboration with companies, public sector bodies and 
civil society; generation of spin out companies from universities and institutes; training of 
a highly skilled workforce; and input to policy development. Research Councils also work 
with businesses and other users of research to understand their agendas and in turn 
influence the research base. 
(Research Councils UK 2010, p.8) 
 
The private sector is listed first in these kinds of collaborations. Various forms of stakeholder 
participation and multidisciplinary working are often a feature for grant proposal guidelines. 
In Fujimura’s (1987) terms, collaborations can increase the do-ability of research by 
increasing resources and by altering work programmes to better align them with 
stakeholders’ goals.  
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Part of the rhetoric of translation is to speed the process of innovation. The Roadmap 
identifies improving collaborations as a way to speed up the realisation of benefits in the 
commercial sector. This is partly through being able to determine the nature of projects and 
also:  
 
It has been shown one of the best ways to speed up [the commercialisation] process is to 
create ‘demonstrators’… In some cases the type of demonstration needed will be 
demonstration of scale, and access to production capability to assist scale-up will be 
important. Some of the facilities needed already exist in the UK. In other cases, 
demonstration will require access to cutting-edge laboratory equipment, and it is 
important that critical equipment is located within the UK – it should be made easier for 
businesses to access the expertise and facilities within the university sector.  
(Technology Strategy Board 2012b, p.22) 
 
According to the Roadmap, collaborations are needed in order to specify how projects will 
be orientated and the production of prototypes is a way to develop technology quickly for 
transfer to market. This requires innovators to have access to technological spaces to scale-
up or refine technologies. Here, collaborations are connected to accessing more resources 
in the name of accelerating commercialisation. As one administrator answered to the 
purpose of ‘a translational agenda’: 
 
I think they’re just trying to progress it all bit faster, aren’t they? I think trying to make that 
link between academics and industrial partners earlier on so that research is meaningful 
to industry and commercialisation sectors in terms of what they want. 
(Research administrator 2 interview, 18th February 2014) 
 
Collaborations are identified as routes for academic research to realise benefits and impact 
more quickly. For translating synthetic biology, this is particularly to establish market benefits 
through partnership with industries. The formation of collaborations is also important as it 
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seems that they result in access to more resources in terms of funding and in terms of 
research and innovation facilities.  
 
In the quotations in this section, collaboration is often treated as a known concept. While a 
dictionary definition of collaboration “suggests the working together of individuals to achieve 
a common goal” the details of both “working together” and “common goal” are not generally 
explored (Katz & Martin 1997, p.7). So, although collaborations are presented as desirable, 
there does not exist a clear agreement for what constitutes collaboration. Collaboration can 
mean different things. The next section explores how institutions such as research councils 
and universities attempt to initiate collaborations and begins to suggest how collaborations in 
synthetic biology are being done.  
 
 
Stimulating Collaboration  
 
There are a number ways that funders and institutions encourage the formation of 
collaborations between researchers and industry. This section describes two mechanisms – 
funding and events.  
 
There is a range of funding opportunities for projects aimed at commercialising bioscience. 
One category of collaborative funding mechanism is called catalysts.  
 
Catalysts are run jointly by Innovate UK and the Research Councils. A Catalyst is a form 
of research and development funding which focuses on a specific priority area and aims 
to help take projects from research to as close to commercial viability as possible. 
(Innovate UK 2015) 
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Innovate UK’s purpose, as the UK ‘innovation agency’, is to support projects that, in the case 
of collaborations with universities, are ‘business-led’. The catalysts are organised, as is 
detailed below, to fund the development and transfer of knowledge from research to market.  
 
The original catalyst is called the Biomedical Catalyst. It is a collaboration between MRC and 
Innovate UK. Catalyst funding is awarded, through competitive calls, to researchers and 
SMEs wanting to develop healthcare research and move it “more quickly from discovery to 
commercialisation” (Medical Research Council 2015a). More catalysts have been launched 
both within and outside the biosciences following the Biomedical catalyst. The three newer 
catalysts are Agri-tech, Energy and Industrial Biotechnology (IB) catalysts.  
 
Via a webinar, I ‘virtually’ (Hine 2007) attended the launch of the IB Catalyst where the 
structure and plans for calls were announced (field notes, 3rd February 2014; see also 
Section 3.3). BBSRC, EPSRC and Innovate UK co-fund the IB catalyst. There are five 
funding streams. Early stage awards are for development of processes and technologies, 
and feasibility projects concerning market opportunities of an “early-stage scientific idea”. 
Early stage translation awards are for academic-led projects at BBSRC and EPSRC eligible 
institutions. Business involvement is suggested at this point, but not mandatory. These 
awards are £2-5M. They aim to:  
 
…encourage the use of new technologies such as systems and synthetic biology 
alongside more traditional approaches such as fermentation and process engineering, 
and biocatalysis; including theory and modelling. 
(BBSRC et al. 2014, p.4) 
 
A separate stream for early-stage feasibility funding can be academic or business-led. It is 
much smaller, with projects funded for a maximum of one year and £250k. The mid-stage 
‘Industrial research awards’ are for projects that develop recent discoveries into technologies 
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or processes which would be commercially viable. These are business-led and up to £5m. 
The business partner must give 50% of the funds. The late-stage awards are for business-
led projects close to proving a process or technology to be commercially and industrially 
viable. Pre-experimental feasibility studies are one-year projects for companies to 
demonstrate scale-up of their proposition. Experimental development awards are for 
businesses in the final stages of testing and demonstrating consistent processes established 
in the pre-experimental feasibility studies. These can be up to £10m. The reason given for 
these awards being so large is because experimentation at industrial scale can be 
expensive (Field notes, IB webinar 3rd February 2014). A hope is that research projects will 
engage with catalysts and that projects will move along the funding stages to 
commercialisation (BBSRC et al. 2014, p.4).  
 
The BBSRC offers other funding for ‘working with business’. Industrial partnership awards 
(IPAs) and ‘stand-alone’ LINK schemes are for developing academic-industry partnerships in 
collaborative research projects. The LINK scheme is for ‘pre-competitive’ research and 
development that would not exist beforehand. IPAs are for collaborative projects between 
universities and UK companies and are “normally funded in preference to standard grants of 
equivalent scientific merit” (Biotechnology and Biological Sciences Research Council 2015). 
Both of these funding streams require written agreements between the parties including 
funding arrangements, deliverables and management of intellectual property.  
 
The research councils have a wide range of mechanisms in their pathways to develop 
collaborations, some of which involve Innovate UK, the UK’s innovation agency. Innovate 
UK co-fund many of the ‘translational’ funding mechanisms with RCUK. The IB catalyst is 
structured in a way that can encourage collaboration and leverage funding from industry. 
These staged awards divide the responsibility for innovation. ‘Translational’ projects are 
academic-led. Meanwhile, the industrial research awards and late stage awards are 
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business-led. The structure of the funding means that development risks begin with publicly 
funded academia in the first stages and are transferred to private companies as the project 
moves through the Catalyst scheme. The BBSRC funds IPAs in preference to research 
projects judged to be of the same scientific value. This highlights the importance of forming 
partnerships for academics wanting to access funding, even for ‘standard’ research.  
 
A second way that collaborations are initiated is through changes in universities. In order to 
develop translation, universities have begun implementing strategies to ensure that 
knowledge production is relevant to stakeholders. One synthetic biologist, academic 
researcher 12, held a senior role in commercialisation and knowledge exchange at their 
institution. They described the initiatives that they had implemented across their university to 
coordinate and improve commercialisation, impact and knowledge exchange. Their 
university had increased the number of non-academic roles related to translation and 
knowledge exchange, increased the funding available for translational activities and 
increased researcher training, including extending courses for students, to help scholars 
learn about translational activities (academic researcher 12 interview, 15th July 2014). 
These activities were also supported with data collection to check that academics were 
meeting with new knowledge exchange personnel and taking up the training opportunities.  
 
Coupled to this, UK researchers are required to demonstrate the relevance of their research 
by describing ‘pathways to impact’ in their funding applications (the process was outlined in 
Section 4.2). These are meant to be specific routes by which knowledge can be 
disseminated and can be expected to contribute to “economic and social impacts” as well as 
academic impacts (RCUK 2014). One research administrator in a ‘grant capture team’ had a 
role to support academics to foster collaborations. In interview, he claimed to be sensitive to 
different groups he interacted with and altered his vocabulary depending on their audience:  
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Because knowledge exchange and impact and industry engagement they’re all kind of 
synonyms in many regards and I do change my language accordingly, depending on who 
I’m talking to, it’s just, part of the academic kind of psyche at the moment to think a bit 
more like that…  
(Research administrator 3 interview, 3rd March 2014) 
 
This administrator explained that they used ‘impact’, ‘engagement’ and ‘exchange’ 
interchangeably, depending on their audience. He also commented the university had 
removed the word “industry” from one opportunity the university offered to make it more 
applicable to some sciences (research administrator 3 interview, 3rd March 2014).  However, 
their overall remit was to increase academic-industry collaboration in a science faculty. He 
argued that establishing a commercial collaboration could be a way for an academic to have 
a clear route to impact. This, in his argument, could make it more likely for an academic to 
get funding by writing a compelling and industrially supported proposal.  
 
Knowledge exchange personnel in universities organise events for academics and industry 
representatives to meet and, hopefully, for collaborations to be started. In the course of this 
research, ‘following the actors’ entailed attending various “showcases”, “bazaars” and 
symposia where research and technical capabilities were displayed with the hope of 
establishing new research and commercial relationships (see Chapter 3). Occasionally, 
these were ‘local’ in the sense that only other researchers from nearby departments or 
universities were invited. More often, the delegate list included representatives from beyond 
academia.   
 
A research bazaar at one university involved numerous presentations from academics in the 
life sciences. There seemed to be a particular emphasis on molecular biology and imaging 
techniques. In a presentation, an academic working on a technology in which proteins could 
‘snare’ other molecules was looking for help to translate findings (field notes, research 
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bazaar, 20th May 2014). A possible application for this idea was as an alternative to 
analgesic drugs and to capture molecules involved in the sensation of pain. Their research 
was at a molecular level and they were looking for collaborators that might help move the 
early technology from ‘simple organisms to humans’. As the researcher wanted to develop 
their findings they wanted additional expertise. Thus, the call for collaborators partly reflects 
an increase in biological complexity. It also reflects increases in social complexity as more 
concerns, such as regulations, become pertinent.  
 
As well as attempting to establish internal collaborations and multidisciplinary working some 
events are staged in order develop external (outside of academia) relationships. CSynBI had 
adopted this kind of approach. The centre held ‘club days’ where industry representatives 
were invited to watch research presentations about on-going work and to pose possible 
research questions to academics affiliated with the centre.  
 
Our centre’s five years old and in the first three years we held industry club days where 
we would… spend a good few months beforehand calling up whoever we thought should 
be interested in synthetic biology and getting them, getting someone from each company 
down to, to Imperial for the day where we would present the kind of work we were doing 
in synthetic biology. They would present problems that they have, we would discuss 
potential ways either that collaborating with us… or maybe they could go elsewhere. But 
it kind of catalysed an interest. And we had, you know, Shell, Glaxo, big companies like 
that and then much smaller companies coming along as well.  
(Academic researcher 10 interview, 1st September 2014) 
 
Holding the club days was a way to spread the word of synthetic biology to possible 
industrial collaborators. Presenting research and sharing problems with one another is a way 
to mix the different domains of academia and industry in a short period of time. However, as 
I argue in Section 5.3, synthetic biology in the UK has entered a new phase in the way that it 
attempts to initiate industry-orientated projects.  
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I also attended an open day at a university where various researchers and administrators 
presented capabilities to other academics and industry representatives (field notes, open 
day, 6th March 2014). The annual event was in its second year, and the emphasis was on 
medical technologies. It took place in a large auditorium, which had been divided into two 
equally sized sections. Near the entrance, set up like a checkers board, were several rows 
of exam tables, each with two chairs. This effectively formed a backstage to the other half of 
the auditorium. A large platform, complete with theatrical lighting, a lectern and amplified 
microphones, faced three stands of raked seats. The delegate list included academics, 
academic administrators and various representatives from commercial and industrial 
companies. Some of these businesses specialised in servicing academic requirements for 
bioscientific equipment and services. Others operated outside the university sector, in 
healthcare and the chemical industry.  
 
The morning programme consisted of a range of academic speakers. They spoke of the 
importance of innovation and the role that could be played by various forms of collaboration 
in ensuring both academic and commercial ends could be met. One academic had spent 
time on sabbatical in the industrial sector and explained how mutually beneficial that had 
been. These talks also highlighted the kinds of opportunities open for collaborations – 
funding, sabbaticals, administrative support.  
 
The afternoon one-to-one session was based on the notion of ‘speed-dating’. This explained 
the layout of the examination tables. Speed-dating is a form of directed interaction where 
participants have time-limited conversations in order to interact with a number of other 
participants in a given session. Before the event, attendees had been provided with a list of 
delegates and had been able to meet with up to three other delegates they thought they 
could establish research relationships with. Each meeting was to take fifteen minutes so 
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attendees were able to outline their research needs, and industrial problems, and see if 
there was the possibility of a future collaboration.  
 
This component of the event was structured for possible collaborators to have ‘meaningful’ 
interactions. However, it also functioned as a way to introduce a number of possible 
collaborators to one another in a short space of time. By providing an ‘opt in’, delegates 
were able to assess the likelihood of collaboration before a meeting. This meant that 
participants had interacted with the delegate list and made a positive judgment regarding the 
meeting. The speed-dating structure relates to the previous point about collaboration being a 
route to accelerate commercialisation. By encouraging representatives to have a series of 
short meetings they could identify possible collaborators and rule-out others in a given 
period of time.  
 
Funders and universities present collaborations as of great importance to the life science 
sector. They connect them to leveraging of further funds, accessing resources and realising 
the impact of academic research outside of universities by suggesting projects be designed 
with non-academic stakeholders. Funders create mechanisms to foster collaboration and 
stage-gate the transfer of risk and knowledge from the public to the private sector. 
Universities employ administrative teams, tasked with increasing ‘grant capture’, who 
attempt to initiate collaborations by staging events for academics and private companies to 
meet and discuss their research and needs. These activities are further bolstered by the 
formal and informal collection and retelling of other successful collaborations.  
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Collaborative Successes  
 
One of the issues with the newness of synthetic biology is that it does not have an 
established history of translation. Success stories can be an important feature in the 
emergence of a scientific communities, particularly in synthetic biology (Molyneux-Hodgson 
& Meyer 2009). Telling ‘success stories’ are a way of increasing institutional memory and 
making a present problem seem surmountable (Deuten & Rip 2000). One administrator 
commented on the importance of being able to collect and retell success stories: 
 
So again it’s part of our responsibility as a team to capture the success stories. And we 
have a series of thirteen, I think, at the moment, and we use those to kind of explain both 
to academics within the faculty what the benefits are. So it could be you know, I got a 
paper out [of] this, or got a patent, or whatever. But also to industry, to say, “these are the 
benefits to the industry”. So those materials are supposed to speak to both audiences at 
the same time. 
(Research administrator 3 interview, 3rd March 2014) 
 
One of the ways the success stories had been ‘captured’ was on a website with case studies 
of successful projects. Although hosted by a university it was accessible via the internet and 
open to any member of the public. This repository of success stories therefore acts as a 
boundary object as it allows “people from different worlds can use or borrow from the 'pile' 
for their own purposes without having directly to negotiate differences in purpose.” (Star & 
Griesemer 1989, p.410). Furthermore, this collection of success stories is an “organic 
infrastructure” that actors have created to respond to “information and work requirements” 
(Star 2010, p.602).  The administrator also pointed to the function of collecting and 
presenting success stories: that they might be able to ‘speak’ to both academic and 
industrial audiences and allow both to see value in partnering with one another.  
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In synthetic biology, the most notable success story has been The Artemisinin Project. 
Artemisinin is a chemical derived from Artemisia Annua, sweet wormwood, and in 2006 was 
highlighted by the WHO as the frontline co-therapy for malaria. Since 2003, Professor Jay 
Keasling and his team at UC Berkeley have been working on and publishing articles 
regarding the creation of a microbe that had been engineered to produce comparatively 
large quantities of an artemisinin pre-cursor, artemisinic acid. In 2004, the project received a 
$42.7m investment from the Bill and Melinda Gates Foundation to develop the technology. 
In 2009, Pharma giant Sanofi-aventis joined the project with a “no loss no profit” agreement 
to licence the technology to produce artemisinin semi-synthetically. On 13th April 2013, there 
were global headlines that the industrial production of artemisinin was about to begin with 
the first year’s yield, of 60 tonnes, being approximately a third of the world’s demand.  
 
At the SB 6.0 conference in 2013, The Artemisinin Project featured in two tracks: 
Transcending technology, transcending industrialisation (mentioned in the Section 4.1) and 
Towards Global Health. Dr Wolfgang Laux, a representative of drug company Sanofi, 
presented his talk “The semi-synthetic Artemisinin Project: Learn from Nature – Go from Lab 
to Industrial Scale” in the Towards Global Health track. Dr Laux discussed the technical 
details of moving from ‘nature to industry’.  
 
Professor Keasling’s talk, titled “Synthetic biology for synthetic chemistry”, began with a 
story of a young boy called George that the professor had met while touring Kenyan medical 
clinics. George was visiting the clinic to collect drugs for his malarial brother. The goal, 
explained Keasling, was to produce artemisinin to stabilise the market, make access to the 
drug more reliable than plant-sourced precursors, and discourage the illicit trade in 
monotherapies (for analyses of how these goals emerged over the course of the project, see 
Marris 2013; Meckin unpublished). He then moved on from talking about artemisinin to 
talking about fuel production, and the possibility of using the Amyris bacterial platform to 
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produce bio-fuels. What Prof Keasling particularly focused on was the difference between 
high value/low volume chemicals like drugs and fragrances and low value/high volume 
chemicals such as oils and fuels (field notes, 11th July 2013).  
 
The Arteminsinin Project was presented at the conference as an example of a successful 
project that had enabled further research to take place. Its importance was highlighted by 
the fact it was the only project to feature in two talks in two tracks. The academic researcher, 
Prof Keasling, presented a story, which had few scientific details but focused on future 
commercialisation and included pictures of people at medical centres in Africa and of 
people-less industrial manufacturing plants in Europe. (The process involves a fermentation 
step outsourced to Huvepharma in Bulgaria and then a photochemical step performed by 
Sanofi in Garessio, Italy (field notes, 11th July, 2013)). The industrial representative, Dr Laux, 
concentrated on the process by which ‘nature’s’ production levels had been scaled up to 
industrial production levels.  
 
The Artemisinin Project has long been the ‘poster child’ for synthetic biology (Marris 2013; 
Molyneux-Hodgson & Meyer 2009). The Artemisinin Project has featured in various scientific 
articles and, perhaps more importantly, there has been a good deal of media coverage (field 
notes, 13th April 2013). Molyneux-Hodgson and Meyer (2009) argue that telling the ‘success 
story’ of artemisinin is one device that helps the emerging synthetic biology community 
cohere. The Artemisinin Project at SB 6.0 became a story about a successfully integrated 
collaboration of academia, charity and industry. It produced further research avenues for 
academics and raised the profile of industry involved in humanitarian work.  
 
In my research, another collaborative success story circulated, but this time among research 
administrators. Two administrators to whom I spoke talked of grant proposals from scientists 
not being funded because of institutional ‘space’ within RCUK.  
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… more and more we’re finding as we try spend this accelerator money that a lot of the 
research is fitting in the gaps between the research council remits.  
(Research administrator 3 interview, 3rd March 2014) 
 
… an ongoing conversation that we’ve been having with the two research councils is the 
need for them to work more collaboratively themselves. Instead of, you know, saying if 
you send it BBSRC they’ll say, no, it’s MRC. If you send it [to] MRC they’ll say no it’s 
BBSRC. That’s what happens.  
Participant places hands palm down as if picking up oranges and then gestures to 
the area between them. A third, empty space.  
… Where does it go then? So sometimes people can kind of lose out.  
(Research administrator 2 interview, 18th February 2014) 
 
These administrators perceive a ‘gap’ in the way that funding is awarded. The structure of 
the research councils, in some cases, means that some projects are not funded because it is 
not clear who should fund them. Synthetic biology, spanning the domains of biology and 
engineering, could be such an example.  
 
However, RCUK created a cross-council working group for synthetic biology that has 
reportedly developed a good reputation within the overall organisation.  
 
So for synthetic biology, actually, we work in a very collegiate cross-council manner. It’s 
really good actually because um, you know when this big chunk of capital got awarded to 
the councils it was an RCUK award; it wasn’t made to any specific council… the funds are 
held by BBSRC which is why we lead on the implementation of the programmes behind it, 
but it’s RCUK. So we have a cross-council working group for synthetic biology, which has 
members from BBSRC, EPSRC, MRC, NERC and ESRC. It’s chaired by BBSRC, but we 
have an additional member who kind of represents our views so that the chairing is 
impartial.  
(Research administrator 10 interview, 18th August 2014) 
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And:  
 
I think synthetic biology’s a good example of [research councils working together].  
(Research administrator 6 interview, 19th August 2014) 
 
According to research administrator 10 above, the problem for RCUK emerged several 
years after the funding for synthetic biology had started. It was not directly related to an 
epistemic issue but to administrative concerns of how to deal with a special governmental 
allocation. The ‘chunk of capital’ was £50 million pledged by George Osborne in the 
November 2012 statement. This is known as the Synthetic Biology for Growth fund (field 
notes, 18th August 2014).  
 
On these accounts, administering those funds requires coordination between the councils 
and this is enabled by a new entity, the working group. This is not to say that the working 
group was established in direct response to the administrators’ (2 and 3) comments earlier in 
the section, but it does address a more general concern that “real-world problems do not 
come in disciplinary shaped boxes” (Jeffrey 2003, p.539). The emergence of synthetic 
biology requires institutions to adapt their working practices in order to accommodate the 
new field of science. Synthetic biology is one of BBSRC’s “new ways of working” (BBSRC 
2014, p.3) not just in terms of science, but in terms of the collaborations and institutions that 
are emerging. Thus, collaborative success stories circulate in synthetic biology to reinforce 
the benefits of working together in different domains.  
 
This section has explored how collaborations result in access to funding and resources, how 
they are initiated and how some collaborations can become stories, or devices, that circulate 
to bond actors in synthetic biology (Molyneux-Hodgson & Meyer 2009). In designing this 
project, I was also interested in how actors understood the problems translation is meant to 
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solve. The next section is an analysis of how participants enacted different problems of 
academic-industry collaborations that emerged in fieldwork and in interviews.  
 
 
5.2 Enacting the Valley of Death  
 
This section picks up the metaphorical cartography of “translation” – roadmaps and 
landscapes – and explores the way that gaps between universities and industries are 
enacted in synthetic biology. The ‘valley of death’ is a common metaphor not just apparent in 
relation to synthetic biology but in the discourse surrounding translational medicine (Kraft 
2013; Butler 2008) and innovation policy (Technology Strategy Board 2014; House of 
Commons Science and Technology Committee 2013). Many of the participants in my 
research had worked ‘on both sides of the fence’ or worked, as administrators, in some form 
of intermediary role (Meyer 2010). These differences were made visible during events where 
industry representatives were invited to a university to take part in discussions about 
network ‘direction’ or to help allocate funding, for example. These became sites for public 
performances of differences between academia and industry. The valley itself is subject to 
various interpretations and understandings of what constitutes the problem. The following 
discussion covers some of the contours of the valley.  
 
In 2013, the UK government produced a report titled Bridging the Valley of Death: Improving 
the Commercialisation of Research (House of Commons Science and Technology 
Committee 2013). The report stated:  
 
There exists the concept of a valley of death that prevents the progress of science from 
the laboratory bench to the point where it provides the basis of a commercially successful 
business or product. The future success of the UK economy has been linked to the 
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success of translating a world class science base to generate new businesses with the 
consequent generation of UK jobs and wealth. 
(House of Commons Science and Technology Committee 2013, p.3) 
 
The report was critical of its own conceptualisation of the ‘valley’ as a substitute for a linear 
model of innovation and found:  
 
There is no single valley of death that all businesses, or even small businesses, must 
cross.  
(House of Commons Science and Technology Committee 2013, p.54) 
 
The report suggested a range of interventions including investment in technology 
companies, subsidies to increase scale-up and test facilities, tax credit support for SMEs 
and more people with industry backgrounds in university faculties. However, in the final 
conclusion the report focused primarily on financial incentives to promote innovation in terms 
of procurement, R&D focus and fiscal policy (House of Commons Science and Technology 
Committee 2013, p.60).  
 
In interview, David Willetts developed possible notions of the valley further, suggesting that 
as well as funding limitations there were also issues with the way science values knowledge:  
 
There’s a problem in public policy that we don’t have enough support for innovation as it 
[gets] closer to market. In the science community I would say the problem is that 
scientists exaggerate the value of what they’ve done in the lab and underestimate the 
extra value that is added before you actually have a real product.  
(David Willetts interview, 2nd September 2014 
 
The idea expressed here is that those scientists who have produced knowledge do not fully 
understand the additional labour it takes to turn knowledge into a commercial proposition. An 
administrator put this a slightly different way:  
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When you sit with academics and industry there’s always this kind of, you know. The 
academics [say] the industry want everything for nothing, the industry says the academics 
want, you know, value their inventions too highly.  
(Research administrator 12 interview, 19th August 2014) 
 
These comments suggest that collaborations between academics and industry can be 
problematic because of differences of value. Value does not necessarily relate to monetary 
value, and can be both a noun and a verb (Kjellberg et al. 2013). Thus, the different ways 
that knowledge or inventions are valued may explain the sense that industry and academia 
argue over the worth of knowledge. This section, following some of the studies on 
Translational Research reviewed in Section 2.3, reimagines the contours of enacted gaps. 
Rather than focusing on financial matters, actors’ comments and actions bring into being 
other differences of value between industry and academia.  
 
 
Phasing   
 
Time is a dimension that appears to shape the valley. Industry, even global corporations, 
were described as able to operate to tight time scales and able to respond quickly to a 
changing environment. For example, a large pharmaceutical company might close down a 
whole research programme at short notice (academic researcher 10 interview, 1st 
September 2014). This was in contrast to academia, where the ability to respond quickly 
was not so crucial, as in this comment from an administrator discussing collaborative 
contracts:  
 
It’s very unusual for an industry partner to be completely flexible about timescales, for 
instance. So, starting a conversation where you go, “oh, it may take three or four years to 
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do this” can make a lot of industry a little bit kind of uncomfortable cause they tend to 
work on a much tighter turnover. 
(Research administrator 3 interview, 3rd March 2014) 
 
And an administrator who had spent a decade in industry before getting employed at a 
university: 
 
When I first started in academia eight years ago, they said, we need a new strategy. I 
said fine. Fine. You know. Oh, we need it by kind of the end of next year. I said, I thought 
you were gonna say the end of next week! You know. I mean. Industry would kind of 
[say], we want a new strategy. Oh yeah? You’ve got eighteen months, you know? No no 
no. We want a new strategy. Oh, what, what today? No no no. that’s fine. You’ve got ‘til 
Friday. 
(Research administrator 12 interview, 19th August 2014) 
 
This administrator’s example describes academia as operating with long time spans while 
industry revise strategies at short notice. Research administrator 12 went on to suggest that 
this was a difference between quangos, too. RCUK funded ‘excellent science’ and wanted to 
fund clear, long-term research projects. They explained Innovate UK had fewer reservations 
about changing the focus of funding. Partly because the criteria of ‘excellent science’ did not 
need to be applied, Innovate UK could turn around quickly and invest money into a new area 
or company (research administrator 12 interview, 19th August 2014). This extends the 
differences in timing to funders as well as researchers and industry.  
 
The notion of long-term plans also emerged in the way an academic explained applying for 
large grants. The idea was that funders would want to see that a proposal involved a 
complex problem that contributed to a long-term area of research.  
 
As a scientific researcher you must have a vision for next five or ten years so your 
research is aimed at next five ten years topic. So, but industry, they want immediate 
Making Research Translatable: Articulations & Contributions 
 
	210 
products from your research… industry want something immediately [that] can be 
converted into product. But if it’s that easy to do, [the] research must be very mature. So 
in that, that’s not science, scientists they really want to do that. Because [if] it’s so mature 
there’s a very little question to do scientific research.  
(Academic researcher 11 interview, 29th August 2014) 
 
The notion of ‘vision’ here is about a project that will lead to a development of knowledge. In 
this researcher’s experience, industry were focused much more on a short term return on 
investment. So, while an academic researcher’s project might be funded for three to five 
years and their overall problem might be anticipated to be a ten-year project, an industry 
project probably needed answers in months. The researcher above draws a boundary – it’s 
not scientific research if the answer can be found quickly. 
 
That said, the ‘intensity’ of the work in each field can be different. For academics moving into 
commercial start-ups the days were very busy, partly because the deadlines were close 
together and work needed to be completed in short time scales (industry rep interview, 1st 
September 2014). Academic working practices tend to be more ‘open’, with self imposed 
deadlines for publications and disseminations, but also more diluted, with the associated 
administration and teaching commitments of researchers in higher education institutions.  
 
This results in a perceived difference as to the types of problems that are tackled and the 
complexity of their solutions. For instance, as mentioned in the previous section, the IKCs 
are funded to create an entirely new industry. They are ‘at the academic end’ and the hope 
is that they will produce radical change in commercial practices (research administrator 1 
interview, 19th August 2014). ‘Incremental’ change in production, to this participant, would be 
a disappointment. However, the view of one researcher was that industry was looking for 
gains in efficiency.  
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I worked with industry a couple of times recently and it’s fine but it depends on the model 
that they run for their R and D. So some of them seem to want things to be very close to 
either products or something that can improve like a product pipeline that they already 
have. And that’s their, that’s where they are with it at the moment. I don’t think they’re 
really thinking that they can use synbio to produce the next super drug… big innovation. 
No, I think they see it and certainly GSK were [at the event] and they see it as a plug-on 
to improve, you know, the production levels of what they’ve got, or reduce the carbon 
footprint, is what they say, to make it more efficient, to cost less.  
(Academic researcher 5 interview, 7th May 2014) 
 
Although synthetic biology is becoming a large programme of research with a long-term 
vision to standardise life, large industry already has a substantial investment in 
infrastructure. In this researcher’s experience, industry wanted mundane advances that 
improve their existing systems. Furthermore, during a presentation by an industrial rep at 
one event, a senior academic muttered to those listening that he knew of at least three 
people who could solve the problem in a few months (field notes, network event, 9th 
September 2014). “Quick wins” (social researcher 1 interview 1st July 2014) and other terms 
are used pejoratively to signal that industrially-orientated work is easier and less challenging 
because it can be done in a shorter period of time.  
 
The idea that industrial problems might be deemed tedious and mundane was 
acknowledged by a researcher with experience of spinning out companies from a university.  
 
Round that time that it really became clear that, in the past, people sort of viewed this sort 
of commercial drive to do science perhaps not the thing to do and that blue skies was the 
thing to do. And that perhaps commercial science was a bit dull. But what we found was 
that the problems posed by the outside world were actually quite a challenge and drove 
the research really nicely. 
(Academic researcher 12 interview, 15th July 2014) 
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In other words, it is not a given that industrial work is short-term and boring. It could, in this 
case, be a guide for the academics and raise questions that were deemed interesting to 
pursue.  
 
Synthetic biologists on other projects did not always recognise this difference between ‘quick 
and easy industry’ and ‘long and visionary academia’. They felt that, yes, academia and 
funding streams can appear slow and cumbersome, yet as soon as money is awarded, the 
project can be much more responsive and flexible (field notes, meeting, December 2014). 
This was coupled with the idea that some forms of industry could be conservative and 
innovation averse with respect to synthetic biology (Molyneux-Hodgson & Balmer 2014).   
 
Academic flexibility was also suggested by how an academic had become involved in 
synthetic biology:   
 
I’ve always been fairly open minded… and wanted to just get involved in loads of stuff 
and was quite aware that I couldn’t really make um I can’t just be a one trick pony… 
always got you know half an eye on an whether, on an exit strategy… So they invited me 
along and it turns out that actually what I’d done had some applications and cos I’m just 
interested in stuff, I didn’t say no.  
(academic researcher 5 interview, 7th May 2014) 
 
This comment complicates the idea that academic funding and research has a longer view 
and is not ‘agile’. Academics can respond in short periods of time at different points in their 
careers, particularly if their expertise becomes applicable to a new area of research or 
innovation. Both industrial and academic research is thought to be able to move into new 
areas and respond to change, given certain motivations.  
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The title of this section, the notion of phasing, is therefore meant to capture the way that 
timescales, work intensity, flexibility and problem complexity can be a nexus of temporal 
issues for collaboration. Phasing suggests different periodicities related to epistemic work.  
 
 
Transforming projects: publications, proposals and profitable patents 
 
Another way actors explain the difference between universities and industry is that the two 
domains are geared towards the production of different outputs. The idea of transforming 
projects is meant to express tensions between the ways that academia and industry value 
different outcomes of project work.   
 
For academics, important outputs were explained to be publications, proposals and further 
projects. Accruing grants became a part of the scientific reward structure in the 1990s and 
raises the status of scientists in their field (Rip 1994). This could be a reason for academics 
to work with a company: a collaboration would hopefully come with money. The money, and 
the collaboration, could be converted into PhD projects, journal papers and further grant 
proposals (Academic researcher 6, 5th Feb 2014). Furthermore, ‘basic scientists’ in other 
fields articulate that they are rewarded for publications rather than patents (Morgan et al. 
2011). This is borne out in research audit policy – the 2014 REF in the UK prioritised quality 
publications over impact (Research Excellence Framework 2011, p.2). In other words, 
academic knowledge production involves publicly raising more questions and following 
further lines of investigation.  
 
Furthermore, administrators gave the reward structure in academia as a reason for some 
senior academics being difficult to enrol in translational activities. Senior academics tend to 
have been in the field longer and have a reputation for publications. According to the 
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administrators, these academics know that they will be able to publish again at some point in 
the future. Therefore, they did not need to engage with teams whose role was about 
fostering industry collaborations. This was because the administrators argued the academics 
could remain in post based on their history of scholarship rather than needing other forms of 
evidence such as income generated through industrial collaboration (research administrator 
2 interview, 18th February 2014; research administrator 3 interview, 3rd March 2014).  
 
For industry, on the other hand, the main output would be a commercial product or service 
that could produce a measurable profit. Research administrator 12 explained how an 
industrial company, “the end users”, could generate a profit from a particular project:  
 
The end users will end up with a specification to either a product or a process and they 
will protect that. They will have their own organism. They won’t give it away. They will 
keep it so that the exploitative property will be either their process or their product.  
(Research administrator 12 interview, 19th August 2014) 
 
An aim for businesses is therefore to maximise their profit. Measuring profit, though it comes 
in different forms (Miller 2012), turns knowledge outcomes into technical objects 
(Rheinberger 1992; Rheinberger 1997). However, since technical objects are materially 
defined and epistemic objects are unfolding, technical objects cannot simultaneously exist 
as epistemic objects (McGivern & Dopson 2010). This exclusivity leads to a problem. If the 
two forms of object cannot coexist, a collaboration between academia and industry cannot 
be orientated toward the production of a single object since it could not satisfy the needs of 
both communities, simultaneously.  
 
Not only this, but collaborating with industry can turn into ethical issues for synthetic biology 
researchers as they may need to decide on whether they would accept support from 
companies with a dubious history.  
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I would say for a materials production, you know, obviously people like Du Pont are very 
well known for their chemical and material production. So the question would be do I, do I 
go with a company like Du Pont, huge American company, you know, with some 
reputation issues, ah, or do I look to found my own company and then what will happen to 
that? It’ll probably get taken over by Du Pont without me being able to do anything about 
it. Who knows?   
(Academic researcher 10 interview, 1st September 2014) 
 
The researcher here expresses the moral difficulties in finding funding and the uncertainty, 
and helplessness, of the future of companies – if one spins a company out of a university it 
may end up being bought by a company with a questionable reputation anyway. In other 
words, entering a profit-orientated, commercial environment could mean leaving one’s 
morals at the door.  
 
This section covered how the different domains of academia and industry are thought to 
transform knowledge into different outputs. For academics, a good publication record and 
successful proposals are ways that their status can be raised. This is related to findings that, 
until more recently, university reward systems are not favourable to interdisciplinary careers 
(Bruce et al. 2004). For companies the overall goal is thought to be profit. Collaborative work 
was therefore problematic from the outset as these goals are valued differently (Packer & 
Webster 1996) and involve the production of different kinds of objects.  
 
 
Disclosing ideas    
 
One way that value became an issue in this study was about how knowledge was protected 
in the different fields. The notion of disclosure can play out in different ways.  
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One outcome for a participant who had attended an event aimed at initiated collaborations 
had signed a confidentiality agreement with a company (academic researcher 5). The 
researcher saw this as a ‘goodwill’ gesture, despite the scepticism the academic displayed 
about whether the conversation would lead to any further collaborative work. This was an 
idea the researcher took to the meeting, and suggested it to the company, but they did not 
have any intention of following it up with a grant proposal without company support (field 
notes, open day, 6th March 2014). Industrial knowledge is protected by three main 
intellectual property (IP) mechanisms: patents, trade secrets and regulatory data protection 
(Nuffield Council on Bioethics 2012). Patents, for instance, allow the holders to use 
knowledge themselves or licence knowledge to others at their discretion. On the other hand, 
academic publishing protects academic knowledge by publicly attaching findings to names. 
The findings can theoretically be used by anyone without incurring costs. These two 
practices therefore appear to be exclusive since patenting involves the power of exclusion, 
while publishing does not. The stakes, because the academic in this case was not intending 
to publish, were low.  
 
At other times, disclosure was more problematic. This became an issue at a launch event for 
a network in biotechnology (field notes, 9th September 2014). The day involved 
presentations from industry representatives who were suggesting problems that the 
academic audience might be interested in solving. Over the course of the event there was 
some frustration about the level of details because academics could not be told which exact 
microbial strains, or their properties, were being used – industrial strains are trade secrets. 
This meant some of the academic researchers felt like they could not fully engage with the 
problems since they did not have full knowledge of the experimental or industrial system 
(field notes, 9th September 2014).  
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At the same event, there was a feedback session at the end of the second day. The aim was 
to share progress and kinds of projects that academics and collaborators might take 
forwards. A group at one table said they could not share their conversation because of 
uncertainties about disclosure and protection. They were not sure that they could not share, 
but thought it prudent to not share with the rest of the network meeting. The exchange of 
glances between people at my table suggested surprise (field notes 10th September 2014). 
This was a way that performed the differences between academia and industry – the 
academics were not able to engage in an ‘open’ conversation in the way they expected.  
 
However, whereas academic practice appears to suggest openness and a drive to sharing, 
pre-publication data can be extremely sensitive (field notes, pre-conference meeting, May 
2013). PhD students were instructed to not ‘pre-disclose’ results while preparing posters for 
a synthetic biology conference. This was because others may be inspired by early results 
and may look to repeat and publish duplicate experiments quickly. Academic work can be 
closely guarded up until the point of publication.  
 
Dealing with IP issues was more common for those with commercial experience. Well-
financed companies can purchase patents as they need them (interviews researcher 
administrator 12; industry representative) or can licence them (field notes, SBLC open 
meeting, 27th November 2014). However, some universities are proactive in securing 
patents for academic research. Yet, they may not be able to find partners to sell to or to 
whom they can license the IP. This can result in a university having potentially valuable IP 
‘sitting on a shelf’. While these patents would not be problematic if they were known it could 
inhibit innovation if start-up synthetic biology companies were trying to second-guess what 
was ‘on the shelf’ (field notes, SBLC open meeting, 27th November 2014). The tension, with 
respect to collaborations, is that the practice of academic institutions patenting research 
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could restrict innovation because start-ups and SMEs would have to spend additional time 
and money checking to ensure they did not infringe a patent.  
 
In this way, different systems of protecting knowledge play out at collaborative events and in 
interviews. The processes of valuing knowledge, in terms of patenting, trade secrets and 
publishing, can become a problem where the stakes of disclosure seem high or uncertain.   
 
 
Competencies 
 
The last area in this analysis is the idea of ‘finding the right people to do a job’. In this 
section, the issue appears to be identifying collaborators who have the will and skill to 
develop projects into successful businesses.  
 
Knowledge and expertise is a central part of an academic’s career (academic researcher 10 
interview, 1st September 2014). This participant argued academics need to have specific 
and unique expertise on a given topic, and this defined their careers. However, their 
knowledge about a part of nature did not extend to the concerns and ways that 
commercialisation happens.  
 
On the other hand, an academic might successfully spin out a company yet become 
frustrated with the work.   
 
A lot of the time the frustration is that they’ve set up a company that’s become quite 
successful but they’re not making any money out of it. Everybody else is… they’ve moved 
away from what they really love. You know, I’ve come across and worked with a number 
of companies over the years where you’ve had to say to the CEO, look, time for you to be 
chairman. Take the money and, you know, pay off your mortgage; buy a speedboat. Do 
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whatever you want. Maybe invest in that other project you wanted to do… because they 
simply aren’t the right people to take it forwards. 
(John Collins interview, 3rd July 2014) 
 
The idea here is that academics can create successful companies but that their motivation 
and abilities can only take them so far. They may become disillusioned or others may see 
them as being no longer effective. Academic researcher 15, a senior synthetic biologist, 
agreed saying that, in order to move their project forward, they would need to recruit a CEO 
who had the skillset and enthusiasm.    
 
It’s about finding the right people, and finding the people with the same ambition as you 
and then finding them the money to do it… I don’t just mean the right scientists. I mean 
somebody that’s gonna help you run with your idea beyond what you can do. You know. 
For somebody that wants to be a CEO of a company rather than a chief scientific officer. 
And got out and get money for you and do all the paperwork, all that kinda stuff. And then 
you also need a sprinkling of cash to get it started. I’m biding my time and looking for the 
the right CEO person. That wants to come and work with me and what we’re doing. Do all 
that stuff for us. Because, I can’t do it. I not I’m not good enough. At doing it. You know, 
it’s not my style. Er, I’ve got too many other things to do. So we need somebody whose 
equipped, been there done that. Sees the potential of our technology and then goes and 
does it for us.  
(Academic researcher 15 interview, 28th August 2014) 
 
Other actors suggested the problem was in academics and inventors not understanding how 
markets work and that innovators would not be able to work within the bureaucratic confines 
of academia (research administrator 12 interview, 19th August 2014).  
 
These ideas suggest that there is an issue with recruiting people with the right skills to 
innovate in synthetic biology. The comments in this section chime with the idea that “SMEs, 
particularly those that arise from academic spin-offs, need better management and 
marketing skills and better financial planning” (Tait & Williams 1999, p.105). In section 5.3, I 
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follow up these points and describe how development of synthetic biology’s infrastructure is 
addressing this problem.  
 
 
Performing differences  
 
This section has explored how participants understand and enact ‘the valley of death’ with 
respect to synthetic biology. I described the enactment of four ‘contours’ that contribute to 
the idea of gaps between academia and industry. In Phasing I sought to explore a number of 
issues connected with the timings of academic and industrial work. The section on 
Transformations covered ways that academia and industry are orientated towards different 
outputs of publishing and profit, respectively. Disclosures was an exploration of how different 
knowledge-value regimes of revealing operate in the two domains and appear to make 
collaborations problematic. Finally, Competencies was an exploration of how a gap towards 
commercialisation may occur because there are not the right people who have the right skills 
to ensure a successful project.  
 
These findings share some commonalties with other studies. There can be tensions in 
academic-industry projects if academic research is pressurised into premature dissemination 
or delays compromise timely commercialisation (Bruce et al. 2004, p.466). In Morgan et al.’s 
(2011) study, basic scientists were reluctant to engage with translational work because it 
counted for less in the academic domain than publishing:  
 
Symbolic capital in most fields of basic science is mainly achieved by publishing in key 
disciplinary journals, being Principal investigator on a grant and establishing a long-term 
programme of research. Several participants therefore described translational research 
as ‘high risk’, in terms of not being sufficiently valued by their peers to form ‘authentic’ 
knowledge that would bestow symbolic capital in their field.  
(Morgan et al. 2011, p.949) 
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Thus, laboratory scientists in biomedicine tend to resist a market-orientated approach on the 
grounds that it is not valued by their communities’ practices. While the term ‘high risk’ does 
not fit with my interpretation, the idea that academia values certain forms of epistemic output 
is comparable with my findings.  
 
However, the findings I presented above suggest that there are other issues as well as 
acquiring forms of capital. The practices of the two domains produce different forms of 
objects. In academia, by encouraging publications and long, complex problems, the 
production of epistemic objects becomes of greater importance (McGivern & Dopson 2010). 
In industry, packaging specifications into patents and measuring profits means that technical 
objects are valued. Since these are mutually exclusive forms of entities this poses a problem 
for collaborations orientated to producing objects for each domain.  
 
Any gaps between academia and industry are multiple and variable and enacted at specific 
sites. These differences concern professional working practices and knowledge value 
systems. In conclusion, the Science and Technology Committee report Bridging the Valley of 
Death focuses on financial remedies and therefore ignores a large of part of the translational 
landscape when it comes to synthetic biology. However, as the next section explores, 
synthetic biology proponents have implemented strategies that may address ‘the valley of 
death’ – by remaking biological research and researchers.  
 
 
5.3 Embedding Industry    
 
There is a section of the roadmap called ‘creating the industrial translation process’ 
(Technology Strategy Board 2012b, p.22), which describes the way that translation may be 
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constructed in synthetic biology. This follows Figure 10 of synthetic biology translation, 
displayed in Section 4.2 (p. 163), and Figure 11, the linear graph below. 
 
 
Figure 11. Graph of increasing the value of synthetic biology  
(Technology Strategy Board 2012b, p.16) 
 
The outline of the plan continues: first, synthetic biology uses knowledge of fundamental 
bioscience to create new parts, host organism chasses, or new ways of assembling parts. 
Next, is to create “industrial engineering methods appropriate for the applications being 
developed and ultimately the development of biofactories” (Technology Strategy Board 
2012b, p.22). An effect of the diagrams and description is to make it seem that all stages in 
the process lead to products and markets.  
 
A Landscape for the future of high value manufacturing in the UK (Technology Strategy 
Board 2012a) was published at approximately the same time as the Roadmap. The 
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document listed five “national competencies” which are “that attribute of the national 
manufacturing industry that enables businesses to respond to the changing global trends 
and drivers in a way that captures value for the UK in the future” (Technology Strategy 
Board 2012a, p.4). These themes were: resource efficiency, manufacturing systems, 
materials integration, manufacturing processes and business models. The Landscape 
highlighted synthetic biology as a component of “securing UK manufacturing technologies 
against scarcity of energy and other resources” (Technology Strategy Board 2012a, p.12), 
which suggests a role for a future synthetic biology industry.  
 
The Roadmap also calls for more interaction, not only between academics and industrialists, 
but also public funding. The document argues that risk needs to be spread out and 
resources for new developments should come from a tripartite arrangement in which:  
 
Public funding contribution would normally be in terms of cash or the de-risking of the 
investment to make it more attractive to potential funders (such as venture capitalists). 
The main university contribution is in terms of research facilities and highly skilled 
research personnel. Industry may contribute cash or know-how. The public and university 
components of the model act as a catalyst to counteract the common causes of failure of 
application projects as seen from industry, for example through provision of training, 
mentoring and expansion of partnership opportunities.  
(Technology Strategy Board 2012b, p.23) 
 
This quote from the plan establishes the roles for the parties in collaborative projects 
(Deuten & Rip 2000, p.79; Callon 1986). Overall, the role of public and university resources 
is to ‘de-risk’ the involvement of companies and investors by insuring them against financial 
loss. It is the role of universities to provide training and partnership opportunities to industry, 
taking into account issues that industry has identified. In this model, industry guides the 
research and other provision by identifying its needs.  
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An argument in the synthetic biology roadmap is to increase collaborations between 
academia, government and industry to produce scalable demonstrators that can be 
developed and sold for profit. However, as described below, this model can be problematic.  
 
Where it starts to go fall flat is when you start taking out of the laboratory and into an 
industrial situation. Currently there’s not the metrology, there’s not the standards, there’s 
not the interoperability. There’s not the culture, there’s not a culture in biology at the 
moment of [an] industrial approach. That’s why in my mind industrial biotechnology 
[hasn’t] become an industry in the UK. 
(John Collins interview, 3rd July 2014)  
 
Collins connects the failure of innovation to a combined issue of infrastructural and cultural 
absence when it comes to industry in bioscience. The infrastructural changes are being 
particularly addressed by the funding of The Flowers Consortium – a group of five 
universities tasked with developing standardisation which “will provide the critical mass and 
synergy necessary to make synthetic biology a well-characterised and usable tool for 
developing applications and products” (The Flowers Consortium 2015). Scholars at the 
University of Edinburgh and King’s College London, who are partners in the consortium, are 
currently conducting social studies of these infrastructural developments.  
 
The next section, following John Collins’ point, focuses on ways that synthetic biology may 
be changing bioscience research culture. I focus on two aspects: aligning synthetic biology 
facilities and the institutionalisation of collaboration and commercialisation training.  
 
 
Aligning facilities  
 
There are many new organisations emerging in synthetic biology. At the start of Section 5.1, 
I argued that the SBRCs, the fundamental research centres for synthetic biology, are 
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orientated towards industry and the commercial sector. This section details the way that 
other organisations in synthetic biology are set up with a commercial orientation. Gaymon 
Bennett writes:  
 
…it seems worth posing the question of what facilities have actually been put into play as 
part of the making of the synthetic biologist… The defining feature [of synthetic biology] 
has been the proposition that the near future of biotechnology depends on inventing of a 
new style of facility for research, design, pedagogy, and production.  
(Bennett 2015, p.128) 
 
Bennett uses “facilities” in the double sense of “organisations” and “capabilities”. He argues 
that in synthetic biology “the facility becomes the primary artefact of collective biotechnical 
practice (Bennett 2015, p.130). I aim to show that the deployment of institutional funding, 
language and computer-assisted automation are bound together in the making of 
commercially orientated facilities in the UK.  
 
SynbiCITE is dedicated to identifying projects that may generate market profits. The name 
‘engine’ is an overt reference to the notion of ‘driving innovation’, and also to industrialised 
processes. The aims of SynbiCITE are:  
 
1. To act as an industrial translation engine which translates university and industry 
based research in synthetic biology into industrial processes and products 
2. To be an effective vehicle for the support of small to medium sized UK companies 
including Start-ups in synthetic biology 
3. To actively engage in open dialogue with the public and other stakeholders 
focusing on the risks and benefits of synthetic biology technologies 
(Engineering and Physical Sciences Research Council 2015a) 
 
SynbiCITE specifically identifies ‘industrial’ outcomes as its main focus, while at the same 
time supporting SMEs and broader societal engagement. The grant proposal lists a large 
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number of academic institutions and businesses, which could form research collaborations. 
Apparently, this was the result of a lot of work on behalf of Professor Kitney:  
 
Dick Kitney, who brought it all together, is quite a political animal, and he made some 
great political alliances and he’s very inclusive. So there’s about seventeen or more 
universities actually in that consortium. Everyone realised that if they threw their lot in with 
Paul [Freemont] and Dick [Kitney] at Imperial at least they’d have a slice.  
(Industry rep 1 interview, 1st September 2014) 
 
Collaborators included synthetic biology startups like Green Biologics Ltd, Oxitec Ltd and 
Synthace Ltd, but also large multinationals such as GSK and Shell. The large amount of co-
investigators and collaborators appears to have been convincing to the funders. The 
successful proposal was funded in 2013 for five years. This links back to the point made at 
the start of the chapter – that forming collaborations can be about leveraging more 
resources.  
 
However, SynbiCITE did not appoint a CEO until mid 2014. In response to this point, an 
administrator explained:  
  
All the IKCs take a long time to get started. They are difficult things to set up. They’re 
doing something different that universities don’t do routinely. So both there’s a capability 
thing and also a whole, you know, they’re pushing against the university administration 
and… in their way they are pushing the, you know, the culture change in universities 
they’re, you know. And aside from recruiting different sorts of people perhaps on different 
sorts of contracts they’re also putting a pressure on the university to be more strategic.  
(Research administrator 1 interview, 19th August 2014) 
 
By having a different remit the IKCs, according to this statement, are part of changing 
cultures within universities. SynbiCITE has recruited staff with industrial experience. Building 
large consortia of this kind can be time-consuming (Bruce et al. 2004, p.464).  As SynbiCITE 
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is hosted in an academic institution, but is ‘outward looking’, it can be understood as a 
boundary organisation in which “technology-transfer specialists thus dwell, Janus-like” 
(Guston 1999, p.105). However, rather than containing a large population of ‘specialists’, 
SynbiCITE has implemented a range of strategies to develop commercially aware 
researchers. The most visible work by SynbiCITE is in the provision of innovation 
laboratories and training for researchers.  
 
SynbiCITE has a number of ways that it supports actors to translate synthetic biology. As 
well as providing meeting rooms, there is also a new DNA synthesis facility.  
 
SynbiCITE is home to a DNA Synthesis and Construction Foundry which we hope will 
establish a common framework to build DNA by using an automated robotic system. With 
a common framework for creating DNA in place, synthetic biologists will be able to scale 
up the volumes of DNA produced to more easily test their new function. 
(SynbiCITE 2015c) 
 
The Foundry is an automated laboratory space for synthetic biology start-ups to be able to 
design, build and test constructs. The foundry is one of five new DNA synthesis facilities 
funded as part of the Synthetic Biology for Growth capital fund. One of the aims of the 
foundry is develop a standard system for building DNA. The British Standards Institute (BSI) 
can be seen as having identified a lack of expertise and requiring a plan to construct 
standards in the synthetic biology community:  
 
In partnership with the Technology Strategy Board (TSB), we’ve been working with 
SynbiCITE to develop a strategy for standards in synthetic biology to help create a digital 
biomanufacturing industry and to accelerate the rate of commercial success using the 
technology. 
(British Standards Institute 2014) 
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The key point in these perspectives is that industrial orientation is ‘embedded’ in the overall 
project of synthetic biology. The idea is that biological innovation will happen in the future 
because synthetic biology will facilitate a better manufacturing, investment and research 
culture.  
 
Biological research is presented in synthetic biology as being a product of design 
(Mackenzie 2009). This is partly achieved through using certain vocabulary. Words more 
readily associated with engineering, words like ‘platform’ and ‘switch’, have come to refer to 
microbes and their constituent parts. Calvert explains: 
 
In order to align itself with engineering, synthetic biology makes heavy but rather 
indiscriminate use of engineering analogies. For example, the word ‘chassis’ is borrowed 
from mechanical engineering to describe the cellular context into which biological parts 
can be put. 
(Calvert 2013, p.410) 
 
The hierarchy of “parts, devices and systems” is used, for instance, when actors are 
explaining synthetic biology to what may be an uninitiated or inexpert audience such as 
students or academics from other disciplines (field notes, SBLC open meeting, 27th 
November 2014). In an induction session for a group of undergraduates entering iGEM, a 
PhD student referred to an ideal DNA construction consisting of a promoter, gene and 
terminator as a “cassette” (field notes, iGEM training, 15th July 2014). A digital technology 
metaphor of “plug and play” gets used to convey the idea that biological parts can put 
together in a predictable way (Isaacs & Collins 2005). This in turn has implications for what 
needs to be done. To enable assembly in this manner the parts need to be consistent and 
regulated so they do not need to be designed and made each time from scratch (Arkin 
2008).  
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Analysing metaphorical language can reveal important aspects about how actors understand 
their world (Lakoff & Johnsen 1980). I argue that the repeated use of this language performs 
the connection to manufacturing and that this connection has extended beyond the 
biological. Synthetic biologists mobilise language that aligns synthetic biology facilities and 
institutions specifically with industrial manufacturing.  
 
 
Aligning Researchers   
 
There are many new institutions emerging in synthetic biology. These are established in line 
with the expectations and promises of synthetic biology and in turn reinforce particular 
visions for the future of the science (Schyfter & Calvert 2015). I suggest that creating a new 
generation of researchers is a primary goal in creating the new institutions (see section 7.2 
for how this contributes to the temporal expansion of synthetic biology). I centre my 
discussion on SynbiCITE, the SBRCs, the new Centre for Doctoral Training (CDT) and the 
iGEM competition (see Section 1.2 for a general description and Section 3.2 for my 
experience of iGEM in the course of this research).  
 
The synthetic biology leadership excellence accelerator programme (LEAP) is aimed 
towards “catalysing a next generation of leaders in synthetic biology by providing the 
environment to learn skills for engaging a broad range of stakeholders in the development of 
the field with a strong ethical foundation for the future” (SynbiCITE 2015d). The international 
programme is a collaboration between SynbiCITE and the Knowledge Transfer Network in 
the UK and the Alfred P. Sloan Foundation, BioBricks Foundation, iGEM, National Science 
Foundation, SynBerc and the Wilson Centre in the USA. The website includes some 
example strategic action plans from 2012 and insight papers from 2015. Some of the 
programme outcomes are explicitly ‘visions’ for creating engagement, partnerships and 
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training. “Many LEAP Fellows have already begun implementing and refining their plans” 
(LEAP 2015). Thus, the LEAP partly functions as a development space for ideas of how to 
expand synthetic biology and ensure its success.  
 
There are a number of actions plans available on the website (LEAP 2015). For example:  
 
• Enhancing undergraduate education to drive responsible growth of the 
bioeconomy (Facciotti 2013)  
• Opening new channels for industry-academic relations (Lindstrom & Agilent 
Technologies 2013) 
• Synthetic biology for global health: a problem-driven approach to healthcare 
innovation (Tyo 2012) 
 
The 2012 plans highlight the way that proponents of synthetic biology aim to educate 
students for economic gains, partner various stakeholders and find problems in other 
societal domains for which they can propose synthetic biology solutions.  
 
One insight paper is titled Technology is not the Problem (Ravi et al. 2015). The paper 
explains that “public engagement is important in the future success of synthetic biology 
applications” (Ravi et al. 2015, p.3) and that “examining existing technologies and their 
relative acceptance by the public (e.g. nuclear power, nanotechnology, GM, space 
exploration), could safeguard against unconscious bias, and reveal proven ideas as to how 
to communicate success stories” (Ravi et al. 2015, p.4). The authors also imagine: 
 
…that the synbio community, as it stands today, will create an organisation that tracks 
how quickly companies using synthetic biology can get, for example, drugs, industrial 
biomaterials or even consumer products to market compared to competing companies 
that do not apply systematic, engineering principles to biology. 
(Ravi et al. 2015, p.2) 
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This insight paper describes how synthetic biology needs to be able to prove its efficacy by 
tracking innovation times, and to effectively communicate successes to ‘the public’. The 
uncertainty of making “consumer products” is signified by the preceding word, “even”. This 
relates to the imaginary of contained bio-manufacturing in the previous chapter as synthetic 
biologists are shaping their field towards making existing compounds. The predominant 
areas for production include manufacturing chemicals and materials.  
 
The researchers do not question synthetic biology. While they acknowledge that synthetic 
biology can occasionally answer ‘no’ to specific applications, overall, they appear to be 
spreading the message that synthetic biology is good. They argue this can be achieved by 
proving synthetic biology does commercialisation faster.  
 
Secondly, SynbiCITE offers ‘The Lean Launchpad’. This is a twelve-week training 
programme in which synthetic biology entrepreneurs can enrol and work out a business 
model for their idea.  
 
This course will allow participants to gain real world, hands-on experience of what it is like 
to start a business. It is not a theory based, classroom activity – rather, it is a practical 
exercise in talking to customers and using these discussions to inform the development of 
a useful, coherent, relevant business model and product. 
(SynbiCITE 2015e) 
 
Both the LEAP and Lean programmes originated in US biotech entrepreneurship training. 
The LEAP began in 2012 and in 2016 will be brought to Europe for the first time. To 
underscore the ethical dimension to the training the 2015 course will be held at Asilomar, 
CA, site of the conference on recombinant DNA held in 1975. The international scope of the 
training, and its focus interacting with ‘real life’ customers, further emphasises the particular 
commercial focus of this arm of synthetic biology.   
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As part of establishing synthetic biology, the CDT was awarded for a collaborative proposal 
submitted by the universities of Bristol, Oxford and Warwick. The CDT is funded for five 
cohorts of overlapping PhD courses and so has a seven-year funding timeline. The aim is 
that new researchers will be trained in synthetic biology and take that forward into their 
future working practices. 
 
The SBCDT will provide five annual 15-student strong cohorts with high-quality and highly 
practical training in Synthetic Biology that will fill this skills gap and deliver the next 
generation of internationally excellent researchers and industrial leaders. 
 (Engineering and Physical Sciences Research Council 2015b) 
 
This addresses the tensions of creating the right competences in the previous section. The 
seven years of the SBCDT is orientated to producing candidates who can drive both the 
underpinning science and commercial profitability of synthetic biology.  
 
Finally, the structure and implementation of the iGEM competition is partly aimed at 
producing researchers that focus on applications. iGEM teams must enter their project into a 
specific competition ‘track’. The ‘traditional’ tracks for iGEM are energy, environment, food 
and nutrition, foundational advance, health and medicine, information processing, 
manufacturing and new application (iGEM 2014). In 2014, the competition also listed seven 
new tracks, including entrepreneurship, policy and practice, and software. Of the 246 teams, 
27 entered ‘foundational advance’, suggesting that most of the work in iGEM is orientated 
towards application. One administrator commented:   
 
… to a certain extent, I feel that translation is something which is kind of innately 
embedded in synthetic biology. So if you look at competitions like the iGEM… you’re 
training people with a very different paradigm to those who are running the show now. 
There’s always kind of a difficulty in trying to allow those people to filter up into the kind of 
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upper echelons of, you know, being the stars, star researchers of tomorrow. So, I think, I 
think… there’s two worlds of thought to be honest… So, I think, what they’re doing now is 
great and I think translation is embedded in the younger generation coming up.  
(Research administrator 15 Interview, 19th August 2014) 
 
The quotation presents translation as an integral part of the ‘design’ of synthetic biology. 
Training researchers disciplines a future generation into considering the uses of their work. 
The comment also suggests a concern that, as the first generation of synthetic biologists get 
superseded by researchers who have been schooled in application and market-orientated 
science, there may be a paradigm shift (Kuhn 2012).  
 
The iGEM competition is particularly important in synthetic biology as it has provided a 
model on which synthetic biology has been established:  
 
The idea that whatever the students built went into the registry [and] the registry was 
provided to everybody the next year, so it’s a level playing field [and] in that sense. 
[Synthetic biology] could bootstrap itself. That I thought was a really good [idea]. The idea 
that everything was pre precompetitive and open source was a good one… Now that ten 
years has passed and several thousand, maybe even ten thousand, students have gone 
through most of them have dropped out of synthetic biology but a minority have now done 
PhDs and some are even starting their own labs. And of course that means that the 
profile of the field has been bootstrapped from this competition. To the point that now, the 
BBSRC in the UK, synthetic biology is actually a research priority and you can get grant 
funding for it. 
(Academic researcher 14 interview, 19th July 2014) 
 
The iGEM competition was based on an ideal for what synthetic biology could be. 
Undergraduate and postgraduate students from the UK and around the world then orientate 
their research towards specific problems and many describe their market orientation. The 
success of the competition, judged by its rapid increase in size and participation, has raised 
the profile of synthetic biology. In the quotation above, the academic researcher connects 
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this success to the funding of synthetic biology. By modelling a scientific community with 
students, by training them and structuring their interactions (Cockerton 2011; Balmer & 
Bulpin 2013), the field has provided a ‘compelling demonstrator’ of itself (Frow & Calvert 
2013a). This is despite the problems, such as a lack of flexibility in the modular connections, 
which are inherent in the BioBrickTM standardisation system (Frow 2013).  
 
In conclusion, manufacturing industry is embedded in synthetic biology in various ways. The 
synthetic biology language choices perform connections to industry. I supplement 
Mackenzie’s point that their vocabulary connects design with life with the notion that it also 
connects life to industrial manufacturing. The words derived from industry and change life 
into an entity which can be treated as an industry. “Foundries” and “factories” are some of 
the key ways manufacturing is embedded in synthetic biology. The future translation of 
synthetic biology is performed in the way SynbiCITE structures the courses and support it 
offers. SynbiCITE is “unfolding” (Knorr-Cetina 1997; Knorr-Cetina 2005a) synthetic biology in 
a specific way. There is an overall push towards automation in order to speed up testing and 
scaling of research and a push towards encouraging entrepreneurship by training scientists.  
 
 
5.4 Conclusion  
 
Synthetic biology has emerged at a time of increased pressure on academics to create 
research ‘impact’. Pressure to turn research into economic value in synthetic biology is not 
within a vacuum. There is a trend, at least in Europe and the US, that academia is being 
held accountable through various means, particularly auditing (Rajan & Leonelli 2013; Shore 
& Wright 2004). As academic work is increasingly required to anticipate the future use or 
application of knowledge and to generate a possible line of revenue, universities and 
research councils have developed a range of mechanisms to foster commercialisation.  
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The first section described how collaborations are argued to be an important route to making 
knowledge relevant. Synthetic biology is under pressure to deliver on synthetic biology’s 
promise to ‘impact’ in areas of health, fuel and food. Administrators use events and funding 
schemes to encourage academics to reach out and form partnerships for contract and 
collaborative research. Section 5.2 explored how, in particular, discussing collaborations (in 
observations and interviews) turn out to be sites where the differences between academia 
and industry are enacted. These differences are articulated with respect to the protection 
and disclosure of knowledge, different research outputs, differences in work vision and 
timing, and the competencies of researchers. Section 5.3 described how synthetic biology in 
the UK and beyond has implemented a set of strategies that ‘embed’ industrial 
manufacturing into the research culture. This occurs through various training schemes, 
funding requirements and by aligning synthetic biology with manufacturing through 
language. By orientating researchers and research to manufacturing, synthetic biology may 
hope to bypass some of the ‘causes of failure’ of innovation as identified by industry.  
 
In response to synthetic biology, new formations are required because synthetic biology 
challenges established boundaries between UK research councils and between research 
fields. People come together from different fields of expertise in order to realise the goals of 
synthetic biology. This produces collaborations and also produces other practices and 
organisational structures. The absence of biological standards can create new entities such 
as research consortia and the production of a plan to formulate standards.  
 
One of the key elements of this chapter is the way that collaborations themselves are a route 
to accessing resources. The act of gathering people and institutions, and co-signing 
proposals, is a way to gain confidence for investment. This means that, in the name of 
building collaborations to accelerate innovation, proponents of synthetic biology have been 
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able to secure a large amount of public funds. These have been used to fund research 
centres, innovation centres and a training centre. Furthermore, these centres are orientated 
to industry to different extents.  
 
What is also clear is the diversity of actors involved in translating synthetic biology. These 
include staff in research councils, universities, industry and government. Calvert has noted:  
 
By making biology into an engineering discipline, synthetic biologists are simultaneously 
broadening the range of voices that can enter into the discussion of their field. The 
boundaries surrounding biotechnology are becoming more permeable, and this is 
opening up synthetic biology to a diverse range of global groups. 
(Calvert 2013, p.417) 
 
This is true for commercialisation, too. By making synthetic biology ‘translational’ and 
prioritising collaborations the field is ‘opened up’ to actors seeking to commercialise 
technology. The way that different groups are enrolled into projects depends on who is 
attempting to define the problem. Thus, research administrator 3 was attempting to 
encourage more academics to ‘reach out’ to industry. This puts the problem of translation as 
a social one. One apparent solution to this is to increase the chances of collaborations by a 
range of techniques, which goes some way to explain the proliferation of showcases, 
bazaars and sandpits across the academic and commercial sector. On the other hand, 
difficulties in collaborations mean those with industrial experience have instituted training 
programmes so that researchers are more aware and knowledgeable when it comes to 
industrial manufacturing and marketing needs. These training practices and institutions 
shape the form that synthetic biology takes as it grows.  
 
However, before tackling this point in more detail, the next chapter turns to examine how 
synthetic biology is made translational at the level of the laboratory.   
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Chapter Six  
 
Cells, Molecules and Engineers  
 
 
 
This chapter focuses on the ‘lab level’ of translation. The two previous chapters focused on 
the way issues of do-ability, such as aligning with sponsors’ needs and fostering academic-
industry interaction, have become embedded in the organisation of people and institutions. 
Here, my focus turns to the material interactions of scientists (Pickering 1995).  
 
I followed a small group of researchers, in what I will collectively refer to as “the skin graft 
project”, as they attempted to produce a synthetic biology solution to a problem in clinical 
practice. In the skin graft project, actors were involved in organising experiments and 
components of biological parts to satisfy criteria in the domains of industrial manufacturing 
and medicine. The skin graft project involved realising these issues in the way the 
experiments and life were designed. Previous writers have argued that technology can 
embody power relations (Winner 1989) and that technologies make social arrangements 
‘durable’ (Latour 1991). Latour calls the process of embedding values in technology 
“delegation” (Johnson 1988; Latour 1993b) (see Section 2.3). This chapter explores the 
processes of enrolment and delegation in the course of scientific work. I examine how the 
creation of a particular solution requires the binding together of a heterogeneous community 
of entities. Some of the themes I discussed in the previous chapters also play out materially 
in this account.  
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In section 6.1, I describe the origins of the bioglue project – how the researchers secured 
funding, what they acquired it for and how, conceptually, they intended to solve the problem 
using synthetic biology. In section 6.2, I detail how the research progressed and how 
researchers and microbes collaborated to produce a chimeric protein, which might be able to 
solve the problem. Section 6.3 explores the difficulties in materially and semiotically aligning 
viral DNA, bacterial biology and researchers’ competencies and theorises these issues as 
the synthetic biologists attempted to translate technology.  
 
In order to maintain the focus on biological work, I have supplemented quotes with ‘rich’ 
technical description (see Section 3.7) to emphasise the material practices involved in 
translating synthetic biology from a laboratory to, in this case, another laboratory. As an aid, 
there is a glossary of relevant biological terms at the end of the thesis. Lastly, a brief 
warning: this chapter contains Figure 14, a graphic depiction of human injury at the start of 
Section 6.2, on p.248. 
 
 
6.1 Patients to Projects    
 
Network origins of a synthetic biology project 
 
The Networks in Synthetic Biology (NSBs) were awarded in 2007 to seven collaborations or 
institutions. As described by Molyneux-Hodgson and Meyer (2009), the initial formulation of 
one NSB began when two academic engineers decided to create a proposal for the network. 
This resulted in a collaborative proposal from three primary investigators – a tissue engineer, 
a chemical engineer and a microbiologist.  
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An outcome of the discussions, conducted partly during a workshop in the Peak District, was 
to orientate the network towards solving a clinical problem in hospital surgery. The problem 
was that the surgical grafting of autologous human cells and tissues to wounds or diseased 
sites often failed because the cells or tissues failed to bond to the new site’s tissue surface. 
The network proposed to address this issue.   
 
Using forward engineering tools to generate biological materials via a synthetic biology 
framework that mimic the basement membrane. This will have major benefits for 
providing materials for tissue engineering, stem cell therapies and regenerative medicine. 
We propose to mimic the complexity of the human extracellular matrix (ECM) using 
microorganism-based synthetic biology chassis as factories to produce and/or modify 
adhesive or embedding macromolecules and matrices for eventual use in tissue 
engineering. 
(Biotechnology and Biological Sciences Research Council 2011) 
 
The NSB’s overarching direction of research was towards producing biomolecules that could 
be applied to a range of surgical and therapeutic procedures. However, the NSBs were 
aimed, not at research, but “to develop and establish communication and networking 
between researchers in the biosciences, engineering and the physical sciences in the area 
of synthetic biology” (Biotechnology and Biological Sciences Research Council 2007). The 
NSB ended in 2011 and the RCUK Gateway to Research website lists a single academic 
publication arising from the NSB. The article discusses the connection of systems biology to 
synthetic biology (Noirel et al. 2009). The website also lists six projects as outcomes from 
the NSB. These are:  
 
• Mass Spectrometry Underpinning Synthetic Biology, Industrial Biotechnology and 
World Class Bioscience  
• Utilising Steel Mill 'Off-Gas' for Chemical Commodity Production using Synthetic 
Biology  
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• C1net: Chemicals from C1 Gas (A network in Industrial biotechnology and 
bioenergy) 
• ROADBLOCK: Towards Programmable Defensive Bacterial Coatings & Skins 
• SynbiCITE - an Imperial College led Innovation and Knowledge Centre (IKC) in 
Synthetic Biology  
• Use of Synthetic Biology in the Development of Bacterial Adhesins for Skin 
Grafting applications  
(Research Councils UK 2015b) 
 
The scale of the various outcomes varies considerably: the grants for these projects range 
from £25k to £5m. Some of outcomes listed are very large and include either multiple 
collaborators, both at the institution and between multiple institutions. For example, by far 
the largest outcome in terms of funding and co-investigators is SynbiCITE, discussed in the 
previous chapter. The emphasis on community construction (Molyneux-Hodgson & Meyer 
2009) is evident in these project outcomes compared to the single research publication. 
 
The “synthetic biology adhesins” (henceforth “the bioglue project”) is the only project related 
to the technical problem addressed by the NSB. According my study participants, the NSB 
was developed into two further research projects developing ideas for the same problem. (In 
section 5.2, I discussed how value is realised in academia through the transformation of 
research into further projects.) A researcher described generating the follow-up 
investigations:  
 
The two projects that came out were the collagen and the bioglue thing, you know, we did 
get a grant on the bioglue which it finished and we’re trying to do some bits and bobs and 
see what decide where we go next with it. The collagen idea that came out was included 
as one of the projects when we applied to the university for this crosscutting PhD 
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network… so I guess it’s just morphed into that PhD network rather than dissipated, but 
the[re are] people who were originally in [the NSB] that are still involved. 
(Academic researcher 5 interview, 7th May 2014) 
 
The bioglue project aimed to engineer molecules that will “help natural skin cells stick to 
surfaces and also improve adherence of these cells in a laboratory based skin grafting 
assay” (Biotechnology and Biological Sciences Research Council 2014).  
 
‘The collagen thing’ is not listed on the RCUK site. The project was also aimed at creating 
skin-grafting applications by using “a synthetic biology approach to generate designer 
collagen molecules using engineered Escherichia coli strains that secrete collagen chains”, 
which “will have major benefits in the areas of tissue engineering, stem cell therapies, 
regenerative medicine and burns wound treatment” (FindAPhD 2015). It was not funded by 
RCUK. The collagen project was funded by a university as part of a PhD network focusing 
on synthetic biology for human health.  
 
In this chapter, I focus on the projects directly related to the NSB. These are the bioglue 
project funded via a responsive mode grant listed on the RCUK site and the collagen PhD 
project investigating the microbial production of collagen. What follows is a brief description 
of the projects and the decisions about which directions to take the work in.  
 
 
Introducing Flagella 
 
The two skin graft projects emerging from the NSB sought to use existing knowledge about 
E. coli, in particular, the way they make flagella. Flagella are bacteria’s ‘tails’ that move the 
cells through their environment. This section is a short account of the way the flagella 
system was described to me, supplemented with additional material.  
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E. coli tend to produce eight to twelve flagella per cell. Flagella are composed of individual 
subunits of “flagellin”, a protein monomer. These are synthesised inside the cell and 
transported to the membrane. At the membrane they pass through the ‘hook’ in ‘type-3 
secretion’. The first flagellin monomers pass across the cell membrane and, instead of 
floating off into the extracellular environment, attach to the outside lip of the channel through 
which they passed. As each successive monomer passes through the channel and attaches 
to the lip, the channel increases in length to become a hollow filament, still attached to the 
external cell surface (see diagram below). 
 
 
Figure 12. Diagram of a bacterial flagellar motor (Alberts et al. 2008, p.943) 
 
The base of the channel is also able to rotate, powered by the hydrolysis of ATP, and this 
energy-releasing reaction allows the flagellum to turn like a long stringy propeller. The 
spinning movement of the filament moves a bacterium through its environment.  
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Overall, the two reasons given for selecting the flagella pathway were that there was 
research expertise in the biology and that it would make the next stage of purification 
simpler. First, one of the researchers in the NSB had spent a number of years working on 
‘the interesting problem’ of flagella assembly. This meant they knew the literature base and 
were familiar with the kinds of techniques that would be needed by the project. Second, 
flagella are assembled outside the cell. If the desired chemical was produced inside the 
microbe then the purification steps would involve breaking open or ‘lysing’ the cells. 
Releasing all the other cellular contents would make purification difficult since the resulting 
‘soup’ would contain many different substances that would be tricky to separate. Instead, the 
filaments self-assemble to make a large macromolecule that can be mechanically sheared 
off the cell. These can be centrifuged to ‘spin down’ the cells and leave the sheared-off 
filaments in solution. To the researchers, the flagella pathway seemed like a good site to 
reengineer because protein monomers could be synthesised internally and the cell did the 
job of exporting the monomers and assembling the proteins externally.  
 
 
Efficient Porcupines  
 
The collagen project sought to reengineer the flagella system in two main ways. One of 
these ways was to make cells that secrete a non-native protein, collagen. The other line of 
engineering was to increase the number of secretion points on each cell so more proteins 
could be manufactured. The aim was to use the bacteria to produce a human protein that 
could then be purified and perhaps, in the future, be used in skin grafting and stem cell 
procedures.  
 
The first element of the project was to engineer E. coli to produce human collagen. To 
researchers, collagen and flagella had similarities. Human collagen, much like the native 
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flagella, is constructed from subunits which self-assemble into fibres. The researchers 
reasoned that if it was possible to express a human gene in bacteria, it would be possible to 
export the subunits through the flagella type 3 secretion pathway and have the units self-
assemble externally, thus having the benefits of more simple purification procedures. The 
process of engineering therefore required both expressing the subunits and having them 
‘tagged’ in such a way that the bacteria would be able to move them the internal membrane 
surface where they would be transported across the membrane, through the ‘hook’.  
 
In engineering cells to produce human collagen the researchers encountered several 
problems. One of these was whether the researchers could know whether subunits were 
being expressed without them being exported. In other words, if they were being expressed 
but not transported, then it was a problem with the ‘tagging’ for transport – less of a concern 
than total non-expression. The researchers undertook many Western Blots (protein assays) 
to try to determine whether the collagen subunits were being expressed. Another problem 
involved the production of the subunits. Collagen is made up partly of a proline derivative 
and the cells were thought to be using proline for their own proteins. The researchers 
devised an experiment to ‘shock’ the cells into using proline to make collagen by using a 
high concentration of proline in the growth medium. This did not appear to have the desired 
effect.  
 
The second investigative strand involved trying to make the bacteria have the ability to make 
more flagella. In laboratory conditions E. coli produce eight to twelve flagella. The 
researchers felt that, in order for the microbe to be a product that could interest industry by 
being an effective ‘factory’, the E. coli would need to be able to produce many more flagella 
and so be able to make and export a far higher volume of collagen subunits. This was 
jokingly referred to as ‘making porcupines’. The expression of more channels in the 
membranes was problematic. There seemed to be difficulty in expressing enough channels 
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to make the project worthwhile, yet not making so many that the bacteria were unable to 
survive. The researchers found they had to balance resources for what the bacteria needed 
to live and what they hoped the bacteria would be able to do. In line with an overall aim of 
synthetic biology, this element of the project was geared to create a ‘modular platform’ that 
could be used to display and export other proteins and so be useful in a wide range of other 
applications.  
 
 
Sticky Chimeras  
 
The bioglue project focused on adhesins and was aimed at reengineering the flagella 
pathway so that instead of being composed of flagellin monomers cells the cells would 
create a filament that would have ‘sticky’ elements along its length (see Figure 13 on the 
next page). The project was “a pilot/proof of principle type project” (Biotechnology and 
Biological Sciences Research Council 2014) which aimed at improving the adherence of 
cells in tissue models. 
 
We aim to produce a 'bioglue' targeted at attaching split thickness skin grafts or cultured 
cells to collagen I. This bioglue must increase adhesion in these situations and persist in 
the body long enough (5-10 days) for adhered skin cells to begin remodelling wound 
beds, promote vasculature and ultimately restore barrier function. Our approach is to use 
a synthetic biology pathway to redesign the bacterial flagellum to produce adhesive 
protein fibres. 
(BBSRC 2015) 
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Figure 13. Sketch of a bioglue molecule  
(Redrawn by the author after meeting, 10th January 2014) 
 
The sticky filaments could then be removed from the microbes, purified and used to help 
temporarily ‘glue’ human cells into place and allow them time to create their own bonds in 
order anchor themselves to the experimental site. The researchers imagined a protein that 
would contain some native flagellin subunits and also the ‘sticky’ sections, which would be 
copied from another organism, perhaps mammalian or viral. This is known as a chimeric 
protein. A chimera, to molecular biologists, is a protein that is formed from splicing together 
genes coding for different protein subunits from different organisms. 
 
The researchers also claimed a range of possible future impacts in terms of biomedical 
research, policy regulations and career advancement for the postdoctoral research 
assistants. One further impact was that the researchers intended the bioglue would be 
translated to industry through a specific collaboration.  
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Overall, the researchers constructed a modular approach: the two projects could, in theory, 
be put back together. The ‘porcupine’ bacterial strain might be able to efficiently produce 
‘sticky chimeras’ in large volumes that could glue cells in place.   
 
 
6.2 Molecules to Tissue (Engineers)  
 
Performing a therapeutic need 
 
The researchers designed the projects following discussions with tissue engineers. More 
specifically, the problem they were attempting to solve was that in certain types of wounds, 
such as burns, skin cell adhesion is problematic because the ‘wound bed’ lacks many key 
macromolecules.  
 
… cultured cells usually fail to attach well to challenging wound beds, as are often 
present in burns or chronic non-healing ulcer patients. These wound beds are 
characterised by poor vasculature and a dearth of extracellular matrix proteins that 
ensure attachment of the epidermis to dermis (i.e. Collagen IV, VII and laminin). They 
contain predominantly Collagen I, are rich in degradative enzymes, sometimes infected 
and usually poorly vascularised. Even conventional split-thickness skin grafts can fail to 
attach well on such wound beds. 
(BBSRC 2015) 
 
The above description moves quickly from patients to skin to molecules. Despite the 
technical, molecular focus of their daily work, the researchers contextualised their work as a 
possible solution to problems with skin grafts. At the opening of talks and presentations, and 
in the introductory text to conference posters, they introduced themselves and the title of 
their project. Then, they led the audience to The Problem. This took the form of displaying 
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photographs of seriously burned legs (see Figure 14). Mottled red limbs pictured on green 
surgical fabric. 
 
 
 
Figure 14. Photographs of burned legs 
(Part of slide from presentation, 10th January 2014) 
 
Two things were particularly notable. First, the title slides of their presentations were often 
textual, or images of microbes or molecules. The researchers did not warn the audience that 
graphic slides were coming up. As the burn images were important to the way the 
researchers framed their investigations, the pictures usually featured on the second or third 
slide of a presentation. Each occasion they were displayed in a matter-of-fact style, which I 
found striking. Although I saw the pictures repeatedly, I was nevertheless surprised each 
time by the sudden appearance of disembodied, wounded legs. The second thing, which I 
asked about, was where the pictures had originated. How did microbiologists have access to 
these images? They had been copied from a presentation used by some of the collaborating 
tissue engineers. The presentation concerned a tissue engineering intervention in the 
process of skin grafting.  
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The researchers’ iterative use of the pictures re-asserted the medical goal of the project 
during each presentation. The surgical details about patients, as happens in my account, 
quickly gave way to molecular and microbial concerns. The presence of the pictures also 
recalled the collaboration. The tissue engineers had experience of collaborating with 
surgeons and with setting up biomedical companies and were therefore important to the 
imagined futures of the porcupines and chimeras. The researchers ‘performed alignment’ 
with the original skin graft problem by repeatedly showing how their research, creating a 
bioglue and human collagen, was relevant to the adhesion of skin cells in surgery.  
 
 
Gene Candidates  
 
The bioglue project used a modified bacterial strain that researchers had created during the 
NSB (BBSRC 2015). The flagellin monomer is normally composed of four subunits. The 
bacterial ‘device’ expressed only two subunits meaning the researchers could display other 
peptides in the middle of the flagellin protein. By searching existing literature the researchers 
had found four possible genes that they could express within their redeveloped E. coli 
flagella to create the chimera. The four candidate genes coded for:  
 
• Human laminin binding protein  
• Hydroxyapatite binding protein   
• Sialoprotein binding protein  
• Streptococcus aureus collagen binding protein  
 
The first three proteins are all derived from the human genome. The last is derived from a 
bacterium, which has become notorious for its methicillin-resistant form – MRSA. This 
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collagen binding protein is key to the microbes’ mode of infection and binds with high affinity 
to collagen 1 (there are many types of collagen).  
 
The researchers intended to capitalise on the existing knowledge of infection and 
appropriate it for the purposes of human health. The bioglue project, and synthetic biology 
more broadly, are aligned with a larger observation about biotechnology.  
 
Biotechnology seeks to instrumentalise the already instrumental capacities of living 
entities along particular lines… This surplus value is produced through setting up certain 
kinds of hierarchies in which marginal forms of vitality—the foetal, the cadaverous and 
extracted tissue, as well as the bodies and body parts of the socially marginal—are 
transformed into technologies to aid in the intensification of vitality for other living beings. 
(Waldby 2002, p.19) 
 
The researchers took sequences of bacterial DNA and, by re-contextualising the DNA 
through the processes of the bioglue project, repurposed it for human health rather than 
human pathology. Yet, it was the existing flagella components of the chimera that proved 
most problematic in terms of aligning the bioglue with medical applications.  
 
 
Preparing An Adhesive  
 
The potential adhesive needed to satisfy two main criteria. Primarily, the researchers 
needed make a bioglue that would work in a tissue model. However, the bioglue needed to 
be made in such a way that it could be of interest to industry. In other words, the preparation 
steps should be scalable and industrially viable. This process is explored in this section.  
 
The researchers needed to express the candidate genes in the modular system they had 
designed. The genes were spliced into plasmids. Microbes were then transformed by 
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inclusion of these novel plasmids into the cells, which were then grown in cultures. Making 
mutants of this kind takes a long time and so finding out whether one can construct what one 
hopes is often a slow process. The first point was to establish whether the chimera was 
exported by the microbes. This was a key step in the process given the researchers’ original 
identification of the flagella system as a production-export mechanism.  
 
 
Figure 15. Slide showing bacterial motility in a growth medium of two controls and 
six mutants (part of slide from presentation, 10th January 2014) 
 
The researchers devised an assay they could use to select which genes they would 
investigate further which I called ‘the swimming test’. First of all, this involved growing a 
culture of mutant bacteria. A small culture of bacteria was then added to a petri dish with 
agar and left for 24 hours. If the bacteria were mobile they would be able to move through 
the growth medium and would disperse more quickly than bacteria that did not have 
functioning flagella. The selection took place by measuring the halo around the initial colony. 
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A small corona would mean the cells were unlikely to be able to move while a larger one 
meant that cells could move and probably had functional flagella. Using this method, the 
researchers selected colonies with a larger halo for further investigation (see Figure 15 on 
the previous page). 
 
The researchers recognised this assay was flawed in the resolution of answers it gave. 
Swimming bacteria would have flagella that facilitated movement. In other words, the 
subunits were made in the cell, exported, assembled and the filament was able to rotate. 
Instead, there were several possible reasons why bacteria might not be able to swim. The 
subunits may not be made, may not be exported, may not self-assemble or may not rotate. 
The assay, however, only selected between assembled, spinning filaments and everything 
else. The ‘not-made’, ‘not-exported’ and ‘not-assembled’ results would not be taken forwards 
because of the anticipated difficulties in purification. However, the swimming assay would 
give a negative result for a situation where the filaments self-assembled but were unable to 
rotate. This was not thought to be a problem because the turning mechanism would be 
attached to the filament and so the filament would have to mechanically prevent rotation, a 
situation the researchers thought unlikely. At any rate, the project had only a short funding 
timescale and so the quicker and easier the assays could be developed to identify ‘goers’, 
the more quickly the project could be advanced to purifying the molecules. Following 
repeated testing and applications of the assay the researchers selected two of the four 
mutants for investigating further. These mutants contained DNA of the S. aureus collagen 
binding domain and the human hydroxyapatite binding domains.  
 
The collagen binding was hoped to act like a double-sided sticky tape and bind both to 
collagen 1 produced by the cells and to collagen 1 that would be in the tissue model assay. 
The other route, with the hydroxyapatite binding domain, was hoped to help with bone 
grafting though this became less important because the project was nearing the end of the 
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fourteen-month funding as the researchers felt that it was best to concentrate on 
demonstrating the function of the S. aureus chimera in cell and tissue models.  
 
Producing the bioglue also required researchers to overcome mechanical problems. One of 
these was that the flagella did not shear away from the cells as easily as expected. One 
suggestion was to use an old stainless steel “french press” which, with its vertical plunger, 
looked like a giant cafetière with a small tap at the bottom. The researchers were able to 
press the plunger and, as the cells were pressurised through the narrow outlet, the 
acceleration sheared the flagella off the cells. Perfecting this required practice and 
subsequent centrifugation – which also needed to be refined because ‘of difficulties with 
pelleting’ – but in the end the researchers were able to generate a suspension to form the 
bioglue. The articulation of existing equipment through action and forming new plans has 
been understood as tuning (Pickering 1995) and tinkering (Knorr Cetina 1981).  
 
The researchers had thus far been able to develop the project in their own lab. This had 
involved one researcher learning a new technique of mammalian cell culture in order to use 
the cell line to test the adhesion of mammalian cells to petri dish plastic. The researcher felt 
the time they spent learning was a minor accommodation – the technique was similar to 
bacterial cell culture and the growth media came ready-mixed (academic researcher 4 
interview, 4th December 2013). The researcher did this by giving the cells time to adhere to 
the plastic in a control and comparing with a petri dish smeared with a thin layer of the 
adhesive.  
 
The articulation work of learning new skills meant the cellular work could continue within the 
synthetic biology laboratory space. However,  
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… the next stage, is we have models for wounds in tissue engineering and so the next 
stage would be that we show it works in tissue in a culture dish. Once it works in tissue in 
a culture dish that’s the time at which we start looking at getting home office approval for 
animal experiments to see if it’ll improve healing at an organism level. Also, we’ve gone 
[through] like a funnel of levels to show how it works. We’ve shown it works at a 
molecular level, we’ve shown it works at a cellular level, and we’ve shown that it works at 
a tissue level, so we’ve got a really good chance that it will work at an animal level.  
(Academic researcher 4 interview, 4th December 2013) 
 
The researcher conceptualised the project as succeeding stages of increasing complexity. 
This imaged future sequence functions as an alignment with developing medical 
technologies. Overall, the regulatory process involves demonstrating safety and efficacy of 
interventions in various models, from molecular to tissue to animal. Once the evidence has 
been collected at these levels, the research can then be developed to human trials. 
However, the current drive for medical innovation is within medical devices rather than drugs 
because of the less onerous regulatory structures. Structural proteins, like the bioglue 
chimera, could well fit within the device market regulations (academic researcher 6 
interview, 5th February 2014). However, because of the complexity, moving testing into 
mammalian tissues would require the expertise of the tissue engineers. The tissue 
engineers marked both a key step in imagining the development of the technology and, 
simultaneously, they were the end point of the bioglue project’s scope.  
 
 
Immunogenicity  
 
The bioglue solution had an inbuilt problem. Overall, the researchers felt they were moving 
toward success by showing that the engineered flagella would bind with a thousand times 
greater affinity to collagen on cells (academic researcher 4 interview, 4th December 2013). 
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However, the choice of engineering bacterial flagella meant that, in order to preserve 
alignment to skin grafting and human medicine, more material work would need to be done.  
 
Whenever I talk about this project to a qualified scientific individual they say “but it’ll never 
work because flagella are immunogenic…” Flagella are well known throughout medicine 
as being a protein that stimulates the innate immune response. Now this could be a bad 
thing in wound healing. It could cause rejection of skin grafts and so forth so we’ve got 
some… assays to find out a) how much the immune response is stimulated using isolated 
mammalian cells and also b) whether a novel version of flagella that’s been genetically 
engineered to be less immunogenic is indeed less immunogenic, having shown already 
that it still works.  
 (Academic researcher 4 interview, 4th December 2013) 
 
The researchers were concerned that their choice of system contained a mechanism for 
causing an immune response in patients who were already ill. Immunogenicity is an 
undesirable quality for any medicine and can justify terminating product development. This 
feature was recognised at the outset since some aims of the project were to “improve both 
yield, purity and efficacy while also reducing any potential immunogenicity” (BBSRC 2015).  
 
The tissue engineers were involved for a number of reasons. Initially, they had identified the 
cell adherence problem, which offered a way to organise the project. They had expertise in 
creating tissue models and so could build a model in which to test the bioglue. They also 
had important experience working with surgeons and forming biomedical companies. One of 
the collaborating tissue engineers described their experience of generating a product that 
had to be reformulated from polyvinyl chloride (PVC) to use medical grade silicon because 
of late-stage testing (I include the whole quote because it begins humorously yet makes a 
serious point about developing devices).  
 
Once you’ve made something that then has to be tested in say, animals or people that’s 
when you’ve got to start thinking, “should we really be making out of neat poison. You 
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know. Should we take the spike? Should we remove the spike? Should we stop making 
out of the material that’s horrifically toxic,” and that kind of thing because you will 
eventually run into the prob[lem]… the MHRA will look at it and say, “well we’d like it not 
to be made of poison” … It seems flippant but we made [X] using PVC and it was PVC 
that was clinical grade. It was clinical grade, useful for packaging and making simple 
devices that could be in contact with people. But when we sent it for sensitivity testing – 
we had to have it tested to see if it would cause any immune response or inflammation or 
in any way make the people sensitised to it. And we thought we’re on a winner here. Of 
course it’s not going to, it’s already been tested, but we have to do it again. And we found 
that the PVC we were using, it did, it failed the sensitivity testing, you know? The animals 
and the cells it was tested on showed a response and it was because it was leaching 
phthalates which are chemicals, they’re plasticisers that are used in the formation of the 
poly, the PVC, there’s hardly any of it there but enough of it was coming out of the plastic 
the way we were using it to have an effect so suddenly we have to reformulate the 
product and use really expensive medical grade silicone.  
(Academic researcher 6 interview, 5th February 2014) 
 
The discovery that PVC turned out to be unsuitable for the product highlights the contingent 
nature of innovation and ‘getting it to work’ in a medical setting. The story works to show the 
important concerns about sensitivity testing and the diligence that needs to be employed to 
meet regulations in order to make a successful medical application. If the synthetic biologists 
wanted to produce a bioglue then it would have to pass immune response tests, and these 
could be a ‘stopper’, or involve expensive redevelopment. Since the flagella were the 
bioglue, this could mean starting again from scratch.  
 
A strand of the research, which proved time-consuming, was to find a way to make flagella 
less immunogenic. The researchers found a DNA sequence in the literature. This also 
proved to generate a positive swimming assay for the S. aureus domain but, unfortunately, 
not the bone morphogenic protein (see the bottom row of photographs in Figure 15).  
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By attending to the safety aspect of the bioglue earlier in the project the researchers sought 
to maintain the problem’s do-ability. At this stage, with a month of funding left, time was 
running short. The researchers focused on developing the bioglue in tissues and decided 
that demonstrating the lower immunogenicity in a model would be done only if there was 
sufficient time. However, the imagined future application was in medicine. Without 
addressing the immunogenicity it may also have been be more difficult to recruit the tissue 
engineers and access facilities to test the bioglue in a wound model. The bioglue 
researchers needed to work on the immunogenic feature of the flagella because doing so 
maintained alignment with the tissue engineers, with skin-grafting applications and with a 
future for the bioglue in medical surgery.  
 
 
 “On the cusp” of translation  
 
In the final few weeks of the project, and in collaboration with the tissue engineers, the 
researchers began testing their adhesive in tissue models. One assay, devised in the final 
week, was designed to show that cells in a homogeneous solution would clump together 
with addition of the adhesive. Back in their own laboratory, with a day left on the staff 
contract, the researchers used a keratinocyte cell culture line (HaCaT) and tried binding 
these to a bioglue coated plate. 3% of these cells were found to have bound to the bioglue 
plate after 60 minutes compared to 0.5% in the non-bioglue plate (field notes 10th January 
2014).  
 
These results were significant but had two problems. The first problem was the binding 
percentage was based on only one repeat. Biological work is conventionally carried out in 
triplicate so variability and precision of an experiment can be assessed. In the final project 
meeting, several of the researchers discussed whether it was problematic having only one 
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repeat. They decided it was valid for their purposes. The second problem was that HaCaT 
cells are an immortal cell line and have survived in laboratories in certain conditions. One of 
their properties is that they adhere to plastic. Again, this was deemed not to be problematic 
due to the controlled experimental procedure. From the point of view of gluing cells to wound 
sites, these results were positive indications.  
 
… And I think what we’ve found is that there’s a small increase in the percentage of 
attachment. I think, the percentage, I mean often the percentage of attachment is about 
one percent so, a little [bit] of an increase in that, like about 2 or 3 per cent would be 
great. And it looks like that’s roughly the order of the magnitude of increase that we’re 
getting. So, I mean, it doesn’t seem like it’s a barn stormer but, that’s, if you can get two 
or three times the number of cells attaching they can start modifying a wound 
environment. 
(Academic researcher 6 inteview, 5th February 2014) 
 
In the end, due to the time constraints, the researchers had only one biological repeat that 
they were comfortable sharing the results of, but were concerned that the results, without 
repeats, were not robust enough to convince others. In the final meeting the project was 
“frustrating” because it was “on the cusp” (field notes, 10th January 2014). In Fujimura’s 
words:  
 
While conducting the tests, however, the researchers ran into 'glitches'. Nature is 
recalcitrant; it does not always do what it is 'supposed' to do. Experiments often fail, and 
presidents of companies get impatient when a product is not ready by established 
deadlines. Colleagues may disagree with interpretations of results. In sum, a project - that 
is, the development of a problem from inception to solution - rarely runs smoothly. 
(Fujimura 1987, p.171) 
 
By the end of the project the main goals had been at least partially met. The researchers 
had been able to produce a bioglue by purifying modified flagella produced by bacteria. They 
had improved the efficacy of the NSB attempts. Theoretically, they had been able to reduce 
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the immunogenicity of the flagella but had not tested this satisfactorily. They had also been 
able to test the bioglue in a solution of cells that was somewhere in between cell and tissue 
scale. The project has been the focus of a number of talks and posters but no publications to 
date.  
 
In this section I have explored how the researchers articulated and maintained alignment in 
their rhetorical and material practices. In one way, the research projects were aimed at 
producing biomaterials efficiently, and in a way that could function in industrial 
manufacturing. This was achieved by working towards an easier purification step. On the 
other hand, the researchers maintained alignment with a surgical application. They worked 
towards this by repeatedly referring to the clinical problem, improving the binding of the 
bioglue and attempting to reduce its immunogenic properties. The difficulties of articulating 
and maintaining alignment through these different channels are explored in the next section.  
 
 
6.3 Containing Bioglue   
 
In this section I argue that, as part of their enrolment strategy (Callon 1986), the researchers 
inscribed values into the DNA of the bacteria using different modes (Latour 1991). The 
enrolment of the bacteria proved successful over the project. However, the enrolment of the 
other actors was problematic. Their collaborators seemed unaware of the complexity of the 
problem and so, in the view of the researchers, did not seem to devote enough resources to 
the project.  
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Skills, time and materiality: “You’ve gotta bring all that together”  
 
I will now discuss some of the processes and tensions that arose in the project and the 
problems of engineering heterogeneous stuff (Law 1993). In the following quotation a 
synthetic biologist, who was at another institution, described their experience of problems in 
trying to move from molecules to patients in a different project: 
 
I wanted to go and do something more translational… the problem is you start hitting 
brick walls. This is what you’ll find all the time. So, first of all, we need to be able to 
produce this these proteins in large enough quantities that cell biologists can basically 
just throw them, well not down the sink, but that sink via doing a whole load cell biology 
science. So the, as a protein engineer or protein designer I’d be quite happy with a few 
micrograms of material to work with. These guys need grams. So all of a sudden we’ve 
gotta scale up by a million-fold. To get enough material to do some cell biology work. 
That’s the first bottleneck. The second one is working with people that have er, not only 
cell biologists, cos you’re trying [to] translate cell biology into the clinic, but also that are 
clinically minded. And the second bottleneck we’ve found is that lots of cell biologists are 
just like us, basic scientists. They wanna know about how cells respond on these gels 
we’ve created. This fibrous materials we’ve created… so we’re still a step away from the 
clinic and it’s only now that we’re starting to talk to the clinicians and say well what do you 
need?… And they’ll say, oh, I need autologous cells from the patients, and need your 
gels, and I need a sprinkling of cell biology to make it work. So you’ve gotta bring all that 
together. So there are many roadblocks in the way of actually doing that piece of work. 
(Academic researcher 15 interview, 28th August 2014) 
 
In order to work with other groups the synthetic biologists need to be able to meet their 
requirements. It is fine doing things at a given scale and with certain values. But ‘translating’ 
in this context means aligning scaling up work in terms of volume and mass. The actor 
identified scaling, medical use and unanticipated requirements as points where alignment 
needs articulating. As the ‘failure story’ of the electric vehicle Aramis shows, bringing 
together different things in order is difficult (Latour 1996), which is important to bear in mind 
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as the work of translation involves creating complex alignments that can be difficult to 
manage and fulfil.  
 
Returning to the “skin-graft project”, the synthetic biologists worked to align their problem 
with a varied set of entities, including:  
 
• The work of the earlier NSB 
• RCUK and universities by addressing both a ‘real world application’ and trying to 
continue to build a ‘critical mass’ of researchers  
• Industrial manufacturing  
• Bacterial and viral DNA  
• Tissue engineers 
• Surgical practice  
 
As I have detailed in the previous sections, the researchers maintained alignment to different 
domains by reorganising their experiments, tinkering with life and learning new skills.  
 
Unfortunately, from the perspective of the synthetic biologists, the tissue engineers were not 
fully committed in terms of time and resources to the project.  
 
The link up with you know with the tissue engineers hadn’t worked as well as we’d hoped 
because I don’t think they really realised quite the scale of what we wanted to do and so 
when we came to actually do those experiments at the end they were like, “oh, we’ve only 
got enough time and people to just do it once...” 
(Academic researcher 5 interview, 7th May 2014) 
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This highlights a difference in the division of the complexity of knowledge work. Instead, from 
the perspective of one of the collaborators, they would have preferred the bioglue to be in a 
more advanced state of development:  
 
Once they’ve [the synthetic biologists] worked out exactly what to make the problem will 
then be working out how to scale it up and trying to get it into some in vitro testing and 
then some in vivo testing to show that it does what you say it’s going to do. I can make 
something in the laboratory that will do a job but it may not have a clinical application 
because you know, it’s also made of solid poison. 
(Academic researcher 6 interview, 5th February 2014) 
 
The collaborators thus wanted a defined object that could be scaled up in terms of volume 
and tested for safety. The synthetic biology technology was not yet ‘packaged’ sufficiently to 
turn it into a ‘technical object’ from the perspective of the tissue engineers (McGivern & 
Dopson 2010).  
 
Similar to the notion of phasing I described in Section 5.2, academic researcher 5 explained 
that the tissue engineers did not understand the researchers’ ambitions. The researchers 
were tackling a complex problem, but the tissue engineers’ commitment in terms of 
resources was low. Thus, academics were thought to engage with long, complex problems 
whereas their industrial collaborators wanted solutions quickly. Despite the efforts to 
materially maintain alignment during the project, it was likely that follow-up funding 
depended on the continued enrolment of the tissue engineers. This is an additional 
problematic on top of the issues with engineering the viral DNA into the bacterial plasmid, 
successfully culturing the cells and shearing off the flagella for purification. The product was 
still in the process of being ‘materially defined’ (Rheinberger 1997) and so was not in a state 
for the tissue engineers to be able to use it.  
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A connected issue, which also relates to Section 5.2, is about the right competencies being 
available:  
 
It’s all new and you’re in a new area there’s almost having somebody with the skill set say 
to be able to do the molecular biology know everything about collagen which even I don’t 
know and the tissue engineering testing. There probably isn’t a person like that and so we 
tried to do it you know with a person that had some of that skill set and who did their best 
but, with the best will in the world, they probably couldn’t make… we should have had 
some better insight into that but it’s easy to look back. Obviously. You know you just 
wanna get stuff going and have a go but you know. Maybe it was always gonna be really 
difficult to expect one person to be able to do all those things and that’s the truth 
probably. 
(Academic researcher 5 interview, 7th May 2014) 
 
In retrospect, the bioglue project was more ambitious than the researchers had initially 
realised. This is despite one researcher developing new skills including using the French 
Press and mammalian cell culture. Furthermore, the tissue engineers were required for their 
competencies in making tissue models. It seems these capabilities did not become available 
soon enough. The project ended without convincing results in models at tissue scale.  
 
Alignment also had a material component whereby futures are coded into technologies 
(Akrich 1992). Here I focus on the alignment of synthetic biology through the manipulation of 
E. coli with both manufacturing and medicine.  
 
One of the project aims was to use synthetic biology to address a clinical problem. This 
supports the existing medical technologies that are used in treating burns. It says, ‘the 
current interventions are on the right path and require refining, rather than rethinking’. By 
generating a bioglue the project cements the existing arrangements of medical and patient 
practices when it comes to burns treatment. It prescribes an existing order within its 
structure of the future. Furthermore, the researchers attempted to maintain this alignment by 
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inscribing medical needs in the project. They addressed efficacy by selecting the chimera 
that promoted the most molecular binding. However, the bioglue seemed incompatible with a 
medical future. They addressed safety by reengineering the flagella with the aim of reducing 
the immune response. In this way, they materially aligned their project with a future of 
medical regulations.  
 
At the same time the project was designed to manufacture as pure a product as possible, 
and to do that as efficiently as possible. This meant that the flagella system had been 
selected as a viable site of modification. The researchers interpreted the existing biology as 
being able to deliver on these manufacturing needs. They inscribed the manufacturing 
possibility on the bacteria from the outset and attempted to ‘optimise’ this inscription in the 
course of their work. The bacteria materially incorporated the alignment for both industrial 
manufacturing and medicine.  
 
Finally, the researchers collaborated with the tissue engineers and co-designed the assays 
meant to test the efficacy of the bioglue. They broadly agreed on the meanings of the test 
results: the additional ‘stickiness’ was not a “barn stormer”, but it was efficacious and could 
be worth pursuing. Both researchers and collaborators were concerned about the effects of 
flagella on an immune system. The immunogenic properties, even if they could still be 
reduced, could still be problematic as soon as the product entered sensitivity testing. At the 
time I ceased collecting data, the skills, materials and meanings of the project were not 
aligned in such a way as to facilitate a transformation of the project. Innovation had reached 
a hiatus.  
 
 
Cells, Molecules & Engineers  
 	 265  
Secure synthetic biology 
 
The researchers designed and manufactured a bioglue that, in their eyes, worked at the 
molecular level. As Mackenzie (2010) notes:  
 
Rather than separating out ethical–social issues from the doing of the science, 
intensification of design generates concrete entanglements and partial connections 
(Haraway, 1999) between sciences, business, state-power, popular and media cultures.  
(Mackenzie 2010, pp.195–6) 
 
Entanglements and connections were materialised in the design of the bioglue project. The 
bioglue partially entangled bits of DNA, humans, bacteria, laboratory equipment, tissue 
engineering knowledge, medical device regulation and industrial production. Researchers 
inscribed the manufacturing and medical goals into the bacterial DNA. On the one hand, 
these were already there in the sense the bacteria provided the starting mechanism of 
flagella export and assembly that could be easy to purify. The selection of the flagella was 
made in order to produce a protein that was easy to purify. This was hoped to be a modular 
platform that could be used to display other proteins. In so doing, they aligned the project 
with the overall synthetic biology project of standardised systems. Flagella were also 
selected because the researchers could imagine a way to optimise production by increasing 
the number of hooks to create ‘porcupines’. On the other hand, the researchers materially 
inscribed ‘efficient production’ and ‘medical efficacy’ through their practices and so the 
bioglue project incorporated values for both industrial production and medical intervention.  
 
The trouble with flagella was they stimulated an immune response in mammals. This causes 
a problem if they are to act as the backbone of a sticky molecule to be used in surgery. In 
these terms, the ambitious nature of the bioglue project is a function of academic funding 
requirements and the likely avenues for dissemination – novelty is a priority for making 
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science fundable and marketable (Fujimura 1987, p.171). The projects required a broad 
range of skills from the researchers. The resource constraints, including project time and the 
competencies of other people, proved difficult to manage.  
 
The researchers used further synthetic biology techniques to attempt to solve the problem 
and maintain alignment with medicine. This involved rewriting the flagella DNA with what 
was hoped to be a sequence that would reduce an immune response. Regardless of the 
lack of experimental proof in the project, this activity was an attempt to preserve the 
alignment of synthetic biology with medicine within the bacterial plasmid DNA. Furthermore, 
a central connecting point between the researchers and bacteria, the modified flagella, was 
not viable in a future medical scenario. In this way, the imaginary industry of contained bio-
manufacture in Section 4.3 played out materially. 
 
The bioglue molecule, with its immunogenic properties, still needed to be contained. It was 
an innovation too disruptive to be released. This is a material realisation of the imagined 
industry of “contained bio-manufacturing” I explored in Section 4.3. Synthetic biology can 
produce synthetic versions of existing compounds if the fabrication process is secured and 
any novelty kept under control. In this project, the synthetic biology novelties in terms of 
molecules and cells, are not releasable. Synthetic biology remained materially contained in 
the petri dish and conical flask.  
 
 
6.4 Conclusion  
 
In this chapter I have focused on the work of alignment at the level of a laboratory. 
Researchers maintain and articulate alignment with rhetorical, pictorial and material work. 
The very sequence of DNA in this project had been delegated duties of alignment. At the 
Cells, Molecules & Engineers  
 	 267  
same time, nature resisted or facilitated only certain kinds of formulations, and so had to be 
accommodated (Pickering 1995).  
 
Translation appears to be dependent on actors aligning different strands of the world. 
Materially, if cells do not sick or if bacteria do not survive, there can be no translation of a 
synthetic biology bioglue. Skills and abilities need to be available at the right times for 
translation to happen: for assays to be done, data made convincing and for meanings to be 
aligned. Thus, phasing, competencies and imaginaries interacted and were salient to this 
particular academic-academic collaboration. The bioglue cohered mammalian cells in the 
laboratory. But, it failed to create adherents among the wider community. Synthetic biology’s 
bioglue remained contained.  
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Chapter Seven  
 
Doable Research, Multiples and Vulnerabilities  
 
 
 
This final chapter summarises the answers to my research questions and then details two 
theoretical contributions to the STS field. The chapter is also an experiment in “academic 
minimalism” described in Section 3.7. The style is deliberately sparse, yet additive. In so 
doing, I aim to ‘layer’ the arguments laid out earlier in the thesis to contribute to overall 
themes of multiplicity and coherence. It is thus a performance of a fractal reality (Law 2002) 
and, where my Introductions was a series of connections, this concluding chapter might be 
considered as multiple extensions.  
 
Throughout this thesis I have explored many different versions of translation. Starting with a 
dictionary definition, translation can entail transferring meaning between languages such as 
French to German, or information between mediums like DNA and RNA. Translation can 
also be the movement of bodies in mathematics and, in theology, formally moving objects 
and people between sites. In academia and innovation, translation can mean the reshaping 
of research (Edge 1995) and alterations to sociotechnical systems (Williams & Edge 1996) 
to suit other contexts. In biomedicine, the term “translational research” suggests moving 
knowledge between laboratory and clinic (Woolf 2008; van der Laan & Boenink 2012; 
Cooksey 2006). In STS theories, the translation metaphor comes in many guises, such as in 
co-ordination work, when actors use correlation studies to move between ultrasound 
readings of pumping blood and angiographs of blood vessels (Mol 2002, pp.72–85). Or, in 
ANT, where actors translate the interests of others into their own projects (Callon & Law 
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1982; Callon 1986), or when they delegate/inscribe actions and morals to technology (Akrich 
1992; Bijker & Law 1992; Johnson 1988; Latour 1991; Latour 1992), or when innovation 
practices transform objects (Law & Callon 1992), or the process of perceiving a world of 
connected hybrids as separate, individual objects (Latour 1993b). All these forms of 
translation involve versions of movement and change.  
 
A limitation of an ANT type approach is knowing when one is at the edges of a network and 
so deciding what is ‘in’ and what is ‘out’ (McLean & Hassard 2004). While I made every 
effort to follow translation in synthetic biology, there were points when the research trail 
appeared to peter out. Furthermore, the final work thesis was also shaped by what was 
pragmatic and possible – it had to fit various institutional timings and requirements. These 
two points necessitated various omissions and exclusions. For instance, the thesis would 
likely have been different if the methodology had prioritised comparison of ‘cases’ of 
translation, or if I had been able to extend the fieldwork to visit SynbiCITE as it began its 
substantive work. The conclusions I present rely on data generated in a particular time and 
place and perhaps offer inspiration for future explorations of these avenues of research.  
 
At the start of the thesis I set out with the overarching aim to find out how synthetic biology is 
made translatable. This involved exploring how multiple actors understood translation, the 
kinds of activities that counted as translation and how these activities shaped synthetic 
biology in the UK. In this study, I explored translation as the way actors align the field of 
synthetic biology and sponsoring state’s goals (Section 4.1, Section 4.3), the alignment of 
technical solutions with possible futures (Section 6.1, Section 6.2), the ways actors collect 
new collaborators (Section 5.1) and other entities (Section 6.2), and the differences between 
research cultures (Section 5.2, Section 6.3). The sensitivity to multiplicities is a particular 
strength of the approach I have taken. As was the methodology of connecting a specific 
project to a range of practices in the wider world. In sum, I encountered multiple translations 
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realised in specific arguments and specific practices. I tackle these research concerns in 
Section 7.1.  
 
Addressing the issue of translatability meant, for me, exploring the kind of object synthetic 
biology might be – the question being, what is translated to what? In Chapter 2 I reviewed 
two strands of theories of objects in STS. ANT and post-ANT researchers conceptualise 
objects as networks of actors and, later, as composites of practices that produce multiple 
objects. Post-social theory conceptualises epistemic objects as partial and unfolding objects, 
composed of more partial objects, through which actors loop their desire for completion. In 
Section 7.2, I identify features of synthetic biology in order to generate a conceptual 
framework that combines post-ANT and post-social theories. My aim is that this could be 
applied to other contemporary objects with fuzzy boundaries e.g. other emerging fields of 
research, open source computer programs, governmental policies, as well as existing 
research programmes that STS researchers analyse.  
 
Finally, throughout the research, as actors made connections to make synthetic biology 
translatable, they pointed out issues in wider society that synthetic biology could address. 
Actors also identified elements of society that posed a threat to synthetic biology. In Section 
7.3, I present an analysis of the way these issues and threats were mobilised and offer a 
theory for how the multiple object discussed in the previous section may cohere. I suggest 
that reframing the way actors argue for resources and for protection of their research 
programme may have important implications for the current research agenda to create 
“science for society, with society” (Owen et al. 2012).  
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7.1 Answering the Research Questions  
 
Research Question 1: In what activities do researchers, administrators and policymakers in 
synthetic biology engage to address “translation” in synthetic biology? 
 
In formulating this question I aimed to be able to comment on how actors understand 
translation in synthetic biology and what they do as translation. There were three main types 
of translational activities – initiating collaborations with events and funding, doing 
collaborative projects and training researchers.  
 
In Chapter 5 I detailed how translation is rendered as collaborative working. Forming 
collaborations can be a way to combine the expertise of different actors in projects. This can 
be within academia, such as with interdisciplinary work, but also with actors outside of 
academia. In synthetic biology, this especially involves connecting researchers with industry. 
In the course of the research I followed actors to a range of events that universities and 
research councils set up to stimulate collaborations, especially with businesses. These 
included ‘showcases’ and ‘open days’ and funding launches. The events were structured to 
bring academics and industry closer together, at least for short periods of time. An aim 
appeared to be to better align the needs of the two communities at an early stage of 
research in the hope of expediting translation.  
 
RCUK and research administrators also identified collaborations as routes to leverage 
further funding. Actors who can demonstrate they have formed a collaboration stand a better 
chance of accessing funds. The BBSRC say that, of two projects of equal scientific merit, 
they will fund the one that has industrial partners contributing at least 10% of the full cost of 
the project in preference (Biotechnology and Biological Sciences Research Council 2015). 
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Collaborations can therefore have a particular effect of facilitating actors’ access to 
resources.  
 
Research administrators in quangos (RCUK and Innovate UK) and in universities have 
created staged funding mechanisms aimed at transferring knowledge. Academics and 
business partners can enter into research collaborations with the initial funding available to 
academics. Over the various stages of the mechanisms, risk is transferred from RCUK and 
academics to Innovate UK and businesses.  
 
Collaborative projects were a significant aspect of doing translational activities. SynbiCITE, 
funded for five years at Imperial College, was the UK’s seventh Innovation and Knowledge 
Centre. This £10m organisational response involved a grant proposal, which listed 52 
partnering organisations, including many UK universities. The proposal also stated 
involvement of multiple businesses, from large international companies such as Shell and 
GlaxoSmithKline, to new start-ups like Synthace and Oxitec. A part of SynbiCITE’s role 
involves bringing together academic researchers with potential collaborators in industry.  
 
At a smaller scale, the skin-graft project was a collaboration between academics in 
biosciences and engineering. The researchers repeatedly spoke of their engagement with 
the future medical application. However, the final part of their project, which involved 
designing and conducting adhesion experiments in tissue models, was difficult to manage.  
 
Finally, various actors have instituted translational training, particularly to academics. These 
can be short courses at universities, international fellow opportunities offered by SynbiCITE, 
and the iGEM competition where students produce projects that can benefit society. 
Translating synthetic biology therefore involves changing the professional expectations of 
researchers.  
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In this research, translational activities were about creating collaborations, funding projects 
which transfer the risk of innovation and educating academics to increase their awareness 
and sensitivity to commercial needs. Initially, this puts the responsibility of translation onto 
academics. Both funding and training begin with academics. The onus of translation is on 
the university sector. Translation is shaping academic bioscience to produce people and 
networks in order to create translatable knowledge.  
 
One prevalent metaphor in the discourse of translation is “the valley of death” (House of 
Commons Science and Technology Committee 2013; Kraft 2013). This suggests there is a 
‘gap’ between academia and industry. In some reports, this can be framed as problems with 
funding and financing innovation. Industry rep 1 spoke of ‘doing the funding rounds’ to get 
investment. On the whole, however, funding for translation did not seem to be a major issue 
for academics or administrators with respect to synthetic biology. In my analysis I generated 
four other ‘gaps’ in the valley of death – phasing, disclosure, transformations and 
competencies. These were four axes along which tensions emerged in interviews and in 
field sites.  
 
Phasing. There are ways in which temporal issues come to fore when people talk about or 
actively begin collaborations. Knowledge-work in industry is imagined to work on tight time 
scales, be responsive to market changes, and to generate solutions to problems quickly. For 
academics, knowledge-work was imagined to take a long time, involve problems that were 
complex and time-consuming, and to operate to self-imposed deadlines. I conceptualised 
this as a problem of phasing or meshing, where the domains were running to different 
periodicities.  
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Transformations. Academia and industry are orientated towards producing different outputs 
from knowledge work, or converting research into other things. Thus, the way credibility can 
achieved in the academic sector is different to the industrial and commercial sectors (Packer 
& Webster 1996). Academics were imagined to want project outcomes that included 
publications, proposals and further projects. Industry was imagined to focus on patents or, 
more importantly, profit. This appeared to be a potential problem for actors initiating 
collaborations.  
 
Disclosure. A third contour appeared to be around the different ways that knowledge is 
protected in academic and commercial settings. For academics, publishing their discoveries 
and findings is a way to ensure their work is attached to their name. For industry, copyrights, 
patents and trade secrets are the main ways that knowledge is protected (Nuffield Council 
on Bioethics 2012). These differences played out in surprising ways. At one event 
attempting to foster collaborations, a table of academics claimed they had an idea but did 
not want to share it because they were uncertain of divulging information in case it 
jeopardised a future patent claim. At the same event, some academics expressed frustration 
with the lack of details from industry because they could not apply their expertise in the 
absence of knowledge of industrial secrets, such as bacterial strains and experimental 
conditions. At another event, an academic happily signed a confidentiality agreement with a 
company because they were unlikely to develop a project without industry support. The 
agreement was a ‘gesture of goodwill’ for the academic. Differences in disclosing knowledge 
can make conversations during initial interactions between academics, industry and 
universities less specific.  
 
Competencies. The final contour concerned the different skillsets and abilities of workers in 
each domain. Academic work is highly specialised and academics have ‘niche’ knowledge. 
Furthermore, academic experts are likely to have specific expertise, even within their own 
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discipline. For industry, knowledge skills were more general. Industrial scientists may need 
to be able to adapt to changes quickly, perhaps by moving to do work in an area they had 
not previously experienced. Furthermore, academics related their expertise to their 
‘interests’. Some academics claimed they were not interested in knowing about markets and 
running a company. They said they would need somebody else to do that work. This implies 
that making synthetic biology translatable involves assembling a network of abilities and 
interests.  
 
In Chapter 6, I argued that the themes of competencies in terms of researcher skills, and 
phasing in terms of timing and problem complexity, interacted and made interdisciplinary 
work difficult. The researchers wanted skills from their collaborators, but the project was 
running out of time. The collaborators wanted the solution to be closer to application before 
they dedicated resources and time. Thus, the skills of the collaborators were not available at 
the right times for the researchers. This suggests that some of these findings may be 
applicable to other forms of collaboration beyond academia and industry in research and 
innovation.  
 
What these findings imply is that collaborative practices play a key role in acting out 
translation. The ‘gaps’ between research cultures can be enacted as different ways to 
achieve credibility. A more profound interpretation might be that academic and industrial 
practices produce epistemic objects with different characteristics. So, where policy focuses 
on financial remedies to encourage translation they may miss some of the other differences 
between academic and industrial knowledge-work. Furthermore, actors intending to embark 
on collaborations may profit from being aware of the kinds of differences between the 
domains of academics and industry.  
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Research Question 2: What connections do researchers, administrators and policymakers 
make and unmake as synthetic biology emerges as a ‘translational science’? 
 
As I worked through my analysis I noted a number of other entities: science, state, industry, 
medicine, human bodies, experiments and bacteria. These seemed to broadly fit with 
Fujimura’s analysis of constructing doable problems. Fujimura notes that scientists select 
problems in part for their ‘technological do-ability’. She goes on to argue that “do-ability is 
better conceptualised as the alignment of several levels of work organisation” (Fujimura 
1987, p.258). I employed a framework of articulating alignment (Fujimura 1987; van Lente & 
van Til 2008) to study the emerging field of synbio. As such, I expanded the use of 
Fujimura’s framework from making a “doable problem” to making a doable field of research.  
 
Furthermore, Fujimura (1987) argues actors construct problems by aligning them with social 
worlds. Implicit in her formulation is the notion that social worlds are stable and antecedent 
to the research problem. I did not make this assumption – through selections of 
characteristics of other entities, actors perform and bring into being entities along with the 
field of research.  
 
 
Alignments  
 
In Chapter 4, I argued that synthetic biology was emerging alongside and in dialogue with 
another entity: the UK state. Throughout my data were enactments of the UK as an entity 
with a history of great bioscience and the potential for making important discoveries, which 
could have dramatic impacts on medicine and energy. Actors connected advances in 
biological understanding to returns for the UK in terms of economic and social impacts. In 
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this project, different actors connected investment in the life sciences, industry, human 
health and the national economy.  
 
The state, I argue, is presented as an ambivalent character. It is the plucky underdog in 
biology on a global scale. The UK ‘punches above its weight’. Research output is repeatedly 
claimed to be world class, both in terms of quality and quantity. The state is supportive of 
bioscience and aims to be “a scientific state” (Sismondo 2010, p.191). The state is also a 
state with a history of global leadership. However, the state has a deficit of knowledge 
translation and is failing to convert knowledge and discoveries into ‘health and wealth’. This 
legitimises funding for converting bioscience to industry and commercial markets.  
 
Actors then connect synthetic biology to features of this state. The connections are 
performed at conferences, during interviews and in ministerial speeches. Actors claim that 
the state is in economic recovery and, by standardising DNA and cellular systems, synthetic 
biology has the potential to create a new industrial revolution. They say this could impact 
health, food production and lead to economic recovery. Synthetic biology can also help the 
UK realise its identity as a global leader in bioscience. This appears to be an aspect of a 
‘compelling start-out story’ in which actors create an impetus for innovation (Deuten & Rip 
2000). These rhetorical alignments are realised in organisational structures. The formation of 
the SBLC connects government, quangos, universities, industry and regulators. Establishing 
SynbiCITE, the innovation and knowledge centre, connects synthetic biology with industrial 
manufacturing. The names actors give to biological parts (Calvert 2013) and facilities 
perform these connections.  
 
Actors connect synthetic biology to a range of other industries and technologies. Synthetic 
biology is aligned with technologies that are seen as desirable and beneficial to the 
contemporary state. They are infrastructural technologies. These include microchips, air 
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travel and fermentation. These connections perform work. They make synthetic biology 
seem innocuous in the sense that it is nonthreatening and good, and that, as an 
infrastructural technology, it could dramatically improve life.  
 
In Chaper 6, I was concerned with the laboratory and experimental levels of alignment. I 
showed how actors perform connections between synthetic biology, medicine and industry in 
their material practices. The actors selected to engineer the bacterial system for producing 
flagella. This was partly because of expertise of biological knowledge in the area. It was also 
because bacteria produce flagella outside of the cell. The actors felt that this would be a 
good mechanism to adapt because it would be easier to separate products rather than have 
to digest the whole cell. There were also ways that production could be ‘optimised’. This 
included increasing the number of secretion points. These reasons align the project with 
industrial manufacturing because actors felt that producing molecules efficiently, and 
creating easy purification steps, could be of interest to an industry. The actors also aligned 
their work with the modularisation aspect of synthetic biology. They argued that they were 
creating mutant bacteria that could theoretically produce other materials, not just collagen 
and sticky chimeras. Thus, they actively aligned their work with an industrial manufacturing 
vision for synthetic biology.  
 
The actors also aligned the project with medicine. Their overall goal was to create solutions 
to clinical practice. Surgical interventions for burns and ulcers can fail. Skin grafts and stem 
cell grafts can fail because wound beds are hostile places. The researchers invoked images 
of human injuries to perform the alignment of their work with health. They collaborated with 
other health scientists who had experience of setting up companies and working with 
surgeons and publicly mentioned this medical goal at the start of research presentations. 
One key aspect of the work was to try to reduce the immunogenic character of flagella. Re-
engineering the flagella in an attempt make it less toxic was also an attempt to preserve the 
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project’s connection to medicine. Without attending to this issue, there could be no clinical 
future for the bioglue element of the project. The connections to medicine and industry were 
written into the DNA of the bacteria.  
 
In this thesis, actors connected synthetic biology to the UK state, to industrial technologies, 
and to clinical practice. These connections were realised in organisational, rhetorical and 
material practices.  
 
 
Demarcations  
 
At the same time as making connections, actors struggled over dismantling other 
connections. In section 4.2 I explored the messy processes of attempting to demarcate 
synthetic biology from other biology. I employed the notions of rhetorical boundary work 
(Gieryn 1983) and material boundary-work (Meyer 2006), which occurred in interviews, at 
events and during the assessment of grant applications.  
 
Proponents of synthetic biology identify problems with the reproducibility of biology, and with 
the ‘culture’ in terms of understanding what it takes to scale up to commercial propositions. 
This can be understood as actors trying to maintain that synthetic biology has the potential 
to make a new contribution to innovation which justifies support. The idea that publics can 
disrupt technological innovation plays out in the distancing of synthetic biology from GM. 
Actors, keen to emphasise the differences of synthetic biology, argued that it offers greater 
control, both over the production processes and over the genetically modified organisms 
themselves.  
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 On the other hand, microbiologists argue that synthetic biology is not novel. At the most 
cynical, synthetic biology is simply rebranding of existing bioscience. It relies on the same 
techniques and processes and does not offer a new contribution. These performances 
reduce the status of synthetic biology. The various connections enact a struggle for 
credibility (Gieryn 1999; Rip 1994).  
 
The practices of connecting and unconnecting can be seen as ways for proponents of 
synthetic biology to preserve both the epistemic commitments of synthetic biology and the 
access to resources. For micro and molecular biologists, maintaining their connection to 
synthetic biology reduces its novelty and preserved their access to funding and an identity of 
cutting-edge research.  
 
 
Research Question 3: How does attending to translation shape the emergence of UK 
synthetic biology?  
 
Imagining industry  
 
Making synthetic biology a doable field of research partly means, in the current academic 
climate of impact, making sure it is connected to realising benefits for the UK. One effect of 
this is to align synthetic biology with the UK’s desire to be a global leader of bioscience (see 
research question 1). At the same time, actors distance their research from GM, claiming 
that the forerunner science ran into difficulties for various reasons. Actors appeared to 
create an imaginary industry, which circulated as a plausible version of an ‘industrial 
revolution’. Certain forms of materials and manufacturing, and public fears, shaped the 
imaginary.  
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This imaginary can be understood as based on the notion of contained bio-manufacturing. In 
terms of containment, this meant that the products of synthetic biology, engineered 
organisms in particular, were not allowed out. Synthetic biology novelties such as 
engineered bacteria must remain trapped in bioreactors or laboratories. This means that 
synthetic biology can be used to make things. Biomaterials, drugs, fragrant chemicals can all 
be manufactured provided the novel aspect remains under control in specific sites.  
 
A contained bio-manufacturing imaginary is performed in various instances. In Chapter 6, 
the researchers imagined they could reengineer the flagella of bacteria to use as a surgical 
adhesive. However, because flagella stimulate immune responses, even reengineering the 
flagella was not enough to convince collaborators that the novelty was safe. Thus, the 
biological novelty remained contained. The imaginary also plays out in The Artmisinin 
Project described in Section 5.1. The artemisinin precursor is not a novel compound. Any 
novel organisms remain in the Huvepharma bioreactors in Bulgaria. Finally, the synthetic 
biology special interest group circulated a new research paper: 'Deadman' and 'Passcode' 
microbial kill switches for bacterial containment (Chan et al. 2015). This paper was about 
engineering bacteria in such ways that they cannot survive outside of contained conditions. 
Thus, an imaginary of contained bio-manufacturing has material consequences for synthetic 
biology realities.  
 
There is a caveat to this narrative. In Section 4.2 I told the story of Ecover claiming it used 
oils from synthetic biology and how this resulted in a public backlash and public relations 
campaign. This suggests that imaginary may not be enough to facilitate the translation of 
synthetic biology.  
 
However, the imaginary does work in the present a plausible, attainable industry, as 
opposed to ‘in the next fifty years, being able to grow houses’ (Industry rep 1, 1st September 
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2014). Thus, actors tell narratives that make connections which constrain and enable future 
actions (Deuten & Rip 2000). Contained bio-manufacturing seems to work in a similar way. It 
facilitates some forms of future industrial contributions and inhibits others. Certain forms of 
research and collaboration become more fundable, and doable, and others become less so.  
 
 
Embedding translation  
 
One way to enhance the do-ability of synthetic biology is to attempt to embed translation, as 
commercial manufacturing, in various institutions, practices and materials. In Chapter 4, I 
argued that the SBLC is an organisational realisation of relations between government, 
industry and academia. Embedding translation is also realised in SynbiCITE and its 
activities, which includes training new researchers. Much of the training in synthetic biology, 
whether in iGEM, through SynbiCITE or through the CDT, has a specific component to 
create industrially aware researchers, who may become future industry leaders. This means 
the future identities of researchers may include orientation to forming collaborations with 
industry and commercialising research.  
 
Synthetic biology is aligned with industry through the naming of various facilitates and 
biological parts. These include automated laboratories called “foundries” and SynbiCITE as 
the “Industrial Translation Engine”. This chimes with the idea that specific expectations are 
tied to the creation of specific institutions (Schyfter & Calvert 2015). In terms of biological 
parts, the proponents of synthetic biology have begun using industrial terms such as 
“chassis”, “switch” and “oscillator”. These align the work of synthetic biology with controllable 
industrial mechanics. Furthermore, actors work on these symbolic findings which can then 
alter their statuses: they can become key infrastructural parts of the research field as 
different promises of controlling biology are realised at different times (Mackenzie 2013b).  
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Finally, in Chapter 6, the futures of industrial manufacturing and surgical application are 
inscribed in the DNA of microbes. The researchers change the genomes to produce more 
materials or change them. They delegate to the bacteria.  
 
The overall aim was to find out how synthetic biology is made translatable. In answer to that 
aim, attending to translation appears to be shaping the emergence of synthetic biology 
towards industrial manufacturing in organisational, epistemic, pedagogic, and material ways.  
 
 
7.2 Synthetic Biology: An Unfolding Multiple  
 
The first theoretical contribution I wish to discuss draws together post-ANT and post-social 
theory to generate a framework for further STS research. I reviewed these starting 
perspectives in detail in Section 2.4. Here, I argue that elements from the two theories can 
help conceptualise synthetic biology as an object. I discuss three features of synthetic 
biology – its generative, expanding and multiple qualities – and suggest that the concept of 
an unfolding multiple can help to research objects such as fields of scientific research in 
STS.  
 
 
Generative  
 
Actors, in their practices associated with synthetic biology, produce new formations. They 
make new definitions and categories of life (Section 5.3), new publications and policies 
(Section 4.1), and new biological standards. There are new institutions in the sense of 
facilities: new computer programs and automated foundries, training centres, research 
Doable Research, Multiples and Vulnerabilities  
 	 285  
centres and innovation centres (Section 4.1, Section 5.1). There are new strains of bacteria, 
new strands of DNA and novel biomolecules (Section 6.2). Actors also produce new 
arguments claiming synthetic biology can make an impact and meet the goals of other 
actors (Section 4.3, Section 5.3, Section 6.1). All of these new things are produced by 
different actors doing their work in, and on, synthetic biology. So how to think of this in 
theory?  
 
Both post-ANT and post-social theory understand objects as generative (see Section 2.4). In 
post-social theory, objects of knowledge are a series of lacks, a chain of absences, about 
which researchers ask questions and act to produce knowledge, and this facilitates the 
identification of further lacks (Knorr-Cetina 2005a; Knorr-Cetina 1997; Knorr Cetina & 
Bruegger 2000). The post-ANT formulation is similar and theorises how lacks are identified 
and produce new specific presences – concatenations of void and existence. So, in the 
process of designing of an aircraft: 
 
…presence, once created, in turn generated novel (perhaps deferred) forms of absence. 
That is, it shaped other new but absent realities: a wing, for instance, of a particular 
shape; a series of wind-tunnel tests of possible wings; and, in due course, an aircraft 
designed in a particular way with particular aerodynamic properties. The argument, then, 
is that we cannot understand objects unless we also think of them as sets of present 
dynamics generated in, and generative of, realities that are necessarily absent. 
(Law & Singleton 2005, pp.346–347) 
 
The quotation articulates the idea that patterns of absence generate new things in the world. 
In the idiom of both strands of STS object theories: absence produces presence, which 
points to further absences.  
 
Actors identify absences of translation in synthetic biology and this produces new meanings 
of biology, new institutions and new professional expectations. More specifically, actors 
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often do translation in synthetic biology as an absence of collaborations. Thus, forming 
collaborations draws in new actors and loops new sets of practices through synthetic 
biology. One effect of this, looking at a short history of UK synthetic biology, is that it 
appears to be rapidly getting larger.  
 
 
Dilation 
 
As synthetic biology is emerging its timescapes (Adam 1998) are changing. The original 
NSBs were funded for comparatively shorter periods of time – three years. Some of these 
networks developed into other projects. In Chapter 6, once the funding had finished for one 
NSB, the primary investigators acquired new funding from their institution. This became a 
new network of three PhD students in 2012, each with a thesis deadline four years hence, 
and a shorter BBSRC-funded project lasting fourteen months (Section 6.1). Furthermore, the 
RCUK website stated that further ‘funding outcomes’ included a one year mass spectrometry 
project, a four year international partnering award, a five year Network in Industrial 
Biotechnology and Bioenergy, a three and a half year collaborative science project and the 
five year multi-partner SynbiCITE (Research Councils UK 2015b). Thus, the NSB projects 
through spacetime in multiple ways.  
 
The subsequent larger awards have been made for longer periods. From 2009 to 2014 the 
Centre for Synthetic Biology and Innovation (CSynBI) was funded at Imperial. In 2012, the 
“Flowers consortium” of Imperial, Cambridge, Edinburgh, LSE and King’s College, and 
Newcastle universities was funded for five years to develop infrastructure for the “platform 
technology” synthetic biology. In 2014, three SBRCs and SynbiCITE were funded, each for 
five years. Three more SBRCs were awarded in early 2015. The five-year SBRCs have 
been awarded to Bristol, Cambridge-Norwich, Edinburgh, Manchester, Nottingham and 
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Warwick. The Centre for Doctoral Training, funded for seven years, is instructing, not just 
researchers, but 90 future leaders of the field (Section 5.3). This means that synthetic 
biology, in an imagined sense, is projecting further and further into the future. Future 
professionals emerging from the organisation may well enact that projection.  
 
Synthetic biology has also dilated across geographic and social space. The NSBs were 
funded at a total of nine institutions and, since then, more and more universities have 
become involved in synthetic biology, either through large grants, responsive mode grants or 
by involvement with the iGEM competition. Thus, synthetic biology is enmeshed in 
universities, people, resources, meanings, practices and microbes (Part II). In its current 
state synthetic biology is expanding.  
 
From the outset of the NSBs, interest and involvement in synthetic biology was not confined 
to biologists and engineers. Social researchers became involved on epistemic and ethical 
grounds. They wanted to ask questions about what life meant to different groups since it 
appeared to be contested in early meetings (social researcher 2, 2nd July 2014). Another, 
interested in academic bioscience, got ‘sucked in’ by accident (social researcher, 1st July 
2014). Some were commissioned to write reports on the social implications of synthetic 
biology (Balmer & Martin 2008) and conduct the ‘dialogue’ to research public opinion (TNS-
BMRB 2010). People beyond academics and funding administrators have also become 
enrolled in synthetic biology including government ministers like David Willetts and various 
companies and businesses registered as collaborators on proposals (see Chapter 5). By 
2015, there were 33 industrial partners and 19 academic organisations listed online as part 
of SynbiCITE.  
 
Dilation of an object (Engestrom et al. 2003) may have discernible effects. Two participants 
(academic researcher 5 and social researcher 2) remarked on a difference between hopes 
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and excitement of synthetic biology at the international synthetic biology conference SB5.0 
held in Stanford, 2011 and the SB6.0 conference held at Imperial in 2013. There was a 
sense here of a difference between the promise of designing biology and reality of 
engineering the materials of life which appear to interact in a probabilistic way. This ‘slowing 
of the pace’ was also touched on by an administrator referencing the innovation ‘hype curve’ 
where, after an initial flurry of engagement with the an exciting novelty, the more mundane 
work of realising what will be feasible takes hold (research administrator 4, 16th July 2014). 
Thus, the dilation of synthetic biology also connotes a reduction of hype. As the field diffuses 
it becomes a more mundane science. So, the dilation of an object occurs across multiple 
domains and there may be a relationship between the expansion in some spaces and the 
perception of a slowing pace in others as discussed as ‘rates of realisation’ (Mackenzie 
2013b). This notion of expansion, then, may account for the perceptions that developments 
in synthetic biology are, in some areas, decelerating.  
 
The outcome of this section is that post-social theory can deal with dynamic objects in a 
more satisfying way that post-ANT. Post-ANT has been worked out with complex medical 
diseases such as atherosclerosis and alcoholic liver disease that, in terms of practices, are 
comparatively stable in comparison to synthetic biology.  
 
 
Multiplicity  
 
Synthetic biology is partly constituted of collaborations between different academic 
disciplines. Thus, the idea of an object multiple (Mol 2002) that is composed of several 
practices was an attractive conceptual option in the first instance. However, it turned out that 
I found trying to ‘operationalise’ the concept for analysis was problematic. For one, Mol’s 
argument is based on convincing the reader that a shift to focusing on material practice 
Doable Research, Multiples and Vulnerabilities  
 	 289  
alters one’s ontology. Thus, an object that is single in theory is multiple in practice. But, 
synthetic biology is not a single object, even ‘in theory’. It is “many things to many people” 
(academic researcher 15, 28th August 2014). Most proponents and other researchers regard 
it as an approach. And one that is not theoretically unified. So, a key argument of The Body 
Multiple is undermined.  
 
In addition, post-ANT and post-social theories have different interpretations of multiplicity. In 
post-ANT, multiplicity arises in large, messy objects that are done differently by groups, even 
though they may be in the same site, referring to the same body, as with an atherosclerotic 
patient and a doctor (Mol 2002). In different sites the different constitutive practices may be 
contradictory, as in both atherosclerosis and alcoholic liver disease (Law & Singleton 2005). 
This is an effect of understanding objects as enacted or performed (Law 2009). In contrast, 
multiplicity for post-social objects arises primarily from an assemblage of partial 
representations. As Knorr Cetina says:  
 
Take the case of detector in a high-energy physics experiment. ‘It’ continually circulates 
through a collaborating community of physicists in the form of partial simulations and 
calculations, technical design drawings, artistic renderings, photographs, test materials, 
prototypes, transparencies, written and verbal reports, and more. These instantiations are 
always partial in the sense of not fully comprising ‘the detector’.  
(Knorr Cetina 2005, p.191) 
 
This idea of ‘circulating representations’ is very similar to the early ANT concept of 
immutable mobiles (and therefore boundary objects) that stabilise networks because they 
are resistant to deformation (Star & Griesemer 1989; Latour 1986). The object of synthetic 
biology does circulate in diagrammatic form (see Section 1.2). However, despite my earlier 
caveats, I suggest it is more compelling and more complete to conceptualise synthetic 
biology as a post-ANT multiple consisting of overlapping bundles of practices involving 
academics, administrators, businesses and government.  
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An unfolding multiple  
 
To think about synthetic biology, I propose drawing together the concepts of heterogeneity 
and generativity of post-ANT and the dynamic, unfolding qualities of post-social objects. But, 
if an object is unfolding in multiple ways is there a theoretical mechanism for this? Knorr 
Cetina’s (Knorr-Cetina 2005a; Knorr-Cetina 1997) thesis on post-sociality employs Lacan’s 
work on desire and, in this psychoanalytic vein, she argues that in epistemic practice 
researchers loop their own desire through the incompleteness of their epistemic or partial 
objects. For her, it is the ability of objects to unfold and give off signs that facilitate a 
relationship where researchers ‘follow’ a chain of lacks. Some knowledge is missing; the 
object ‘signals’ the way. In the case of a financial market:   
 
The articulation of the object, the market, is looped through the subject: as a structure of 
lacks, of the questions it poses and the things that "it" needs, the market receives the kind 
of extension that the subject determines.  
(Knorr Cetina & Bruegger 2000, p.157) 
 
This ‘binds’ the researcher to the object and, as such, an object like a financial market can 
become a space in which the self can be embedded (Knorr Cetina & Bruegger 2000).  
 
It may be possible to extend this idea to groups. If the self can be embedded in unfolding 
objects, so groups can be integral to unfolding multiples. At the end of Chapter 5 I noted how 
synthetic biology is ‘opening up’ as many different actors identify translational absences in 
synthetic biology. Whether scientific, commercial, pedagogical or social. A standards 
agency, for example, finds a lack of standards key to translation (British Standards Institute 
2014). They loop their practices through synthetic biology, and unfold it. Another example of 
the way groups identify lacks is in the way the proposal for the CDT referred to a ‘skills gap’ 
(Engineering and Physical Sciences Research Council 2015b). It could have been, for 
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instance, that all the skills for synthetic biology were already ‘out there’ and needed bringing 
together. This would have created a different absence and a different solution. An absence 
of training, once funded, altered the way that synthetic biology emerged. These groups 
unfold synthetic biology in ways that are relevant to the questions they ask (see table in 
Figure 16 below).  
 
Figure 16. Table of different groups’ extensions of synthetic biology  
Group Lines of Extension  
Engineers   Systematic design, abstraction, 
modularisation, standards in biology 
Microbiologists Knowledge about manipulating and 
maintaining (laboratory) life  
Computer scientists Programs that can predict and simulate 
biological environments and reactions  
RCUK UK capacity for synthetic biology 
expertise  
Government  Strategic leadership, specific funding  
Innovation leaders IP, business collaborations, markets, 
profit  
Social studies academics Ethical, legal, social changes  
Standardisers Experience in creating and managing 
standards  
 
This chapter has shown how different groups engage with synthetic biology and unfold it in 
different ways. A multiple object such as synthetic biology contains a vast array of 
actors/subjects who work to unfold the object in their own ways.  
 
A question then becomes, how do these practices and different actors stay together? An 
implication of unfolding multiple is how it configures the approach to sociality. Knorr Cetina 
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suggests that, while unfolding and sign-giving are the two important characteristics for 
researcher-object relations, it is their representational multiplicity that may allow integration:  
 
In expert contexts, the binding role of knowledge objects may rest on their multiple 
instantiations; for example on their ability to circulate as test materials, visual displays, 
maps, prototypes, substances, etc. This form of objectual integration may create 
communities 'in thought' (compare Hutchins, 1995), collective obligations towards the 
lacks displayed by partial objects, and emotional affiliation through the concentration of 
feelings, images and metaphors on central objects. I assume that objectual integration 
plays a crucial role in the formation of research groups (Geison, 1993) and experimental 
systems (Rheinberger, 1992), across generations of participants. 
(Knorr Cetina 1997, pp.24–25) 
 
Knorr Cetina’s proposition is that it might be the multiple instantiations of objects that 
facilitates integration.  
 
My account means objects are able to be at the centre of a different mode of objectual 
integration because an unfolding multiple concept facilitates a range of practices operating 
along the lines of ‘a structure of wanting’. There may well be a concentration of metaphors 
that create collective obligations but, for synthetic biology, the lacks and absences are 
different for various groups. A task, which I begin to address in the following section, is to 
identify potential integrating metaphors and images. However, it may be as much about how 
objects have the capability to unfold in multiple directions, and so loosely weave together 
diverse bundles of practice, that might account a ‘binding’ quality. In Section 7.3, I explore a 
mode of coherence for synthetic biology.  
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Implications  
 
An unfolding multiple is a theoretical entity that can be used to conceptualise objects of 
research in STS. Thus, whether in terms of epistemic objects or partial, multiple objects 
more generally, this notion allows researchers a way to understand an object that is spread 
out, that contains materials, representations and practices. It also offers a way to understand 
the way objects change over time – dilation may simply be a phase of an object lifecycle 
(Engestrom & Blackler 2005; McGivern & Dopson 2010). There are, I suggest, three 
domains for an analyst to chart:  
 
1. The multiple practices constituting an object 
2. The unfolding of meanings, materials, facilities and skills, and the effects of 
expansion and contraction  
3. Modes of coherence  
 
Reflexivity is built into this theory. Researchers can play a part in shaping the technologies 
they study (Williams & Edge 1996, p.892). I, as a social researcher, contributed to the 
expansion or extension of synthetic biology in specific ways. I performed the importance of 
translation to a small selection of people, and also performed the idea that social 
researchers could create social knowledge from synthetic biology (see Section 3.5). The 
unfolding multiple concept therefore links the personal and the communal (Wright Mills 
2000) and sensitises the researcher to their role in creating an object, how their own desires 
for knowledge and action extend an object.  
 
It is also, then, weakly predictive. If specific types of actors, say scientific researchers, policy 
makers, government ministers, specific industries, involve themselves in synthetic biology, if 
they loop through their desire, then synthetic biology expands in specific directions.  
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Making synthetic biology translatable might mean actors creating an object with a permeable 
ontology that allows for interweaving of multiple practices. This leads to the final section of 
this thesis, in which I suggest a mode of coherence that may function to loosely bind various 
practices.  
 
 
7.3 Mobilising Vulnerabilities: Society, Surgery and Synthetic Biology 
 
Synthetic biology can be understood as an unfolding multiple that is generative and 
expanding. The mechanism for expansion is that various groups loop their interests through 
the object and unfold it in multiple dimensions – epistemic, political, medical and so on. 
However, there is a problem of understanding coherence. How does such a composite 
object ‘hang together’?  
 
In this section, I argue that mobilising vulnerabilities can effect coherence of a complex 
object. Many stories cast synthetic biology as an object with an heroic character, or as a 
panacea, with the ability to solve many problems. It turns out that synthetic biology is a 
solution to many vulnerabilities in the world. These include issues for the UK state, the 
public, industry, and surgical processes.  
 
I use the term vulnerability in a dual sense. It means 1) exposure to the possibility of harm 2) 
the incapability of a (socio-technical) system to withstand change. This second meaning is 
extensively explored in literatures in climate studies, geography, development studies, 
engineering, health, disaster management and security studies. These literatures tend to 
focus on defining vulnerability, and reducing it. An edited STS collection sought to explore 
“what vulnerability can mean and how it affects cultures and societies” (Bijker et al. 2014, 
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p.3). Thus, the meanings have implications for the conceptual frameworks that people use 
and for the governance of vulnerabilities. Instead, my focus is on how actors deploy 
vulnerabilities in the pursuit of resources.  
 
 
A Panacea 
 
This section explores how synthetic biology is performed (on verbal and textual ‘stages’) as 
the solution to many problems. In the course of asking for investment and justifying requests 
for resources, actors liberally deploy vulnerabilities. It is a key part of making synthetic 
biology translatable as actors translate the interests of others into the (claimed) abilities of 
the field (Callon & Law 1982; Callon 1986).  
 
In the skin graft project, actors presented wounds that did not heal and remained open to the 
environment. Bodies were materially exposed. Pathogens could enter the body through 
these sites. Wound beds were inhospitable places for cells because of their lack of an ECM. 
Skins cells died because they did not adhere well enough. Furthermore, collagen is a key 
component of the ECM to which cells adhere. Collagen could be used in surgical 
techniques. However, partly because of regulations emerging from the BSE crisis, collagen 
could not be easily sourced (academic researcher 6, 5th February 2014). Therefore, 
synthetic biology is proposed as a solution to risks to sourcing and using mammalian 
collagen. Thus, the human body is cast as a vulnerable site. 
 
In Jay Keasling’s SB 6.0 conference talk George’s brother was struggling with malaria. He 
was also a vulnerable body that synthetic biology can save. Furthermore, in Keasling’s 
account, George’s mother contributed to the wider community’s vulnerability by not 
completing the course of antimalarials. This is an issue that synthetic biology can solve by 
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making cheaper drugs that are more accessible (Hale et al. 2007). So, actors mobilise 
vulnerabilities of human bodies and communities to make synthetic biology into a solution. 
The mobilisation of bodily peril legitimises the intervention of synthetic biology. It connects 
the science with protection and recovery.  
 
But, innovation itself is precarious. As I showed, several actors claim biology is not 
reproducible (Section 5.2). Innovation in biology is vulnerable and knowledge cannot be 
easily translated because the science is not robust enough. Thus, by making life easier to 
engineer, the proponents argue that an industry is more likely because it will improve 
reproducibility. Synthetic biology is a hero that can ensure and speed the transfer of 
knowledge into application.  
 
Standardising biology will have further effects. Actors present the UK nation as a vulnerable 
state. There is international competition for status, science and profit. Synthetic biology can 
realise the state’s desire for international status. By setting standards and regulations in the 
UK, the nation can exert some power in the administration of the (global) field. Finally, 
synthetic biology can support economic recovery because it encourages investment. 
Synthetic biology, with the proper support, can save the UK state. So, mobilising 
vulnerabilities creates a hero (Deuten & Rip 2000) capable of great feats, from repairing 
human bodies to bolstering a state’s economy.  
 
This creates a potential object which cannot be ignored. It binds different groups to the 
future of synthetic biology by creating a passage point (Callon 1986), which leads to many 
benefits. Potentially, this establishes a coherent moral obligation to supporting synthetic 
biology, as not supporting the field could prevent benefits to society.  
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Maintaining Beneficial Qualities  
 
Throughout Part II, I argued that synthetic biology novelties currently remain contained in 
both imaginaries and realities, partly because of the safety testing in medical technology 
development. However, even when the skin graft project appeared flawed synthetic biology 
‘was not the problem’.  
 
The researchers acknowledged that the use of flagella was problematic. The immanent 
feature of mammalian immunogenicity threatened the overall conceit of using flagella as a 
scaffold for their bioglue. Instead of abandoning the project, or choosing a different scaffold, 
the researchers sought to use synthetic biology to remedy the problem. By reengineering the 
parts of the flagella to be less immunogenic, the researchers preserve the panacea – 
synthetic biology can solve many problems.  
 
This kind of activity has another precedent. The early promises of the Arteminisin Project 
were to produce an antimalarial drug “inexpensively for the people of the developing world 
and potentially save one or two million lives every year” (Keasling 2004). However, over 
time, different promises emerged. The semi-synthetic production of artemisinin became a 
way to ‘stabilise’ the market prices and make a more reliable source for artemisinin (Hale et 
al. 2007). But, instead of understanding the changing promises of the Artemisinin Project as 
problematic for synthetic biology (Marris 2013), I want to reframe them as being integral to 
maintaining synthetic biology as an object of great potential.  
 
Synthetic biology is also maintained by how it does allow groups to realise their goals. At 
RCUK actors talked of how synthetic biology was a good example of cross-council funding. 
Academic researcher 18 said, “synthetic biology has a lot to be thanked for”. These help 
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keep synthetic biology together, to protect it in its emergence by acknowledging interim 
successes.  
 
 
But, synthetic biology is in peril  
 
Synthetic biology, actors argue, can have major industrial, health and economic benefits. 
Above, I described how synthetic biology is expanding. A persistent metaphor in the context 
of UK synthetic biology is that it is ‘emerging’ or ‘growing’.  
 
As a discipline, I’m going to say immaturity here. And I think you know the polite 
interpretation is that, you know, it’s technological development. But actually it does 
describe how some of the community behave as well. It’s an area that does seem to 
attract a certain amount of in fighting. I don’t know if that’s something that. It’s not. It 
needs to mature on several fronts.  
(Research administrator 1 interview, 19th August 2014) 
 
The idea of maturation suggests that synthetic biology needs nurturing. Some parenting. It is 
juvenile. It seems to be at risk if the community does not agree and work together.  
 
The environment surrounding synthetic biology can also be hostile. In Section 4.3 David 
Willetts connected the public, the media and an outspoken US scientist. Some synthetic 
biologists try to distance themselves from Craig Venter. He is cast as a liability that threatens 
synthetic biology. The media and public may also cause synthetic biology problems. Willetts 
also said some of his actions were about trying to prepare people for a turbulent time. Thus, 
the immaturity of synthetic biology is problematic and justifies support. These comments 
externalise synthetic biology and make it an object separate from the community. Yet the 
environment still poses a threat.  
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Synthetic biology is at risk to people not legitimately engaged in the project. They can ruin it 
by ‘diluting’ it (Academic researcher 24). If they do work, but do not contribute to standards 
and modules and contribute to the community, synthetic biology could fail. Also, if people are 
too focused on applications, synthetic biology may fail because not enough resources are 
allocated to the underpinning development (Schyfter & Calvert 2015). There is a tension 
between underpinning infrastructure and impact. This is further exemplified in the extended 
quote from CSynBI at the start of Chapter 4. There, the UK infrastructure can threaten an 
innovation. The statement argues that proponents of microchips did not do enough, that they 
did not support their innovations loudly enough.  
 
Finally, regulations in synthetic biology. The examples of nanotechnology and medical 
technologies were highlighted as possible threats to realising potential (John Collins, 
industry rep 1 & academic researcher 6). Saying regulations threaten synthetic biology 
appears to be attempts to inhibit them: synthetic biology researchers should be allowed to 
regulate themselves since external regulation could prevent innovation. Thus, mobilising 
vulnerabilities shapes the future industry of synthetic biology.  
 
 
7.4 Conclusion   
 
I have shown how vulnerabilities are mobilised in two ways. They are used to construct a 
panacea. A single character capable of great contributions to society. In this way, actors 
mobilise vulnerabilities to gather resources for their projects. Vulnerabilities are also 
deployed, almost in reverse, to construct a hostile environment, and justify protective 
support for synthetic biology. Thus, the mobilisation of vulnerabilities creates an ethic of 
support and protection towards synthetic biology.  
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Object relations and resources  
 
I suggest that mobilising vulnerabilities helps establish a single object of synthetic biology. 
They contribute to coherence by performing emotional and ethical affiliations (Knorr-Cetina 
2005a) towards the immature object of synthetic biology and towards its potential to benefit 
society.  
 
In their work on markets, Knorr Cetina and Bruegger suggest that coherence is an 
achievement of “the articulation and management of lacks” (Knorr Cetina & Bruegger 2000, 
p.155). Knorr Cetina posits that there must be shared ‘emotional affiliation’ with central 
objects – feelings, images and metaphors. For Mol (2002), cohering the various practices is 
accomplished via translations. ‘Emerging coherence’ in innovation and product creation can 
be accounted for by understanding narrative infrastructure (Deuten & Rip 2000). Although 
the latter authors focus on ‘product creation’, I suggest that a similar approach may be 
fruitful in understanding the formation of a scientific field. I drew on these ideas, which I 
covered in more detail in Chapter 2, to suggest a mode of coherence for synthetic biology. 
Thus, the stories of synthetic biology as capable of solving many problems, yet also 
vulnerable to its environment, may establish emotional affiliation and create an apparently 
singular object.  
 
Secondly, engineers and scientists look for problems. What are they doing when they 
identify problems? Synthetic biologists publish ideas such as a problem-driven approach to 
healthcare innovation (Tyo 2012). Or they proclaim “malaria is a global health problem” (Ro 
et al. 2006, p.940). Indeed, scientists do more than identify doable problems. They actively 
construct them (Fujimura 1987). In this process, they instrumentalise vulnerabilities. They 
turn them into ways of securing resources for their projects. So what of vulnerabilities? 
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As a provocation to policy and practice (Russell & Williams 2002a, p.149) mobilising 
vulnerabilities implies a conceptual shift. For instance, it is one thing to say, “scientists need 
resources to fix a problem”. Here, resources are allocated because the solution is imminent. 
It is quite another thing to say, “scientists identify vulnerabilities to get resources”. This 
suggests a more indefinite connection between ‘the problem’ and resources. Scientists are 
capable of saying where problems lie in order to create convincing proposals. Perhaps this 
practice is the product of a risk society (Beck 1992). Talking of vulnerabilities shifts the focus 
from the future promise of benefits onto the present practice of acquiring resources.  
 
This has implications for funding and resource allocation for science. Responsible research 
and innovation (RRI) has become a buzzword in science administration (Owen 2014; Owen 
et al. 2012). I suggest that vulnerabilities are a way to sensitise actors to the potential 
benefits they propound, the way promises change, and why they mobilise specific attributes. 
New questions can be foregrounded: “how is an actor mobilising a vulnerability? What is 
vulnerable? What are they asking for?” This highlights the relationships between problems 
and solutions. So, reframing the construction of problems as mobilising vulnerabilities also 
raises the question of reflexivity for scientists, and asks them to critically assess their 
reasons for making claims. Are the resources they are asking for going to contribute to 
ameliorating vulnerability? Is the mobilisation of vulnerability ‘fair’ in terms of the emotional 
connections they make?   
 
In this last chapter I summarised my main findings as responses to the research questions I 
posed at the end of Chapter Two. I went on to outline two academic contributions. The first 
of these, an unfolding multiple, is a contribution aimed at the STS research community. It is 
a reflexive framework for understanding and researching complex, multiple and dynamic 
objects. The second, the notion of mobilising vulnerabilities, offers a mode of coherence for 
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complex objects. Furthermore, I suggest, it offers a provocative reframing of ‘constructing 
problems’ to emphasise double-sided deployment of vulnerability – both to highlight the 
potential for beneficial contributions and to gain resources for one’s endeavours. This may 
be of use for researchers, funders and public bodies in assessing the contribution of different 
programmes of research.  
 
Throughout this thesis I have tried to show the complex processes that make an emerging 
field of research into a relevant and fundable science. Making synthetic biology translatable 
involves aligning science with other stakeholders in rhetorical, organisational and material 
ways. Thus, synthetic biology is made into an object that needs to be supported to realise its 
potential benefits to the UK state, academic science, commercial industry and society.  
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Glossary  
 
 
AHRC Arts and Humanities Research Council  
ALD  Alcoholic liver disease  
ANT Actor-network theory  
Atherosclerosis Disease characterised by fatty deposits causing a smaller 
lumen and a thickening and hardening of arterial walls  
BBSRC  Biotechnology and Biological Sciences Research Council  
BIS Department for Business, Innovation and Skills (UK 
government) 
Catalyst  RCUK & Innovate UK collaborative funding mechanism  
CDT Centre for Doctoral Training (e.g. SBCDT) 
Chimera  A protein coded by DNA from genetically different sources  
CSynBI Centre for Synthetic Biology and Innovation (Imperial 
College) 
Culture (cell) Growth of cells (e.g. bacterial, mammalian etc), usually in a 
laboratory, in a medium containing nutrients  
DNA  Deoxyribonucleic acid  
E. coli Escheria coli, ‘gut’ bacteria commonly used in biotechnology 
ECM Extracellular matrix. The mesh of macromolecules that helps 
binds cells to one another.  
EPSRC Engineering and Physical Sciences Research Council  
ESRC Economic and Social Research Council  
ETC Group Erosion, Technology and Concentration Group. A campaign 
organisation which raises awareness of the impact of 
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technology on poor and vulnerable communities.   
Express  Act of bacteria showing signs that a particular gene is having 
an effect. i.e. making a protein or demonstrating antibiotic 
resistance. 
Gene  Unit of DNA that determines amino acid sequence in a 
protein.  
Genome Full (haploid) set of chromosomes in an organism  
GM Genetic modification  
HaCaT cells Immortal cell line derived from human skins cells, used in 
biomedical science  
HEFCE Higher Education Funding Council for England  
HGP Human Genome Project  
IKC Innovation and Knowledge Centre  
Innovate UK Innovation agency (new name for the Technology Strategy 
Board) 
MHRA Medicines and Healthcare Products Regulatory Agency in 
the UK 
Microbe  Micro-organisms e.g. bacteria, fungi, viruses  
MRC Medical Research Council  
MRSA Methycillin resistant staphylococcus aureus 
Mutant  A non-wild version of an organism; has usually been 
‘transformed’  
NERC Nature and Environment Research Council  
NSB Network in Synthetic Biology  
Plasmid  Nonchromosomal DNA that can independently replicate, 
typically a small circle of DNA in bacterial cytoplasm. Used 
extensively in bioscience to manipulate genes.  
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RCUK Research Councils UK (collective of seven councils)  
RCT Randomised controlled trial  
REF Research Excellence Framework – quality assurance 
exercise for UK research conducted by quangos.  
SB Synthetic biology  
SBRC Synthetic biology research centre. Six centres funded by 
RCUK. 
SCR Stem cell research 
Sequence  Specific strand of DNA 
Splice  Insert one sequence of DNA into another  
STS Science and Technology Studies, sometimes Science, 
Technology and Society 
SynbiCITE Synthetic Biology Commercial and Industrial Translation 
Engine (the synthetic biology IKC at Imperial)   
Synbio Synthetic biology  
Transformation Act of inserting an experimental plasmid into a bacteria, 
usually duaeying antibiotic resistance among other genes. 
Bacteria that failed to take up the plasmid die when the 
culture is grown on a medium with a specific antibiotic.  
TSB  Technology Strategy Board (now called Innovate UK)  
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Appendix I  
Lists of Participants & Interviews  
 
Participants:  
Participant Code Role and/or affiliation  
Academic Researcher 1  PhD candidate. Microbiology.   
Academic Researcher 2 Professor. Bioinformatics  
Academic Researcher 3 PhD candidate. Microbiology. 
Academic Researcher 4 Postdoctoral Research Assistant. Microbiology.  
Academic Researcher 5 Senior Lecturer. Microbiology.  
Academic Researcher 6 Research Associate. Engineering. 
Academic Researcher 7 Masters student. Microbiology. 
Academic Researcher 8 Professor. Engineering.  
Academic Researcher 9 Masters student. Microbiology.  
Academic Researcher 10 Senior Lecturer. Synthetic biology.  
Academic Researcher 11 Professor. Synthetic biology. 
Academic Researcher 12 Professor. Biotechnology. Head of translation.  
Academic Researcher 13 PhD candidate. Synthetic biology. 
Academic Researcher 14 Group Leader. Bioinformatics.  
Academic Researcher 15 Professor. Biochemistry.  
Academic Researcher 16 PhD candidate. Synthetic biology.  
Academic Researcher 17 PhD candidate. Synthetic biology.  
Academic Researcher 18 Professor. Molecular micribiology.  
Academic Researcher 19 Lecturer. Computing Science.  
Social Researcher 1 Reader. Sociology.  
Social Researcher 2 Senior Lecturer. Sociology.  
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Research Administrator 1 RCUK   
Research Administrator 2 University. Grant capture.  
Research Administrator 3 University. Science-industry relations.   
Research Administrator 4 RCUK 
Research Administrator 6 RCUK.  
Research Administrator 7 Dr John Collins, Commercial Director, SyniCITE  
Research Administrator 10 RCUK  
Research Administrator 12 RCUK 
Research Administrator 15 RCUK  
Research Administrator 16 Rt Hon David Willetts   
Industry representative 1 Synthetic biology startup   
Industry representative 2 Synthetic biology SME   
 
Interviews:  
Participant Code Interview date   Mode of interaction  
Academic Researcher 2 28th July 2014   In person; unrecorded 
Academic Researcher 4 4th December 2013   In person 
Academic Researcher 5 7th May 2014  In person  
Academic Researcher 6 5th February 2014  In person  
Academic Researcher 7 28th July 2014 In person  
Academic Researcher 9 28th July 2014 In person  
Academic Researcher 10 1st September 2014 In person 
Academic Researcher 11 29th August 2014 In person 
Academic Researcher 12 15th July 2014   Telephone  
Academic Researcher 14 19th August 2014   Video internet call  
Academic Researcher 15 28th August 2014  Video internet call 
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Academic Researcher 18 28th July 2014  In person  
Academic Researcher 19 28th July 2014   In person; unrecorded 
Social Researcher 1 1st July 2014  Video internet call 
Social Researcher 2 2nd July 2014 In person  
Research Administrator 1 19th August 2014 In person  
Research Administrator 2 18th February 2014  In person 
Research Administrator 3 3rd March 2014   In person 
Research Administrator 4 16th July 2014  Voice internet call  
Research Administrator 6 19th August 2014 In person  
Research Administrator 7 3rd July 2014  Video internet call  
Research Administrator 10 18th August 2014 In person  
Research Administrator 12 19th August 2014 In person  
Research Administrator 15 19th August 2014 In person  
Research Administrator 16 2nd September 2014   In person  
Industry representative 1 1st September 2014 In person  
Industry representative 2 10th September 2014  In person; unrecorded  			
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Appendix II  
Research Ethics Documentation 
		 	
 
 
  Department  
  Of Sociological  
  Studies. 
 
 
 
Rob Meckin 
Department of Sociological Studies  
 Department Ethics Co-ordinator 
Dr Harriet Churchill 
 
The University of Sheffield 
Department of Sociological Studies 
Elmfield, Northumberland Road 
Sheffield, S10 2TU 
 
10 January 2014 Telephone: +44 (0) 114 222 6440 
Fax: +44 (0) 114 276 8125 
Email: h.churchill@sheffield.ac.uk 
 
 
Dear Rob 
 
PROJECT TITLE: The meaning and practice of translational research in Biomedicine 
 
On behalf of the University ethics reviewers who reviewed your project, I am pleased to 
inform you that on 10 January 2014 the above-named project was approved on ethics 
grounds, on the basis that you will adhere to the following documents that you submitted 
for ethics review: 
 
 Ethics application form dated 7 January 2014 
 Participant information sheet dated 23 September 2013 
 Participant consent form dated 23 September 2013 
 
If during the course of the project you need to deviate from the above-approved documents 
please inform me. Written approval will be required for significant deviations from or 
significant changes to the above-approved documents. Please also inform me should you 
decide to terminate the project prematurely. 
 
Yours sincerely 
 
Dr Harriet Churchill 
Department Ethics Co-ordinator 
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Participant	Consent	Form			 Title	 of	 Research	 Project:	 The	 practice	 of	 translational	 research	 in	 synthetic	
biology:	a	sociological	study		Name	of	Lead	Researcher:	Robert	Meckin			
Participant	Identification	Number	for	this	project:	 																																											Please	
initial	box	
	1. I	confirm	that	I	have	read	and	understand	the	information	sheet	and	I	have		had	the	opportunity	to	ask	questions	about	the	project.		2. I	understand	that	my	participation	is	voluntary	and	that	I	am	free	to	withdraw	at	any	time	without	giving	any	reason	and	without	there	being	any	negative	consequences.	In	addition,	should	I	not	wish	to	answer	any	particular	question	or	questions,	I	am	free	to	decline.			3. I	understand	that	my	responses	will	be	kept	confidential.	I	give	permission	for	other	members	of	the	research	team	to	have	access	to	my	anonymised	responses.	I	understand	that	my	name	will	not	be	linked	with	the	research	materials,	and	I	will	not	be	identified	or	identifiable	in	the	report	or	reports	that	result	from	the	research	unless	I	give	my	consent.				4.					I	agree	for	the	data	collected	from	me	to	be	used	in	future	research				5. I	agree	to	take	part	in	the	above	research	project.			________________________	 ________________									____________________	Name	of	Participant	 Date	 Signature				 _________________________	 ________________									____________________	Name	of	person	taking	consent	 Date	 Signature	(if	different	from	lead	researcher)	
		_________________________	 ________________									____________________		Lead	Researcher	 Date	 Signature		Copies:		
Once	this	has	been	signed	by	relevant	parties	the	participant	will	receive	a	copy,	to	keep	with	the	
information	 sheet	 and	 any	 other	 written	 information	 provided.	 A	 copy	 of	 the	 signed	 and	 dated	
consent	form	will	be	placed	in	the	project’s	secure	storage.		
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INFORMATION	SHEET	for	RESEARCH	PARTICIPANTS	
	
	
PROJECT	TITLE			
The	practice	of	translational	research	in	synthetic	biology:	a	sociological	study		
INVITATION		You	have	been	contacted	because	you	are	a	member	of	a	synthetic	biology	group	or	are	working	in	a	related	area	(another	scientific	field,	policy	arena,	industry	etc).		You	are	being	invited	to	take	part	in	a	research	project	that	is	studying	the	development	of	the	field	of	synthetic	biology	in	the	UK	and	beyond.	In	particular,	this	study	focuses	on	the	translational	research	aspect	of	synthetic	biology.			Before	you	decide	whether	to	take	part	in	the	research,	it	is	important	for	you	to	understand	why	the	research	is	being	done	and	what	it	will	involve.	Please	take	time	to	read	the	following	information	carefully	and	discuss	it	with	others	if	you	wish.	Ask	me	(Rob	Meckin)	if	there	is	anything	that	is	not	clear	or	if	you	would	like	more	information.			Thank	you	for	reading	this.		
PURPOSE	of	the	RESEARCH	To	investigate	and	understand	how	a	new	scientific	field	is	created,	defined	and	practiced.			
COMMITMENT		It	is	up	to	you	to	decide	whether	or	not	to	take	part.	If	you	do	decide	to	take	part	you	will	be	given	this	information	sheet	to	keep	has	it	contains	my	contact	details.	You	will	be	able	to	withdraw	from	taking	part	in	the	research	at	any	time	by	contacting	me.	If	you	decide	not	take	part	or	wish	to	withdraw	please,	please	ensure	I	have	been	informed.			
WHAT	TO	EXPECT	I	may	visit	your	place	of	work	and	record	(often	written	notes)	some	of	the	activities	that	take	place	there.	I	may	also	ask	you	to	take	part	in	recorded	conversations	or	individual	/	group	discussions	about	your	research.	My	visits	are	intended	to	be	informal	occasions	and	I	may	ask	to	simply	follow	you	around	for	a	while	as	you	do	your	everyday	work.	There	will	hopefully	be	little	disturbance	to	you	and	your	on-going	activities.	Although	I	will	spend	time	with	you	as	an	individual,	the	research	is	not	studying	you	as	a	person,	rather	just	the	kinds	of	things	that	go	on	in	your	work	and	what	you	feel	about	those	and	your	area	of	work	more	generally.	I	do	have	a	background	in	biomedical	science,	but	have	not	practised	in	recent	years	so	sometimes	I	may	ask	seemingly	simple	or	odd	questions	in	order	to	understand	what	is	going	on.		
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BENEFITS	While	there	are	no	immediate	benefits	to	people	taking	part	in	the	project,	it	is	hoped	that	this	work	will	contribute	to	understanding	how	translational	research	is	undertaken	in	synthetic	biology	and	may	raise	awareness	among	scientists	and	engineers	about	some	of	the	factors	impacting	the	way	contemporary	science	is	conducted	and	developed.		
	
CONFIDENTIALITY	Any	information	that	I	collect	will	not	be	attributed	to	individuals	without	explicit	consent.	Any	reports	or	papers	that	I	write	will	contain	anonymised	information	and	I	will	aim	to	keep	the	identification	of	labs	and	institutions	to	a	minimum	when	this	is	appropriate.		
	
INFORMATION	Any	digital	recordings	(audio/photo)	made	during	this	research	will	be	used	during	analysis	and	may	be	used	for	illustration	in	conference	presentations	or	lectures.	No	other	use	will	be	made	of	them	without	your	written	permission,	and	no	one	outside	of	myself	or	my	supervisors	will	be	allowed	access	to	the	original	recordings.	If	being	interviewed	using	digital	audio,	you	will	be	asked	to	give	verbal	consent	to	the	interview.	
	
RESULTS	My	primary	aim	is	to	write	up	the	analysis	of	the	data	as	a	doctoral	thesis.	Some	of	the	anonymised	data	will	likely	be	used	for	presentations	and	academic	publications.		
	
ETHICAL	APPROVAL	The	project	has	received	ethical	approval	from	the	University	of	Sheffield,	Department	of	Sociological	Studies	Ethics	Committee	and	will	follow	professional	guidelines	laid	down	by	the	British	Sociological	Association.	
	
CONTACT		If	you	have	any	questions	about	the	work	or	about	the	conduct	of	the	researchers,	then	please	contact	me,	Rob	Meckin:		Email	:	r.meckin@sheffield.ac.uk			Or	my	supervisor,	Dr	Molyneux-Hodgson	:	s.hodgson@sheffield.ac.uk						If	you	decide	to	take	part	in	the	research,	please	sign	the	Consent	Form	attached.		
MANY	THANKS		
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Appendix III  
Publications & Participation in Science and Technology Studies 
 
Publications 
 
Meckin R, 2015. Innovation and STS in Torun: The EASST Conference as a Generative 
Object. EASST Review, 33(4) pp. 25-28  
 
Haywood, G., Nilsson, J., Franklin, M., Gilbert, P., Krafve, L. J., Linden, L., MacGillivray, M. 
and Meckin, R. 2014. Valuation Studies: A Collaborative Valuation in Practice. Valuation 
Studies, 2 (1): 71-85. DOI: 10.3384/vs.2001-5992.1421. Open Access. 
 
Academic participation – training and presenting  
Year Month Event Role  
2012 October EASST & 4S conference (Copenhagen)  Student, observer  
2013 April Dimensions of Value (Edinburgh)  Student participant  
  Med tech conference (Sheffield) Observer  
 May Ian Hacking seminar (Leeds) Student participant  
 June  PGR conference (Sheffield)  Organiser, presenter  
  STS Italia Summer School (Puglia) Student participant  
  PFGS colloquium (Leeds) Presenter  
  Sheffield study in peak district (Eyam) Student participant 
 July  SB 6.0 (Imperial) PhD researcher  
  ChELSI symposium (Sheffield)  PhD researcher  
  Making Science Public (Nottingham) Observer  
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 October Bio-objects training (York) Student participant 
 December MRI symposium (Sheffield) Student participant 
2014 February Valuation Practices (Edinburgh) Student participant 
 March Innovations in Healthcare (Sheffield) PhD researcher 
 May Life Science Research Bazaar (Sheffield) PhD researcher 
 June Nurturing Genetics Symposium (Leeds)  Student participant 
 July  Challenge of Translational Research (KCL) Student participant 
  PGR Showcase (Sheffield) Student participant 
 September Young SB conference (Wellcome, London)  PhD researcher 
  Crossing membranes  (Sheffield) PhD researcher 
  EASST Conference (Torun)  
 
Presenter and panel 
chair 
 October  Quagos workshop (Wellcome Trust) Participant  
  iGEM (Boston) Participant, advisor, PhD 
researcher  
 December Bio-objects (Brussels) Student participant 
2015 February Translational symposium (Sheffield) Self-initiated organiser  
 April  ESRC final year conference (Oxford) Senior student 
participant 
 May Making sense of clinical translation 
(Geneva) 
Awarded competitive 
place to present 
  PGR conference  Senior student 
participant 
 June ESRC overseas institutional visit 
(Maastricht) 
Awarded funding for visit 
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